{"idB": "749647_12_item1_p133_s0", "idA": "749647_11_item1_p100_s2", "sentA": "Executive officers Michael H. Tardugno, Jeffrey W. Church, Dr. Nicholas Borys and Dr. Robert A. Reed were awarded options to purchase 180,000, 70,000, 70,000 and 70,000 shares of Common Stock respectively.", "sentB": "Robert A. Reed, Ph.D. Dr. Reed joined Celsion on May 11, 2009 as Executive Director, CMC and Technical Operations.", "type": 1, "words": ["<tag1>", "Executive", "officers", "Michael", "H.", "Tardugno,", "Jeffrey", "W.", "Church,", "Dr.", "Nicholas", "Borys", "and", "Dr.", "Robert", "A.", "Reed", "were", "awarded", "options", "to", "purchase", "180,000,", "70,000,", "70,000", "and", "70,000", "shares", "of", "Common", "Stock", "respectively.", "<tag2>", "Robert", "A.", "Reed,", "Ph.D.", "Dr.", "Reed", "joined", "Celsion", "on", "May", "11,", "2009", "as", "Executive", "Director,", "CMC", "and", "Technical", "Operations.", "<tag3>"], "wordsA": ["Executive", "officers", "Michael", "H.", "Tardugno,", "Jeffrey", "W.", "Church,", "Dr.", "Nicholas", "Borys", "and", "Dr.", "Robert", "A.", "Reed", "were", "awarded", "options", "to", "purchase", "180,000,", "70,000,", "70,000", "and", "70,000", "shares", "of", "Common", "Stock", "respectively."], "wordsB": ["Robert", "A.", "Reed,", "Ph.D.", "Dr.", "Reed", "joined", "Celsion", "on", "May", "11,", "2009", "as", "Executive", "Director,", "CMC", "and", "Technical", "Operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p13_s1", "idA": "749647_11_item1_p100_s3", "sentA": "All options granted have a 10 year term and vest equally over three years.", "sentB": "Clinical development successes and failures can have a disproportionate positive or negative impact on our scientific and medical prospects, financial prospects, financial condition, and market value.", "type": 1, "words": ["<tag1>", "All", "options", "granted", "have", "a", "10", "year", "term", "and", "vest", "equally", "over", "three", "years.", "<tag2>", "Clinical", "development", "successes", "and", "failures", "can", "have", "a", "disproportionate", "positive", "or", "negative", "impact", "on", "our", "scientific", "and", "medical", "prospects,", "financial", "prospects,", "financial", "condition,", "and", "market", "value.", "<tag3>"], "wordsA": ["All", "options", "granted", "have", "a", "10", "year", "term", "and", "vest", "equally", "over", "three", "years."], "wordsB": ["Clinical", "development", "successes", "and", "failures", "can", "have", "a", "disproportionate", "positive", "or", "negative", "impact", "on", "our", "scientific", "and", "medical", "prospects,", "financial", "prospects,", "financial", "condition,", "and", "market", "value."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p63_s0", "idA": "749647_11_item1_p100_s3", "sentA": "All options granted have a 10 year term and vest equally over three years.", "sentB": "Up to 25% of patients with colorectal cancer present with liver metastases and another 50% develop liver metastases within 5 years.", "type": 1, "words": ["<tag1>", "All", "options", "granted", "have", "a", "10", "year", "term", "and", "vest", "equally", "over", "three", "years.", "<tag2>", "Up", "to", "25%", "of", "patients", "with", "colorectal", "cancer", "present", "with", "liver", "metastases", "and", "another", "50%", "develop", "liver", "metastases", "within", "5", "years.", "<tag3>"], "wordsA": ["All", "options", "granted", "have", "a", "10", "year", "term", "and", "vest", "equally", "over", "three", "years."], "wordsB": ["Up", "to", "25%", "of", "patients", "with", "colorectal", "cancer", "present", "with", "liver", "metastases", "and", "another", "50%", "develop", "liver", "metastases", "within", "5", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s6", "idA": "749647_11_item1_p15_s0", "sentA": "In 2005, the Company made a strategic decision to divest its medical device business.", "sentB": "From 1999 to 2002, Mr. Weaver was Chief Financial Officer of Ilex Oncology Inc., a public cancer drug development company, and from 1996 to 1998, he was Chief Financial Officer of Prism Technologies, a privately-held medical device manufacturer.", "type": 1, "words": ["<tag1>", "In", "2005,", "the", "Company", "made", "a", "strategic", "decision", "to", "divest", "its", "medical", "device", "business.", "<tag2>", "From", "1999", "to", "2002,", "Mr.", "Weaver", "was", "Chief", "Financial", "Officer", "of", "Ilex", "Oncology", "Inc.,", "a", "public", "cancer", "drug", "development", "company,", "and", "from", "1996", "to", "1998,", "he", "was", "Chief", "Financial", "Officer", "of", "Prism", "Technologies,", "a", "privately-held", "medical", "device", "manufacturer.", "<tag3>"], "wordsA": ["In", "2005,", "the", "Company", "made", "a", "strategic", "decision", "to", "divest", "its", "medical", "device", "business."], "wordsB": ["From", "1999", "to", "2002,", "Mr.", "Weaver", "was", "Chief", "Financial", "Officer", "of", "Ilex", "Oncology", "Inc.,", "a", "public", "cancer", "drug", "development", "company,", "and", "from", "1996", "to", "1998,", "he", "was", "Chief", "Financial", "Officer", "of", "Prism", "Technologies,", "a", "privately-held", "medical", "device", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p65_s0", "idA": "749647_11_item1_p22_s0", "sentA": "Our heat-activated liposomes circulate within the tumor tissue and leaky tumor vessels vasculature.", "sentB": "While RFA can be effective in treating these tumors, it is often limited to smaller metastases within the liver.", "type": 1, "words": ["<tag1>", "Our", "heat-activated", "liposomes", "circulate", "within", "the", "tumor", "tissue", "and", "leaky", "tumor", "vessels", "vasculature.", "<tag2>", "While", "RFA", "can", "be", "effective", "in", "treating", "these", "tumors,", "it", "is", "often", "limited", "to", "smaller", "metastases", "within", "the", "liver.", "<tag3>"], "wordsA": ["Our", "heat-activated", "liposomes", "circulate", "within", "the", "tumor", "tissue", "and", "leaky", "tumor", "vessels", "vasculature."], "wordsB": ["While", "RFA", "can", "be", "effective", "in", "treating", "these", "tumors,", "it", "is", "often", "limited", "to", "smaller", "metastases", "within", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p126_s1", "idA": "749647_11_item1_p24_s1", "sentA": "It ranks as the fifth most common solid tumor cancer.", "sentB": "From 2002 until 2004 he served as the Vice President and Chief Medical Officer of Taiho Pharma USA, a Japanese start-up oncology therapeutics company.", "type": 1, "words": ["<tag1>", "It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer.", "<tag2>", "From", "2002", "until", "2004", "he", "served", "as", "the", "Vice", "President", "and", "Chief", "Medical", "Officer", "of", "Taiho", "Pharma", "USA,", "a", "Japanese", "start-up", "oncology", "therapeutics", "company.", "<tag3>"], "wordsA": ["It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer."], "wordsB": ["From", "2002", "until", "2004", "he", "served", "as", "the", "Vice", "President", "and", "Chief", "Medical", "Officer", "of", "Taiho", "Pharma", "USA,", "a", "Japanese", "start-up", "oncology", "therapeutics", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p134_s0", "idA": "749647_11_item1_p24_s1", "sentA": "It ranks as the fifth most common solid tumor cancer.", "sentB": "Mr. Tumminello joined Celsion as Assistant Controller in April, 2009 and was appointed as the Company's Controller and Interim Chief Accounting Officer on January 6, 2010.", "type": 1, "words": ["<tag1>", "It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer.", "<tag2>", "Mr.", "Tumminello", "joined", "Celsion", "as", "Assistant", "Controller", "in", "April,", "2009", "and", "was", "appointed", "as", "the", "Company's", "Controller", "and", "Interim", "Chief", "Accounting", "Officer", "on", "January", "6,", "2010.", "<tag3>"], "wordsA": ["It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer."], "wordsB": ["Mr.", "Tumminello", "joined", "Celsion", "as", "Assistant", "Controller", "in", "April,", "2009", "and", "was", "appointed", "as", "the", "Company's", "Controller", "and", "Interim", "Chief", "Accounting", "Officer", "on", "January", "6,", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p72_s1", "idA": "749647_11_item1_p24_s2", "sentA": "It is estimated that up to 90% of liver cancer patients will die within five years of diagnosis.", "sentB": "We have focused in particular on the Asia Pacific region where the incidence of hepatitis B, a leading cause of liver cancer, is widespread.", "type": 1, "words": ["<tag1>", "It", "is", "estimated", "that", "up", "to", "90%", "of", "liver", "cancer", "patients", "will", "die", "within", "five", "years", "of", "diagnosis.", "<tag2>", "We", "have", "focused", "in", "particular", "on", "the", "Asia", "Pacific", "region", "where", "the", "incidence", "of", "hepatitis", "B,", "a", "leading", "cause", "of", "liver", "cancer,", "is", "widespread.", "<tag3>"], "wordsA": ["It", "is", "estimated", "that", "up", "to", "90%", "of", "liver", "cancer", "patients", "will", "die", "within", "five", "years", "of", "diagnosis."], "wordsB": ["We", "have", "focused", "in", "particular", "on", "the", "Asia", "Pacific", "region", "where", "the", "incidence", "of", "hepatitis", "B,", "a", "leading", "cause", "of", "liver", "cancer,", "is", "widespread."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p72_s0", "idA": "749647_11_item1_p25_s0", "sentA": "The incidence of primary liver cancer is approximately 20,000 cases per year in the United States, approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 750,000 cases per year.", "sentB": "With primary liver cancer representing a major global challenge, we have implemented a streamlined, global regulatory strategy aimed at addressing as many markets as possible, as rapidly as possible, with our HEAT study.", "type": 1, "words": ["<tag1>", "The", "incidence", "of", "primary", "liver", "cancer", "is", "approximately", "20,000", "cases", "per", "year", "in", "the", "United", "States,", "approximately", "40,000", "cases", "per", "year", "in", "Europe", "and", "is", "rapidly", "growing", "worldwide", "at", "approximately", "750,000", "cases", "per", "year.", "<tag2>", "With", "primary", "liver", "cancer", "representing", "a", "major", "global", "challenge,", "we", "have", "implemented", "a", "streamlined,", "global", "regulatory", "strategy", "aimed", "at", "addressing", "as", "many", "markets", "as", "possible,", "as", "rapidly", "as", "possible,", "with", "our", "HEAT", "study.", "<tag3>"], "wordsA": ["The", "incidence", "of", "primary", "liver", "cancer", "is", "approximately", "20,000", "cases", "per", "year", "in", "the", "United", "States,", "approximately", "40,000", "cases", "per", "year", "in", "Europe", "and", "is", "rapidly", "growing", "worldwide", "at", "approximately", "750,000", "cases", "per", "year."], "wordsB": ["With", "primary", "liver", "cancer", "representing", "a", "major", "global", "challenge,", "we", "have", "implemented", "a", "streamlined,", "global", "regulatory", "strategy", "aimed", "at", "addressing", "as", "many", "markets", "as", "possible,", "as", "rapidly", "as", "possible,", "with", "our", "HEAT", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p134_s1", "idA": "749647_11_item1_p27_s0", "sentA": "At an early stage, the standard first line treatment for liver cancer is surgical resection of the tumor, up to 80% of patients are ineligible for surgery at time of diagnosis as early stage liver cancer generally has few symptoms and when finally detected the tumor frequently is too large for surgery.", "sentB": "At the time of Mr. Church s appointment as Chief Financial Officer in July 2010, Mr. Tumminello was named the Chief Accounting Officer.", "type": 1, "words": ["<tag1>", "At", "an", "early", "stage,", "the", "standard", "first", "line", "treatment", "for", "liver", "cancer", "is", "surgical", "resection", "of", "the", "tumor,", "up", "to", "80%", "of", "patients", "are", "ineligible", "for", "surgery", "at", "time", "of", "diagnosis", "as", "early", "stage", "liver", "cancer", "generally", "has", "few", "symptoms", "and", "when", "finally", "detected", "the", "tumor", "frequently", "is", "too", "large", "for", "surgery.", "<tag2>", "At", "the", "time", "of", "Mr.", "Church", "s", "appointment", "as", "Chief", "Financial", "Officer", "in", "July", "2010,", "Mr.", "Tumminello", "was", "named", "the", "Chief", "Accounting", "Officer.", "<tag3>"], "wordsA": ["At", "an", "early", "stage,", "the", "standard", "first", "line", "treatment", "for", "liver", "cancer", "is", "surgical", "resection", "of", "the", "tumor,", "up", "to", "80%", "of", "patients", "are", "ineligible", "for", "surgery", "at", "time", "of", "diagnosis", "as", "early", "stage", "liver", "cancer", "generally", "has", "few", "symptoms", "and", "when", "finally", "detected", "the", "tumor", "frequently", "is", "too", "large", "for", "surgery."], "wordsB": ["At", "the", "time", "of", "Mr.", "Church", "s", "appointment", "as", "Chief", "Financial", "Officer", "in", "July", "2010,", "Mr.", "Tumminello", "was", "named", "the", "Chief", "Accounting", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p127_s0", "idA": "749647_11_item1_p27_s3", "sentA": "Local recurrence rates after RFA are directly correlated to the size of the tumor.", "sentB": "Dr. Borys attended Rutgers University and holds an M.D. Degree from American University of the Caribbean.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "Dr.", "Borys", "attended", "Rutgers", "University", "and", "holds", "an", "M.D.", "Degree", "from", "American", "University", "of", "the", "Caribbean.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["Dr.", "Borys", "attended", "Rutgers", "University", "and", "holds", "an", "M.D.", "Degree", "from", "American", "University", "of", "the", "Caribbean."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p26_s1", "idA": "749647_11_item1_p27_s3", "sentA": "Local recurrence rates after RFA are directly correlated to the size of the tumor.", "sentB": "The ABLATE Study is expected to enroll up to 88 patients with colorectal cancer metastasized to the liver.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "The", "ABLATE", "Study", "is", "expected", "to", "enroll", "up", "to", "88", "patients", "with", "colorectal", "cancer", "metastasized", "to", "the", "liver.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["The", "ABLATE", "Study", "is", "expected", "to", "enroll", "up", "to", "88", "patients", "with", "colorectal", "cancer", "metastasized", "to", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p43_s3", "idA": "749647_11_item1_p27_s3", "sentA": "Local recurrence rates after RFA are directly correlated to the size of the tumor.", "sentB": "No other element of the SPA were affected by this change.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p66_s1", "idA": "749647_11_item1_p27_s3", "sentA": "Local recurrence rates after RFA are directly correlated to the size of the tumor.", "sentB": "The ABLATE Study is expected to enroll up to 88 patients with colorectal cancer metastasized to the liver.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "The", "ABLATE", "Study", "is", "expected", "to", "enroll", "up", "to", "88", "patients", "with", "colorectal", "cancer", "metastasized", "to", "the", "liver.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "are", "directly", "correlated", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["The", "ABLATE", "Study", "is", "expected", "to", "enroll", "up", "to", "88", "patients", "with", "colorectal", "cancer", "metastasized", "to", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p14_s1", "idA": "749647_11_item1_p33_s1", "sentA": "The HEAT study is designed to evaluate the efficacy of ThermoDox in combination with RFA when compared to patients who receive RFA alone as the control.", "sentB": "Based on feedback and guidance received from the EMA, we expect that future results demonstrating a convincing magnitude of improvement in progression-free survival, the study's primary endpoint, along with a favorable benefit-risk ratio in the HEAT Study, would be sufficient as the primary basis for registration of ThermoDox in Europe.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control.", "<tag2>", "Based", "on", "feedback", "and", "guidance", "received", "from", "the", "EMA,", "we", "expect", "that", "future", "results", "demonstrating", "a", "convincing", "magnitude", "of", "improvement", "in", "progression-free", "survival,", "the", "study's", "primary", "endpoint,", "along", "with", "a", "favorable", "benefit-risk", "ratio", "in", "the", "HEAT", "Study,", "would", "be", "sufficient", "as", "the", "primary", "basis", "for", "registration", "of", "ThermoDox", "in", "Europe.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control."], "wordsB": ["Based", "on", "feedback", "and", "guidance", "received", "from", "the", "EMA,", "we", "expect", "that", "future", "results", "demonstrating", "a", "convincing", "magnitude", "of", "improvement", "in", "progression-free", "survival,", "the", "study's", "primary", "endpoint,", "along", "with", "a", "favorable", "benefit-risk", "ratio", "in", "the", "HEAT", "Study,", "would", "be", "sufficient", "as", "the", "primary", "basis", "for", "registration", "of", "ThermoDox", "in", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p50_s1", "idA": "749647_11_item1_p33_s1", "sentA": "The HEAT study is designed to evaluate the efficacy of ThermoDox in combination with RFA when compared to patients who receive RFA alone as the control.", "sentB": "Based on feedback and guidance received from the EMA, we expect that future results demonstrating a convincing magnitude of improvement in progression-free survival, the study's primary endpoint, along with a favorable benefit-risk ratio in the HEAT Study, would be sufficient as the primary basis for registration of ThermoDox in Europe.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control.", "<tag2>", "Based", "on", "feedback", "and", "guidance", "received", "from", "the", "EMA,", "we", "expect", "that", "future", "results", "demonstrating", "a", "convincing", "magnitude", "of", "improvement", "in", "progression-free", "survival,", "the", "study's", "primary", "endpoint,", "along", "with", "a", "favorable", "benefit-risk", "ratio", "in", "the", "HEAT", "Study,", "would", "be", "sufficient", "as", "the", "primary", "basis", "for", "registration", "of", "ThermoDox", "in", "Europe.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control."], "wordsB": ["Based", "on", "feedback", "and", "guidance", "received", "from", "the", "EMA,", "we", "expect", "that", "future", "results", "demonstrating", "a", "convincing", "magnitude", "of", "improvement", "in", "progression-free", "survival,", "the", "study's", "primary", "endpoint,", "along", "with", "a", "favorable", "benefit-risk", "ratio", "in", "the", "HEAT", "Study,", "would", "be", "sufficient", "as", "the", "primary", "basis", "for", "registration", "of", "ThermoDox", "in", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p77_s0", "idA": "749647_11_item1_p33_s1", "sentA": "The HEAT study is designed to evaluate the efficacy of ThermoDox in combination with RFA when compared to patients who receive RFA alone as the control.", "sentB": "Our clinical development team has taken great care to ensure that these studies are supportive of potential Compendia listing of ThermoDox in their respective indications.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control.", "<tag2>", "Our", "clinical", "development", "team", "has", "taken", "great", "care", "to", "ensure", "that", "these", "studies", "are", "supportive", "of", "potential", "Compendia", "listing", "of", "ThermoDox", "in", "their", "respective", "indications.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "is", "designed", "to", "evaluate", "the", "efficacy", "of", "ThermoDox", "in", "combination", "with", "RFA", "when", "compared", "to", "patients", "who", "receive", "RFA", "alone", "as", "the", "control."], "wordsB": ["Our", "clinical", "development", "team", "has", "taken", "great", "care", "to", "ensure", "that", "these", "studies", "are", "supportive", "of", "potential", "Compendia", "listing", "of", "ThermoDox", "in", "their", "respective", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p22_s1", "idA": "749647_11_item1_p33_s4", "sentA": "A pre-planned, unblinded interim efficacy analysis will be performed by an independent Data Monitoring Committee when enrollment in the HEAT study is complete and 190 PFS events are realized in the study population.", "sentB": "The target enrollment figure is designed to ensure that the study s primary end point, progression-free survival, can be achieved with adequate statistical power, and is one of two triggers for an interim efficacy analysis by the study s DMC.", "type": 1, "words": ["<tag1>", "A", "pre-planned,", "unblinded", "interim", "efficacy", "analysis", "will", "be", "performed", "by", "an", "independent", "Data", "Monitoring", "Committee", "when", "enrollment", "in", "the", "HEAT", "study", "is", "complete", "and", "190", "PFS", "events", "are", "realized", "in", "the", "study", "population.", "<tag2>", "The", "target", "enrollment", "figure", "is", "designed", "to", "ensure", "that", "the", "study", "s", "primary", "end", "point,", "progression-free", "survival,", "can", "be", "achieved", "with", "adequate", "statistical", "power,", "and", "is", "one", "of", "two", "triggers", "for", "an", "interim", "efficacy", "analysis", "by", "the", "study", "s", "DMC.", "<tag3>"], "wordsA": ["A", "pre-planned,", "unblinded", "interim", "efficacy", "analysis", "will", "be", "performed", "by", "an", "independent", "Data", "Monitoring", "Committee", "when", "enrollment", "in", "the", "HEAT", "study", "is", "complete", "and", "190", "PFS", "events", "are", "realized", "in", "the", "study", "population."], "wordsB": ["The", "target", "enrollment", "figure", "is", "designed", "to", "ensure", "that", "the", "study", "s", "primary", "end", "point,", "progression-free", "survival,", "can", "be", "achieved", "with", "adequate", "statistical", "power,", "and", "is", "one", "of", "two", "triggers", "for", "an", "interim", "efficacy", "analysis", "by", "the", "study", "s", "DMC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s8", "idA": "749647_11_item1_p37_s0", "sentA": "In August 2010, the FDA designated the HEAT Study of the Company s investigational drug, ThermoDox@, in combination with RFA, as a Fast Track Development Program.", "sentB": "Mr. Weaver has also served as a Director and Chairman of the Audit Committee of SCOLR Pharmaceuticals, a public drug delivery company from 2007 to 2009.", "type": 1, "words": ["<tag1>", "In", "August", "2010,", "the", "FDA", "designated", "the", "HEAT", "Study", "of", "the", "Company", "s", "investigational", "drug,", "ThermoDox@,", "in", "combination", "with", "RFA,", "as", "a", "Fast", "Track", "Development", "Program.", "<tag2>", "Mr.", "Weaver", "has", "also", "served", "as", "a", "Director", "and", "Chairman", "of", "the", "Audit", "Committee", "of", "SCOLR", "Pharmaceuticals,", "a", "public", "drug", "delivery", "company", "from", "2007", "to", "2009.", "<tag3>"], "wordsA": ["In", "August", "2010,", "the", "FDA", "designated", "the", "HEAT", "Study", "of", "the", "Company", "s", "investigational", "drug,", "ThermoDox@,", "in", "combination", "with", "RFA,", "as", "a", "Fast", "Track", "Development", "Program."], "wordsB": ["Mr.", "Weaver", "has", "also", "served", "as", "a", "Director", "and", "Chairman", "of", "the", "Audit", "Committee", "of", "SCOLR", "Pharmaceuticals,", "a", "public", "drug", "delivery", "company", "from", "2007", "to", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p73_s2", "idA": "749647_11_item1_p38_s2", "sentA": "This permits the FDA to review sections of the NDA in advance of receiving the complete submission.", "sentB": "Additionally, FDA has provided support for a 505(b) 2 NDA submission.", "type": 1, "words": ["<tag1>", "This", "permits", "the", "FDA", "to", "review", "sections", "of", "the", "NDA", "in", "advance", "of", "receiving", "the", "complete", "submission.", "<tag2>", "Additionally,", "FDA", "has", "provided", "support", "for", "a", "505(b)", "2", "NDA", "submission.", "<tag3>"], "wordsA": ["This", "permits", "the", "FDA", "to", "review", "sections", "of", "the", "NDA", "in", "advance", "of", "receiving", "the", "complete", "submission."], "wordsB": ["Additionally,", "FDA", "has", "provided", "support", "for", "a", "505(b)", "2", "NDA", "submission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p123_s2", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Before Mylan, from 1998 to 2005, Mr. Tardugno was Executive Vice President of Songbird Hearing, Inc.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Before", "Mylan,", "from", "1998", "to", "2005,", "Mr.", "Tardugno", "was", "Executive", "Vice", "President", "of", "Songbird", "Hearing,", "Inc.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Before", "Mylan,", "from", "1998", "to", "2005,", "Mr.", "Tardugno", "was", "Executive", "Vice", "President", "of", "Songbird", "Hearing,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p126_s2", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Prior to that he held increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Prior", "to", "that", "he", "held", "increasingly", "senior", "positions", "at", "Cytogen", "Corporation,", "Anthra", "Pharmaceuticals,", "Inc.,", "Amersham", "Healthcare,", "Inc.", "and", "Hoffmann", "La-Roche", "Inc.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Prior", "to", "that", "he", "held", "increasingly", "senior", "positions", "at", "Cytogen", "Corporation,", "Anthra", "Pharmaceuticals,", "Inc.,", "Amersham", "Healthcare,", "Inc.", "and", "Hoffmann", "La-Roche", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s0", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Mr. Weaver joined the Celsion management team as Senior Vice President and Chief Financial Officer effective July 8, 2011.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Mr.", "Weaver", "joined", "the", "Celsion", "management", "team", "as", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "effective", "July", "8,", "2011.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Mr.", "Weaver", "joined", "the", "Celsion", "management", "team", "as", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "effective", "July", "8,", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p131_s0", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Mr. Church joined Celsion on July 6, 2010 as Vice President and Chief Financial Officer until he was appointed as Senior Vice President, Corporate Strategy and Investor Relations in July 2011.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Mr.", "Church", "joined", "Celsion", "on", "July", "6,", "2010", "as", "Vice", "President", "and", "Chief", "Financial", "Officer", "until", "he", "was", "appointed", "as", "Senior", "Vice", "President,", "Corporate", "Strategy", "and", "Investor", "Relations", "in", "July", "2011.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Mr.", "Church", "joined", "Celsion", "on", "July", "6,", "2010", "as", "Vice", "President", "and", "Chief", "Financial", "Officer", "until", "he", "was", "appointed", "as", "Senior", "Vice", "President,", "Corporate", "Strategy", "and", "Investor", "Relations", "in", "July", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p131_s4", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Prior to that, he held senior financial positions at BioSpherics Corporation and Meridian Medical Technologies, both publicly traded companies.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Prior", "to", "that,", "he", "held", "senior", "financial", "positions", "at", "BioSpherics", "Corporation", "and", "Meridian", "Medical", "Technologies,", "both", "publicly", "traded", "companies.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Prior", "to", "that,", "he", "held", "senior", "financial", "positions", "at", "BioSpherics", "Corporation", "and", "Meridian", "Medical", "Technologies,", "both", "publicly", "traded", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p133_s1", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "In this position Dr. Reed oversees the CMC, QA and Technical Operations functions for Celsion.", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "In", "this", "position", "Dr.", "Reed", "oversees", "the", "CMC,", "QA", "and", "Technical", "Operations", "functions", "for", "Celsion.", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["In", "this", "position", "Dr.", "Reed", "oversees", "the", "CMC,", "QA", "and", "Technical", "Operations", "functions", "for", "Celsion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p25_s1", "idA": "749647_11_item1_p39_s0", "sentA": "We have received written guidance from the FDA stating that, assuming the results of our ongoing studies are adequate, we may submit our New Drug Application ( NDA ) for ThermoDox pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.", "sentB": "Other important feedback received from this review process were:", "type": 1, "words": ["<tag1>", "We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act.", "<tag2>", "Other", "important", "feedback", "received", "from", "this", "review", "process", "were:", "<tag3>"], "wordsA": ["We", "have", "received", "written", "guidance", "from", "the", "FDA", "stating", "that,", "assuming", "the", "results", "of", "our", "ongoing", "studies", "are", "adequate,", "we", "may", "submit", "our", "New", "Drug", "Application", "(", "NDA", ")", "for", "ThermoDox", "pursuant", "to", "Section", "505(b)(2)", "of", "the", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act."], "wordsB": ["Other", "important", "feedback", "received", "from", "this", "review", "process", "were:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p14_s2", "idA": "749647_11_item1_p41_s0", "sentA": "Breast cancer is the most common malignancy in women in both the United States and the world.", "sentB": "The EMA also supported our manufacturing strategy and technology transfer protocols, which will allow us to establish multiple manufacturing sites to support commercialization of ThermoDox outside the United States.", "type": 1, "words": ["<tag1>", "Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world.", "<tag2>", "The", "EMA", "also", "supported", "our", "manufacturing", "strategy", "and", "technology", "transfer", "protocols,", "which", "will", "allow", "us", "to", "establish", "multiple", "manufacturing", "sites", "to", "support", "commercialization", "of", "ThermoDox", "outside", "the", "United", "States.", "<tag3>"], "wordsA": ["Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world."], "wordsB": ["The", "EMA", "also", "supported", "our", "manufacturing", "strategy", "and", "technology", "transfer", "protocols,", "which", "will", "allow", "us", "to", "establish", "multiple", "manufacturing", "sites", "to", "support", "commercialization", "of", "ThermoDox", "outside", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p50_s2", "idA": "749647_11_item1_p41_s0", "sentA": "Breast cancer is the most common malignancy in women in both the United States and the world.", "sentB": "The EMA also supported our manufacturing strategy and technology transfer protocols, which will allow us to establish multiple manufacturing sites to support commercialization of ThermoDox outside the United States.", "type": 1, "words": ["<tag1>", "Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world.", "<tag2>", "The", "EMA", "also", "supported", "our", "manufacturing", "strategy", "and", "technology", "transfer", "protocols,", "which", "will", "allow", "us", "to", "establish", "multiple", "manufacturing", "sites", "to", "support", "commercialization", "of", "ThermoDox", "outside", "the", "United", "States.", "<tag3>"], "wordsA": ["Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world."], "wordsB": ["The", "EMA", "also", "supported", "our", "manufacturing", "strategy", "and", "technology", "transfer", "protocols,", "which", "will", "allow", "us", "to", "establish", "multiple", "manufacturing", "sites", "to", "support", "commercialization", "of", "ThermoDox", "outside", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p8_s0", "idA": "749647_11_item1_p42_s0", "sentA": "Despite a variety of therapeutic approaches, up to 40% of the estimated 95,000 patients in the United States undergoing a mastectomy as their primary treatment will develop locally recurrent RCW breast cancer.", "sentB": "The Celsion brand and product names, including but not limited to Celsion , contained in this document are trademarks, registered trademarks or service marks of Celsion Corporation in the United States (U.S.) and certain other countries.", "type": 1, "words": ["<tag1>", "Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer.", "<tag2>", "The", "Celsion", "brand", "and", "product", "names,", "including", "but", "not", "limited", "to", "Celsion", ",", "contained", "in", "this", "document", "are", "trademarks,", "registered", "trademarks", "or", "service", "marks", "of", "Celsion", "Corporation", "in", "the", "United", "States", "(U.S.)", "and", "certain", "other", "countries.", "<tag3>"], "wordsA": ["Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer."], "wordsB": ["The", "Celsion", "brand", "and", "product", "names,", "including", "but", "not", "limited", "to", "Celsion", ",", "contained", "in", "this", "document", "are", "trademarks,", "registered", "trademarks", "or", "service", "marks", "of", "Celsion", "Corporation", "in", "the", "United", "States", "(U.S.)", "and", "certain", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p72_s4", "idA": "749647_11_item1_p42_s1", "sentA": "There is currently no effective chemotherapeutic standard of care for RCW breast cancer and as a result, many of these patients will die within two years of the recurrence.", "sentB": "In Japan, our partner Yakult, remains enthusiastic about ThermoDox and has indicated its plans to continue evaluation of ThermoDox separately from the HEAT study, due to the different standard of care in Japan.", "type": 1, "words": ["<tag1>", "There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence.", "<tag2>", "In", "Japan,", "our", "partner", "Yakult,", "remains", "enthusiastic", "about", "ThermoDox", "and", "has", "indicated", "its", "plans", "to", "continue", "evaluation", "of", "ThermoDox", "separately", "from", "the", "HEAT", "study,", "due", "to", "the", "different", "standard", "of", "care", "in", "Japan.", "<tag3>"], "wordsA": ["There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence."], "wordsB": ["In", "Japan,", "our", "partner", "Yakult,", "remains", "enthusiastic", "about", "ThermoDox", "and", "has", "indicated", "its", "plans", "to", "continue", "evaluation", "of", "ThermoDox", "separately", "from", "the", "HEAT", "study,", "due", "to", "the", "different", "standard", "of", "care", "in", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p123_s4", "idA": "749647_11_item1_p44_s2", "sentA": "Studies at Duke University and other centers have indicated that heat may improve the therapeutic action of non-temperature sensitive liposomal doxorubicin formulations in advanced loco-regional breast cancer.", "sentB": "Mr. Tardugno holds a B.S. degree in Biology from St. Bonaventure University and completed the Harvard Business School, Program for Management Development.", "type": 1, "words": ["<tag1>", "Studies", "at", "Duke", "University", "and", "other", "centers", "have", "indicated", "that", "heat", "may", "improve", "the", "therapeutic", "action", "of", "non-temperature", "sensitive", "liposomal", "doxorubicin", "formulations", "in", "advanced", "loco-regional", "breast", "cancer.", "<tag2>", "Mr.", "Tardugno", "holds", "a", "B.S.", "degree", "in", "Biology", "from", "St.", "Bonaventure", "University", "and", "completed", "the", "Harvard", "Business", "School,", "Program", "for", "Management", "Development.", "<tag3>"], "wordsA": ["Studies", "at", "Duke", "University", "and", "other", "centers", "have", "indicated", "that", "heat", "may", "improve", "the", "therapeutic", "action", "of", "non-temperature", "sensitive", "liposomal", "doxorubicin", "formulations", "in", "advanced", "loco-regional", "breast", "cancer."], "wordsB": ["Mr.", "Tardugno", "holds", "a", "B.S.", "degree", "in", "Biology", "from", "St.", "Bonaventure", "University", "and", "completed", "the", "Harvard", "Business", "School,", "Program", "for", "Management", "Development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p125_s0", "idA": "749647_11_item1_p47_s1", "sentA": "Thus, just heating cancer cells with a microwave device for sixty minutes at 43 C has been found to be tumoricidal.", "sentB": "Dr. Borys has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology.", "type": 1, "words": ["<tag1>", "Thus,", "just", "heating", "cancer", "cells", "with", "a", "microwave", "device", "for", "sixty", "minutes", "at", "43", "C", "has", "been", "found", "to", "be", "tumoricidal.", "<tag2>", "Dr.", "Borys", "has", "accumulated", "extensive", "experience", "in", "all", "phases", "of", "pharmaceutical", "development", "with", "a", "focus", "in", "oncology.", "<tag3>"], "wordsA": ["Thus,", "just", "heating", "cancer", "cells", "with", "a", "microwave", "device", "for", "sixty", "minutes", "at", "43", "C", "has", "been", "found", "to", "be", "tumoricidal."], "wordsB": ["Dr.", "Borys", "has", "accumulated", "extensive", "experience", "in", "all", "phases", "of", "pharmaceutical", "development", "with", "a", "focus", "in", "oncology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s2", "idA": "749647_11_item1_p48_s2", "sentA": "The Company has completed enrollment of the Phase I portion (9 patients) of the study in 2010.", "sentB": "Mr. Weaver served as Poniard Pharmaceuticals Chief Financial Officer and Senior Vice President from August 2009 to August 2010.", "type": 1, "words": ["<tag1>", "The", "Company", "has", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "(9", "patients)", "of", "the", "study", "in", "2010.", "<tag2>", "Mr.", "Weaver", "served", "as", "Poniard", "Pharmaceuticals", "Chief", "Financial", "Officer", "and", "Senior", "Vice", "President", "from", "August", "2009", "to", "August", "2010.", "<tag3>"], "wordsA": ["The", "Company", "has", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "(9", "patients)", "of", "the", "study", "in", "2010."], "wordsB": ["Mr.", "Weaver", "served", "as", "Poniard", "Pharmaceuticals", "Chief", "Financial", "Officer", "and", "Senior", "Vice", "President", "from", "August", "2009", "to", "August", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p131_s1", "idA": "749647_11_item1_p48_s2", "sentA": "The Company has completed enrollment of the Phase I portion (9 patients) of the study in 2010.", "sentB": "Immediately prior to joining Celsion, Mr. Church served as Chief Financial Officer and Corporate Secretary of Alba Therapeutics Corporation, a privately held life science company from 2007 until 2010.", "type": 1, "words": ["<tag1>", "The", "Company", "has", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "(9", "patients)", "of", "the", "study", "in", "2010.", "<tag2>", "Immediately", "prior", "to", "joining", "Celsion,", "Mr.", "Church", "served", "as", "Chief", "Financial", "Officer", "and", "Corporate", "Secretary", "of", "Alba", "Therapeutics", "Corporation,", "a", "privately", "held", "life", "science", "company", "from", "2007", "until", "2010.", "<tag3>"], "wordsA": ["The", "Company", "has", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "(9", "patients)", "of", "the", "study", "in", "2010."], "wordsB": ["Immediately", "prior", "to", "joining", "Celsion,", "Mr.", "Church", "served", "as", "Chief", "Financial", "Officer", "and", "Corporate", "Secretary", "of", "Alba", "Therapeutics", "Corporation,", "a", "privately", "held", "life", "science", "company", "from", "2007", "until", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p59_s2", "idA": "749647_11_item1_p49_s0", "sentA": "Duke University is also conducting a Phase I dose escalating ThermoDox study in patients with RCW breast cancer.", "sentB": "The Dignity Study is also planned to evaluate kinetics in ThermoDox produced from more then one manufacturing site.", "type": 1, "words": ["<tag1>", "Duke", "University", "is", "also", "conducting", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer.", "<tag2>", "The", "Dignity", "Study", "is", "also", "planned", "to", "evaluate", "kinetics", "in", "ThermoDox", "produced", "from", "more", "then", "one", "manufacturing", "site.", "<tag3>"], "wordsA": ["Duke", "University", "is", "also", "conducting", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer."], "wordsB": ["The", "Dignity", "Study", "is", "also", "planned", "to", "evaluate", "kinetics", "in", "ThermoDox", "produced", "from", "more", "then", "one", "manufacturing", "site."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p63_s1", "idA": "749647_11_item1_p49_s0", "sentA": "Duke University is also conducting a Phase I dose escalating ThermoDox study in patients with RCW breast cancer.", "sentB": "Median survival of patients with colorectal liver metastases (CRLM) is 6-12 months if untreated.", "type": 1, "words": ["<tag1>", "Duke", "University", "is", "also", "conducting", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer.", "<tag2>", "Median", "survival", "of", "patients", "with", "colorectal", "liver", "metastases", "(CRLM)", "is", "6-12", "months", "if", "untreated.", "<tag3>"], "wordsA": ["Duke", "University", "is", "also", "conducting", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer."], "wordsB": ["Median", "survival", "of", "patients", "with", "colorectal", "liver", "metastases", "(CRLM)", "is", "6-12", "months", "if", "untreated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s7", "idA": "749647_11_item1_p50_s3", "sentA": "In addition, the Company has developed a third stable heat activated liposomal formulation.", "sentB": "In addition, Mr. Weaver held increasingly senior positions with Fidelity Capital in Boston and Arthur Andersen LLP.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "Company", "has", "developed", "a", "third", "stable", "heat", "activated", "liposomal", "formulation.", "<tag2>", "In", "addition,", "Mr.", "Weaver", "held", "increasingly", "senior", "positions", "with", "Fidelity", "Capital", "in", "Boston", "and", "Arthur", "Andersen", "LLP.", "<tag3>"], "wordsA": ["In", "addition,", "the", "Company", "has", "developed", "a", "third", "stable", "heat", "activated", "liposomal", "formulation."], "wordsB": ["In", "addition,", "Mr.", "Weaver", "held", "increasingly", "senior", "positions", "with", "Fidelity", "Capital", "in", "Boston", "and", "Arthur", "Andersen", "LLP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p63_s3", "idA": "749647_11_item1_p52_s0", "sentA": "An element of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications.", "sentB": "Because RFA is both efficacious and widely accepted, a rational strategy is to attempt to increase its efficacy for medium (3.1-5.0 cm) and large ( 5.0 cm) CRLM tumors with an adjuvant such as ThermoDox .", "type": 1, "words": ["<tag1>", "An", "element", "of", "our", "business", "strategy", "is", "to", "pursue,", "as", "resources", "permit,", "the", "research", "and", "development", "of", "a", "range", "of", "product", "candidates", "for", "a", "variety", "of", "indications.", "<tag2>", "Because", "RFA", "is", "both", "efficacious", "and", "widely", "accepted,", "a", "rational", "strategy", "is", "to", "attempt", "to", "increase", "its", "efficacy", "for", "medium", "(3.1-5.0", "cm)", "and", "large", "(", "5.0", "cm)", "CRLM", "tumors", "with", "an", "adjuvant", "such", "as", "ThermoDox", ".", "<tag3>"], "wordsA": ["An", "element", "of", "our", "business", "strategy", "is", "to", "pursue,", "as", "resources", "permit,", "the", "research", "and", "development", "of", "a", "range", "of", "product", "candidates", "for", "a", "variety", "of", "indications."], "wordsB": ["Because", "RFA", "is", "both", "efficacious", "and", "widely", "accepted,", "a", "rational", "strategy", "is", "to", "attempt", "to", "increase", "its", "efficacy", "for", "medium", "(3.1-5.0", "cm)", "and", "large", "(", "5.0", "cm)", "CRLM", "tumors", "with", "an", "adjuvant", "such", "as", "ThermoDox", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p64_s1", "idA": "749647_11_item1_p52_s1", "sentA": "This is intended to allow us to diversify the risks associated with our research and development expenditures.", "sentB": "Addressing these metastases allows us to improve three- and five-year survival rates among patients with this aggressive disease.", "type": 1, "words": ["<tag1>", "This", "is", "intended", "to", "allow", "us", "to", "diversify", "the", "risks", "associated", "with", "our", "research", "and", "development", "expenditures.", "<tag2>", "Addressing", "these", "metastases", "allows", "us", "to", "improve", "three-", "and", "five-year", "survival", "rates", "among", "patients", "with", "this", "aggressive", "disease.", "<tag3>"], "wordsA": ["This", "is", "intended", "to", "allow", "us", "to", "diversify", "the", "risks", "associated", "with", "our", "research", "and", "development", "expenditures."], "wordsB": ["Addressing", "these", "metastases", "allows", "us", "to", "improve", "three-", "and", "five-year", "survival", "rates", "among", "patients", "with", "this", "aggressive", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p78_s2", "idA": "749647_11_item1_p54_s2", "sentA": "These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy.", "sentB": "Furthermore, as ThermoDox represents an attractive, late-stage asset, we continue to explore partnering opportunities which would complement and advance our global commercialization strategy.", "type": 1, "words": ["<tag1>", "These", "uncertainties", "could", "force", "us", "to", "seek", "additional,", "external", "sources", "of", "financing", "from", "time", "to", "time", "in", "order", "to", "continue", "with", "our", "business", "strategy.", "<tag2>", "Furthermore,", "as", "ThermoDox", "represents", "an", "attractive,", "late-stage", "asset,", "we", "continue", "to", "explore", "partnering", "opportunities", "which", "would", "complement", "and", "advance", "our", "global", "commercialization", "strategy.", "<tag3>"], "wordsA": ["These", "uncertainties", "could", "force", "us", "to", "seek", "additional,", "external", "sources", "of", "financing", "from", "time", "to", "time", "in", "order", "to", "continue", "with", "our", "business", "strategy."], "wordsB": ["Furthermore,", "as", "ThermoDox", "represents", "an", "attractive,", "late-stage", "asset,", "we", "continue", "to", "explore", "partnering", "opportunities", "which", "would", "complement", "and", "advance", "our", "global", "commercialization", "strategy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p74_s0", "idA": "749647_11_item1_p57_s1", "sentA": "The majority of the spending in research and development is for the funding of ThermoDox clinical trials.", "sentB": "We have a comprehensive program to address the chemistry, manufacturing and controls portion of the application by working to complete three registration batches of ThermoDox , the foundation for an uninterrupted, global commercial supply at launch.", "type": 1, "words": ["<tag1>", "The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials.", "<tag2>", "We", "have", "a", "comprehensive", "program", "to", "address", "the", "chemistry,", "manufacturing", "and", "controls", "portion", "of", "the", "application", "by", "working", "to", "complete", "three", "registration", "batches", "of", "ThermoDox", ",", "the", "foundation", "for", "an", "uninterrupted,", "global", "commercial", "supply", "at", "launch.", "<tag3>"], "wordsA": ["The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials."], "wordsB": ["We", "have", "a", "comprehensive", "program", "to", "address", "the", "chemistry,", "manufacturing", "and", "controls", "portion", "of", "the", "application", "by", "working", "to", "complete", "three", "registration", "batches", "of", "ThermoDox", ",", "the", "foundation", "for", "an", "uninterrupted,", "global", "commercial", "supply", "at", "launch."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p24_s2", "idA": "749647_11_item1_p60_s0", "sentA": "Pre-clinical tests include laboratory evaluation of product chemistry, formulation and stability, as well as animal studies, to assess the potential safety and efficacy of the product.", "sentB": "Continued enrollment also has the potential to reduce the timeline of the final data read out, though we cannot guarantee such a result.", "type": 1, "words": ["<tag1>", "Pre-clinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product.", "<tag2>", "Continued", "enrollment", "also", "has", "the", "potential", "to", "reduce", "the", "timeline", "of", "the", "final", "data", "read", "out,", "though", "we", "cannot", "guarantee", "such", "a", "result.", "<tag3>"], "wordsA": ["Pre-clinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product."], "wordsB": ["Continued", "enrollment", "also", "has", "the", "potential", "to", "reduce", "the", "timeline", "of", "the", "final", "data", "read", "out,", "though", "we", "cannot", "guarantee", "such", "a", "result."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p133_s4", "idA": "749647_11_item1_p61_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "He holds a Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill and was the recipient of a 3 year NIH Postdoctoral Individual Award at Princeton University.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "He", "holds", "a", "Ph.D.", "in", "Analytical", "Chemistry", "from", "The", "University", "of", "North", "Carolina", "at", "Chapel", "Hill", "and", "was", "the", "recipient", "of", "a", "3", "year", "NIH", "Postdoctoral", "Individual", "Award", "at", "Princeton", "University.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["He", "holds", "a", "Ph.D.", "in", "Analytical", "Chemistry", "from", "The", "University", "of", "North", "Carolina", "at", "Chapel", "Hill", "and", "was", "the", "recipient", "of", "a", "3", "year", "NIH", "Postdoctoral", "Individual", "Award", "at", "Princeton", "University."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p124_s1", "idA": "749647_11_item1_p61_s3", "sentA": "An IRB will consider, among other things, ethical factors, and the safety of human subjects and the possible liability of the institution conducting the clinical trials.", "sentB": "In this position, Dr. Borys manages the clinical development program for Celsion.", "type": 1, "words": ["<tag1>", "An", "IRB", "will", "consider,", "among", "other", "things,", "ethical", "factors,", "and", "the", "safety", "of", "human", "subjects", "and", "the", "possible", "liability", "of", "the", "institution", "conducting", "the", "clinical", "trials.", "<tag2>", "In", "this", "position,", "Dr.", "Borys", "manages", "the", "clinical", "development", "program", "for", "Celsion.", "<tag3>"], "wordsA": ["An", "IRB", "will", "consider,", "among", "other", "things,", "ethical", "factors,", "and", "the", "safety", "of", "human", "subjects", "and", "the", "possible", "liability", "of", "the", "institution", "conducting", "the", "clinical", "trials."], "wordsB": ["In", "this", "position,", "Dr.", "Borys", "manages", "the", "clinical", "development", "program", "for", "Celsion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p76_s0", "idA": "749647_11_item1_p63_s1", "sentA": "Phase II trials are generally larger trials conducted in the target population.", "sentB": "Bone cancers, the subject of a planned Phase II study with joint research partner Philips Healthcare.", "type": 1, "words": ["<tag1>", "Phase", "II", "trials", "are", "generally", "larger", "trials", "conducted", "in", "the", "target", "population.", "<tag2>", "Bone", "cancers,", "the", "subject", "of", "a", "planned", "Phase", "II", "study", "with", "joint", "research", "partner", "Philips", "Healthcare.", "<tag3>"], "wordsA": ["Phase", "II", "trials", "are", "generally", "larger", "trials", "conducted", "in", "the", "target", "population."], "wordsB": ["Bone", "cancers,", "the", "subject", "of", "a", "planned", "Phase", "II", "study", "with", "joint", "research", "partner", "Philips", "Healthcare."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p59_s1", "idA": "749647_11_item1_p65_s0", "sentA": "When a drug or biological compound has shown evidence of efficacy and an acceptable safety profile in Phase II evaluations, Phase III clinical trials are undertaken to serve as the pivotal trials to demonstrate clinical efficacy and safety in an expanded patient population.", "sentB": "The Dignity Study is designed to establish a safe therapeutic dose in Phase I, and in Phase II to demonstrate local control, including complete and partial responses, and stable disease as its primary endpoint.", "type": 1, "words": ["<tag1>", "When", "a", "drug", "or", "biological", "compound", "has", "shown", "evidence", "of", "efficacy", "and", "an", "acceptable", "safety", "profile", "in", "Phase", "II", "evaluations,", "Phase", "III", "clinical", "trials", "are", "undertaken", "to", "serve", "as", "the", "pivotal", "trials", "to", "demonstrate", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population.", "<tag2>", "The", "Dignity", "Study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint.", "<tag3>"], "wordsA": ["When", "a", "drug", "or", "biological", "compound", "has", "shown", "evidence", "of", "efficacy", "and", "an", "acceptable", "safety", "profile", "in", "Phase", "II", "evaluations,", "Phase", "III", "clinical", "trials", "are", "undertaken", "to", "serve", "as", "the", "pivotal", "trials", "to", "demonstrate", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population."], "wordsB": ["The", "Dignity", "Study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p8_s1", "idA": "749647_11_item1_p77_s0", "sentA": "Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic products.", "sentB": "This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.", "type": 1, "words": ["<tag1>", "Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products.", "<tag2>", "This", "document", "also", "contains", "references", "to", "trademarks", "and", "service", "marks", "of", "other", "companies", "that", "are", "the", "property", "of", "their", "respective", "owners.", "<tag3>"], "wordsA": ["Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products."], "wordsB": ["This", "document", "also", "contains", "references", "to", "trademarks", "and", "service", "marks", "of", "other", "companies", "that", "are", "the", "property", "of", "their", "respective", "owners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p133_s3", "idA": "749647_11_item1_p78_s0", "sentA": "Competition in the discovery and development of new methods for treating and preventing disease is intense.", "sentB": "Prior to joining Celsion, Dr. Reed was Vice President, Pharmaceutical Operations at XenoPort, Inc., has 20+ years of experience responsibility across XenoPort, Inc, 2006 to 2009, Merck Company, Inc., 1993 to 2005, and The Liposome Company, Inc., 1990 to 1993, with extensive scientific and regulatory experience in the design and development of pharmaceutical products.", "type": 1, "words": ["<tag1>", "Competition", "in", "the", "discovery", "and", "development", "of", "new", "methods", "for", "treating", "and", "preventing", "disease", "is", "intense.", "<tag2>", "Prior", "to", "joining", "Celsion,", "Dr.", "Reed", "was", "Vice", "President,", "Pharmaceutical", "Operations", "at", "XenoPort,", "Inc.,", "has", "20+", "years", "of", "experience", "responsibility", "across", "XenoPort,", "Inc,", "2006", "to", "2009,", "Merck", "Company,", "Inc.,", "1993", "to", "2005,", "and", "The", "Liposome", "Company,", "Inc.,", "1990", "to", "1993,", "with", "extensive", "scientific", "and", "regulatory", "experience", "in", "the", "design", "and", "development", "of", "pharmaceutical", "products.", "<tag3>"], "wordsA": ["Competition", "in", "the", "discovery", "and", "development", "of", "new", "methods", "for", "treating", "and", "preventing", "disease", "is", "intense."], "wordsB": ["Prior", "to", "joining", "Celsion,", "Dr.", "Reed", "was", "Vice", "President,", "Pharmaceutical", "Operations", "at", "XenoPort,", "Inc.,", "has", "20+", "years", "of", "experience", "responsibility", "across", "XenoPort,", "Inc,", "2006", "to", "2009,", "Merck", "Company,", "Inc.,", "1993", "to", "2005,", "and", "The", "Liposome", "Company,", "Inc.,", "1990", "to", "1993,", "with", "extensive", "scientific", "and", "regulatory", "experience", "in", "the", "design", "and", "development", "of", "pharmaceutical", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p75_s2", "idA": "749647_11_item1_p78_s1", "sentA": "We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad.", "sentB": "We continue to move forward with planning and execution of additional studies where ThermoDox has demonstrated potential for significant benefit, including:", "type": 1, "words": ["<tag1>", "We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad.", "<tag2>", "We", "continue", "to", "move", "forward", "with", "planning", "and", "execution", "of", "additional", "studies", "where", "ThermoDox", "has", "demonstrated", "potential", "for", "significant", "benefit,", "including:", "<tag3>"], "wordsA": ["We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad."], "wordsB": ["We", "continue", "to", "move", "forward", "with", "planning", "and", "execution", "of", "additional", "studies", "where", "ThermoDox", "has", "demonstrated", "potential", "for", "significant", "benefit,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p123_s3", "idA": "749647_11_item1_p78_s2", "sentA": "We face significant competition from organizations pursuing the same or similar technologies used by us in our drug discovery efforts and from organizations developing pharmaceuticals that are competitive with our product candidates.", "sentB": "From 1996 to 1998, he was Senior Vice President of Technical Operations for Bristol-Myers Squibb, and from 1977 to 1995, he held increasingly senior executive positions with Bausch Lomb and Abbott Laboratories.", "type": 1, "words": ["<tag1>", "We", "face", "significant", "competition", "from", "organizations", "pursuing", "the", "same", "or", "similar", "technologies", "used", "by", "us", "in", "our", "drug", "discovery", "efforts", "and", "from", "organizations", "developing", "pharmaceuticals", "that", "are", "competitive", "with", "our", "product", "candidates.", "<tag2>", "From", "1996", "to", "1998,", "he", "was", "Senior", "Vice", "President", "of", "Technical", "Operations", "for", "Bristol-Myers", "Squibb,", "and", "from", "1977", "to", "1995,", "he", "held", "increasingly", "senior", "executive", "positions", "with", "Bausch", "Lomb", "and", "Abbott", "Laboratories.", "<tag3>"], "wordsA": ["We", "face", "significant", "competition", "from", "organizations", "pursuing", "the", "same", "or", "similar", "technologies", "used", "by", "us", "in", "our", "drug", "discovery", "efforts", "and", "from", "organizations", "developing", "pharmaceuticals", "that", "are", "competitive", "with", "our", "product", "candidates."], "wordsB": ["From", "1996", "to", "1998,", "he", "was", "Senior", "Vice", "President", "of", "Technical", "Operations", "for", "Bristol-Myers", "Squibb,", "and", "from", "1977", "to", "1995,", "he", "held", "increasingly", "senior", "executive", "positions", "with", "Bausch", "Lomb", "and", "Abbott", "Laboratories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p131_s3", "idA": "749647_11_item1_p80_s2", "sentA": "Our ability to compete successfully with other companies in the pharmaceutical and biotechnology field also depends on the status of our collaborations and on the continuing availability of capital to us.", "sentB": "From 1998 until 2006, he served as Vice President, CFO and Corporate Secretary for GenVec, Inc., a publicly traded life science and biotechnology company.", "type": 1, "words": ["<tag1>", "Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us.", "<tag2>", "From", "1998", "until", "2006,", "he", "served", "as", "Vice", "President,", "CFO", "and", "Corporate", "Secretary", "for", "GenVec,", "Inc.,", "a", "publicly", "traded", "life", "science", "and", "biotechnology", "company.", "<tag3>"], "wordsA": ["Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us."], "wordsB": ["From", "1998", "until", "2006,", "he", "served", "as", "Vice", "President,", "CFO", "and", "Corporate", "Secretary", "for", "GenVec,", "Inc.,", "a", "publicly", "traded", "life", "science", "and", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p123_s1", "idA": "749647_11_item1_p81_s0", "sentA": "Although there are many drugs and devices marketed and under development for the treatment of cancer, the Company is not aware of any other heat activated drug delivery product either being marketed or in human clinical development.", "sentB": "Prior to joining the Company and for the period from February 2005 to December 2006, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies, Inc., a subsidiary of Mylan Laboratories.", "type": 1, "words": ["<tag1>", "Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development.", "<tag2>", "Prior", "to", "joining", "the", "Company", "and", "for", "the", "period", "from", "February", "2005", "to", "December", "2006,", "Mr.", "Tardugno", "served", "as", "Senior", "Vice", "President", "and", "General", "Manager", "of", "Mylan", "Technologies,", "Inc.,", "a", "subsidiary", "of", "Mylan", "Laboratories.", "<tag3>"], "wordsA": ["Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development."], "wordsB": ["Prior", "to", "joining", "the", "Company", "and", "for", "the", "period", "from", "February", "2005", "to", "December", "2006,", "Mr.", "Tardugno", "served", "as", "Senior", "Vice", "President", "and", "General", "Manager", "of", "Mylan", "Technologies,", "Inc.,", "a", "subsidiary", "of", "Mylan", "Laboratories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s5", "idA": "749647_11_item1_p81_s0", "sentA": "Although there are many drugs and devices marketed and under development for the treatment of cancer, the Company is not aware of any other heat activated drug delivery product either being marketed or in human clinical development.", "sentB": "From 2002 to 2005, Mr. Weaver was Chief Financial Officer of Nastech Pharmaceuticals, a public drug delivery company.", "type": 1, "words": ["<tag1>", "Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development.", "<tag2>", "From", "2002", "to", "2005,", "Mr.", "Weaver", "was", "Chief", "Financial", "Officer", "of", "Nastech", "Pharmaceuticals,", "a", "public", "drug", "delivery", "company.", "<tag3>"], "wordsA": ["Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development."], "wordsB": ["From", "2002", "to", "2005,", "Mr.", "Weaver", "was", "Chief", "Financial", "Officer", "of", "Nastech", "Pharmaceuticals,", "a", "public", "drug", "delivery", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p132_s0", "idA": "749647_11_item1_p86_s2", "sentA": "The European application can result in coverage in the European Community.", "sentB": "He started his career in the Baltimore office of Price Waterhouse from 1979 until 1986.", "type": 1, "words": ["<tag1>", "The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community.", "<tag2>", "He", "started", "his", "career", "in", "the", "Baltimore", "office", "of", "Price", "Waterhouse", "from", "1979", "until", "1986.", "<tag3>"], "wordsA": ["The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community."], "wordsB": ["He", "started", "his", "career", "in", "the", "Baltimore", "office", "of", "Price", "Waterhouse", "from", "1979", "until", "1986."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p134_s3", "idA": "749647_11_item1_p86_s2", "sentA": "The European application can result in coverage in the European Community.", "sentB": "Mr. Tumminello was employed in the Baltimore office of Deloitte Touche LLP from 1991 until 1997.", "type": 1, "words": ["<tag1>", "The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community.", "<tag2>", "Mr.", "Tumminello", "was", "employed", "in", "the", "Baltimore", "office", "of", "Deloitte", "Touche", "LLP", "from", "1991", "until", "1997.", "<tag3>"], "wordsA": ["The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community."], "wordsB": ["Mr.", "Tumminello", "was", "employed", "in", "the", "Baltimore", "office", "of", "Deloitte", "Touche", "LLP", "from", "1991", "until", "1997."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p72_s2", "idA": "749647_11_item1_p86_s2", "sentA": "The European application can result in coverage in the European Community.", "sentB": "The HEAT Study has already reached sufficient local enrollment to support registration filings in two important markets in the Asia-Pacific region, South Korea and Taiwan.", "type": 1, "words": ["<tag1>", "The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community.", "<tag2>", "The", "HEAT", "Study", "has", "already", "reached", "sufficient", "local", "enrollment", "to", "support", "registration", "filings", "in", "two", "important", "markets", "in", "the", "Asia-Pacific", "region,", "South", "Korea", "and", "Taiwan.", "<tag3>"], "wordsA": ["The", "European", "application", "can", "result", "in", "coverage", "in", "the", "European", "Community."], "wordsB": ["The", "HEAT", "Study", "has", "already", "reached", "sufficient", "local", "enrollment", "to", "support", "registration", "filings", "in", "two", "important", "markets", "in", "the", "Asia-Pacific", "region,", "South", "Korea", "and", "Taiwan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p120_s0", "idA": "749647_11_item1_p89_s0", "sentA": "As of March 15, 2011, we employed 16 full-time employees.", "sentB": "The following table sets forth the names, ages and positions of our executive officers as of March 14, 2012:", "type": 1, "words": ["<tag1>", "As", "of", "March", "15,", "2011,", "we", "employed", "16", "full-time", "employees.", "<tag2>", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "March", "14,", "2012:", "<tag3>"], "wordsA": ["As", "of", "March", "15,", "2011,", "we", "employed", "16", "full-time", "employees."], "wordsB": ["The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "March", "14,", "2012:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s3", "idA": "749647_11_item1_p8_s0", "sentA": "Celsion Corporation is an innovative oncology drug development company focused on the development of therapeutics for those suffering with difficult to treat forms of cancer.", "sentB": "Prior to joining Poniard, a public oncology drug development company, Mr. Weaver served as Chief Financial Officer of Talyst, Inc., a privately-held pharmacy information product company, from 2007 to 2008.", "type": 1, "words": ["<tag1>", "Celsion", "Corporation", "is", "an", "innovative", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "therapeutics", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer.", "<tag2>", "Prior", "to", "joining", "Poniard,", "a", "public", "oncology", "drug", "development", "company,", "Mr.", "Weaver", "served", "as", "Chief", "Financial", "Officer", "of", "Talyst,", "Inc.,", "a", "privately-held", "pharmacy", "information", "product", "company,", "from", "2007", "to", "2008.", "<tag3>"], "wordsA": ["Celsion", "Corporation", "is", "an", "innovative", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "therapeutics", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer."], "wordsB": ["Prior", "to", "joining", "Poniard,", "a", "public", "oncology", "drug", "development", "company,", "Mr.", "Weaver", "served", "as", "Chief", "Financial", "Officer", "of", "Talyst,", "Inc.,", "a", "privately-held", "pharmacy", "information", "product", "company,", "from", "2007", "to", "2008."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p131_s2", "idA": "749647_11_item1_p8_s0", "sentA": "Celsion Corporation is an innovative oncology drug development company focused on the development of therapeutics for those suffering with difficult to treat forms of cancer.", "sentB": "From 2006 until 2007, he served as Vice President, CFO and Corporate Secretary for Novavax, Inc., a publicly traded vaccine development company.", "type": 1, "words": ["<tag1>", "Celsion", "Corporation", "is", "an", "innovative", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "therapeutics", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer.", "<tag2>", "From", "2006", "until", "2007,", "he", "served", "as", "Vice", "President,", "CFO", "and", "Corporate", "Secretary", "for", "Novavax,", "Inc.,", "a", "publicly", "traded", "vaccine", "development", "company.", "<tag3>"], "wordsA": ["Celsion", "Corporation", "is", "an", "innovative", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "therapeutics", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer."], "wordsB": ["From", "2006", "until", "2007,", "he", "served", "as", "Vice", "President,", "CFO", "and", "Corporate", "Secretary", "for", "Novavax,", "Inc.,", "a", "publicly", "traded", "vaccine", "development", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p129_s0", "idA": "749647_11_item1_p90_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "Mr. Weaver is a certified public accountant and received his MBA from Boston College and his B.S. in accounting from Trinity University.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "Mr.", "Weaver", "is", "a", "certified", "public", "accountant", "and", "received", "his", "MBA", "from", "Boston", "College", "and", "his", "B.S.", "in", "accounting", "from", "Trinity", "University.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["Mr.", "Weaver", "is", "a", "certified", "public", "accountant", "and", "received", "his", "MBA", "from", "Boston", "College", "and", "his", "B.S.", "in", "accounting", "from", "Trinity", "University."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p63_s2", "idA": "749647_11_item1_p90_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "While hepatic resection is potentially curative, most CRLM patients are inoperable and therefore radiofrequency ablation (RFA) is a commonly used local treatment modality.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "While", "hepatic", "resection", "is", "potentially", "curative,", "most", "CRLM", "patients", "are", "inoperable", "and", "therefore", "radiofrequency", "ablation", "(RFA)", "is", "a", "commonly", "used", "local", "treatment", "modality.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["While", "hepatic", "resection", "is", "potentially", "curative,", "most", "CRLM", "patients", "are", "inoperable", "and", "therefore", "radiofrequency", "ablation", "(RFA)", "is", "a", "commonly", "used", "local", "treatment", "modality."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p64_s0", "idA": "749647_11_item1_p90_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "The liver is a common site of metastases for cancers of the colon and rectum, as it provides a favorable environment for their growth and proliferation.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "The", "liver", "is", "a", "common", "site", "of", "metastases", "for", "cancers", "of", "the", "colon", "and", "rectum,", "as", "it", "provides", "a", "favorable", "environment", "for", "their", "growth", "and", "proliferation.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["The", "liver", "is", "a", "common", "site", "of", "metastases", "for", "cancers", "of", "the", "colon", "and", "rectum,", "as", "it", "provides", "a", "favorable", "environment", "for", "their", "growth", "and", "proliferation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p65_s1", "idA": "749647_11_item1_p90_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "Adding ThermoDox to RFA as adjuvant therapy is a combination which has demonstrated early clinical promise in treating larger tumors and multifocal disease.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "Adding", "ThermoDox", "to", "RFA", "as", "adjuvant", "therapy", "is", "a", "combination", "which", "has", "demonstrated", "early", "clinical", "promise", "in", "treating", "larger", "tumors", "and", "multifocal", "disease.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["Adding", "ThermoDox", "to", "RFA", "as", "adjuvant", "therapy", "is", "a", "combination", "which", "has", "demonstrated", "early", "clinical", "promise", "in", "treating", "larger", "tumors", "and", "multifocal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p126_s0", "idA": "749647_11_item1_p92_s1", "sentA": "On January 11, 2011, the Company entered into an amendment to the Yakult Agreement (the Amendment ) that provides for (i) a payment by Yakult to the Company of $2 million that the Company received on January 12, 2011 in consideration of a partial reduction in the Approval Milestone, and (ii) if and when the DMC permits the resumption of patient enrollment in Japan for pivotal Phase III clinical study for ThermoDox , a payment by Yakult to the Company of an additional $2 million in consideration of an additional, partial reduction in the Approval Milestone.", "sentB": "Immediately prior to joining Celsion, Dr. Borys served as Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc., a molecular imaging and nuclear oncology pharmaceutical start-up company, from 2004 until 2007.", "type": 1, "words": ["<tag1>", "On", "January", "11,", "2011,", "the", "Company", "entered", "into", "an", "amendment", "to", "the", "Yakult", "Agreement", "(the", "Amendment", ")", "that", "provides", "for", "(i)", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "$2", "million", "that", "the", "Company", "received", "on", "January", "12,", "2011", "in", "consideration", "of", "a", "partial", "reduction", "in", "the", "Approval", "Milestone,", "and", "(ii)", "if", "and", "when", "the", "DMC", "permits", "the", "resumption", "of", "patient", "enrollment", "in", "Japan", "for", "pivotal", "Phase", "III", "clinical", "study", "for", "ThermoDox", ",", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "an", "additional", "$2", "million", "in", "consideration", "of", "an", "additional,", "partial", "reduction", "in", "the", "Approval", "Milestone.", "<tag2>", "Immediately", "prior", "to", "joining", "Celsion,", "Dr.", "Borys", "served", "as", "Chief", "Medical", "Officer", "of", "Molecular", "Insight", "Pharmaceuticals,", "Inc.,", "a", "molecular", "imaging", "and", "nuclear", "oncology", "pharmaceutical", "start-up", "company,", "from", "2004", "until", "2007.", "<tag3>"], "wordsA": ["On", "January", "11,", "2011,", "the", "Company", "entered", "into", "an", "amendment", "to", "the", "Yakult", "Agreement", "(the", "Amendment", ")", "that", "provides", "for", "(i)", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "$2", "million", "that", "the", "Company", "received", "on", "January", "12,", "2011", "in", "consideration", "of", "a", "partial", "reduction", "in", "the", "Approval", "Milestone,", "and", "(ii)", "if", "and", "when", "the", "DMC", "permits", "the", "resumption", "of", "patient", "enrollment", "in", "Japan", "for", "pivotal", "Phase", "III", "clinical", "study", "for", "ThermoDox", ",", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "an", "additional", "$2", "million", "in", "consideration", "of", "an", "additional,", "partial", "reduction", "in", "the", "Approval", "Milestone."], "wordsB": ["Immediately", "prior", "to", "joining", "Celsion,", "Dr.", "Borys", "served", "as", "Chief", "Medical", "Officer", "of", "Molecular", "Insight", "Pharmaceuticals,", "Inc.,", "a", "molecular", "imaging", "and", "nuclear", "oncology", "pharmaceutical", "start-up", "company,", "from", "2004", "until", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p134_s2", "idA": "749647_11_item1_p92_s1", "sentA": "On January 11, 2011, the Company entered into an amendment to the Yakult Agreement (the Amendment ) that provides for (i) a payment by Yakult to the Company of $2 million that the Company received on January 12, 2011 in consideration of a partial reduction in the Approval Milestone, and (ii) if and when the DMC permits the resumption of patient enrollment in Japan for pivotal Phase III clinical study for ThermoDox , a payment by Yakult to the Company of an additional $2 million in consideration of an additional, partial reduction in the Approval Milestone.", "sentB": "Prior to Celsion, Mr. Tumminello was employed by IC Isaacs Company, Inc., a publicly traded company, from 1997 to 2009 and held various positions during his tenure that included serving as Vice President, Controller and Principal Financial Officer.", "type": 1, "words": ["<tag1>", "On", "January", "11,", "2011,", "the", "Company", "entered", "into", "an", "amendment", "to", "the", "Yakult", "Agreement", "(the", "Amendment", ")", "that", "provides", "for", "(i)", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "$2", "million", "that", "the", "Company", "received", "on", "January", "12,", "2011", "in", "consideration", "of", "a", "partial", "reduction", "in", "the", "Approval", "Milestone,", "and", "(ii)", "if", "and", "when", "the", "DMC", "permits", "the", "resumption", "of", "patient", "enrollment", "in", "Japan", "for", "pivotal", "Phase", "III", "clinical", "study", "for", "ThermoDox", ",", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "an", "additional", "$2", "million", "in", "consideration", "of", "an", "additional,", "partial", "reduction", "in", "the", "Approval", "Milestone.", "<tag2>", "Prior", "to", "Celsion,", "Mr.", "Tumminello", "was", "employed", "by", "IC", "Isaacs", "Company,", "Inc.,", "a", "publicly", "traded", "company,", "from", "1997", "to", "2009", "and", "held", "various", "positions", "during", "his", "tenure", "that", "included", "serving", "as", "Vice", "President,", "Controller", "and", "Principal", "Financial", "Officer.", "<tag3>"], "wordsA": ["On", "January", "11,", "2011,", "the", "Company", "entered", "into", "an", "amendment", "to", "the", "Yakult", "Agreement", "(the", "Amendment", ")", "that", "provides", "for", "(i)", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "$2", "million", "that", "the", "Company", "received", "on", "January", "12,", "2011", "in", "consideration", "of", "a", "partial", "reduction", "in", "the", "Approval", "Milestone,", "and", "(ii)", "if", "and", "when", "the", "DMC", "permits", "the", "resumption", "of", "patient", "enrollment", "in", "Japan", "for", "pivotal", "Phase", "III", "clinical", "study", "for", "ThermoDox", ",", "a", "payment", "by", "Yakult", "to", "the", "Company", "of", "an", "additional", "$2", "million", "in", "consideration", "of", "an", "additional,", "partial", "reduction", "in", "the", "Approval", "Milestone."], "wordsB": ["Prior", "to", "Celsion,", "Mr.", "Tumminello", "was", "employed", "by", "IC", "Isaacs", "Company,", "Inc.,", "a", "publicly", "traded", "company,", "from", "1997", "to", "2009", "and", "held", "various", "positions", "during", "his", "tenure", "that", "included", "serving", "as", "Vice", "President,", "Controller", "and", "Principal", "Financial", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_12_item1_p128_s4", "idA": "749647_11_item1_p98_s0", "sentA": "Concurrent with the issuance and sale of the Units, the Company issued a warrant (the Placement Agent Warrant ) to purchase up to 350 shares of Preferred Stock at an exercise price of $1,000 per whole share of Preferred Stock to Dominick Dominick LLC, as placement agent.", "sentB": "Prior to that, he served as Senior Vice President and Chief Financial Officer of Sirna Therapeutics, a public RNAI therapeutics company until the sale of the company to Merck, Inc. in 2006.", "type": 1, "words": ["<tag1>", "Concurrent", "with", "the", "issuance", "and", "sale", "of", "the", "Units,", "the", "Company", "issued", "a", "warrant", "(the", "Placement", "Agent", "Warrant", ")", "to", "purchase", "up", "to", "350", "shares", "of", "Preferred", "Stock", "at", "an", "exercise", "price", "of", "$1,000", "per", "whole", "share", "of", "Preferred", "Stock", "to", "Dominick", "Dominick", "LLC,", "as", "placement", "agent.", "<tag2>", "Prior", "to", "that,", "he", "served", "as", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "of", "Sirna", "Therapeutics,", "a", "public", "RNAI", "therapeutics", "company", "until", "the", "sale", "of", "the", "company", "to", "Merck,", "Inc.", "in", "2006.", "<tag3>"], "wordsA": ["Concurrent", "with", "the", "issuance", "and", "sale", "of", "the", "Units,", "the", "Company", "issued", "a", "warrant", "(the", "Placement", "Agent", "Warrant", ")", "to", "purchase", "up", "to", "350", "shares", "of", "Preferred", "Stock", "at", "an", "exercise", "price", "of", "$1,000", "per", "whole", "share", "of", "Preferred", "Stock", "to", "Dominick", "Dominick", "LLC,", "as", "placement", "agent."], "wordsB": ["Prior", "to", "that,", "he", "served", "as", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "of", "Sirna", "Therapeutics,", "a", "public", "RNAI", "therapeutics", "company", "until", "the", "sale", "of", "the", "company", "to", "Merck,", "Inc.", "in", "2006."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p43_s0", "idA": "749647_12_item1_p100_s0", "sentA": "Competition in the discovery and development of new methods for treating and preventing disease is intense.", "sentB": "On January 18, 2013, we broadened our relationship with Hisun by entering into a technology development contract, pursuant to which Hisun paid us a non-refundable research and development fee of $5.0 million to support our development of ThermoDox and we will provide research data and other technical support in relation to a regulatory filing by Hisun with the SFDA for approval of ThermoDox for manufacturing and sale in the China territory.", "type": 1, "words": ["<tag1>", "Competition", "in", "the", "discovery", "and", "development", "of", "new", "methods", "for", "treating", "and", "preventing", "disease", "is", "intense.", "<tag2>", "On", "January", "18,", "2013,", "we", "broadened", "our", "relationship", "with", "Hisun", "by", "entering", "into", "a", "technology", "development", "contract,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5.0", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "with", "the", "SFDA", "for", "approval", "of", "ThermoDox", "for", "manufacturing", "and", "sale", "in", "the", "China", "territory.", "<tag3>"], "wordsA": ["Competition", "in", "the", "discovery", "and", "development", "of", "new", "methods", "for", "treating", "and", "preventing", "disease", "is", "intense."], "wordsB": ["On", "January", "18,", "2013,", "we", "broadened", "our", "relationship", "with", "Hisun", "by", "entering", "into", "a", "technology", "development", "contract,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5.0", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "with", "the", "SFDA", "for", "approval", "of", "ThermoDox", "for", "manufacturing", "and", "sale", "in", "the", "China", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p104_s2", "idA": "749647_12_item1_p100_s1", "sentA": "We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad.", "sentB": "Celsion's newly issued patents pertain specifically to methods of storing stabilized, temperature-sensitive liposomal formulations and will assist in the protection of global rights.", "type": 1, "words": ["<tag1>", "We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad.", "<tag2>", "Celsion's", "newly", "issued", "patents", "pertain", "specifically", "to", "methods", "of", "storing", "stabilized,", "temperature-sensitive", "liposomal", "formulations", "and", "will", "assist", "in", "the", "protection", "of", "global", "rights.", "<tag3>"], "wordsA": ["We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad."], "wordsB": ["Celsion's", "newly", "issued", "patents", "pertain", "specifically", "to", "methods", "of", "storing", "stabilized,", "temperature-sensitive", "liposomal", "formulations", "and", "will", "assist", "in", "the", "protection", "of", "global", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p115_s2", "idA": "749647_12_item1_p100_s1", "sentA": "We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad.", "sentB": "The warrants are immediately exercisable for cash or by net exercise and will expire seven years after their issuance.", "type": 1, "words": ["<tag1>", "We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad.", "<tag2>", "The", "warrants", "are", "immediately", "exercisable", "for", "cash", "or", "by", "net", "exercise", "and", "will", "expire", "seven", "years", "after", "their", "issuance.", "<tag3>"], "wordsA": ["We", "face,", "and", "will", "continue", "to", "face,", "intense", "competition", "from", "pharmaceutical", "and", "biotechnology", "companies,", "as", "well", "as", "academic", "and", "research", "institutions", "and", "government", "agencies", "both", "in", "the", "U.S.", "and", "abroad."], "wordsB": ["The", "warrants", "are", "immediately", "exercisable", "for", "cash", "or", "by", "net", "exercise", "and", "will", "expire", "seven", "years", "after", "their", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p114_s1", "idA": "749647_12_item1_p103_s0", "sentA": "Although there are many drugs and devices marketed and under development for the treatment of cancer, the Company is not aware of any other heat activated drug delivery product either being marketed or in human clinical development.", "sentB": "For an initial period extending for the Term A Loan through May 1, 2013, the Company is only required to make interest payments, after which the Company is required to make consecutive equal monthly payments of principle and interest to each lender as calculated pursuant to the Credit Agreement.", "type": 1, "words": ["<tag1>", "Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development.", "<tag2>", "For", "an", "initial", "period", "extending", "for", "the", "Term", "A", "Loan", "through", "May", "1,", "2013,", "the", "Company", "is", "only", "required", "to", "make", "interest", "payments,", "after", "which", "the", "Company", "is", "required", "to", "make", "consecutive", "equal", "monthly", "payments", "of", "principle", "and", "interest", "to", "each", "lender", "as", "calculated", "pursuant", "to", "the", "Credit", "Agreement.", "<tag3>"], "wordsA": ["Although", "there", "are", "many", "drugs", "and", "devices", "marketed", "and", "under", "development", "for", "the", "treatment", "of", "cancer,", "the", "Company", "is", "not", "aware", "of", "any", "other", "heat", "activated", "drug", "delivery", "product", "either", "being", "marketed", "or", "in", "human", "clinical", "development."], "wordsB": ["For", "an", "initial", "period", "extending", "for", "the", "Term", "A", "Loan", "through", "May", "1,", "2013,", "the", "Company", "is", "only", "required", "to", "make", "interest", "payments,", "after", "which", "the", "Company", "is", "required", "to", "make", "consecutive", "equal", "monthly", "payments", "of", "principle", "and", "interest", "to", "each", "lender", "as", "calculated", "pursuant", "to", "the", "Credit", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p118_s3", "idA": "749647_12_item1_p104_s0", "sentA": "In 1999, the Company entered into a license agreement with Duke University under which the we received exclusive rights (subject to certain exceptions) to commercialize and use Duke s thermo-liposome technology.", "sentB": "The exclusive option agreement contemplated payments of an upfront license fee, milestone payments and royalties to us if the exclusive license agreement were entered into.", "type": 1, "words": ["<tag1>", "In", "1999,", "the", "Company", "entered", "into", "a", "license", "agreement", "with", "Duke", "University", "under", "which", "the", "we", "received", "exclusive", "rights", "(subject", "to", "certain", "exceptions)", "to", "commercialize", "and", "use", "Duke", "s", "thermo-liposome", "technology.", "<tag2>", "The", "exclusive", "option", "agreement", "contemplated", "payments", "of", "an", "upfront", "license", "fee,", "milestone", "payments", "and", "royalties", "to", "us", "if", "the", "exclusive", "license", "agreement", "were", "entered", "into.", "<tag3>"], "wordsA": ["In", "1999,", "the", "Company", "entered", "into", "a", "license", "agreement", "with", "Duke", "University", "under", "which", "the", "we", "received", "exclusive", "rights", "(subject", "to", "certain", "exceptions)", "to", "commercialize", "and", "use", "Duke", "s", "thermo-liposome", "technology."], "wordsB": ["The", "exclusive", "option", "agreement", "contemplated", "payments", "of", "an", "upfront", "license", "fee,", "milestone", "payments", "and", "royalties", "to", "us", "if", "the", "exclusive", "license", "agreement", "were", "entered", "into."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p43_s3", "idA": "749647_12_item1_p104_s0", "sentA": "In 1999, the Company entered into a license agreement with Duke University under which the we received exclusive rights (subject to certain exceptions) to commercialize and use Duke s thermo-liposome technology.", "sentB": "The exclusive option agreement contemplated payments of an upfront license fee, milestone payments and royalties to us if the exclusive license agreement were entered into.", "type": 1, "words": ["<tag1>", "In", "1999,", "the", "Company", "entered", "into", "a", "license", "agreement", "with", "Duke", "University", "under", "which", "the", "we", "received", "exclusive", "rights", "(subject", "to", "certain", "exceptions)", "to", "commercialize", "and", "use", "Duke", "s", "thermo-liposome", "technology.", "<tag2>", "The", "exclusive", "option", "agreement", "contemplated", "payments", "of", "an", "upfront", "license", "fee,", "milestone", "payments", "and", "royalties", "to", "us", "if", "the", "exclusive", "license", "agreement", "were", "entered", "into.", "<tag3>"], "wordsA": ["In", "1999,", "the", "Company", "entered", "into", "a", "license", "agreement", "with", "Duke", "University", "under", "which", "the", "we", "received", "exclusive", "rights", "(subject", "to", "certain", "exceptions)", "to", "commercialize", "and", "use", "Duke", "s", "thermo-liposome", "technology."], "wordsB": ["The", "exclusive", "option", "agreement", "contemplated", "payments", "of", "an", "upfront", "license", "fee,", "milestone", "payments", "and", "royalties", "to", "us", "if", "the", "exclusive", "license", "agreement", "were", "entered", "into."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p120_s2", "idA": "749647_12_item1_p105_s0", "sentA": "In 2003, our obligations under the license agreement with Duke University with respect to the testing and regulatory milestones and other licensed technology performance deadlines were eliminated in exchange for a payment of shares of our common stock.", "sentB": "Under the Agreement, Cantor may sell ATM Shares by any method deemed to be an at-the-market offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the our common stock or to or through a market maker.", "type": 1, "words": ["<tag1>", "In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock.", "<tag2>", "Under", "the", "Agreement,", "Cantor", "may", "sell", "ATM", "Shares", "by", "any", "method", "deemed", "to", "be", "an", "at-the-market", "offering", "as", "defined", "in", "Rule", "415", "promulgated", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "including", "sales", "made", "directly", "on", "The", "NASDAQ", "Capital", "Market,", "on", "any", "other", "existing", "trading", "market", "for", "the", "our", "common", "stock", "or", "to", "or", "through", "a", "market", "maker.", "<tag3>"], "wordsA": ["In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock."], "wordsB": ["Under", "the", "Agreement,", "Cantor", "may", "sell", "ATM", "Shares", "by", "any", "method", "deemed", "to", "be", "an", "at-the-market", "offering", "as", "defined", "in", "Rule", "415", "promulgated", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "including", "sales", "made", "directly", "on", "The", "NASDAQ", "Capital", "Market,", "on", "any", "other", "existing", "trading", "market", "for", "the", "our", "common", "stock", "or", "to", "or", "through", "a", "market", "maker."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p127_s1", "idA": "749647_12_item1_p105_s0", "sentA": "In 2003, our obligations under the license agreement with Duke University with respect to the testing and regulatory milestones and other licensed technology performance deadlines were eliminated in exchange for a payment of shares of our common stock.", "sentB": "However, our future capital requirements will depend upon numerous unpredictable factors, including, without limitation, the cost, timing and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates, our efforts to implement new collaborations, licenses and strategic transactions, general and administrative expenses, capital expenditures and other uses of cash.", "type": 1, "words": ["<tag1>", "In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock.", "<tag2>", "However,", "our", "future", "capital", "requirements", "will", "depend", "upon", "numerous", "unpredictable", "factors,", "including,", "without", "limitation,", "the", "cost,", "timing", "and", "outcomes", "of", "clinical", "studies", "and", "regulatory", "reviews", "of", "our", "proprietary", "drug", "candidates,", "our", "efforts", "to", "implement", "new", "collaborations,", "licenses", "and", "strategic", "transactions,", "general", "and", "administrative", "expenses,", "capital", "expenditures", "and", "other", "uses", "of", "cash.", "<tag3>"], "wordsA": ["In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock."], "wordsB": ["However,", "our", "future", "capital", "requirements", "will", "depend", "upon", "numerous", "unpredictable", "factors,", "including,", "without", "limitation,", "the", "cost,", "timing", "and", "outcomes", "of", "clinical", "studies", "and", "regulatory", "reviews", "of", "our", "proprietary", "drug", "candidates,", "our", "efforts", "to", "implement", "new", "collaborations,", "licenses", "and", "strategic", "transactions,", "general", "and", "administrative", "expenses,", "capital", "expenditures", "and", "other", "uses", "of", "cash."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p111_s3", "idA": "749647_12_item1_p10_s0", "sentA": "Our lead product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer.", "sentB": "The first tranche (the Term A Loan ) of $5 million was made available to the Company on June 27, 2012 and the second tranche (the Term B Loan ) was to be made available, if at all, during the period beginning on the date that the Company achieved positive data in its Phase III clinical trial of RFA and ThermoDox (the HEAT study) and ending on March 31, 2013.", "type": 1, "words": ["<tag1>", "Our", "lead", "product", "ThermoDox", "is", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial", "for", "primary", "liver", "cancer", "(the", "HEAT", "study),", "a", "Phase", "II", "clinical", "trial", "for", "colorectal", "liver", "metastasis", "(CRLM)", "and", "a", "Phase", "II", "clinical", "trial", "for", "recurrent", "chest", "wall", "breast", "cancer.", "<tag2>", "The", "first", "tranche", "(the", "Term", "A", "Loan", ")", "of", "$5", "million", "was", "made", "available", "to", "the", "Company", "on", "June", "27,", "2012", "and", "the", "second", "tranche", "(the", "Term", "B", "Loan", ")", "was", "to", "be", "made", "available,", "if", "at", "all,", "during", "the", "period", "beginning", "on", "the", "date", "that", "the", "Company", "achieved", "positive", "data", "in", "its", "Phase", "III", "clinical", "trial", "of", "RFA", "and", "ThermoDox", "(the", "HEAT", "study)", "and", "ending", "on", "March", "31,", "2013.", "<tag3>"], "wordsA": ["Our", "lead", "product", "ThermoDox", "is", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial", "for", "primary", "liver", "cancer", "(the", "HEAT", "study),", "a", "Phase", "II", "clinical", "trial", "for", "colorectal", "liver", "metastasis", "(CRLM)", "and", "a", "Phase", "II", "clinical", "trial", "for", "recurrent", "chest", "wall", "breast", "cancer."], "wordsB": ["The", "first", "tranche", "(the", "Term", "A", "Loan", ")", "of", "$5", "million", "was", "made", "available", "to", "the", "Company", "on", "June", "27,", "2012", "and", "the", "second", "tranche", "(the", "Term", "B", "Loan", ")", "was", "to", "be", "made", "available,", "if", "at", "all,", "during", "the", "period", "beginning", "on", "the", "date", "that", "the", "Company", "achieved", "positive", "data", "in", "its", "Phase", "III", "clinical", "trial", "of", "RFA", "and", "ThermoDox", "(the", "HEAT", "study)", "and", "ending", "on", "March", "31,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p114_s2", "idA": "749647_12_item1_p112_s3", "sentA": "The Company s website is www.celsion.com .", "sentB": "The Company was also obligated to pay other customary facility fees for a credit facility of this size and type.", "type": 1, "words": ["<tag1>", "The", "Company", "s", "website", "is", "www.celsion.com", ".", "<tag2>", "The", "Company", "was", "also", "obligated", "to", "pay", "other", "customary", "facility", "fees", "for", "a", "credit", "facility", "of", "this", "size", "and", "type.", "<tag3>"], "wordsA": ["The", "Company", "s", "website", "is", "www.celsion.com", "."], "wordsB": ["The", "Company", "was", "also", "obligated", "to", "pay", "other", "customary", "facility", "fees", "for", "a", "credit", "facility", "of", "this", "size", "and", "type."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p111_s2", "idA": "749647_12_item1_p113_s3", "sentA": "Copies of these documents may be obtained, free of charge, from our website.", "sentB": "The aggregate loan amount may be advanced in two tranches of $5 million each.", "type": 1, "words": ["<tag1>", "Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website.", "<tag2>", "The", "aggregate", "loan", "amount", "may", "be", "advanced", "in", "two", "tranches", "of", "$5", "million", "each.", "<tag3>"], "wordsA": ["Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website."], "wordsB": ["The", "aggregate", "loan", "amount", "may", "be", "advanced", "in", "two", "tranches", "of", "$5", "million", "each."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p39_s2", "idA": "749647_12_item1_p113_s4", "sentA": "In addition, copies of these documents will be made available free of charge upon written request.", "sentB": "The future of these activities will be part of our strategic planning as we analyze the data announced on January 31, 2013 and will affect our partnership with Hisun described below.", "type": 1, "words": ["<tag1>", "In", "addition,", "copies", "of", "these", "documents", "will", "be", "made", "available", "free", "of", "charge", "upon", "written", "request.", "<tag2>", "The", "future", "of", "these", "activities", "will", "be", "part", "of", "our", "strategic", "planning", "as", "we", "analyze", "the", "data", "announced", "on", "January", "31,", "2013", "and", "will", "affect", "our", "partnership", "with", "Hisun", "described", "below.", "<tag3>"], "wordsA": ["In", "addition,", "copies", "of", "these", "documents", "will", "be", "made", "available", "free", "of", "charge", "upon", "written", "request."], "wordsB": ["The", "future", "of", "these", "activities", "will", "be", "part", "of", "our", "strategic", "planning", "as", "we", "analyze", "the", "data", "announced", "on", "January", "31,", "2013", "and", "will", "affect", "our", "partnership", "with", "Hisun", "described", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p124_s1", "idA": "749647_12_item1_p117_s1", "sentA": "This includes approximately $433,000 of gross proceeds received from the exercise of certain warrants issued by the Company to certain holders thereof into approximately 157,000 shares of common stock.", "sentB": "Each warrant has an exercise price of $1.18 per share, equal to the closing bid price of common stock on February 21, 2013.", "type": 1, "words": ["<tag1>", "This", "includes", "approximately", "$433,000", "of", "gross", "proceeds", "received", "from", "the", "exercise", "of", "certain", "warrants", "issued", "by", "the", "Company", "to", "certain", "holders", "thereof", "into", "approximately", "157,000", "shares", "of", "common", "stock.", "<tag2>", "Each", "warrant", "has", "an", "exercise", "price", "of", "$1.18", "per", "share,", "equal", "to", "the", "closing", "bid", "price", "of", "common", "stock", "on", "February", "21,", "2013.", "<tag3>"], "wordsA": ["This", "includes", "approximately", "$433,000", "of", "gross", "proceeds", "received", "from", "the", "exercise", "of", "certain", "warrants", "issued", "by", "the", "Company", "to", "certain", "holders", "thereof", "into", "approximately", "157,000", "shares", "of", "common", "stock."], "wordsB": ["Each", "warrant", "has", "an", "exercise", "price", "of", "$1.18", "per", "share,", "equal", "to", "the", "closing", "bid", "price", "of", "common", "stock", "on", "February", "21,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p47_s2", "idA": "749647_12_item1_p11_s1", "sentA": "Localized heat at mild hyperthermia temperatures (greater than 40 degrees Celsius) releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor.", "sentB": "The UW research is expected to include animal models to confirm the ability of HIFU to target high concentrations of doxorubicin in proprietary pancreatic cancer cell lines and in vivo studies to assess the response to these tumors treated using ThermoDox with and without HIFU-induced hyperthermia.", "type": 1, "words": ["<tag1>", "Localized", "heat", "at", "mild", "hyperthermia", "temperatures", "(greater", "than", "40", "degrees", "Celsius)", "releases", "the", "encapsulated", "doxorubicin", "from", "the", "liposome", "enabling", "high", "concentrations", "of", "doxorubicin", "to", "be", "deposited", "preferentially", "in", "and", "around", "the", "targeted", "tumor.", "<tag2>", "The", "UW", "research", "is", "expected", "to", "include", "animal", "models", "to", "confirm", "the", "ability", "of", "HIFU", "to", "target", "high", "concentrations", "of", "doxorubicin", "in", "proprietary", "pancreatic", "cancer", "cell", "lines", "and", "in", "vivo", "studies", "to", "assess", "the", "response", "to", "these", "tumors", "treated", "using", "ThermoDox", "with", "and", "without", "HIFU-induced", "hyperthermia.", "<tag3>"], "wordsA": ["Localized", "heat", "at", "mild", "hyperthermia", "temperatures", "(greater", "than", "40", "degrees", "Celsius)", "releases", "the", "encapsulated", "doxorubicin", "from", "the", "liposome", "enabling", "high", "concentrations", "of", "doxorubicin", "to", "be", "deposited", "preferentially", "in", "and", "around", "the", "targeted", "tumor."], "wordsB": ["The", "UW", "research", "is", "expected", "to", "include", "animal", "models", "to", "confirm", "the", "ability", "of", "HIFU", "to", "target", "high", "concentrations", "of", "doxorubicin", "in", "proprietary", "pancreatic", "cancer", "cell", "lines", "and", "in", "vivo", "studies", "to", "assess", "the", "response", "to", "these", "tumors", "treated", "using", "ThermoDox", "with", "and", "without", "HIFU-induced", "hyperthermia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p112_s0", "idA": "749647_12_item1_p124_s0", "sentA": "Dr. Borys joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer of the Company.", "sentB": "The Term A Loan is scheduled to mature on October 15, 2015.", "type": 1, "words": ["<tag1>", "Dr.", "Borys", "joined", "Celsion", "on", "October", "1,", "2007", "as", "Vice", "President", "and", "Chief", "Medical", "Officer", "of", "the", "Company.", "<tag2>", "The", "Term", "A", "Loan", "is", "scheduled", "to", "mature", "on", "October", "15,", "2015.", "<tag3>"], "wordsA": ["Dr.", "Borys", "joined", "Celsion", "on", "October", "1,", "2007", "as", "Vice", "President", "and", "Chief", "Medical", "Officer", "of", "the", "Company."], "wordsB": ["The", "Term", "A", "Loan", "is", "scheduled", "to", "mature", "on", "October", "15,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p72_s4", "idA": "749647_12_item1_p17_s0", "sentA": "An element of our business strategy is to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications.", "sentB": "Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.", "type": 1, "words": ["<tag1>", "An", "element", "of", "our", "business", "strategy", "is", "to", "pursue,", "as", "resources", "permit,", "the", "research", "and", "development", "of", "a", "range", "of", "product", "candidates", "for", "a", "variety", "of", "indications.", "<tag2>", "Our", "inability", "to", "raise", "additional", "capital,", "or", "to", "do", "so", "on", "terms", "reasonably", "acceptable", "to", "us,", "would", "jeopardize", "the", "future", "success", "of", "our", "business.", "<tag3>"], "wordsA": ["An", "element", "of", "our", "business", "strategy", "is", "to", "pursue,", "as", "resources", "permit,", "the", "research", "and", "development", "of", "a", "range", "of", "product", "candidates", "for", "a", "variety", "of", "indications."], "wordsB": ["Our", "inability", "to", "raise", "additional", "capital,", "or", "to", "do", "so", "on", "terms", "reasonably", "acceptable", "to", "us,", "would", "jeopardize", "the", "future", "success", "of", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p120_s3", "idA": "749647_12_item1_p18_s1", "sentA": "The Company sold this medical device business to Boston Scientific Corporation (Boston Scientific) in 2007 for net aggregate payments of $43 million, receiving $13 million in 2007 and $15 million in each of 2008 and 2009.", "sentB": "From February 1, 2013 through February 25, 2013, the Company sold and issued 5,381,670 ATM shares under the ATM Agreement, receiving approximately $6.8 million in net proceeds.", "type": 1, "words": ["<tag1>", "The", "Company", "sold", "this", "medical", "device", "business", "to", "Boston", "Scientific", "Corporation", "(Boston", "Scientific)", "in", "2007", "for", "net", "aggregate", "payments", "of", "$43", "million,", "receiving", "$13", "million", "in", "2007", "and", "$15", "million", "in", "each", "of", "2008", "and", "2009.", "<tag2>", "From", "February", "1,", "2013", "through", "February", "25,", "2013,", "the", "Company", "sold", "and", "issued", "5,381,670", "ATM", "shares", "under", "the", "ATM", "Agreement,", "receiving", "approximately", "$6.8", "million", "in", "net", "proceeds.", "<tag3>"], "wordsA": ["The", "Company", "sold", "this", "medical", "device", "business", "to", "Boston", "Scientific", "Corporation", "(Boston", "Scientific)", "in", "2007", "for", "net", "aggregate", "payments", "of", "$43", "million,", "receiving", "$13", "million", "in", "2007", "and", "$15", "million", "in", "each", "of", "2008", "and", "2009."], "wordsB": ["From", "February", "1,", "2013", "through", "February", "25,", "2013,", "the", "Company", "sold", "and", "issued", "5,381,670", "ATM", "shares", "under", "the", "ATM", "Agreement,", "receiving", "approximately", "$6.8", "million", "in", "net", "proceeds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p118_s0", "idA": "749647_12_item1_p19_s0", "sentA": "On December 5, 2008, we entered into a development, product supply and commercialization agreement with Yakult Honsha Co. (the Yakult Agreement) under which Yakult was granted the exclusive right to commercialize and market ThermoDox for the Japanese market.", "sentB": "On January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to support our development of ThermoDox and we will provide research data and other technical support in relation to a regulatory filing by Hisun with the SFDA for approval of ThermoDox for manufacturing and sale in mainland China, Hong Kong and Macau.", "type": 1, "words": ["<tag1>", "On", "December", "5,", "2008,", "we", "entered", "into", "a", "development,", "product", "supply", "and", "commercialization", "agreement", "with", "Yakult", "Honsha", "Co.", "(the", "Yakult", "Agreement)", "under", "which", "Yakult", "was", "granted", "the", "exclusive", "right", "to", "commercialize", "and", "market", "ThermoDox", "for", "the", "Japanese", "market.", "<tag2>", "On", "January", "18,", "2013,", "we", "entered", "into", "a", "technology", "development", "contract", "with", "Hisun,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "with", "the", "SFDA", "for", "approval", "of", "ThermoDox", "for", "manufacturing", "and", "sale", "in", "mainland", "China,", "Hong", "Kong", "and", "Macau.", "<tag3>"], "wordsA": ["On", "December", "5,", "2008,", "we", "entered", "into", "a", "development,", "product", "supply", "and", "commercialization", "agreement", "with", "Yakult", "Honsha", "Co.", "(the", "Yakult", "Agreement)", "under", "which", "Yakult", "was", "granted", "the", "exclusive", "right", "to", "commercialize", "and", "market", "ThermoDox", "for", "the", "Japanese", "market."], "wordsB": ["On", "January", "18,", "2013,", "we", "entered", "into", "a", "technology", "development", "contract", "with", "Hisun,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "with", "the", "SFDA", "for", "approval", "of", "ThermoDox", "for", "manufacturing", "and", "sale", "in", "mainland", "China,", "Hong", "Kong", "and", "Macau."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p118_s2", "idA": "749647_12_item1_p19_s4", "sentA": "The terms of the Yakult Agreement provided for the payment to us of $2.0 million upon the closing of the preferred equity financing and an additional $2.0 million conditioned upon the resumption of enrollment of Japanese patients in the Japan cohort of the HEAT Study.", "sentB": "Hisun agreed to pay us an additional $5 million within sixty days after the signing of the exclusive option agreement if it has not been terminated within such time period.", "type": 1, "words": ["<tag1>", "The", "terms", "of", "the", "Yakult", "Agreement", "provided", "for", "the", "payment", "to", "us", "of", "$2.0", "million", "upon", "the", "closing", "of", "the", "preferred", "equity", "financing", "and", "an", "additional", "$2.0", "million", "conditioned", "upon", "the", "resumption", "of", "enrollment", "of", "Japanese", "patients", "in", "the", "Japan", "cohort", "of", "the", "HEAT", "Study.", "<tag2>", "Hisun", "agreed", "to", "pay", "us", "an", "additional", "$5", "million", "within", "sixty", "days", "after", "the", "signing", "of", "the", "exclusive", "option", "agreement", "if", "it", "has", "not", "been", "terminated", "within", "such", "time", "period.", "<tag3>"], "wordsA": ["The", "terms", "of", "the", "Yakult", "Agreement", "provided", "for", "the", "payment", "to", "us", "of", "$2.0", "million", "upon", "the", "closing", "of", "the", "preferred", "equity", "financing", "and", "an", "additional", "$2.0", "million", "conditioned", "upon", "the", "resumption", "of", "enrollment", "of", "Japanese", "patients", "in", "the", "Japan", "cohort", "of", "the", "HEAT", "Study."], "wordsB": ["Hisun", "agreed", "to", "pay", "us", "an", "additional", "$5", "million", "within", "sixty", "days", "after", "the", "signing", "of", "the", "exclusive", "option", "agreement", "if", "it", "has", "not", "been", "terminated", "within", "such", "time", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p43_s2", "idA": "749647_12_item1_p19_s4", "sentA": "The terms of the Yakult Agreement provided for the payment to us of $2.0 million upon the closing of the preferred equity financing and an additional $2.0 million conditioned upon the resumption of enrollment of Japanese patients in the Japan cohort of the HEAT Study.", "sentB": "Hisun agreed to pay us an additional $5.0 million within sixty days after the signing of the exclusive option agreement if it has not been terminated within such time period.", "type": 1, "words": ["<tag1>", "The", "terms", "of", "the", "Yakult", "Agreement", "provided", "for", "the", "payment", "to", "us", "of", "$2.0", "million", "upon", "the", "closing", "of", "the", "preferred", "equity", "financing", "and", "an", "additional", "$2.0", "million", "conditioned", "upon", "the", "resumption", "of", "enrollment", "of", "Japanese", "patients", "in", "the", "Japan", "cohort", "of", "the", "HEAT", "Study.", "<tag2>", "Hisun", "agreed", "to", "pay", "us", "an", "additional", "$5.0", "million", "within", "sixty", "days", "after", "the", "signing", "of", "the", "exclusive", "option", "agreement", "if", "it", "has", "not", "been", "terminated", "within", "such", "time", "period.", "<tag3>"], "wordsA": ["The", "terms", "of", "the", "Yakult", "Agreement", "provided", "for", "the", "payment", "to", "us", "of", "$2.0", "million", "upon", "the", "closing", "of", "the", "preferred", "equity", "financing", "and", "an", "additional", "$2.0", "million", "conditioned", "upon", "the", "resumption", "of", "enrollment", "of", "Japanese", "patients", "in", "the", "Japan", "cohort", "of", "the", "HEAT", "Study."], "wordsB": ["Hisun", "agreed", "to", "pay", "us", "an", "additional", "$5.0", "million", "within", "sixty", "days", "after", "the", "signing", "of", "the", "exclusive", "option", "agreement", "if", "it", "has", "not", "been", "terminated", "within", "such", "time", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p122_s1", "idA": "749647_12_item1_p22_s2", "sentA": "The second trigger was the occurrence of 190 progression-free survival (PFS) events in the study population.", "sentB": "The ATM Agreement may be terminated by Cantor or Celsion at any time upon 10 days' notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material adverse change in Celsion.", "type": 1, "words": ["<tag1>", "The", "second", "trigger", "was", "the", "occurrence", "of", "190", "progression-free", "survival", "(PFS)", "events", "in", "the", "study", "population.", "<tag2>", "The", "ATM", "Agreement", "may", "be", "terminated", "by", "Cantor", "or", "Celsion", "at", "any", "time", "upon", "10", "days'", "notice", "to", "the", "other", "party,", "or", "by", "Cantor", "at", "any", "time", "in", "certain", "circumstances,", "including", "the", "occurrence", "of", "a", "material", "adverse", "change", "in", "Celsion.", "<tag3>"], "wordsA": ["The", "second", "trigger", "was", "the", "occurrence", "of", "190", "progression-free", "survival", "(PFS)", "events", "in", "the", "study", "population."], "wordsB": ["The", "ATM", "Agreement", "may", "be", "terminated", "by", "Cantor", "or", "Celsion", "at", "any", "time", "upon", "10", "days'", "notice", "to", "the", "other", "party,", "or", "by", "Cantor", "at", "any", "time", "in", "certain", "circumstances,", "including", "the", "occurrence", "of", "a", "material", "adverse", "change", "in", "Celsion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p72_s2", "idA": "749647_12_item1_p27_s0", "sentA": "Our current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development and commercialization of our product candidates.", "sentB": "While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development and clinical trials or whether we are in a position to pursue manufacturing or commercialization activities, it is clear we will need significant additional capital to develop our product candidates through clinical development, manufacturing and commercialization.", "type": 1, "words": ["<tag1>", "Our", "current", "business", "strategy", "includes", "the", "possibility", "of", "entering", "into", "collaborative", "arrangements", "with", "third", "parties", "to", "complete", "the", "development", "and", "commercialization", "of", "our", "product", "candidates.", "<tag2>", "While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "and", "clinical", "trials", "or", "whether", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "it", "is", "clear", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "clinical", "development,", "manufacturing", "and", "commercialization.", "<tag3>"], "wordsA": ["Our", "current", "business", "strategy", "includes", "the", "possibility", "of", "entering", "into", "collaborative", "arrangements", "with", "third", "parties", "to", "complete", "the", "development", "and", "commercialization", "of", "our", "product", "candidates."], "wordsB": ["While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "and", "clinical", "trials", "or", "whether", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "it", "is", "clear", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "clinical", "development,", "manufacturing", "and", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p122_s3", "idA": "749647_12_item1_p30_s1", "sentA": "Heating creates channels in the liposome bilayer that allow an encapsulated drug to rapidly disperse into the surrounding tissue.", "sentB": "The Company also agreed to reimburse Cantor for legal fees and disbursements, not to exceed $50,000 in the aggregate, in connection with entering into the ATM Agreement.", "type": 1, "words": ["<tag1>", "Heating", "creates", "channels", "in", "the", "liposome", "bilayer", "that", "allow", "an", "encapsulated", "drug", "to", "rapidly", "disperse", "into", "the", "surrounding", "tissue.", "<tag2>", "The", "Company", "also", "agreed", "to", "reimburse", "Cantor", "for", "legal", "fees", "and", "disbursements,", "not", "to", "exceed", "$50,000", "in", "the", "aggregate,", "in", "connection", "with", "entering", "into", "the", "ATM", "Agreement.", "<tag3>"], "wordsA": ["Heating", "creates", "channels", "in", "the", "liposome", "bilayer", "that", "allow", "an", "encapsulated", "drug", "to", "rapidly", "disperse", "into", "the", "surrounding", "tissue."], "wordsB": ["The", "Company", "also", "agreed", "to", "reimburse", "Cantor", "for", "legal", "fees", "and", "disbursements,", "not", "to", "exceed", "$50,000", "in", "the", "aggregate,", "in", "connection", "with", "entering", "into", "the", "ATM", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p124_s2", "idA": "749647_12_item1_p33_s2", "sentA": "It is estimated that up to 90% of liver cancer patients will die within five years of diagnosis.", "sentB": "The warrants are immediately exercisable and expire five years after its issuance.", "type": 1, "words": ["<tag1>", "It", "is", "estimated", "that", "up", "to", "90%", "of", "liver", "cancer", "patients", "will", "die", "within", "five", "years", "of", "diagnosis.", "<tag2>", "The", "warrants", "are", "immediately", "exercisable", "and", "expire", "five", "years", "after", "its", "issuance.", "<tag3>"], "wordsA": ["It", "is", "estimated", "that", "up", "to", "90%", "of", "liver", "cancer", "patients", "will", "die", "within", "five", "years", "of", "diagnosis."], "wordsB": ["The", "warrants", "are", "immediately", "exercisable", "and", "expire", "five", "years", "after", "its", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p114_s0", "idA": "749647_12_item1_p34_s1", "sentA": "HCC has the fastest rate of growth of all cancers and is projected to be the most prevalent form of cancer by 2020.", "sentB": "The Term A Loan bears interest at a fixed rate of 11.75%.", "type": 1, "words": ["<tag1>", "HCC", "has", "the", "fastest", "rate", "of", "growth", "of", "all", "cancers", "and", "is", "projected", "to", "be", "the", "most", "prevalent", "form", "of", "cancer", "by", "2020.", "<tag2>", "The", "Term", "A", "Loan", "bears", "interest", "at", "a", "fixed", "rate", "of", "11.75%.", "<tag3>"], "wordsA": ["HCC", "has", "the", "fastest", "rate", "of", "growth", "of", "all", "cancers", "and", "is", "projected", "to", "be", "the", "most", "prevalent", "form", "of", "cancer", "by", "2020."], "wordsB": ["The", "Term", "A", "Loan", "bears", "interest", "at", "a", "fixed", "rate", "of", "11.75%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p121_s3", "idA": "749647_12_item1_p36_s3", "sentA": "Local recurrence rates after RFA directly correlates to the size of the tumor.", "sentB": "In addition, pursuant to the terms and conditions of the ATM Agreement and subject to the instructions of Celsion, Cantor may sell ATM Shares by any other method permitted by law, including in privately negotiated transactions.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "In", "addition,", "pursuant", "to", "the", "terms", "and", "conditions", "of", "the", "ATM", "Agreement", "and", "subject", "to", "the", "instructions", "of", "Celsion,", "Cantor", "may", "sell", "ATM", "Shares", "by", "any", "other", "method", "permitted", "by", "law,", "including", "in", "privately", "negotiated", "transactions.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["In", "addition,", "pursuant", "to", "the", "terms", "and", "conditions", "of", "the", "ATM", "Agreement", "and", "subject", "to", "the", "instructions", "of", "Celsion,", "Cantor", "may", "sell", "ATM", "Shares", "by", "any", "other", "method", "permitted", "by", "law,", "including", "in", "privately", "negotiated", "transactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p40_s3", "idA": "749647_12_item1_p36_s3", "sentA": "Local recurrence rates after RFA directly correlates to the size of the tumor.", "sentB": "The batches are expected to be successfully delivered in mid-2013, and repayment of the development costs will occur at any time on or prior to the fourth year anniversary of the signing of the agreement, which we expect in total to be approximately $2.0 million.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "The", "batches", "are", "expected", "to", "be", "successfully", "delivered", "in", "mid-2013,", "and", "repayment", "of", "the", "development", "costs", "will", "occur", "at", "any", "time", "on", "or", "prior", "to", "the", "fourth", "year", "anniversary", "of", "the", "signing", "of", "the", "agreement,", "which", "we", "expect", "in", "total", "to", "be", "approximately", "$2.0", "million.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["The", "batches", "are", "expected", "to", "be", "successfully", "delivered", "in", "mid-2013,", "and", "repayment", "of", "the", "development", "costs", "will", "occur", "at", "any", "time", "on", "or", "prior", "to", "the", "fourth", "year", "anniversary", "of", "the", "signing", "of", "the", "agreement,", "which", "we", "expect", "in", "total", "to", "be", "approximately", "$2.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p46_s2", "idA": "749647_12_item1_p42_s2", "sentA": "The study is being conducted in 79 clinical sites in the United States, Canada, Italy, China, Taiwan, Hong Kong, Korea, Thailand, Malaysia and the Philippines, and we reached our preplanned enrollment objective of 600 patients in August 2011.", "sentB": "This early phase clinical study is being finalized and will require approval from a local ethics committee.", "type": 1, "words": ["<tag1>", "The", "study", "is", "being", "conducted", "in", "79", "clinical", "sites", "in", "the", "United", "States,", "Canada,", "Italy,", "China,", "Taiwan,", "Hong", "Kong,", "Korea,", "Thailand,", "Malaysia", "and", "the", "Philippines,", "and", "we", "reached", "our", "preplanned", "enrollment", "objective", "of", "600", "patients", "in", "August", "2011.", "<tag2>", "This", "early", "phase", "clinical", "study", "is", "being", "finalized", "and", "will", "require", "approval", "from", "a", "local", "ethics", "committee.", "<tag3>"], "wordsA": ["The", "study", "is", "being", "conducted", "in", "79", "clinical", "sites", "in", "the", "United", "States,", "Canada,", "Italy,", "China,", "Taiwan,", "Hong", "Kong,", "Korea,", "Thailand,", "Malaysia", "and", "the", "Philippines,", "and", "we", "reached", "our", "preplanned", "enrollment", "objective", "of", "600", "patients", "in", "August", "2011."], "wordsB": ["This", "early", "phase", "clinical", "study", "is", "being", "finalized", "and", "will", "require", "approval", "from", "a", "local", "ethics", "committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p104_s3", "idA": "749647_12_item1_p43_s3", "sentA": "No other element of the SPA were affected by this change.", "sentB": "These patents will extend the overall term of the ThermoDox patent portfolio to 2026.", "type": 1, "words": ["<tag1>", "No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change.", "<tag2>", "These", "patents", "will", "extend", "the", "overall", "term", "of", "the", "ThermoDox", "patent", "portfolio", "to", "2026.", "<tag3>"], "wordsA": ["No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change."], "wordsB": ["These", "patents", "will", "extend", "the", "overall", "term", "of", "the", "ThermoDox", "patent", "portfolio", "to", "2026."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p109_s6", "idA": "749647_12_item1_p43_s3", "sentA": "No other element of the SPA were affected by this change.", "sentB": "The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.", "type": 1, "words": ["<tag1>", "No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change.", "<tag2>", "The", "public", "may", "obtain", "information", "on", "the", "operation", "of", "the", "Public", "Reference", "Room", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330.", "<tag3>"], "wordsA": ["No", "other", "element", "of", "the", "SPA", "were", "affected", "by", "this", "change."], "wordsB": ["The", "public", "may", "obtain", "information", "on", "the", "operation", "of", "the", "Public", "Reference", "Room", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p122_s2", "idA": "749647_12_item1_p60_s0", "sentA": "The Company completed enrollment of the Phase I portion of the study in 2010 and an independent Data Safety Monitoring Board declared 50mg/m 2 to be the phase II dose.", "sentB": "The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of ATM Shares and has agreed to provide Cantor with customary indemnification and contribution rights.", "type": 1, "words": ["<tag1>", "The", "Company", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "of", "the", "study", "in", "2010", "and", "an", "independent", "Data", "Safety", "Monitoring", "Board", "declared", "50mg/m", "2", "to", "be", "the", "phase", "II", "dose.", "<tag2>", "The", "Company", "will", "pay", "Cantor", "a", "commission", "of", "3.0%", "of", "the", "aggregate", "gross", "proceeds", "from", "each", "sale", "of", "ATM", "Shares", "and", "has", "agreed", "to", "provide", "Cantor", "with", "customary", "indemnification", "and", "contribution", "rights.", "<tag3>"], "wordsA": ["The", "Company", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "of", "the", "study", "in", "2010", "and", "an", "independent", "Data", "Safety", "Monitoring", "Board", "declared", "50mg/m", "2", "to", "be", "the", "phase", "II", "dose."], "wordsB": ["The", "Company", "will", "pay", "Cantor", "a", "commission", "of", "3.0%", "of", "the", "aggregate", "gross", "proceeds", "from", "each", "sale", "of", "ATM", "Shares", "and", "has", "agreed", "to", "provide", "Cantor", "with", "customary", "indemnification", "and", "contribution", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p121_s2", "idA": "749647_12_item1_p6_s0", "sentA": "We disclaim any obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf.", "sentB": "Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company s instructions, including any price, time or size limits or other customary parameters or conditions Celsion may impose.", "type": 1, "words": ["<tag1>", "We", "disclaim", "any", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf.", "<tag2>", "Subject", "to", "the", "terms", "and", "conditions", "of", "the", "ATM", "Agreement,", "Cantor", "will", "use", "commercially", "reasonable", "efforts,", "consistent", "with", "its", "normal", "trading", "and", "sales", "practices", "and", "applicable", "state", "and", "federal", "law,", "rules", "and", "regulations", "and", "the", "rules", "of", "The", "NASDAQ", "Capital", "Market,", "to", "sell", "ATM", "Shares", "from", "time", "to", "time", "based", "upon", "the", "Company", "s", "instructions,", "including", "any", "price,", "time", "or", "size", "limits", "or", "other", "customary", "parameters", "or", "conditions", "Celsion", "may", "impose.", "<tag3>"], "wordsA": ["We", "disclaim", "any", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf."], "wordsB": ["Subject", "to", "the", "terms", "and", "conditions", "of", "the", "ATM", "Agreement,", "Cantor", "will", "use", "commercially", "reasonable", "efforts,", "consistent", "with", "its", "normal", "trading", "and", "sales", "practices", "and", "applicable", "state", "and", "federal", "law,", "rules", "and", "regulations", "and", "the", "rules", "of", "The", "NASDAQ", "Capital", "Market,", "to", "sell", "ATM", "Shares", "from", "time", "to", "time", "based", "upon", "the", "Company", "s", "instructions,", "including", "any", "price,", "time", "or", "size", "limits", "or", "other", "customary", "parameters", "or", "conditions", "Celsion", "may", "impose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p72_s3", "idA": "749647_12_item1_p6_s0", "sentA": "We disclaim any obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf.", "sentB": "We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders.", "type": 1, "words": ["<tag1>", "We", "disclaim", "any", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf.", "<tag2>", "We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders.", "<tag3>"], "wordsA": ["We", "disclaim", "any", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf."], "wordsB": ["We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p37_s1", "idA": "749647_12_item1_p72_s4", "sentA": "In Japan, our partner Yakult, remains enthusiastic about ThermoDox and has indicated its plans to continue evaluation of ThermoDox separately from the HEAT study, due to the different standard of care in Japan.", "sentB": "We plan to continue with related partnerships, such as our arrangement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) described below, to the extent feasible.", "type": 1, "words": ["<tag1>", "In", "Japan,", "our", "partner", "Yakult,", "remains", "enthusiastic", "about", "ThermoDox", "and", "has", "indicated", "its", "plans", "to", "continue", "evaluation", "of", "ThermoDox", "separately", "from", "the", "HEAT", "study,", "due", "to", "the", "different", "standard", "of", "care", "in", "Japan.", "<tag2>", "We", "plan", "to", "continue", "with", "related", "partnerships,", "such", "as", "our", "arrangement", "with", "Zhejiang", "Hisun", "Pharmaceutical", "Co.", "Ltd.", "(Hisun)", "described", "below,", "to", "the", "extent", "feasible.", "<tag3>"], "wordsA": ["In", "Japan,", "our", "partner", "Yakult,", "remains", "enthusiastic", "about", "ThermoDox", "and", "has", "indicated", "its", "plans", "to", "continue", "evaluation", "of", "ThermoDox", "separately", "from", "the", "HEAT", "study,", "due", "to", "the", "different", "standard", "of", "care", "in", "Japan."], "wordsB": ["We", "plan", "to", "continue", "with", "related", "partnerships,", "such", "as", "our", "arrangement", "with", "Zhejiang", "Hisun", "Pharmaceutical", "Co.", "Ltd.", "(Hisun)", "described", "below,", "to", "the", "extent", "feasible."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p117_s1", "idA": "749647_12_item1_p73_s0", "sentA": "In the United States, we have secured several designations which will support our clinical, regulatory and commercial strategies.", "sentB": "In the trial, ThermoDox was well-tolerated with no unexpected serious adverse events.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies.", "<tag2>", "In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies."], "wordsB": ["In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p13_s0", "idA": "749647_12_item1_p73_s0", "sentA": "In the United States, we have secured several designations which will support our clinical, regulatory and commercial strategies.", "sentB": "In the trial, ThermoDox was well-tolerated with no unexpected serious adverse events.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies.", "<tag2>", "In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies."], "wordsB": ["In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p36_s1", "idA": "749647_12_item1_p73_s0", "sentA": "In the United States, we have secured several designations which will support our clinical, regulatory and commercial strategies.", "sentB": "In the trial, ThermoDox was well-tolerated with no unexpected serious adverse events.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies.", "<tag2>", "In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "we", "have", "secured", "several", "designations", "which", "will", "support", "our", "clinical,", "regulatory", "and", "commercial", "strategies."], "wordsB": ["In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p111_s1", "idA": "749647_12_item1_p73_s2", "sentA": "Additionally, FDA has provided support for a 505(b) 2 NDA submission.", "sentB": "The Credit Agreement provides for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon.", "type": 1, "words": ["<tag1>", "Additionally,", "FDA", "has", "provided", "support", "for", "a", "505(b)", "2", "NDA", "submission.", "<tag2>", "The", "Credit", "Agreement", "provides", "for", "a", "secured", "term", "loan", "of", "up", "to", "$10", "million,", "with", "50%", "of", "any", "loans", "to", "be", "funded", "by", "Oxford", "and", "50%", "to", "be", "funded", "by", "Horizon.", "<tag3>"], "wordsA": ["Additionally,", "FDA", "has", "provided", "support", "for", "a", "505(b)", "2", "NDA", "submission."], "wordsB": ["The", "Credit", "Agreement", "provides", "for", "a", "secured", "term", "loan", "of", "up", "to", "$10", "million,", "with", "50%", "of", "any", "loans", "to", "be", "funded", "by", "Oxford", "and", "50%", "to", "be", "funded", "by", "Horizon."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p16_s2", "idA": "749647_12_item1_p80_s1", "sentA": "The majority of the spending in research and development is for the funding of ThermoDox clinical trials.", "sentB": "On January 18, 2013, we broadened our relationship with Hisun by entering into a technology development contract, pursuant to which Hisun paid us a non-refundable research and development fee of $5.0 million to support our development of ThermoDox and we will provide research data and other technical support in relation to a regulatory filing by Hisun in China for approval of ThermoDox .", "type": 1, "words": ["<tag1>", "The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials.", "<tag2>", "On", "January", "18,", "2013,", "we", "broadened", "our", "relationship", "with", "Hisun", "by", "entering", "into", "a", "technology", "development", "contract,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5.0", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "in", "China", "for", "approval", "of", "ThermoDox", ".", "<tag3>"], "wordsA": ["The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials."], "wordsB": ["On", "January", "18,", "2013,", "we", "broadened", "our", "relationship", "with", "Hisun", "by", "entering", "into", "a", "technology", "development", "contract,", "pursuant", "to", "which", "Hisun", "paid", "us", "a", "non-refundable", "research", "and", "development", "fee", "of", "$5.0", "million", "to", "support", "our", "development", "of", "ThermoDox", "and", "we", "will", "provide", "research", "data", "and", "other", "technical", "support", "in", "relation", "to", "a", "regulatory", "filing", "by", "Hisun", "in", "China", "for", "approval", "of", "ThermoDox", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p40_s1", "idA": "749647_12_item1_p80_s1", "sentA": "The majority of the spending in research and development is for the funding of ThermoDox clinical trials.", "sentB": "In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registrational and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox .", "type": 1, "words": ["<tag1>", "The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials.", "<tag2>", "In", "accordance", "with", "the", "terms", "of", "the", "agreement,", "Hisun", "will", "be", "responsible", "for", "providing", "all", "of", "the", "technical", "and", "regulatory", "support", "services,", "including", "the", "costs", "of", "all", "technical", "transfer,", "registrational", "and", "bioequivalence", "studies,", "technical", "transfer", "costs,", "Celsion", "consultative", "support", "costs", "and", "the", "purchase", "of", "any", "necessary", "equipment", "and", "additional", "facility", "costs", "necessary", "to", "support", "capacity", "requirements", "for", "the", "manufacture", "of", "ThermoDox", ".", "<tag3>"], "wordsA": ["The", "majority", "of", "the", "spending", "in", "research", "and", "development", "is", "for", "the", "funding", "of", "ThermoDox", "clinical", "trials."], "wordsB": ["In", "accordance", "with", "the", "terms", "of", "the", "agreement,", "Hisun", "will", "be", "responsible", "for", "providing", "all", "of", "the", "technical", "and", "regulatory", "support", "services,", "including", "the", "costs", "of", "all", "technical", "transfer,", "registrational", "and", "bioequivalence", "studies,", "technical", "transfer", "costs,", "Celsion", "consultative", "support", "costs", "and", "the", "purchase", "of", "any", "necessary", "equipment", "and", "additional", "facility", "costs", "necessary", "to", "support", "capacity", "requirements", "for", "the", "manufacture", "of", "ThermoDox", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p41_s0", "idA": "749647_12_item1_p84_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "Hisun is also obligated to certain performance requirements under the agreement.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "Hisun", "is", "also", "obligated", "to", "certain", "performance", "requirements", "under", "the", "agreement.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["Hisun", "is", "also", "obligated", "to", "certain", "performance", "requirements", "under", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_13_item1_p109_s5", "idA": "749647_12_item1_p94_s0", "sentA": "Each U.S. drug manufacturing establishment must be registered with the FDA.", "sentB": "The public may read and copy any materials filed with the SEC at the SEC s Public Reference Room at 100 F Street, NE, Washington, DC 20549.", "type": 1, "words": ["<tag1>", "Each", "U.S.", "drug", "manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA.", "<tag2>", "The", "public", "may", "read", "and", "copy", "any", "materials", "filed", "with", "the", "SEC", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "DC", "20549.", "<tag3>"], "wordsA": ["Each", "U.S.", "drug", "manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA."], "wordsB": ["The", "public", "may", "read", "and", "copy", "any", "materials", "filed", "with", "the", "SEC", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "DC", "20549."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p103_s2", "idA": "749647_13_item1_p102_s2", "sentA": "The European grant provides coverage in the European Community.", "sentB": "If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states.", "type": 1, "words": ["<tag1>", "The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community.", "<tag2>", "If", "a", "member", "state", "does", "not", "recognize", "the", "marketing", "authorization,", "the", "disputed", "points", "are", "eventually", "referred", "to", "the", "European", "Commission,", "whose", "decision", "is", "binding", "on", "all", "member", "states.", "<tag3>"], "wordsA": ["The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community."], "wordsB": ["If", "a", "member", "state", "does", "not", "recognize", "the", "marketing", "authorization,", "the", "disputed", "points", "are", "eventually", "referred", "to", "the", "European", "Commission,", "whose", "decision", "is", "binding", "on", "all", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p19_s1", "idA": "749647_13_item1_p106_s2", "sentA": "Please refer to Item 1A, Risk Factors, including, but not limited to, Our business depends on licensing agreements with third parties to permit us to use patented technologies.", "sentB": "Strategic alternatives the Company may pursue could include, but are not limited to, continuing its current operating plan, partnering or other collaboration agreements, acquisition of another company s business or assets, or a merger or other strategic transaction.", "type": 1, "words": ["<tag1>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including,", "but", "not", "limited", "to,", "Our", "business", "depends", "on", "licensing", "agreements", "with", "third", "parties", "to", "permit", "us", "to", "use", "patented", "technologies.", "<tag2>", "Strategic", "alternatives", "the", "Company", "may", "pursue", "could", "include,", "but", "are", "not", "limited", "to,", "continuing", "its", "current", "operating", "plan,", "partnering", "or", "other", "collaboration", "agreements,", "acquisition", "of", "another", "company", "s", "business", "or", "assets,", "or", "a", "merger", "or", "other", "strategic", "transaction.", "<tag3>"], "wordsA": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including,", "but", "not", "limited", "to,", "Our", "business", "depends", "on", "licensing", "agreements", "with", "third", "parties", "to", "permit", "us", "to", "use", "patented", "technologies."], "wordsB": ["Strategic", "alternatives", "the", "Company", "may", "pursue", "could", "include,", "but", "are", "not", "limited", "to,", "continuing", "its", "current", "operating", "plan,", "partnering", "or", "other", "collaboration", "agreements,", "acquisition", "of", "another", "company", "s", "business", "or", "assets,", "or", "a", "merger", "or", "other", "strategic", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p26_s0", "idA": "749647_13_item1_p106_s3", "sentA": "The loss of any of our rights under these agreements could impair our ability to develop and market our products.", "sentB": "As a clinical stage biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals are subject to numerous risks and uncertainties.", "type": 1, "words": ["<tag1>", "The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products.", "<tag2>", "As", "a", "clinical", "stage", "biopharmaceutical", "company,", "our", "business", "and", "our", "ability", "to", "execute", "our", "strategy", "to", "achieve", "our", "corporate", "goals", "are", "subject", "to", "numerous", "risks", "and", "uncertainties.", "<tag3>"], "wordsA": ["The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products."], "wordsB": ["As", "a", "clinical", "stage", "biopharmaceutical", "company,", "our", "business", "and", "our", "ability", "to", "execute", "our", "strategy", "to", "achieve", "our", "corporate", "goals", "are", "subject", "to", "numerous", "risks", "and", "uncertainties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p45_s1", "idA": "749647_13_item1_p107_s1", "sentA": "We also maintain active independent contractor relationships with various individuals, most of whom have month-to-month or annual consulting agreements.", "sentB": "We also completed computational modeling with supplementary preclinical animal studies supporting the relationship between heating duration and clinical outcomes.", "type": 1, "words": ["<tag1>", "We", "also", "maintain", "active", "independent", "contractor", "relationships", "with", "various", "individuals,", "most", "of", "whom", "have", "month-to-month", "or", "annual", "consulting", "agreements.", "<tag2>", "We", "also", "completed", "computational", "modeling", "with", "supplementary", "preclinical", "animal", "studies", "supporting", "the", "relationship", "between", "heating", "duration", "and", "clinical", "outcomes.", "<tag3>"], "wordsA": ["We", "also", "maintain", "active", "independent", "contractor", "relationships", "with", "various", "individuals,", "most", "of", "whom", "have", "month-to-month", "or", "annual", "consulting", "agreements."], "wordsB": ["We", "also", "completed", "computational", "modeling", "with", "supplementary", "preclinical", "animal", "studies", "supporting", "the", "relationship", "between", "heating", "duration", "and", "clinical", "outcomes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p102_s2", "idA": "749647_13_item1_p111_s1", "sentA": "The Credit Agreement provides for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon.", "sentB": "The decentralized procedure provides for mutual recognition of national approval decisions.", "type": 1, "words": ["<tag1>", "The", "Credit", "Agreement", "provides", "for", "a", "secured", "term", "loan", "of", "up", "to", "$10", "million,", "with", "50%", "of", "any", "loans", "to", "be", "funded", "by", "Oxford", "and", "50%", "to", "be", "funded", "by", "Horizon.", "<tag2>", "The", "decentralized", "procedure", "provides", "for", "mutual", "recognition", "of", "national", "approval", "decisions.", "<tag3>"], "wordsA": ["The", "Credit", "Agreement", "provides", "for", "a", "secured", "term", "loan", "of", "up", "to", "$10", "million,", "with", "50%", "of", "any", "loans", "to", "be", "funded", "by", "Oxford", "and", "50%", "to", "be", "funded", "by", "Horizon."], "wordsB": ["The", "decentralized", "procedure", "provides", "for", "mutual", "recognition", "of", "national", "approval", "decisions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p125_s1", "idA": "749647_13_item1_p111_s3", "sentA": "The first tranche (the Term A Loan ) of $5 million was made available to the Company on June 27, 2012 and the second tranche (the Term B Loan ) was to be made available, if at all, during the period beginning on the date that the Company achieved positive data in its Phase III clinical trial of RFA and ThermoDox (the HEAT study) and ending on March 31, 2013.", "sentB": "The Company drew the first tranche of $5 million at the closing under the Hercules Credit Agreement on November 25, 2013 and may request, subject to Hercules consent in its sole discretion, an additional $15 million in up to three advances with each advance in a minimum amount of $5 million, unless otherwise agreed upon by the Company and Hercules, before June 30, 2014 unless extended upon Hercules consent.", "type": 1, "words": ["<tag1>", "The", "first", "tranche", "(the", "Term", "A", "Loan", ")", "of", "$5", "million", "was", "made", "available", "to", "the", "Company", "on", "June", "27,", "2012", "and", "the", "second", "tranche", "(the", "Term", "B", "Loan", ")", "was", "to", "be", "made", "available,", "if", "at", "all,", "during", "the", "period", "beginning", "on", "the", "date", "that", "the", "Company", "achieved", "positive", "data", "in", "its", "Phase", "III", "clinical", "trial", "of", "RFA", "and", "ThermoDox", "(the", "HEAT", "study)", "and", "ending", "on", "March", "31,", "2013.", "<tag2>", "The", "Company", "drew", "the", "first", "tranche", "of", "$5", "million", "at", "the", "closing", "under", "the", "Hercules", "Credit", "Agreement", "on", "November", "25,", "2013", "and", "may", "request,", "subject", "to", "Hercules", "consent", "in", "its", "sole", "discretion,", "an", "additional", "$15", "million", "in", "up", "to", "three", "advances", "with", "each", "advance", "in", "a", "minimum", "amount", "of", "$5", "million,", "unless", "otherwise", "agreed", "upon", "by", "the", "Company", "and", "Hercules,", "before", "June", "30,", "2014", "unless", "extended", "upon", "Hercules", "consent.", "<tag3>"], "wordsA": ["The", "first", "tranche", "(the", "Term", "A", "Loan", ")", "of", "$5", "million", "was", "made", "available", "to", "the", "Company", "on", "June", "27,", "2012", "and", "the", "second", "tranche", "(the", "Term", "B", "Loan", ")", "was", "to", "be", "made", "available,", "if", "at", "all,", "during", "the", "period", "beginning", "on", "the", "date", "that", "the", "Company", "achieved", "positive", "data", "in", "its", "Phase", "III", "clinical", "trial", "of", "RFA", "and", "ThermoDox", "(the", "HEAT", "study)", "and", "ending", "on", "March", "31,", "2013."], "wordsB": ["The", "Company", "drew", "the", "first", "tranche", "of", "$5", "million", "at", "the", "closing", "under", "the", "Hercules", "Credit", "Agreement", "on", "November", "25,", "2013", "and", "may", "request,", "subject", "to", "Hercules", "consent", "in", "its", "sole", "discretion,", "an", "additional", "$15", "million", "in", "up", "to", "three", "advances", "with", "each", "advance", "in", "a", "minimum", "amount", "of", "$5", "million,", "unless", "otherwise", "agreed", "upon", "by", "the", "Company", "and", "Hercules,", "before", "June", "30,", "2014", "unless", "extended", "upon", "Hercules", "consent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p46_s3", "idA": "749647_13_item1_p116_s0", "sentA": "On January 31, 2013, we announced that ThermoDox in combination with RFA did not meet the primary endpoint of the HEAT study in patients with hepatocellular carcinoma, also known as primary liver cancer.", "sentB": "The post-hoc data suggest that ThermoDox may substantially improve overall survival, when compared to the control group, in patients if their tumors undergo optimal RFA treatment.", "type": 1, "words": ["<tag1>", "On", "January", "31,", "2013,", "we", "announced", "that", "ThermoDox", "in", "combination", "with", "RFA", "did", "not", "meet", "the", "primary", "endpoint", "of", "the", "HEAT", "study", "in", "patients", "with", "hepatocellular", "carcinoma,", "also", "known", "as", "primary", "liver", "cancer.", "<tag2>", "The", "post-hoc", "data", "suggest", "that", "ThermoDox", "may", "substantially", "improve", "overall", "survival,", "when", "compared", "to", "the", "control", "group,", "in", "patients", "if", "their", "tumors", "undergo", "optimal", "RFA", "treatment.", "<tag3>"], "wordsA": ["On", "January", "31,", "2013,", "we", "announced", "that", "ThermoDox", "in", "combination", "with", "RFA", "did", "not", "meet", "the", "primary", "endpoint", "of", "the", "HEAT", "study", "in", "patients", "with", "hepatocellular", "carcinoma,", "also", "known", "as", "primary", "liver", "cancer."], "wordsB": ["The", "post-hoc", "data", "suggest", "that", "ThermoDox", "may", "substantially", "improve", "overall", "survival,", "when", "compared", "to", "the", "control", "group,", "in", "patients", "if", "their", "tumors", "undergo", "optimal", "RFA", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p66_s7", "idA": "749647_13_item1_p116_s0", "sentA": "On January 31, 2013, we announced that ThermoDox in combination with RFA did not meet the primary endpoint of the HEAT study in patients with hepatocellular carcinoma, also known as primary liver cancer.", "sentB": "A local response rate of over 60 percent was reported in 14 of the 23 evaluable patients with five complete responses and nine partial responses.", "type": 1, "words": ["<tag1>", "On", "January", "31,", "2013,", "we", "announced", "that", "ThermoDox", "in", "combination", "with", "RFA", "did", "not", "meet", "the", "primary", "endpoint", "of", "the", "HEAT", "study", "in", "patients", "with", "hepatocellular", "carcinoma,", "also", "known", "as", "primary", "liver", "cancer.", "<tag2>", "A", "local", "response", "rate", "of", "over", "60", "percent", "was", "reported", "in", "14", "of", "the", "23", "evaluable", "patients", "with", "five", "complete", "responses", "and", "nine", "partial", "responses.", "<tag3>"], "wordsA": ["On", "January", "31,", "2013,", "we", "announced", "that", "ThermoDox", "in", "combination", "with", "RFA", "did", "not", "meet", "the", "primary", "endpoint", "of", "the", "HEAT", "study", "in", "patients", "with", "hepatocellular", "carcinoma,", "also", "known", "as", "primary", "liver", "cancer."], "wordsB": ["A", "local", "response", "rate", "of", "over", "60", "percent", "was", "reported", "in", "14", "of", "the", "23", "evaluable", "patients", "with", "five", "complete", "responses", "and", "nine", "partial", "responses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p39_s0", "idA": "749647_13_item1_p117_s0", "sentA": "The HEAT study was designed to show a 33 percent improvement in PFS with 80 percent power and a p-value = 0.05.", "sentB": "As reported in January 2014, post-hoc data from the Company s HEAT Study demonstrate that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (285 patients or 63% of single lesion patients), experienced a 55% improvement in overall survival, with a Hazard Ratio of 0.64 (95% CI 0.41 - 1.00) and a P-value = 0.0495.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "was", "designed", "to", "show", "a", "33", "percent", "improvement", "in", "PFS", "with", "80", "percent", "power", "and", "a", "p-value", "=", "0.05.", "<tag2>", "As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "Company", "s", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "was", "designed", "to", "show", "a", "33", "percent", "improvement", "in", "PFS", "with", "80", "percent", "power", "and", "a", "p-value", "=", "0.05."], "wordsB": ["As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "Company", "s", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p13_s1", "idA": "749647_13_item1_p117_s2", "sentA": "We will continue following the patients enrolled in the HEAT study to the secondary endpoint, overall survival.", "sentB": "Median overall survival for this subgroup has not yet been reached.", "type": 1, "words": ["<tag1>", "We", "will", "continue", "following", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint,", "overall", "survival.", "<tag2>", "Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached.", "<tag3>"], "wordsA": ["We", "will", "continue", "following", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint,", "overall", "survival."], "wordsB": ["Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p46_s2", "idA": "749647_13_item1_p117_s2", "sentA": "We will continue following the patients enrolled in the HEAT study to the secondary endpoint, overall survival.", "sentB": "Median overall survival for this subgroup has not yet been reached.", "type": 1, "words": ["<tag1>", "We", "will", "continue", "following", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint,", "overall", "survival.", "<tag2>", "Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached.", "<tag3>"], "wordsA": ["We", "will", "continue", "following", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint,", "overall", "survival."], "wordsB": ["Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p15_s0", "idA": "749647_13_item1_p122_s3", "sentA": "The Company also agreed to reimburse Cantor for legal fees and disbursements, not to exceed $50,000 in the aggregate, in connection with entering into the ATM Agreement.", "sentB": "The Company also completed computational modeling with supplementary preclinical animal studies supporting the relationship between heating duration and clinical outcomes.", "type": 1, "words": ["<tag1>", "The", "Company", "also", "agreed", "to", "reimburse", "Cantor", "for", "legal", "fees", "and", "disbursements,", "not", "to", "exceed", "$50,000", "in", "the", "aggregate,", "in", "connection", "with", "entering", "into", "the", "ATM", "Agreement.", "<tag2>", "The", "Company", "also", "completed", "computational", "modeling", "with", "supplementary", "preclinical", "animal", "studies", "supporting", "the", "relationship", "between", "heating", "duration", "and", "clinical", "outcomes.", "<tag3>"], "wordsA": ["The", "Company", "also", "agreed", "to", "reimburse", "Cantor", "for", "legal", "fees", "and", "disbursements,", "not", "to", "exceed", "$50,000", "in", "the", "aggregate,", "in", "connection", "with", "entering", "into", "the", "ATM", "Agreement."], "wordsB": ["The", "Company", "also", "completed", "computational", "modeling", "with", "supplementary", "preclinical", "animal", "studies", "supporting", "the", "relationship", "between", "heating", "duration", "and", "clinical", "outcomes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p13_s0", "idA": "749647_13_item1_p13_s2", "sentA": "We will also conduct additional analyses of the data from the HEAT study to assess the future strategic value of ThermoDox .", "sentB": "As reported in January 2014, post-hoc data from the HEAT Study demonstrate that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (285 patients or 63% of single lesion patients), experienced a 55% improvement in overall survival, with a Hazard Ratio of 0.64 (95% CI 0.41 - 1.00) and a P-value = 0.0495.", "type": 1, "words": ["<tag1>", "We", "will", "also", "conduct", "additional", "analyses", "of", "the", "data", "from", "the", "HEAT", "study", "to", "assess", "the", "future", "strategic", "value", "of", "ThermoDox", ".", "<tag2>", "As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495.", "<tag3>"], "wordsA": ["We", "will", "also", "conduct", "additional", "analyses", "of", "the", "data", "from", "the", "HEAT", "study", "to", "assess", "the", "future", "strategic", "value", "of", "ThermoDox", "."], "wordsB": ["As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p102_s0", "idA": "749647_13_item1_p35_s0", "sentA": "The HEAT study for ThermoDox , in combination with radiofrequency ablation (RFA), is being conducted under a Special Protocol Assessment agreed to with the U.S. Food and Drug Administration (FDA).", "sentB": "Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "for", "ThermoDox", ",", "in", "combination", "with", "radiofrequency", "ablation", "(RFA),", "is", "being", "conducted", "under", "a", "Special", "Protocol", "Assessment", "agreed", "to", "with", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA).", "<tag2>", "Under", "European", "Union", "regulatory", "systems,", "a", "company", "may", "submit", "marketing", "authorization", "applications", "either", "under", "a", "centralized", "or", "decentralized", "procedure.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "for", "ThermoDox", ",", "in", "combination", "with", "radiofrequency", "ablation", "(RFA),", "is", "being", "conducted", "under", "a", "Special", "Protocol", "Assessment", "agreed", "to", "with", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)."], "wordsB": ["Under", "European", "Union", "regulatory", "systems,", "a", "company", "may", "submit", "marketing", "authorization", "applications", "either", "under", "a", "centralized", "or", "decentralized", "procedure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p19_s0", "idA": "749647_13_item1_p35_s4", "sentA": "Specifically, we determined, after conferring with the DMC, that the HEAT study did not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for the HEAT study.", "sentB": "In April 2013, we engaged Cantor Fitzgerald Co. to conduct a comprehensive review of merger and acquisition opportunities with the goal of identifying novel products with high potential, or companies, to acquire.", "type": 1, "words": ["<tag1>", "Specifically,", "we", "determined,", "after", "conferring", "with", "the", "DMC,", "that", "the", "HEAT", "study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "persuasive", "evidence", "of", "clinical", "effectiveness", "that", "could", "form", "the", "basis", "for", "regulatory", "approval", "in", "the", "population", "chosen", "for", "the", "HEAT", "study.", "<tag2>", "In", "April", "2013,", "we", "engaged", "Cantor", "Fitzgerald", "Co.", "to", "conduct", "a", "comprehensive", "review", "of", "merger", "and", "acquisition", "opportunities", "with", "the", "goal", "of", "identifying", "novel", "products", "with", "high", "potential,", "or", "companies,", "to", "acquire.", "<tag3>"], "wordsA": ["Specifically,", "we", "determined,", "after", "conferring", "with", "the", "DMC,", "that", "the", "HEAT", "study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "persuasive", "evidence", "of", "clinical", "effectiveness", "that", "could", "form", "the", "basis", "for", "regulatory", "approval", "in", "the", "population", "chosen", "for", "the", "HEAT", "study."], "wordsB": ["In", "April", "2013,", "we", "engaged", "Cantor", "Fitzgerald", "Co.", "to", "conduct", "a", "comprehensive", "review", "of", "merger", "and", "acquisition", "opportunities", "with", "the", "goal", "of", "identifying", "novel", "products", "with", "high", "potential,", "or", "companies,", "to", "acquire."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p52_s0", "idA": "749647_13_item1_p36_s0", "sentA": "The HEAT study was designed to show a 33 percent improvement in PFS with 80 percent power and a p-value = 0.05.", "sentB": "As reported in January 2014, post-hoc data from the Company's HEAT Study demonstrate that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (285 patients or 63% of single lesion patients), experienced a 55% improvement in overall survival, with a Hazard Ratio of 0.64 (95% CI 0.41 - 1.00) and a P-value = 0.0495.", "type": 1, "words": ["<tag1>", "The", "HEAT", "study", "was", "designed", "to", "show", "a", "33", "percent", "improvement", "in", "PFS", "with", "80", "percent", "power", "and", "a", "p-value", "=", "0.05.", "<tag2>", "As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "Company's", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495.", "<tag3>"], "wordsA": ["The", "HEAT", "study", "was", "designed", "to", "show", "a", "33", "percent", "improvement", "in", "PFS", "with", "80", "percent", "power", "and", "a", "p-value", "=", "0.05."], "wordsB": ["As", "reported", "in", "January", "2014,", "post-hoc", "data", "from", "the", "Company's", "HEAT", "Study", "demonstrate", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes", "(285", "patients", "or", "63%", "of", "single", "lesion", "patients),", "experienced", "a", "55%", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p125_s3", "idA": "749647_13_item1_p41_s0", "sentA": "Hisun is also obligated to certain performance requirements under the agreement.", "sentB": "The Company anticipates that it will use any additional funding up to $15 million as provided under the agreement for working capital or in support of its previously announced strategic acquisition initiative, which is designed to identify new technologies and clinical stage products for its development pipeline.", "type": 1, "words": ["<tag1>", "Hisun", "is", "also", "obligated", "to", "certain", "performance", "requirements", "under", "the", "agreement.", "<tag2>", "The", "Company", "anticipates", "that", "it", "will", "use", "any", "additional", "funding", "up", "to", "$15", "million", "as", "provided", "under", "the", "agreement", "for", "working", "capital", "or", "in", "support", "of", "its", "previously", "announced", "strategic", "acquisition", "initiative,", "which", "is", "designed", "to", "identify", "new", "technologies", "and", "clinical", "stage", "products", "for", "its", "development", "pipeline.", "<tag3>"], "wordsA": ["Hisun", "is", "also", "obligated", "to", "certain", "performance", "requirements", "under", "the", "agreement."], "wordsB": ["The", "Company", "anticipates", "that", "it", "will", "use", "any", "additional", "funding", "up", "to", "$15", "million", "as", "provided", "under", "the", "agreement", "for", "working", "capital", "or", "in", "support", "of", "its", "previously", "announced", "strategic", "acquisition", "initiative,", "which", "is", "designed", "to", "identify", "new", "technologies", "and", "clinical", "stage", "products", "for", "its", "development", "pipeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p126_s1", "idA": "749647_13_item1_p46_s3", "sentA": "Enrollment of the first patient in this clinical study is targeted for the first half of 2013.", "sentB": "Payments under the loan agreement are interest only for the first twelve months after loan closing, followed by a 30-month amortization period of principal and interest through the scheduled maturity date.", "type": 1, "words": ["<tag1>", "Enrollment", "of", "the", "first", "patient", "in", "this", "clinical", "study", "is", "targeted", "for", "the", "first", "half", "of", "2013.", "<tag2>", "Payments", "under", "the", "loan", "agreement", "are", "interest", "only", "for", "the", "first", "twelve", "months", "after", "loan", "closing,", "followed", "by", "a", "30-month", "amortization", "period", "of", "principal", "and", "interest", "through", "the", "scheduled", "maturity", "date.", "<tag3>"], "wordsA": ["Enrollment", "of", "the", "first", "patient", "in", "this", "clinical", "study", "is", "targeted", "for", "the", "first", "half", "of", "2013."], "wordsB": ["Payments", "under", "the", "loan", "agreement", "are", "interest", "only", "for", "the", "first", "twelve", "months", "after", "loan", "closing,", "followed", "by", "a", "30-month", "amortization", "period", "of", "principal", "and", "interest", "through", "the", "scheduled", "maturity", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p130_s3", "idA": "749647_13_item1_p56_s1", "sentA": "The DIGNITY study is designed to establish a safe therapeutic dose in Phase I, and in Phase II to demonstrate local control, including complete and partial responses, and stable disease as its primary endpoint.", "sentB": "The OPTIMA study is designed with extensive input from globally recognized HCC researchers and clinicians and after formal consultation with FDA.", "type": 1, "words": ["<tag1>", "The", "DIGNITY", "study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint.", "<tag2>", "The", "OPTIMA", "study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians", "and", "after", "formal", "consultation", "with", "FDA.", "<tag3>"], "wordsA": ["The", "DIGNITY", "study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint."], "wordsB": ["The", "OPTIMA", "study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians", "and", "after", "formal", "consultation", "with", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p13_s2", "idA": "749647_13_item1_p57_s0", "sentA": "The Company completed enrollment of the Phase I portion of the study in 2010 and an independent Data Safety Monitoring Board declared 50mg/m2 to be the Phase II dose.", "sentB": "We may choose to end this analysis of overall survival once the median is reached for either or both arms of the study .", "type": 1, "words": ["<tag1>", "The", "Company", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "of", "the", "study", "in", "2010", "and", "an", "independent", "Data", "Safety", "Monitoring", "Board", "declared", "50mg/m2", "to", "be", "the", "Phase", "II", "dose.", "<tag2>", "We", "may", "choose", "to", "end", "this", "analysis", "of", "overall", "survival", "once", "the", "median", "is", "reached", "for", "either", "or", "both", "arms", "of", "the", "study", ".", "<tag3>"], "wordsA": ["The", "Company", "completed", "enrollment", "of", "the", "Phase", "I", "portion", "of", "the", "study", "in", "2010", "and", "an", "independent", "Data", "Safety", "Monitoring", "Board", "declared", "50mg/m2", "to", "be", "the", "Phase", "II", "dose."], "wordsB": ["We", "may", "choose", "to", "end", "this", "analysis", "of", "overall", "survival", "once", "the", "median", "is", "reached", "for", "either", "or", "both", "arms", "of", "the", "study", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p67_s1", "idA": "749647_13_item1_p61_s1", "sentA": "Addressing these metastases allows us to improve three- and five-year survival rates among patients with this aggressive disease.", "sentB": "Based on the data available to date, a local response rate of approximately 80 percent has been observed in the five evaluable patients with refractory disease, notably two complete responses, two partial responses and one patient with stable disease.", "type": 1, "words": ["<tag1>", "Addressing", "these", "metastases", "allows", "us", "to", "improve", "three-", "and", "five-year", "survival", "rates", "among", "patients", "with", "this", "aggressive", "disease.", "<tag2>", "Based", "on", "the", "data", "available", "to", "date,", "a", "local", "response", "rate", "of", "approximately", "80", "percent", "has", "been", "observed", "in", "the", "five", "evaluable", "patients", "with", "refractory", "disease,", "notably", "two", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease.", "<tag3>"], "wordsA": ["Addressing", "these", "metastases", "allows", "us", "to", "improve", "three-", "and", "five-year", "survival", "rates", "among", "patients", "with", "this", "aggressive", "disease."], "wordsB": ["Based", "on", "the", "data", "available", "to", "date,", "a", "local", "response", "rate", "of", "approximately", "80", "percent", "has", "been", "observed", "in", "the", "five", "evaluable", "patients", "with", "refractory", "disease,", "notably", "two", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p100_s1", "idA": "749647_13_item1_p75_s1", "sentA": "The steps ordinarily required before such products can be marketed in the U.S. include (a) pre-clinical and clinical studies; (b) the submission to the FDA of an application for, or approval, as an Investigational New Drug application (IND), which must become effective before human clinical trials may commence; (c) adequate and well-controlled human clinical trials to establish the safety and efficacy of the product; (d) the submission to the FDA of a New Drug Application (NDA); and (e) FDA approval of the application, including approval of all product labeling.", "sentB": "Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union and China, before we may market products in those countries or areas.", "type": 1, "words": ["<tag1>", "The", "steps", "ordinarily", "required", "before", "such", "products", "can", "be", "marketed", "in", "the", "U.S.", "include", "(a)", "pre-clinical", "and", "clinical", "studies;", "(b)", "the", "submission", "to", "the", "FDA", "of", "an", "application", "for,", "or", "approval,", "as", "an", "Investigational", "New", "Drug", "application", "(IND),", "which", "must", "become", "effective", "before", "human", "clinical", "trials", "may", "commence;", "(c)", "adequate", "and", "well-controlled", "human", "clinical", "trials", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "product;", "(d)", "the", "submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA);", "and", "(e)", "FDA", "approval", "of", "the", "application,", "including", "approval", "of", "all", "product", "labeling.", "<tag2>", "Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "countries", "outside", "of", "the", "U.S.", "before", "we", "can", "commence", "clinical", "trials", "in", "such", "countries", "and", "approval", "of", "the", "regulators", "of", "such", "countries", "or", "economic", "areas,", "such", "as", "the", "European", "Union", "and", "China,", "before", "we", "may", "market", "products", "in", "those", "countries", "or", "areas.", "<tag3>"], "wordsA": ["The", "steps", "ordinarily", "required", "before", "such", "products", "can", "be", "marketed", "in", "the", "U.S.", "include", "(a)", "pre-clinical", "and", "clinical", "studies;", "(b)", "the", "submission", "to", "the", "FDA", "of", "an", "application", "for,", "or", "approval,", "as", "an", "Investigational", "New", "Drug", "application", "(IND),", "which", "must", "become", "effective", "before", "human", "clinical", "trials", "may", "commence;", "(c)", "adequate", "and", "well-controlled", "human", "clinical", "trials", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "product;", "(d)", "the", "submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA);", "and", "(e)", "FDA", "approval", "of", "the", "application,", "including", "approval", "of", "all", "product", "labeling."], "wordsB": ["Whether", "or", "not", "we", "obtain", "FDA", "approval", "for", "a", "product,", "we", "must", "obtain", "approval", "by", "the", "comparable", "regulatory", "authorities", "of", "countries", "outside", "of", "the", "U.S.", "before", "we", "can", "commence", "clinical", "trials", "in", "such", "countries", "and", "approval", "of", "the", "regulators", "of", "such", "countries", "or", "economic", "areas,", "such", "as", "the", "European", "Union", "and", "China,", "before", "we", "may", "market", "products", "in", "those", "countries", "or", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p103_s1", "idA": "749647_13_item1_p79_s3", "sentA": "However, the FDA may require additional, post-market trials as a condition of approval.", "sentB": "Within 90 days of receiving the applications and assessments report, each member state must decide whether to recognize approval.", "type": 1, "words": ["<tag1>", "However,", "the", "FDA", "may", "require", "additional,", "post-market", "trials", "as", "a", "condition", "of", "approval.", "<tag2>", "Within", "90", "days", "of", "receiving", "the", "applications", "and", "assessments", "report,", "each", "member", "state", "must", "decide", "whether", "to", "recognize", "approval.", "<tag3>"], "wordsA": ["However,", "the", "FDA", "may", "require", "additional,", "post-market", "trials", "as", "a", "condition", "of", "approval."], "wordsB": ["Within", "90", "days", "of", "receiving", "the", "applications", "and", "assessments", "report,", "each", "member", "state", "must", "decide", "whether", "to", "recognize", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p103_s0", "idA": "749647_13_item1_p92_s1", "sentA": "These regulations require, among other things, the reporting to the FDA of adverse events alleged to have been associated with the use of a product or in connection with certain product failures.", "sentB": "Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states.", "type": 1, "words": ["<tag1>", "These", "regulations", "require,", "among", "other", "things,", "the", "reporting", "to", "the", "FDA", "of", "adverse", "events", "alleged", "to", "have", "been", "associated", "with", "the", "use", "of", "a", "product", "or", "in", "connection", "with", "certain", "product", "failures.", "<tag2>", "Under", "this", "procedure,", "the", "holder", "of", "a", "national", "marketing", "authorization", "may", "submit", "an", "application", "to", "the", "remaining", "member", "states.", "<tag3>"], "wordsA": ["These", "regulations", "require,", "among", "other", "things,", "the", "reporting", "to", "the", "FDA", "of", "adverse", "events", "alleged", "to", "have", "been", "associated", "with", "the", "use", "of", "a", "product", "or", "in", "connection", "with", "certain", "product", "failures."], "wordsB": ["Under", "this", "procedure,", "the", "holder", "of", "a", "national", "marketing", "authorization", "may", "submit", "an", "application", "to", "the", "remaining", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p16_s3", "idA": "749647_13_item1_p93_s0", "sentA": "Labeling and promotional activities are also regulated by the FDA.", "sentB": "The OPTIMA Study is designed with extensive input from globally recognized HCC researchers and clinicians and after formal written consultation with FDA.", "type": 1, "words": ["<tag1>", "Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA.", "<tag2>", "The", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians", "and", "after", "formal", "written", "consultation", "with", "FDA.", "<tag3>"], "wordsA": ["Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA."], "wordsB": ["The", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians", "and", "after", "formal", "written", "consultation", "with", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p51_s0", "idA": "749647_13_item1_p93_s0", "sentA": "Labeling and promotional activities are also regulated by the FDA.", "sentB": "The Phase III OPTIMA Study is designed with extensive input from globally recognized HCC researchers and clinicians, and after formal consultation with FDA.", "type": 1, "words": ["<tag1>", "Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA.", "<tag2>", "The", "Phase", "III", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians,", "and", "after", "formal", "consultation", "with", "FDA.", "<tag3>"], "wordsA": ["Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA."], "wordsB": ["The", "Phase", "III", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians,", "and", "after", "formal", "consultation", "with", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p85_s0", "idA": "749647_13_item1_p93_s0", "sentA": "Labeling and promotional activities are also regulated by the FDA.", "sentB": "The Phase III OPTIMA Study is designed with extensive input from globally recognized HCC researchers and clinicians, and after formal consultation with FDA.", "type": 1, "words": ["<tag1>", "Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA.", "<tag2>", "The", "Phase", "III", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians,", "and", "after", "formal", "consultation", "with", "FDA.", "<tag3>"], "wordsA": ["Labeling", "and", "promotional", "activities", "are", "also", "regulated", "by", "the", "FDA."], "wordsB": ["The", "Phase", "III", "OPTIMA", "Study", "is", "designed", "with", "extensive", "input", "from", "globally", "recognized", "HCC", "researchers", "and", "clinicians,", "and", "after", "formal", "consultation", "with", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_14_item1_p102_s1", "idA": "749647_13_item1_p9_s0", "sentA": "Celsion is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer.", "sentB": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "type": 1, "words": ["<tag1>", "Celsion", "is", "an", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "treatments", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer.", "<tag2>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag3>"], "wordsA": ["Celsion", "is", "an", "oncology", "drug", "development", "company", "focused", "on", "the", "development", "of", "treatments", "for", "those", "suffering", "with", "difficult", "to", "treat", "forms", "of", "cancer."], "wordsB": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p159_s0", "idA": "749647_14_item1_p0_s1", "sentA": "In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements.", "sentB": "For the TheraPlas technology, we own three US and international patent families and related applications with claims and methods and compositions of matters that cover various aspects of TheraPlas and GEN-1 technologies, with expiration dates ranging from 2020 to 2028.", "type": 1, "words": ["<tag1>", "In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements.", "<tag2>", "For", "the", "TheraPlas", "technology,", "we", "own", "three", "US", "and", "international", "patent", "families", "and", "related", "applications", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "TheraPlas", "and", "GEN-1", "technologies,", "with", "expiration", "dates", "ranging", "from", "2020", "to", "2028.", "<tag3>"], "wordsA": ["In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements."], "wordsB": ["For", "the", "TheraPlas", "technology,", "we", "own", "three", "US", "and", "international", "patent", "families", "and", "related", "applications", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "TheraPlas", "and", "GEN-1", "technologies,", "with", "expiration", "dates", "ranging", "from", "2020", "to", "2028."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p160_s0", "idA": "749647_14_item1_p0_s1", "sentA": "In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements.", "sentB": "For the TheraSilence technology, we own multiple US and international patent families and related applications with claims and methods and compositions of matters that cover various aspects of TheraSilence technology, with expiration dates to 2031.", "type": 1, "words": ["<tag1>", "In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements.", "<tag2>", "For", "the", "TheraSilence", "technology,", "we", "own", "multiple", "US", "and", "international", "patent", "families", "and", "related", "applications", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "TheraSilence", "technology,", "with", "expiration", "dates", "to", "2031.", "<tag3>"], "wordsA": ["In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements."], "wordsB": ["For", "the", "TheraSilence", "technology,", "we", "own", "multiple", "US", "and", "international", "patent", "families", "and", "related", "applications", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "TheraSilence", "technology,", "with", "expiration", "dates", "to", "2031."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p161_s0", "idA": "749647_14_item1_p0_s1", "sentA": "In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements.", "sentB": "For the RAST technology, we own US and international patents with claims and methods and compositions of matters that cover various aspects of RAST technology, with expiration dates to 2030.", "type": 1, "words": ["<tag1>", "In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements.", "<tag2>", "For", "the", "RAST", "technology,", "we", "own", "US", "and", "international", "patents", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "RAST", "technology,", "with", "expiration", "dates", "to", "2030.", "<tag3>"], "wordsA": ["In", "addition,", "from", "time", "to", "time", "we", "may", "publish", "forward-looking", "statements", "relating", "to", "such", "matters", "as", "anticipated", "financial", "performance,", "business", "prospects,", "technological", "developments,", "product", "pipelines,", "clinical", "trials", "and", "research", "and", "development", "activities,", "the", "adequacy", "of", "capital", "reserves", "and", "anticipated", "operating", "results", "and", "cash", "expenditures,", "current", "and", "potential", "collaborations,", "strategic", "alternatives", "and", "other", "aspects", "of", "our", "present", "and", "future", "business", "operations", "and", "similar", "matters", "that", "also", "constitute", "such", "forward-looking", "statements."], "wordsB": ["For", "the", "RAST", "technology,", "we", "own", "US", "and", "international", "patents", "with", "claims", "and", "methods", "and", "compositions", "of", "matters", "that", "cover", "various", "aspects", "of", "RAST", "technology,", "with", "expiration", "dates", "to", "2030."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p162_s2", "idA": "749647_14_item1_p100_s0", "sentA": "In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates.", "sentB": "Issued patents can be subject to oppositions, interferences and other third party challenges that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).", "type": 1, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates.", "<tag2>", "Issued", "patents", "can", "be", "subject", "to", "oppositions,", "interferences", "and", "other", "third", "party", "challenges", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage).", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates."], "wordsB": ["Issued", "patents", "can", "be", "subject", "to", "oppositions,", "interferences", "and", "other", "third", "party", "challenges", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p164_s0", "idA": "749647_14_item1_p100_s0", "sentA": "In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates.", "sentB": "Development and commercialization of pharmaceutical products can be subject to substantial delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short period of time following commercialization.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates.", "<tag2>", "Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization.", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates."], "wordsB": ["Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p107_s1", "idA": "749647_14_item1_p102_s1", "sentA": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "sentB": "Using this delivery system we have been able to show in mice that delivery of a siRNA molecule that targets anti-vascular endothelial receptor 2 (VEGF2), a protein that is critical for the growth of new blood vessels in tumors, can significantly inhibit lung tumor growth.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "Using", "this", "delivery", "system", "we", "have", "been", "able", "to", "show", "in", "mice", "that", "delivery", "of", "a", "siRNA", "molecule", "that", "targets", "anti-vascular", "endothelial", "receptor", "2", "(VEGF2),", "a", "protein", "that", "is", "critical", "for", "the", "growth", "of", "new", "blood", "vessels", "in", "tumors,", "can", "significantly", "inhibit", "lung", "tumor", "growth.", "<tag3>"], "wordsA": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "which", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["Using", "this", "delivery", "system", "we", "have", "been", "able", "to", "show", "in", "mice", "that", "delivery", "of", "a", "siRNA", "molecule", "that", "targets", "anti-vascular", "endothelial", "receptor", "2", "(VEGF2),", "a", "protein", "that", "is", "critical", "for", "the", "growth", "of", "new", "blood", "vessels", "in", "tumors,", "can", "significantly", "inhibit", "lung", "tumor", "growth."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p97_s2", "idA": "749647_14_item1_p110_s2", "sentA": "We have also licensed from Valentis, CA certain global rights covering the use of pegylation for temperature sensitive liposomes.", "sentB": "We have used molecular functionalization strategies to improve the activity of low molecular weight PEIs without augmenting their cytotoxicity.", "type": 1, "words": ["<tag1>", "We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes.", "<tag2>", "We", "have", "used", "molecular", "functionalization", "strategies", "to", "improve", "the", "activity", "of", "low", "molecular", "weight", "PEIs", "without", "augmenting", "their", "cytotoxicity.", "<tag3>"], "wordsA": ["We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes."], "wordsB": ["We", "have", "used", "molecular", "functionalization", "strategies", "to", "improve", "the", "activity", "of", "low", "molecular", "weight", "PEIs", "without", "augmenting", "their", "cytotoxicity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p106_s3", "idA": "749647_14_item1_p111_s0", "sentA": "In 2003, our obligations under the license agreement with Duke University with respect to the testing and regulatory milestones and other licensed technology performance deadlines were eliminated in exchange for a payment of shares of our common stock.", "sentB": "In addition, these systems are chemically flexible and amenable to attachment of tissue-targeted ligands, in vivo stabilizing agents and other functional moieties which can tailor a formulation for a particular application and delivery modality.", "type": 1, "words": ["<tag1>", "In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock.", "<tag2>", "In", "addition,", "these", "systems", "are", "chemically", "flexible", "and", "amenable", "to", "attachment", "of", "tissue-targeted", "ligands,", "in", "vivo", "stabilizing", "agents", "and", "other", "functional", "moieties", "which", "can", "tailor", "a", "formulation", "for", "a", "particular", "application", "and", "delivery", "modality.", "<tag3>"], "wordsA": ["In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock."], "wordsB": ["In", "addition,", "these", "systems", "are", "chemically", "flexible", "and", "amenable", "to", "attachment", "of", "tissue-targeted", "ligands,", "in", "vivo", "stabilizing", "agents", "and", "other", "functional", "moieties", "which", "can", "tailor", "a", "formulation", "for", "a", "particular", "application", "and", "delivery", "modality."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p21_s1", "idA": "749647_14_item1_p118_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "CLSN Laboratories, Inc., a Delaware corporation and a wholly-owned subsidiary of ours (CLSN Laboratories), acquired all of EGEN s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "CLSN", "Laboratories,", "Inc.,", "a", "Delaware", "corporation", "and", "a", "wholly-owned", "subsidiary", "of", "ours", "(CLSN", "Laboratories),", "acquired", "all", "of", "EGEN", "s", "right,", "title", "and", "interest", "in", "and", "to", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "including", "cash", "and", "cash", "equivalents,", "patents,", "trademarks", "and", "other", "intellectual", "property", "rights,", "clinical", "data,", "certain", "contracts,", "licenses", "and", "permits,", "equipment,", "furniture,", "office", "equipment,", "furnishings,", "supplies", "and", "other", "tangible", "personal", "property.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["CLSN", "Laboratories,", "Inc.,", "a", "Delaware", "corporation", "and", "a", "wholly-owned", "subsidiary", "of", "ours", "(CLSN", "Laboratories),", "acquired", "all", "of", "EGEN", "s", "right,", "title", "and", "interest", "in", "and", "to", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "including", "cash", "and", "cash", "equivalents,", "patents,", "trademarks", "and", "other", "intellectual", "property", "rights,", "clinical", "data,", "certain", "contracts,", "licenses", "and", "permits,", "equipment,", "furniture,", "office", "equipment,", "furnishings,", "supplies", "and", "other", "tangible", "personal", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p82_s4", "idA": "749647_14_item1_p118_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "The platinum-resistant group has a platinum-free interval of shorter than six months and is resistant to additional platinum-based treatments.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "The", "platinum-resistant", "group", "has", "a", "platinum-free", "interval", "of", "shorter", "than", "six", "months", "and", "is", "resistant", "to", "additional", "platinum-based", "treatments.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["The", "platinum-resistant", "group", "has", "a", "platinum-free", "interval", "of", "shorter", "than", "six", "months", "and", "is", "resistant", "to", "additional", "platinum-based", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p95_s0", "idA": "749647_14_item1_p118_s0", "sentA": "Celsion was founded in 1982 and is a Delaware corporation.", "sentB": "TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.", "type": 1, "words": ["<tag1>", "Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation.", "<tag2>", "TheraPlas", "is", "a", "technology", "platform", "for", "the", "delivery", "of", "DNA", "and", "messenger", "RNA", "(mRNA)", "therapeutics", "via", "synthetic", "non-viral", "carriers", "and", "is", "capable", "of", "providing", "cell", "transfection", "for", "double-stranded", "DNA", "plasmids", "and", "large", "therapeutic", "RNA", "segments", "such", "as", "mRNA.", "<tag3>"], "wordsA": ["Celsion", "was", "founded", "in", "1982", "and", "is", "a", "Delaware", "corporation."], "wordsB": ["TheraPlas", "is", "a", "technology", "platform", "for", "the", "delivery", "of", "DNA", "and", "messenger", "RNA", "(mRNA)", "therapeutics", "via", "synthetic", "non-viral", "carriers", "and", "is", "capable", "of", "providing", "cell", "transfection", "for", "double-stranded", "DNA", "plasmids", "and", "large", "therapeutic", "RNA", "segments", "such", "as", "mRNA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p106_s2", "idA": "749647_14_item1_p118_s4", "sentA": "The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report on Form 10-K.", "sentB": "We have developed proprietary, novel structures that are able to interact with the RNAi molecules forming protective nanoparticles that can be readily taken up into cells.", "type": 1, "words": ["<tag1>", "The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report", "on", "Form", "10-K.", "<tag2>", "We", "have", "developed", "proprietary,", "novel", "structures", "that", "are", "able", "to", "interact", "with", "the", "RNAi", "molecules", "forming", "protective", "nanoparticles", "that", "can", "be", "readily", "taken", "up", "into", "cells.", "<tag3>"], "wordsA": ["The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report", "on", "Form", "10-K."], "wordsB": ["We", "have", "developed", "proprietary,", "novel", "structures", "that", "are", "able", "to", "interact", "with", "the", "RNAi", "molecules", "forming", "protective", "nanoparticles", "that", "can", "be", "readily", "taken", "up", "into", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p103_s1", "idA": "749647_14_item1_p119_s3", "sentA": "Copies of these documents may be obtained, free of charge, from our website.", "sentB": "The biocompatibility of these polymers reduces the risk of adverse immune response, thus allowing for repeated administration.", "type": 1, "words": ["<tag1>", "Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website.", "<tag2>", "The", "biocompatibility", "of", "these", "polymers", "reduces", "the", "risk", "of", "adverse", "immune", "response,", "thus", "allowing", "for", "repeated", "administration.", "<tag3>"], "wordsA": ["Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website."], "wordsB": ["The", "biocompatibility", "of", "these", "polymers", "reduces", "the", "risk", "of", "adverse", "immune", "response,", "thus", "allowing", "for", "repeated", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p165_s2", "idA": "749647_14_item1_p119_s3", "sentA": "Copies of these documents may be obtained, free of charge, from our website.", "sentB": "Should we need to defend ourselves and our partners against any such claims, substantial costs may be incurred.", "type": 1, "words": ["<tag1>", "Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website.", "<tag2>", "Should", "we", "need", "to", "defend", "ourselves", "and", "our", "partners", "against", "any", "such", "claims,", "substantial", "costs", "may", "be", "incurred.", "<tag3>"], "wordsA": ["Copies", "of", "these", "documents", "may", "be", "obtained,", "free", "of", "charge,", "from", "our", "website."], "wordsB": ["Should", "we", "need", "to", "defend", "ourselves", "and", "our", "partners", "against", "any", "such", "claims,", "substantial", "costs", "may", "be", "incurred."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p26_s2", "idA": "749647_14_item1_p11_s4", "sentA": "In April 2013, we announced the deferral of expenses associated with the Company s Phase II study of ThermoDox in combination with RFA for the treatment of colorectal liver metastases (The ABLATE Study) until such time as the Company finalizes its plans for the continuation of its development program with ThermoDox in HCC.", "sentB": "In March 2015, results of stability tests performed by Hisun demonstrated it successfully completed three registration batches of ThermoDox , all of which show substantial chemical equivalence with investigational product produced by the Company s current contract manufacturer.", "type": 1, "words": ["<tag1>", "In", "April", "2013,", "we", "announced", "the", "deferral", "of", "expenses", "associated", "with", "the", "Company", "s", "Phase", "II", "study", "of", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "colorectal", "liver", "metastases", "(The", "ABLATE", "Study)", "until", "such", "time", "as", "the", "Company", "finalizes", "its", "plans", "for", "the", "continuation", "of", "its", "development", "program", "with", "ThermoDox", "in", "HCC.", "<tag2>", "In", "March", "2015,", "results", "of", "stability", "tests", "performed", "by", "Hisun", "demonstrated", "it", "successfully", "completed", "three", "registration", "batches", "of", "ThermoDox", ",", "all", "of", "which", "show", "substantial", "chemical", "equivalence", "with", "investigational", "product", "produced", "by", "the", "Company", "s", "current", "contract", "manufacturer.", "<tag3>"], "wordsA": ["In", "April", "2013,", "we", "announced", "the", "deferral", "of", "expenses", "associated", "with", "the", "Company", "s", "Phase", "II", "study", "of", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "colorectal", "liver", "metastases", "(The", "ABLATE", "Study)", "until", "such", "time", "as", "the", "Company", "finalizes", "its", "plans", "for", "the", "continuation", "of", "its", "development", "program", "with", "ThermoDox", "in", "HCC."], "wordsB": ["In", "March", "2015,", "results", "of", "stability", "tests", "performed", "by", "Hisun", "demonstrated", "it", "successfully", "completed", "three", "registration", "batches", "of", "ThermoDox", ",", "all", "of", "which", "show", "substantial", "chemical", "equivalence", "with", "investigational", "product", "produced", "by", "the", "Company", "s", "current", "contract", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p101_s1", "idA": "749647_14_item1_p122_s1", "sentA": "All of the shares of Series A 0% convertible preferred stock have been converted into 2,682,764 shares of common stock.", "sentB": "Two cross-linked polymers have been synthesized with this approach and optimized for transfection activity.", "type": 1, "words": ["<tag1>", "All", "of", "the", "shares", "of", "Series", "A", "0%", "convertible", "preferred", "stock", "have", "been", "converted", "into", "2,682,764", "shares", "of", "common", "stock.", "<tag2>", "Two", "cross-linked", "polymers", "have", "been", "synthesized", "with", "this", "approach", "and", "optimized", "for", "transfection", "activity.", "<tag3>"], "wordsA": ["All", "of", "the", "shares", "of", "Series", "A", "0%", "convertible", "preferred", "stock", "have", "been", "converted", "into", "2,682,764", "shares", "of", "common", "stock."], "wordsB": ["Two", "cross-linked", "polymers", "have", "been", "synthesized", "with", "this", "approach", "and", "optimized", "for", "transfection", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p21_s4", "idA": "749647_14_item1_p122_s1", "sentA": "All of the shares of Series A 0% convertible preferred stock have been converted into 2,682,764 shares of common stock.", "sentB": "Additional consideration included contingent value rights totaling $30.4 million, payable in cash, shares of Celsion common stock or a combination thereof, at Celsion s option, upon acheivement of three major milestone events as follows:", "type": 1, "words": ["<tag1>", "All", "of", "the", "shares", "of", "Series", "A", "0%", "convertible", "preferred", "stock", "have", "been", "converted", "into", "2,682,764", "shares", "of", "common", "stock.", "<tag2>", "Additional", "consideration", "included", "contingent", "value", "rights", "totaling", "$30.4", "million,", "payable", "in", "cash,", "shares", "of", "Celsion", "common", "stock", "or", "a", "combination", "thereof,", "at", "Celsion", "s", "option,", "upon", "acheivement", "of", "three", "major", "milestone", "events", "as", "follows:", "<tag3>"], "wordsA": ["All", "of", "the", "shares", "of", "Series", "A", "0%", "convertible", "preferred", "stock", "have", "been", "converted", "into", "2,682,764", "shares", "of", "common", "stock."], "wordsB": ["Additional", "consideration", "included", "contingent", "value", "rights", "totaling", "$30.4", "million,", "payable", "in", "cash,", "shares", "of", "Celsion", "common", "stock", "or", "a", "combination", "thereof,", "at", "Celsion", "s", "option,", "upon", "acheivement", "of", "three", "major", "milestone", "events", "as", "follows:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p80_s1", "idA": "749647_14_item1_p126_s0", "sentA": "The loan bears interest at a floating per annum rate equal to the greater of (i) 11.25 percent and (ii) the sum of 11.25 per cent plus the prime rate minus 3.25 per cent.", "sentB": "Most women with ovarian cancer are not diagnosed until Stages III or IV, when the disease has spread outside the pelvis to the abdomen and areas beyond causing swelling and pain, where the five-year survival rates are 25 to 41 percent and 11 percent, respectively.", "type": 1, "words": ["<tag1>", "The", "loan", "bears", "interest", "at", "a", "floating", "per", "annum", "rate", "equal", "to", "the", "greater", "of", "(i)", "11.25", "percent", "and", "(ii)", "the", "sum", "of", "11.25", "per", "cent", "plus", "the", "prime", "rate", "minus", "3.25", "per", "cent.", "<tag2>", "Most", "women", "with", "ovarian", "cancer", "are", "not", "diagnosed", "until", "Stages", "III", "or", "IV,", "when", "the", "disease", "has", "spread", "outside", "the", "pelvis", "to", "the", "abdomen", "and", "areas", "beyond", "causing", "swelling", "and", "pain,", "where", "the", "five-year", "survival", "rates", "are", "25", "to", "41", "percent", "and", "11", "percent,", "respectively.", "<tag3>"], "wordsA": ["The", "loan", "bears", "interest", "at", "a", "floating", "per", "annum", "rate", "equal", "to", "the", "greater", "of", "(i)", "11.25", "percent", "and", "(ii)", "the", "sum", "of", "11.25", "per", "cent", "plus", "the", "prime", "rate", "minus", "3.25", "per", "cent."], "wordsB": ["Most", "women", "with", "ovarian", "cancer", "are", "not", "diagnosed", "until", "Stages", "III", "or", "IV,", "when", "the", "disease", "has", "spread", "outside", "the", "pelvis", "to", "the", "abdomen", "and", "areas", "beyond", "causing", "swelling", "and", "pain,", "where", "the", "five-year", "survival", "rates", "are", "25", "to", "41", "percent", "and", "11", "percent,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p85_s1", "idA": "749647_14_item1_p130_s1", "sentA": "The OPTIMA Study trial design is based on the comprehensive analysis of data from the Phase III HEAT study, which demonstrated that treatment with ThermoDox resulted in a 55 percent improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment.", "sentB": "The precedence for a therapeutic role of IL-12 in ovarian cancer is based on epidemiologic and preclinical data.", "type": 1, "words": ["<tag1>", "The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment.", "<tag2>", "The", "precedence", "for", "a", "therapeutic", "role", "of", "IL-12", "in", "ovarian", "cancer", "is", "based", "on", "epidemiologic", "and", "preclinical", "data.", "<tag3>"], "wordsA": ["The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment."], "wordsB": ["The", "precedence", "for", "a", "therapeutic", "role", "of", "IL-12", "in", "ovarian", "cancer", "is", "based", "on", "epidemiologic", "and", "preclinical", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p93_s2", "idA": "749647_14_item1_p130_s1", "sentA": "The OPTIMA Study trial design is based on the comprehensive analysis of data from the Phase III HEAT study, which demonstrated that treatment with ThermoDox resulted in a 55 percent improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment.", "sentB": "The highest number of partial responses was found at the highest dose level (36 mg/m 2 dose of GEN-1 combined with 50 mg/m 2 Doxil) which demonstrated that the maximum tolerated dose was not exceeded.", "type": 1, "words": ["<tag1>", "The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment.", "<tag2>", "The", "highest", "number", "of", "partial", "responses", "was", "found", "at", "the", "highest", "dose", "level", "(36", "mg/m", "2", "dose", "of", "GEN-1", "combined", "with", "50", "mg/m", "2", "Doxil)", "which", "demonstrated", "that", "the", "maximum", "tolerated", "dose", "was", "not", "exceeded.", "<tag3>"], "wordsA": ["The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment."], "wordsB": ["The", "highest", "number", "of", "partial", "responses", "was", "found", "at", "the", "highest", "dose", "level", "(36", "mg/m", "2", "dose", "of", "GEN-1", "combined", "with", "50", "mg/m", "2", "Doxil)", "which", "demonstrated", "that", "the", "maximum", "tolerated", "dose", "was", "not", "exceeded."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p97_s0", "idA": "749647_14_item1_p130_s1", "sentA": "The OPTIMA Study trial design is based on the comprehensive analysis of data from the Phase III HEAT study, which demonstrated that treatment with ThermoDox resulted in a 55 percent improvement in overall survival in a substantial number of HCC patients that received an optimized RFA treatment.", "sentB": "The design of TheraPlas delivery systems is based on molecular functionalization of polyethyleneimine (PEI), a cationic delivery polymer with a distinct ability to escape from the endosomes due to heavy protonation.", "type": 1, "words": ["<tag1>", "The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment.", "<tag2>", "The", "design", "of", "TheraPlas", "delivery", "systems", "is", "based", "on", "molecular", "functionalization", "of", "polyethyleneimine", "(PEI),", "a", "cationic", "delivery", "polymer", "with", "a", "distinct", "ability", "to", "escape", "from", "the", "endosomes", "due", "to", "heavy", "protonation.", "<tag3>"], "wordsA": ["The", "OPTIMA", "Study", "trial", "design", "is", "based", "on", "the", "comprehensive", "analysis", "of", "data", "from", "the", "Phase", "III", "HEAT", "study,", "which", "demonstrated", "that", "treatment", "with", "ThermoDox", "resulted", "in", "a", "55", "percent", "improvement", "in", "overall", "survival", "in", "a", "substantial", "number", "of", "HCC", "patients", "that", "received", "an", "optimized", "RFA", "treatment."], "wordsB": ["The", "design", "of", "TheraPlas", "delivery", "systems", "is", "based", "on", "molecular", "functionalization", "of", "polyethyleneimine", "(PEI),", "a", "cationic", "delivery", "polymer", "with", "a", "distinct", "ability", "to", "escape", "from", "the", "endosomes", "due", "to", "heavy", "protonation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p83_s1", "idA": "749647_14_item1_p13_s1", "sentA": "Median overall survival for this subgroup has not yet been reached.", "sentB": "The overall response rate for these therapies is 10 to 20 percent with median overall survival of eleven to twelve months.", "type": 1, "words": ["<tag1>", "Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached.", "<tag2>", "The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months.", "<tag3>"], "wordsA": ["Median", "overall", "survival", "for", "this", "subgroup", "has", "not", "yet", "been", "reached."], "wordsB": ["The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p107_s2", "idA": "749647_14_item1_p25_s0", "sentA": "As a result of the risks and uncertainties discussed in this Annual Report on Form 10-K, among others, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product.", "sentB": "Additionally, delivery of an anti-micro RNA molecule into rats with experimentally induced pulmonary arterial hypertension was able to normalize vascular remodeling that occurs in the lung and restore cardiac function that is compromised as a result of the disease.", "type": 1, "words": ["<tag1>", "As", "a", "result", "of", "the", "risks", "and", "uncertainties", "discussed", "in", "this", "Annual", "Report", "on", "Form", "10-K,", "among", "others,", "we", "are", "unable", "to", "estimate", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects", "or", "when,", "if", "ever,", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "the", "commercialization", "and", "sale", "of", "a", "product.", "<tag2>", "Additionally,", "delivery", "of", "an", "anti-micro", "RNA", "molecule", "into", "rats", "with", "experimentally", "induced", "pulmonary", "arterial", "hypertension", "was", "able", "to", "normalize", "vascular", "remodeling", "that", "occurs", "in", "the", "lung", "and", "restore", "cardiac", "function", "that", "is", "compromised", "as", "a", "result", "of", "the", "disease.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "risks", "and", "uncertainties", "discussed", "in", "this", "Annual", "Report", "on", "Form", "10-K,", "among", "others,", "we", "are", "unable", "to", "estimate", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects", "or", "when,", "if", "ever,", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "the", "commercialization", "and", "sale", "of", "a", "product."], "wordsB": ["Additionally,", "delivery", "of", "an", "anti-micro", "RNA", "molecule", "into", "rats", "with", "experimentally", "induced", "pulmonary", "arterial", "hypertension", "was", "able", "to", "normalize", "vascular", "remodeling", "that", "occurs", "in", "the", "lung", "and", "restore", "cardiac", "function", "that", "is", "compromised", "as", "a", "result", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p106_s1", "idA": "749647_14_item1_p25_s3", "sentA": "We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders.", "sentB": "Specifically, a delivery system needs to be able to protect the RNAi from nuclease degradation, transfer the molecule across the cellular membranes and release the material so that it can be available to the endogenous RNA silencing machinery.", "type": 1, "words": ["<tag1>", "We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders.", "<tag2>", "Specifically,", "a", "delivery", "system", "needs", "to", "be", "able", "to", "protect", "the", "RNAi", "from", "nuclease", "degradation,", "transfer", "the", "molecule", "across", "the", "cellular", "membranes", "and", "release", "the", "material", "so", "that", "it", "can", "be", "available", "to", "the", "endogenous", "RNA", "silencing", "machinery.", "<tag3>"], "wordsA": ["We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders."], "wordsB": ["Specifically,", "a", "delivery", "system", "needs", "to", "be", "able", "to", "protect", "the", "RNAi", "from", "nuclease", "degradation,", "transfer", "the", "molecule", "across", "the", "cellular", "membranes", "and", "release", "the", "material", "so", "that", "it", "can", "be", "available", "to", "the", "endogenous", "RNA", "silencing", "machinery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p86_s2", "idA": "749647_14_item1_p26_s0", "sentA": "As a clinical stage biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals are subject to numerous risks and uncertainties.", "sentB": "In this approach, our GEN-1 immunotherapy is combined with standard chemotherapy drugs to achieve better clinical outcome than with chemotherapy alone.", "type": 1, "words": ["<tag1>", "As", "a", "clinical", "stage", "biopharmaceutical", "company,", "our", "business", "and", "our", "ability", "to", "execute", "our", "strategy", "to", "achieve", "our", "corporate", "goals", "are", "subject", "to", "numerous", "risks", "and", "uncertainties.", "<tag2>", "In", "this", "approach,", "our", "GEN-1", "immunotherapy", "is", "combined", "with", "standard", "chemotherapy", "drugs", "to", "achieve", "better", "clinical", "outcome", "than", "with", "chemotherapy", "alone.", "<tag3>"], "wordsA": ["As", "a", "clinical", "stage", "biopharmaceutical", "company,", "our", "business", "and", "our", "ability", "to", "execute", "our", "strategy", "to", "achieve", "our", "corporate", "goals", "are", "subject", "to", "numerous", "risks", "and", "uncertainties."], "wordsB": ["In", "this", "approach,", "our", "GEN-1", "immunotherapy", "is", "combined", "with", "standard", "chemotherapy", "drugs", "to", "achieve", "better", "clinical", "outcome", "than", "with", "chemotherapy", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p151_s0", "idA": "749647_14_item1_p2_s0", "sentA": "In evaluating such forward-looking statements, you should specifically consider various factors, including the risks outlined under Risk Factors.", "sentB": "In evaluating the competitive landscape for both indications, early stage indications are treated with chemotherapy (temozolomide, BCNU, CCNU for brain cancer; docetaxel, doxil and cisplatinum for ovarian cancer), while later stage ovarian and GBM cancer are treated with Bevacizumab - Avastin , an anti-angiogenesis inhibitor.", "type": 1, "words": ["<tag1>", "In", "evaluating", "such", "forward-looking", "statements,", "you", "should", "specifically", "consider", "various", "factors,", "including", "the", "risks", "outlined", "under", "Risk", "Factors.", "<tag2>", "In", "evaluating", "the", "competitive", "landscape", "for", "both", "indications,", "early", "stage", "indications", "are", "treated", "with", "chemotherapy", "(temozolomide,", "BCNU,", "CCNU", "for", "brain", "cancer;", "docetaxel,", "doxil", "and", "cisplatinum", "for", "ovarian", "cancer),", "while", "later", "stage", "ovarian", "and", "GBM", "cancer", "are", "treated", "with", "Bevacizumab", "-", "Avastin", ",", "an", "anti-angiogenesis", "inhibitor.", "<tag3>"], "wordsA": ["In", "evaluating", "such", "forward-looking", "statements,", "you", "should", "specifically", "consider", "various", "factors,", "including", "the", "risks", "outlined", "under", "Risk", "Factors."], "wordsB": ["In", "evaluating", "the", "competitive", "landscape", "for", "both", "indications,", "early", "stage", "indications", "are", "treated", "with", "chemotherapy", "(temozolomide,", "BCNU,", "CCNU", "for", "brain", "cancer;", "docetaxel,", "doxil", "and", "cisplatinum", "for", "ovarian", "cancer),", "while", "later", "stage", "ovarian", "and", "GBM", "cancer", "are", "treated", "with", "Bevacizumab", "-", "Avastin", ",", "an", "anti-angiogenesis", "inhibitor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p150_s0", "idA": "749647_14_item1_p31_s1", "sentA": "It ranks as the fifth most common solid tumor cancer.", "sentB": "GEN-1 s studied indications include ovarian cancer and glioblastoma multiforme (GBM) brain cancer.", "type": 1, "words": ["<tag1>", "It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer.", "<tag2>", "GEN-1", "s", "studied", "indications", "include", "ovarian", "cancer", "and", "glioblastoma", "multiforme", "(GBM)", "brain", "cancer.", "<tag3>"], "wordsA": ["It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer."], "wordsB": ["GEN-1", "s", "studied", "indications", "include", "ovarian", "cancer", "and", "glioblastoma", "multiforme", "(GBM)", "brain", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p83_s0", "idA": "749647_14_item1_p31_s1", "sentA": "It ranks as the fifth most common solid tumor cancer.", "sentB": "Pegylated liposomal doxorubicin, topotecan, and Avastin are the only approved second-line therapies for platinum-resistant ovarian cancer.", "type": 1, "words": ["<tag1>", "It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer.", "<tag2>", "Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["It", "ranks", "as", "the", "fifth", "most", "common", "solid", "tumor", "cancer."], "wordsB": ["Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p95_s1", "idA": "749647_14_item1_p35_s0", "sentA": "There are few alternative treatments, since radiation therapy and chemotherapy are largely ineffective.", "sentB": "There are two components of a TheraPlas system, a plasmid DNA or mRNA payload encoding a therapeutic protein, and a delivery system.", "type": 1, "words": ["<tag1>", "There", "are", "few", "alternative", "treatments,", "since", "radiation", "therapy", "and", "chemotherapy", "are", "largely", "ineffective.", "<tag2>", "There", "are", "two", "components", "of", "a", "TheraPlas", "system,", "a", "plasmid", "DNA", "or", "mRNA", "payload", "encoding", "a", "therapeutic", "protein,", "and", "a", "delivery", "system.", "<tag3>"], "wordsA": ["There", "are", "few", "alternative", "treatments,", "since", "radiation", "therapy", "and", "chemotherapy", "are", "largely", "ineffective."], "wordsB": ["There", "are", "two", "components", "of", "a", "TheraPlas", "system,", "a", "plasmid", "DNA", "or", "mRNA", "payload", "encoding", "a", "therapeutic", "protein,", "and", "a", "delivery", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p103_s0", "idA": "749647_14_item1_p35_s1", "sentA": "For tumors generally up to 5 centimeters in diameter, RFA has emerged as the standard of care treatment which directly destroys the tumor tissue through the application of high temperatures by a probe inserted into the core of the tumor.", "sentB": "TheraPlas has emerged as a viable alternative to current approaches due to several distinguishing characteristics such as excellent molecular versatility that allows for complex modifications to improve activity and safety with little difficulty.", "type": 1, "words": ["<tag1>", "For", "tumors", "generally", "up", "to", "5", "centimeters", "in", "diameter,", "RFA", "has", "emerged", "as", "the", "standard", "of", "care", "treatment", "which", "directly", "destroys", "the", "tumor", "tissue", "through", "the", "application", "of", "high", "temperatures", "by", "a", "probe", "inserted", "into", "the", "core", "of", "the", "tumor.", "<tag2>", "TheraPlas", "has", "emerged", "as", "a", "viable", "alternative", "to", "current", "approaches", "due", "to", "several", "distinguishing", "characteristics", "such", "as", "excellent", "molecular", "versatility", "that", "allows", "for", "complex", "modifications", "to", "improve", "activity", "and", "safety", "with", "little", "difficulty.", "<tag3>"], "wordsA": ["For", "tumors", "generally", "up", "to", "5", "centimeters", "in", "diameter,", "RFA", "has", "emerged", "as", "the", "standard", "of", "care", "treatment", "which", "directly", "destroys", "the", "tumor", "tissue", "through", "the", "application", "of", "high", "temperatures", "by", "a", "probe", "inserted", "into", "the", "core", "of", "the", "tumor."], "wordsB": ["TheraPlas", "has", "emerged", "as", "a", "viable", "alternative", "to", "current", "approaches", "due", "to", "several", "distinguishing", "characteristics", "such", "as", "excellent", "molecular", "versatility", "that", "allows", "for", "complex", "modifications", "to", "improve", "activity", "and", "safety", "with", "little", "difficulty."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p102_s1", "idA": "749647_14_item1_p35_s2", "sentA": "Local recurrence rates after RFA directly correlates to the size of the tumor.", "sentB": "Intravenous administration of the nanoparticles carrying DNA or mRNA payload in mice has produced expression with high degree of lung specificity.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "Intravenous", "administration", "of", "the", "nanoparticles", "carrying", "DNA", "or", "mRNA", "payload", "in", "mice", "has", "produced", "expression", "with", "high", "degree", "of", "lung", "specificity.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["Intravenous", "administration", "of", "the", "nanoparticles", "carrying", "DNA", "or", "mRNA", "payload", "in", "mice", "has", "produced", "expression", "with", "high", "degree", "of", "lung", "specificity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p76_s0", "idA": "749647_14_item1_p35_s2", "sentA": "Local recurrence rates after RFA directly correlates to the size of the tumor.", "sentB": "The EGEN Purchase Agreement contains customary representations and warranties regarding EGEN and Celsion, covenants regarding the conduct of EGEN s business prior to the consummation of the Acquisition, indemnification provisions, termination and other provisions customary for transactions of this nature.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "The", "EGEN", "Purchase", "Agreement", "contains", "customary", "representations", "and", "warranties", "regarding", "EGEN", "and", "Celsion,", "covenants", "regarding", "the", "conduct", "of", "EGEN", "s", "business", "prior", "to", "the", "consummation", "of", "the", "Acquisition,", "indemnification", "provisions,", "termination", "and", "other", "provisions", "customary", "for", "transactions", "of", "this", "nature.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["The", "EGEN", "Purchase", "Agreement", "contains", "customary", "representations", "and", "warranties", "regarding", "EGEN", "and", "Celsion,", "covenants", "regarding", "the", "conduct", "of", "EGEN", "s", "business", "prior", "to", "the", "consummation", "of", "the", "Acquisition,", "indemnification", "provisions,", "termination", "and", "other", "provisions", "customary", "for", "transactions", "of", "this", "nature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p78_s1", "idA": "749647_14_item1_p35_s2", "sentA": "Local recurrence rates after RFA directly correlates to the size of the tumor.", "sentB": "This poor outcome is due in part to the lack of effective prevention and early detection strategies.", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "This", "poor", "outcome", "is", "due", "in", "part", "to", "the", "lack", "of", "effective", "prevention", "and", "early", "detection", "strategies.", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlates", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["This", "poor", "outcome", "is", "due", "in", "part", "to", "the", "lack", "of", "effective", "prevention", "and", "early", "detection", "strategies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p100_s0", "idA": "749647_14_item1_p35_s3", "sentA": "For tumors 3 cm or smaller in diameter the recurrence rate has been reported to be 10 20%; however, for tumors greater than 3 cm, local recurrence rates of 40% or higher have been observed.", "sentB": "The PPC manufacturing process has been scaled up from bench scale (1-2 g) to 0.6Kg, and several cGMP lots have been produced with reproducible quality.", "type": 1, "words": ["<tag1>", "For", "tumors", "3", "cm", "or", "smaller", "in", "diameter", "the", "recurrence", "rate", "has", "been", "reported", "to", "be", "10", "20%;", "however,", "for", "tumors", "greater", "than", "3", "cm,", "local", "recurrence", "rates", "of", "40%", "or", "higher", "have", "been", "observed.", "<tag2>", "The", "PPC", "manufacturing", "process", "has", "been", "scaled", "up", "from", "bench", "scale", "(1-2", "g)", "to", "0.6Kg,", "and", "several", "cGMP", "lots", "have", "been", "produced", "with", "reproducible", "quality.", "<tag3>"], "wordsA": ["For", "tumors", "3", "cm", "or", "smaller", "in", "diameter", "the", "recurrence", "rate", "has", "been", "reported", "to", "be", "10", "20%;", "however,", "for", "tumors", "greater", "than", "3", "cm,", "local", "recurrence", "rates", "of", "40%", "or", "higher", "have", "been", "observed."], "wordsB": ["The", "PPC", "manufacturing", "process", "has", "been", "scaled", "up", "from", "bench", "scale", "(1-2", "g)", "to", "0.6Kg,", "and", "several", "cGMP", "lots", "have", "been", "produced", "with", "reproducible", "quality."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p102_s3", "idA": "749647_14_item1_p37_s2", "sentA": "This approach will also increase the delivery of the doxorubicin at the desired tumor site while potentially reducing drug exposure distant to the tumor site.", "sentB": "These results demonstrate potential clinical utility for delivery of therapeutic DNA and RNA for lung diseases and pulmonary disorders.", "type": 1, "words": ["<tag1>", "This", "approach", "will", "also", "increase", "the", "delivery", "of", "the", "doxorubicin", "at", "the", "desired", "tumor", "site", "while", "potentially", "reducing", "drug", "exposure", "distant", "to", "the", "tumor", "site.", "<tag2>", "These", "results", "demonstrate", "potential", "clinical", "utility", "for", "delivery", "of", "therapeutic", "DNA", "and", "RNA", "for", "lung", "diseases", "and", "pulmonary", "disorders.", "<tag3>"], "wordsA": ["This", "approach", "will", "also", "increase", "the", "delivery", "of", "the", "doxorubicin", "at", "the", "desired", "tumor", "site", "while", "potentially", "reducing", "drug", "exposure", "distant", "to", "the", "tumor", "site."], "wordsB": ["These", "results", "demonstrate", "potential", "clinical", "utility", "for", "delivery", "of", "therapeutic", "DNA", "and", "RNA", "for", "lung", "diseases", "and", "pulmonary", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p96_s0", "idA": "749647_14_item1_p37_s2", "sentA": "This approach will also increase the delivery of the doxorubicin at the desired tumor site while potentially reducing drug exposure distant to the tumor site.", "sentB": "We designed the delivery system of TheraPlas by chemically modifying the low molecular weight polymer to improve its gene transfer activity without increasing toxicity.", "type": 1, "words": ["<tag1>", "This", "approach", "will", "also", "increase", "the", "delivery", "of", "the", "doxorubicin", "at", "the", "desired", "tumor", "site", "while", "potentially", "reducing", "drug", "exposure", "distant", "to", "the", "tumor", "site.", "<tag2>", "We", "designed", "the", "delivery", "system", "of", "TheraPlas", "by", "chemically", "modifying", "the", "low", "molecular", "weight", "polymer", "to", "improve", "its", "gene", "transfer", "activity", "without", "increasing", "toxicity.", "<tag3>"], "wordsA": ["This", "approach", "will", "also", "increase", "the", "delivery", "of", "the", "doxorubicin", "at", "the", "desired", "tumor", "site", "while", "potentially", "reducing", "drug", "exposure", "distant", "to", "the", "tumor", "site."], "wordsB": ["We", "designed", "the", "delivery", "system", "of", "TheraPlas", "by", "chemically", "modifying", "the", "low", "molecular", "weight", "polymer", "to", "improve", "its", "gene", "transfer", "activity", "without", "increasing", "toxicity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p20_s2", "idA": "749647_14_item1_p40_s0", "sentA": "In the second quarter of 2007, we completed our first Phase I single dose escalation clinical trial that investigated ThermoDox in combination with RFA for the treatment of primary and metastatic liver cancer.", "sentB": "We also filed a request for a Voluntary Harmonization Procedure (VHP) in Europe, which provides for the assessment of multinational clinical trial applications across several European countries, including Germany, Italy and Spain.", "type": 1, "words": ["<tag1>", "In", "the", "second", "quarter", "of", "2007,", "we", "completed", "our", "first", "Phase", "I", "single", "dose", "escalation", "clinical", "trial", "that", "investigated", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "primary", "and", "metastatic", "liver", "cancer.", "<tag2>", "We", "also", "filed", "a", "request", "for", "a", "Voluntary", "Harmonization", "Procedure", "(VHP)", "in", "Europe,", "which", "provides", "for", "the", "assessment", "of", "multinational", "clinical", "trial", "applications", "across", "several", "European", "countries,", "including", "Germany,", "Italy", "and", "Spain.", "<tag3>"], "wordsA": ["In", "the", "second", "quarter", "of", "2007,", "we", "completed", "our", "first", "Phase", "I", "single", "dose", "escalation", "clinical", "trial", "that", "investigated", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "primary", "and", "metastatic", "liver", "cancer."], "wordsB": ["We", "also", "filed", "a", "request", "for", "a", "Voluntary", "Harmonization", "Procedure", "(VHP)", "in", "Europe,", "which", "provides", "for", "the", "assessment", "of", "multinational", "clinical", "trial", "applications", "across", "several", "European", "countries,", "including", "Germany,", "Italy", "and", "Spain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p55_s2", "idA": "749647_14_item1_p40_s0", "sentA": "In the second quarter of 2007, we completed our first Phase I single dose escalation clinical trial that investigated ThermoDox in combination with RFA for the treatment of primary and metastatic liver cancer.", "sentB": "We also filed a request for a Voluntary Harmonization Procedure (VHP) in Europe, which provides for the assessment of multinational clinical trial applications across several European countries, including Germany, Italy and Spain.", "type": 1, "words": ["<tag1>", "In", "the", "second", "quarter", "of", "2007,", "we", "completed", "our", "first", "Phase", "I", "single", "dose", "escalation", "clinical", "trial", "that", "investigated", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "primary", "and", "metastatic", "liver", "cancer.", "<tag2>", "We", "also", "filed", "a", "request", "for", "a", "Voluntary", "Harmonization", "Procedure", "(VHP)", "in", "Europe,", "which", "provides", "for", "the", "assessment", "of", "multinational", "clinical", "trial", "applications", "across", "several", "European", "countries,", "including", "Germany,", "Italy", "and", "Spain.", "<tag3>"], "wordsA": ["In", "the", "second", "quarter", "of", "2007,", "we", "completed", "our", "first", "Phase", "I", "single", "dose", "escalation", "clinical", "trial", "that", "investigated", "ThermoDox", "in", "combination", "with", "RFA", "for", "the", "treatment", "of", "primary", "and", "metastatic", "liver", "cancer."], "wordsB": ["We", "also", "filed", "a", "request", "for", "a", "Voluntary", "Harmonization", "Procedure", "(VHP)", "in", "Europe,", "which", "provides", "for", "the", "assessment", "of", "multinational", "clinical", "trial", "applications", "across", "several", "European", "countries,", "including", "Germany,", "Italy", "and", "Spain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p23_s2", "idA": "749647_14_item1_p41_s2", "sentA": "This clinical trial was completed in 2008.", "sentB": "The clinical trial will identify a safe, tolerable and potentially therapeutically active dose of GEN-1 while maximizing an immune response.", "type": 1, "words": ["<tag1>", "This", "clinical", "trial", "was", "completed", "in", "2008.", "<tag2>", "The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response.", "<tag3>"], "wordsA": ["This", "clinical", "trial", "was", "completed", "in", "2008."], "wordsB": ["The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p90_s0", "idA": "749647_14_item1_p44_s0", "sentA": "As provided for in the SPA, we continue to follow the patients enrolled in the HEAT study to the secondary endpoint of Overall Survival (OS).", "sentB": "A Phase I dose-escalation trial of IP GEN-1 (12 mg/m 2 , 18 mg/m 2 and 24 mg/m 2 ) plus IV carboplatin (AUC 5)/docetaxel (75 mg/m 2 ) was examined in recurrent ovarian cancer patients who had previously treated with first-line chemotherapy and had disease recurrence 6 months after treatment (the platinum-sensitive disease) with a total of 13 patients enrolled in the study.", "type": 1, "words": ["<tag1>", "As", "provided", "for", "in", "the", "SPA,", "we", "continue", "to", "follow", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint", "of", "Overall", "Survival", "(OS).", "<tag2>", "A", "Phase", "I", "dose-escalation", "trial", "of", "IP", "GEN-1", "(12", "mg/m", "2", ",", "18", "mg/m", "2", "and", "24", "mg/m", "2", ")", "plus", "IV", "carboplatin", "(AUC", "5)/docetaxel", "(75", "mg/m", "2", ")", "was", "examined", "in", "recurrent", "ovarian", "cancer", "patients", "who", "had", "previously", "treated", "with", "first-line", "chemotherapy", "and", "had", "disease", "recurrence", "6", "months", "after", "treatment", "(the", "platinum-sensitive", "disease)", "with", "a", "total", "of", "13", "patients", "enrolled", "in", "the", "study.", "<tag3>"], "wordsA": ["As", "provided", "for", "in", "the", "SPA,", "we", "continue", "to", "follow", "the", "patients", "enrolled", "in", "the", "HEAT", "study", "to", "the", "secondary", "endpoint", "of", "Overall", "Survival", "(OS)."], "wordsB": ["A", "Phase", "I", "dose-escalation", "trial", "of", "IP", "GEN-1", "(12", "mg/m", "2", ",", "18", "mg/m", "2", "and", "24", "mg/m", "2", ")", "plus", "IV", "carboplatin", "(AUC", "5)/docetaxel", "(75", "mg/m", "2", ")", "was", "examined", "in", "recurrent", "ovarian", "cancer", "patients", "who", "had", "previously", "treated", "with", "first-line", "chemotherapy", "and", "had", "disease", "recurrence", "6", "months", "after", "treatment", "(the", "platinum-sensitive", "disease)", "with", "a", "total", "of", "13", "patients", "enrolled", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p101_s0", "idA": "749647_14_item1_p46_s0", "sentA": "In January 2014, we announced that the latest overall survival data from the post-hoc analysis of results from the HEAT study support continued clinical development of ThermoDox through a prospective pivotal Phase III study, subject to regulatory review and agreement.", "sentB": "Another approach to improve PEI activity involved crosslinking low-molecular-weight PEIs through degradable linkages to create larger and degradable structures.", "type": 1, "words": ["<tag1>", "In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement.", "<tag2>", "Another", "approach", "to", "improve", "PEI", "activity", "involved", "crosslinking", "low-molecular-weight", "PEIs", "through", "degradable", "linkages", "to", "create", "larger", "and", "degradable", "structures.", "<tag3>"], "wordsA": ["In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement."], "wordsB": ["Another", "approach", "to", "improve", "PEI", "activity", "involved", "crosslinking", "low-molecular-weight", "PEIs", "through", "degradable", "linkages", "to", "create", "larger", "and", "degradable", "structures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p88_s0", "idA": "749647_14_item1_p46_s0", "sentA": "In January 2014, we announced that the latest overall survival data from the post-hoc analysis of results from the HEAT study support continued clinical development of ThermoDox through a prospective pivotal Phase III study, subject to regulatory review and agreement.", "sentB": "All four weekly treatments of IP administered GEN-1 at escalating doses were well tolerated.", "type": 1, "words": ["<tag1>", "In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement.", "<tag2>", "All", "four", "weekly", "treatments", "of", "IP", "administered", "GEN-1", "at", "escalating", "doses", "were", "well", "tolerated.", "<tag3>"], "wordsA": ["In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement."], "wordsB": ["All", "four", "weekly", "treatments", "of", "IP", "administered", "GEN-1", "at", "escalating", "doses", "were", "well", "tolerated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p97_s4", "idA": "749647_14_item1_p46_s0", "sentA": "In January 2014, we announced that the latest overall survival data from the post-hoc analysis of results from the HEAT study support continued clinical development of ThermoDox through a prospective pivotal Phase III study, subject to regulatory review and agreement.", "sentB": "Together, the cholesterol and PEG modifications produced approximately 20-fold enhancement in transfection activity.", "type": 1, "words": ["<tag1>", "In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement.", "<tag2>", "Together,", "the", "cholesterol", "and", "PEG", "modifications", "produced", "approximately", "20-fold", "enhancement", "in", "transfection", "activity.", "<tag3>"], "wordsA": ["In", "January", "2014,", "we", "announced", "that", "the", "latest", "overall", "survival", "data", "from", "the", "post-hoc", "analysis", "of", "results", "from", "the", "HEAT", "study", "support", "continued", "clinical", "development", "of", "ThermoDox", "through", "a", "prospective", "pivotal", "Phase", "III", "study,", "subject", "to", "regulatory", "review", "and", "agreement."], "wordsB": ["Together,", "the", "cholesterol", "and", "PEG", "modifications", "produced", "approximately", "20-fold", "enhancement", "in", "transfection", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p82_s2", "idA": "749647_14_item1_p46_s1", "sentA": "The post-hoc data demonstrated that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes, which represents 285 patients or 63 percent of single lesion patients, experienced a 55 percent improvement in overall survival, with a Hazard Ratio of 0.64 (95% CI 0.41 - 1.00) and a P-value = 0.0495.", "sentB": "The platinum-sensitive group has a platinum-free interval of longer than six months.", "type": 1, "words": ["<tag1>", "The", "post-hoc", "data", "demonstrated", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes,", "which", "represents", "285", "patients", "or", "63", "percent", "of", "single", "lesion", "patients,", "experienced", "a", "55", "percent", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495.", "<tag2>", "The", "platinum-sensitive", "group", "has", "a", "platinum-free", "interval", "of", "longer", "than", "six", "months.", "<tag3>"], "wordsA": ["The", "post-hoc", "data", "demonstrated", "that", "the", "patient", "subgroup", "in", "the", "ThermoDox", "arm", "whose", "RFA", "procedure", "lasted", "longer", "than", "45", "minutes,", "which", "represents", "285", "patients", "or", "63", "percent", "of", "single", "lesion", "patients,", "experienced", "a", "55", "percent", "improvement", "in", "overall", "survival,", "with", "a", "Hazard", "Ratio", "of", "0.64", "(95%", "CI", "0.41", "-", "1.00)", "and", "a", "P-value", "=", "0.0495."], "wordsB": ["The", "platinum-sensitive", "group", "has", "a", "platinum-free", "interval", "of", "longer", "than", "six", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p93_s3", "idA": "749647_14_item1_p47_s3", "sentA": "Data from four OS sweeps have been conducted since the top line PFS data from the HEAT Study was announced in January 2013, with each showing progressive improvement in statistical significance.", "sentB": "These results from the combination trial are highly encouraging since the historical Objective Response Rate in Doxil treated patients is less than 15%.", "type": 1, "words": ["<tag1>", "Data", "from", "four", "OS", "sweeps", "have", "been", "conducted", "since", "the", "top", "line", "PFS", "data", "from", "the", "HEAT", "Study", "was", "announced", "in", "January", "2013,", "with", "each", "showing", "progressive", "improvement", "in", "statistical", "significance.", "<tag2>", "These", "results", "from", "the", "combination", "trial", "are", "highly", "encouraging", "since", "the", "historical", "Objective", "Response", "Rate", "in", "Doxil", "treated", "patients", "is", "less", "than", "15%.", "<tag3>"], "wordsA": ["Data", "from", "four", "OS", "sweeps", "have", "been", "conducted", "since", "the", "top", "line", "PFS", "data", "from", "the", "HEAT", "Study", "was", "announced", "in", "January", "2013,", "with", "each", "showing", "progressive", "improvement", "in", "statistical", "significance."], "wordsB": ["These", "results", "from", "the", "combination", "trial", "are", "highly", "encouraging", "since", "the", "historical", "Objective", "Response", "Rate", "in", "Doxil", "treated", "patients", "is", "less", "than", "15%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p92_s1", "idA": "749647_14_item1_p4_s1", "sentA": "Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time.", "sentB": "Since the clinical responses to second line therapies is poor (historically the objective response rates are less than 15%), it is hypothesized that the addition of GEN-1 would improve the clinical outcome in this difficult to treat patient population.", "type": 1, "words": ["<tag1>", "Therefore,", "it", "is", "likely", "that", "new", "risks", "will", "emerge,", "and", "that", "the", "nature", "and", "elements", "of", "existing", "risks", "will", "change,", "over", "time.", "<tag2>", "Since", "the", "clinical", "responses", "to", "second", "line", "therapies", "is", "poor", "(historically", "the", "objective", "response", "rates", "are", "less", "than", "15%),", "it", "is", "hypothesized", "that", "the", "addition", "of", "GEN-1", "would", "improve", "the", "clinical", "outcome", "in", "this", "difficult", "to", "treat", "patient", "population.", "<tag3>"], "wordsA": ["Therefore,", "it", "is", "likely", "that", "new", "risks", "will", "emerge,", "and", "that", "the", "nature", "and", "elements", "of", "existing", "risks", "will", "change,", "over", "time."], "wordsB": ["Since", "the", "clinical", "responses", "to", "second", "line", "therapies", "is", "poor", "(historically", "the", "objective", "response", "rates", "are", "less", "than", "15%),", "it", "is", "hypothesized", "that", "the", "addition", "of", "GEN-1", "would", "improve", "the", "clinical", "outcome", "in", "this", "difficult", "to", "treat", "patient", "population."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p98_s0", "idA": "749647_14_item1_p56_s1", "sentA": "The studies are being conducted at the University of Washington (UW) School of Medicine.", "sentB": "Biodistribution studies following intraperitoneal or subcutaneous administration of DNA/PPC nanocomplexes showed DNA delivery localized primarily at the injection site with only small amount escaped into systemic circulation.", "type": 1, "words": ["<tag1>", "The", "studies", "are", "being", "conducted", "at", "the", "University", "of", "Washington", "(UW)", "School", "of", "Medicine.", "<tag2>", "Biodistribution", "studies", "following", "intraperitoneal", "or", "subcutaneous", "administration", "of", "DNA/PPC", "nanocomplexes", "showed", "DNA", "delivery", "localized", "primarily", "at", "the", "injection", "site", "with", "only", "small", "amount", "escaped", "into", "systemic", "circulation.", "<tag3>"], "wordsA": ["The", "studies", "are", "being", "conducted", "at", "the", "University", "of", "Washington", "(UW)", "School", "of", "Medicine."], "wordsB": ["Biodistribution", "studies", "following", "intraperitoneal", "or", "subcutaneous", "administration", "of", "DNA/PPC", "nanocomplexes", "showed", "DNA", "delivery", "localized", "primarily", "at", "the", "injection", "site", "with", "only", "small", "amount", "escaped", "into", "systemic", "circulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p96_s1", "idA": "749647_14_item1_p56_s3", "sentA": "We believe that these collaborations are providing important new device technologies such as HIFU to activate our low heat sensitive liposomal technology in difficult-to-treat cancers.", "sentB": "We believe that TheraPlas is a viable alternative to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to improve activity and safety.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "these", "collaborations", "are", "providing", "important", "new", "device", "technologies", "such", "as", "HIFU", "to", "activate", "our", "low", "heat", "sensitive", "liposomal", "technology", "in", "difficult-to-treat", "cancers.", "<tag2>", "We", "believe", "that", "TheraPlas", "is", "a", "viable", "alternative", "to", "current", "approaches", "to", "gene", "delivery", "due", "to", "several", "distinguishing", "characteristics,", "including", "enhanced", "molecular", "versatility", "that", "allows", "for", "complex", "modifications", "to", "improve", "activity", "and", "safety.", "<tag3>"], "wordsA": ["We", "believe", "that", "these", "collaborations", "are", "providing", "important", "new", "device", "technologies", "such", "as", "HIFU", "to", "activate", "our", "low", "heat", "sensitive", "liposomal", "technology", "in", "difficult-to-treat", "cancers."], "wordsB": ["We", "believe", "that", "TheraPlas", "is", "a", "viable", "alternative", "to", "current", "approaches", "to", "gene", "delivery", "due", "to", "several", "distinguishing", "characteristics,", "including", "enhanced", "molecular", "versatility", "that", "allows", "for", "complex", "modifications", "to", "improve", "activity", "and", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p106_s0", "idA": "749647_14_item1_p57_s0", "sentA": "Breast cancer is the most common malignancy in women in both the United States and the world.", "sentB": "The TheraSilence technology addresses the primary obstacle to nucleic acid-based therapeutics which is the efficient delivery to target cells.", "type": 1, "words": ["<tag1>", "Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world.", "<tag2>", "The", "TheraSilence", "technology", "addresses", "the", "primary", "obstacle", "to", "nucleic", "acid-based", "therapeutics", "which", "is", "the", "efficient", "delivery", "to", "target", "cells.", "<tag3>"], "wordsA": ["Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "United", "States", "and", "the", "world."], "wordsB": ["The", "TheraSilence", "technology", "addresses", "the", "primary", "obstacle", "to", "nucleic", "acid-based", "therapeutics", "which", "is", "the", "efficient", "delivery", "to", "target", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p151_s1", "idA": "749647_14_item1_p58_s1", "sentA": "There is currently no effective chemotherapeutic standard of care for RCW breast cancer and as a result, many of these patients will die within two years of the recurrence.", "sentB": "Avastin is currently also being evaluated for early stage disease.", "type": 1, "words": ["<tag1>", "There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence.", "<tag2>", "Avastin", "is", "currently", "also", "being", "evaluated", "for", "early", "stage", "disease.", "<tag3>"], "wordsA": ["There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence."], "wordsB": ["Avastin", "is", "currently", "also", "being", "evaluated", "for", "early", "stage", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p81_s1", "idA": "749647_14_item1_p58_s1", "sentA": "There is currently no effective chemotherapeutic standard of care for RCW breast cancer and as a result, many of these patients will die within two years of the recurrence.", "sentB": "Although this first line of treatment has an approximate 80 percent response rate, 55 to 75 percent of women will develop recurrent ovarian cancer within two years and ultimately will not respond to platinum therapy.", "type": 1, "words": ["<tag1>", "There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence.", "<tag2>", "Although", "this", "first", "line", "of", "treatment", "has", "an", "approximate", "80", "percent", "response", "rate,", "55", "to", "75", "percent", "of", "women", "will", "develop", "recurrent", "ovarian", "cancer", "within", "two", "years", "and", "ultimately", "will", "not", "respond", "to", "platinum", "therapy.", "<tag3>"], "wordsA": ["There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence."], "wordsB": ["Although", "this", "first", "line", "of", "treatment", "has", "an", "approximate", "80", "percent", "response", "rate,", "55", "to", "75", "percent", "of", "women", "will", "develop", "recurrent", "ovarian", "cancer", "within", "two", "years", "and", "ultimately", "will", "not", "respond", "to", "platinum", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p86_s4", "idA": "749647_14_item1_p58_s1", "sentA": "There is currently no effective chemotherapeutic standard of care for RCW breast cancer and as a result, many of these patients will die within two years of the recurrence.", "sentB": "The activation of the body s immune system will potentially eliminate the chemotherapy resistant cells and lower the risk of recurrence.", "type": 1, "words": ["<tag1>", "There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence.", "<tag2>", "The", "activation", "of", "the", "body", "s", "immune", "system", "will", "potentially", "eliminate", "the", "chemotherapy", "resistant", "cells", "and", "lower", "the", "risk", "of", "recurrence.", "<tag3>"], "wordsA": ["There", "is", "currently", "no", "effective", "chemotherapeutic", "standard", "of", "care", "for", "RCW", "breast", "cancer", "and", "as", "a", "result,", "many", "of", "these", "patients", "will", "die", "within", "two", "years", "of", "the", "recurrence."], "wordsB": ["The", "activation", "of", "the", "body", "s", "immune", "system", "will", "potentially", "eliminate", "the", "chemotherapy", "resistant", "cells", "and", "lower", "the", "risk", "of", "recurrence."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p129_s1", "idA": "749647_14_item1_p5_s0", "sentA": "Except as required by law, we assume no obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf for any reason, even if new information becomes available in the future.", "sentB": "Additionally, an FDA-approved drug may be eligible for Biologics Exclusivity of 12 years in the US, ten years in Europe, five years in Australia, eight years in Canada and eight years in Japan.", "type": 1, "words": ["<tag1>", "Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future.", "<tag2>", "Additionally,", "an", "FDA-approved", "drug", "may", "be", "eligible", "for", "Biologics", "Exclusivity", "of", "12", "years", "in", "the", "US,", "ten", "years", "in", "Europe,", "five", "years", "in", "Australia,", "eight", "years", "in", "Canada", "and", "eight", "years", "in", "Japan.", "<tag3>"], "wordsA": ["Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future."], "wordsB": ["Additionally,", "an", "FDA-approved", "drug", "may", "be", "eligible", "for", "Biologics", "Exclusivity", "of", "12", "years", "in", "the", "US,", "ten", "years", "in", "Europe,", "five", "years", "in", "Australia,", "eight", "years", "in", "Canada", "and", "eight", "years", "in", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p141_s5", "idA": "749647_14_item1_p61_s0", "sentA": "Our liposomal encapsulated doxorubicin is released by heat generated from an external microwave tissue hyperthermia device that is placed on a woman s chest.", "sentB": "We typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements .", "type": 1, "words": ["<tag1>", "Our", "liposomal", "encapsulated", "doxorubicin", "is", "released", "by", "heat", "generated", "from", "an", "external", "microwave", "tissue", "hyperthermia", "device", "that", "is", "placed", "on", "a", "woman", "s", "chest.", "<tag2>", "We", "typically", "order", "raw", "materials", "and", "services", "on", "a", "purchase", "order", "basis", "and", "do", "not", "enter", "into", "long-term", "dedicated", "capacity", "or", "minimum", "supply", "arrangements", ".", "<tag3>"], "wordsA": ["Our", "liposomal", "encapsulated", "doxorubicin", "is", "released", "by", "heat", "generated", "from", "an", "external", "microwave", "tissue", "hyperthermia", "device", "that", "is", "placed", "on", "a", "woman", "s", "chest."], "wordsB": ["We", "typically", "order", "raw", "materials", "and", "services", "on", "a", "purchase", "order", "basis", "and", "do", "not", "enter", "into", "long-term", "dedicated", "capacity", "or", "minimum", "supply", "arrangements", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p101_s2", "idA": "749647_14_item1_p61_s3", "sentA": "As in our liver cancer program, we use a commercially available thermotherapy device to heat the target tissue and activate ThermoDox at the desired target site.", "sentB": "Both cross-linked polymers expressed several fold higher transfection activity than their respective monomers and lower cyotoxicity than a commercially available 25 kDa polymer.", "type": 1, "words": ["<tag1>", "As", "in", "our", "liver", "cancer", "program,", "we", "use", "a", "commercially", "available", "thermotherapy", "device", "to", "heat", "the", "target", "tissue", "and", "activate", "ThermoDox", "at", "the", "desired", "target", "site.", "<tag2>", "Both", "cross-linked", "polymers", "expressed", "several", "fold", "higher", "transfection", "activity", "than", "their", "respective", "monomers", "and", "lower", "cyotoxicity", "than", "a", "commercially", "available", "25", "kDa", "polymer.", "<tag3>"], "wordsA": ["As", "in", "our", "liver", "cancer", "program,", "we", "use", "a", "commercially", "available", "thermotherapy", "device", "to", "heat", "the", "target", "tissue", "and", "activate", "ThermoDox", "at", "the", "desired", "target", "site."], "wordsB": ["Both", "cross-linked", "polymers", "expressed", "several", "fold", "higher", "transfection", "activity", "than", "their", "respective", "monomers", "and", "lower", "cyotoxicity", "than", "a", "commercially", "available", "25", "kDa", "polymer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p102_s2", "idA": "749647_14_item1_p62_s0", "sentA": "Microwave hyperthermia as a separate standalone treatment has been found to have the ability to kill breast cancer cells.", "sentB": "The lung specificity and safety for mRNA delivery following intravenous administration in mice has been confirmed in non-human primates.", "type": 1, "words": ["<tag1>", "Microwave", "hyperthermia", "as", "a", "separate", "standalone", "treatment", "has", "been", "found", "to", "have", "the", "ability", "to", "kill", "breast", "cancer", "cells.", "<tag2>", "The", "lung", "specificity", "and", "safety", "for", "mRNA", "delivery", "following", "intravenous", "administration", "in", "mice", "has", "been", "confirmed", "in", "non-human", "primates.", "<tag3>"], "wordsA": ["Microwave", "hyperthermia", "as", "a", "separate", "standalone", "treatment", "has", "been", "found", "to", "have", "the", "ability", "to", "kill", "breast", "cancer", "cells."], "wordsB": ["The", "lung", "specificity", "and", "safety", "for", "mRNA", "delivery", "following", "intravenous", "administration", "in", "mice", "has", "been", "confirmed", "in", "non-human", "primates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p105_s1", "idA": "749647_14_item1_p63_s1", "sentA": "Thus heating cancer cells with a microwave device for sixty minutes at 43 C has been found to be tumoricidal.", "sentB": "Inhibitory RNA based therapies have tremendous potential for targeting virtually any disease related gene with a high degree of specificity and thus eliminating so called non-drugable target classes.", "type": 1, "words": ["<tag1>", "Thus", "heating", "cancer", "cells", "with", "a", "microwave", "device", "for", "sixty", "minutes", "at", "43", "C", "has", "been", "found", "to", "be", "tumoricidal.", "<tag2>", "Inhibitory", "RNA", "based", "therapies", "have", "tremendous", "potential", "for", "targeting", "virtually", "any", "disease", "related", "gene", "with", "a", "high", "degree", "of", "specificity", "and", "thus", "eliminating", "so", "called", "non-drugable", "target", "classes.", "<tag3>"], "wordsA": ["Thus", "heating", "cancer", "cells", "with", "a", "microwave", "device", "for", "sixty", "minutes", "at", "43", "C", "has", "been", "found", "to", "be", "tumoricidal."], "wordsB": ["Inhibitory", "RNA", "based", "therapies", "have", "tremendous", "potential", "for", "targeting", "virtually", "any", "disease", "related", "gene", "with", "a", "high", "degree", "of", "specificity", "and", "thus", "eliminating", "so", "called", "non-drugable", "target", "classes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p82_s3", "idA": "749647_14_item1_p63_s2", "sentA": "We expect that the combination of microwave hyperthermia and ThermoDox will be more efficacious than microwave hyperthermia alone or treatment with existing non-heat activated liposomal formulations.", "sentB": "This group generally responds to additional treatment with platinum-based therapies.", "type": 1, "words": ["<tag1>", "We", "expect", "that", "the", "combination", "of", "microwave", "hyperthermia", "and", "ThermoDox", "will", "be", "more", "efficacious", "than", "microwave", "hyperthermia", "alone", "or", "treatment", "with", "existing", "non-heat", "activated", "liposomal", "formulations.", "<tag2>", "This", "group", "generally", "responds", "to", "additional", "treatment", "with", "platinum-based", "therapies.", "<tag3>"], "wordsA": ["We", "expect", "that", "the", "combination", "of", "microwave", "hyperthermia", "and", "ThermoDox", "will", "be", "more", "efficacious", "than", "microwave", "hyperthermia", "alone", "or", "treatment", "with", "existing", "non-heat", "activated", "liposomal", "formulations."], "wordsB": ["This", "group", "generally", "responds", "to", "additional", "treatment", "with", "platinum-based", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p95_s2", "idA": "749647_14_item1_p64_s1", "sentA": "The DIGNITY study is designed to establish a safe therapeutic dose in Phase I, and in Phase II to demonstrate local control, including complete and partial responses, and stable disease as its primary endpoint.", "sentB": "The delivery system is designed to protect the DNA/RNA from degradation and promote trafficking into cells and through intracellular compartments.", "type": 1, "words": ["<tag1>", "The", "DIGNITY", "study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint.", "<tag2>", "The", "delivery", "system", "is", "designed", "to", "protect", "the", "DNA/RNA", "from", "degradation", "and", "promote", "trafficking", "into", "cells", "and", "through", "intracellular", "compartments.", "<tag3>"], "wordsA": ["The", "DIGNITY", "study", "is", "designed", "to", "establish", "a", "safe", "therapeutic", "dose", "in", "Phase", "I,", "and", "in", "Phase", "II", "to", "demonstrate", "local", "control,", "including", "complete", "and", "partial", "responses,", "and", "stable", "disease", "as", "its", "primary", "endpoint."], "wordsB": ["The", "delivery", "system", "is", "designed", "to", "protect", "the", "DNA/RNA", "from", "degradation", "and", "promote", "trafficking", "into", "cells", "and", "through", "intracellular", "compartments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p72_s0", "idA": "749647_14_item1_p66_s0", "sentA": "Duke University conducted a Phase I dose escalating ThermoDox study in patients with RCW breast cancer and has presented preliminary results from the 16 enrolled patients that characterize the safety of the drug in RCW patients and the feasibility of ThermoDox administration in these patients .", "sentB": "The primary objectives of the Euro-DIGNITY Study will be (i) to evaluate efficacy in patients after 3 cycles of ThermoDox plus Hyperthermia measuring tumor diameter as a response to therapy and (ii) to evaluate loco-regional breast tumor control in patients who undergo ThermoDox /hyperthermia/radiotherapy as measured by target lesion clinical response rate combining a RECIST criteria with digital photography to gauge response.", "type": 1, "words": ["<tag1>", "Duke", "University", "conducted", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer", "and", "has", "presented", "preliminary", "results", "from", "the", "16", "enrolled", "patients", "that", "characterize", "the", "safety", "of", "the", "drug", "in", "RCW", "patients", "and", "the", "feasibility", "of", "ThermoDox", "administration", "in", "these", "patients", ".", "<tag2>", "The", "primary", "objectives", "of", "the", "Euro-DIGNITY", "Study", "will", "be", "(i)", "to", "evaluate", "efficacy", "in", "patients", "after", "3", "cycles", "of", "ThermoDox", "plus", "Hyperthermia", "measuring", "tumor", "diameter", "as", "a", "response", "to", "therapy", "and", "(ii)", "to", "evaluate", "loco-regional", "breast", "tumor", "control", "in", "patients", "who", "undergo", "ThermoDox", "/hyperthermia/radiotherapy", "as", "measured", "by", "target", "lesion", "clinical", "response", "rate", "combining", "a", "RECIST", "criteria", "with", "digital", "photography", "to", "gauge", "response.", "<tag3>"], "wordsA": ["Duke", "University", "conducted", "a", "Phase", "I", "dose", "escalating", "ThermoDox", "study", "in", "patients", "with", "RCW", "breast", "cancer", "and", "has", "presented", "preliminary", "results", "from", "the", "16", "enrolled", "patients", "that", "characterize", "the", "safety", "of", "the", "drug", "in", "RCW", "patients", "and", "the", "feasibility", "of", "ThermoDox", "administration", "in", "these", "patients", "."], "wordsB": ["The", "primary", "objectives", "of", "the", "Euro-DIGNITY", "Study", "will", "be", "(i)", "to", "evaluate", "efficacy", "in", "patients", "after", "3", "cycles", "of", "ThermoDox", "plus", "Hyperthermia", "measuring", "tumor", "diameter", "as", "a", "response", "to", "therapy", "and", "(ii)", "to", "evaluate", "loco-regional", "breast", "tumor", "control", "in", "patients", "who", "undergo", "ThermoDox", "/hyperthermia/radiotherapy", "as", "measured", "by", "target", "lesion", "clinical", "response", "rate", "combining", "a", "RECIST", "criteria", "with", "digital", "photography", "to", "gauge", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p87_s0", "idA": "749647_14_item1_p66_s4", "sentA": "Both studies employed an open label 3+3 dose escalation study design to determine the Maximum Tolerated Dose, evaluate safety and determine early effects of ThermoDox in combination with mild hyperthermia.", "sentB": "The First-In-Man, Phase 1 clinical trial of GEN-1 monotherapy was conducted to determine the safety/tolerability of IP administered GEN-1 in platinum-resistant (Stage III and IV) ovarian cancer patients who had received 2-6 prior chemotherapy treatments.", "type": 1, "words": ["<tag1>", "Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia.", "<tag2>", "The", "First-In-Man,", "Phase", "1", "clinical", "trial", "of", "GEN-1", "monotherapy", "was", "conducted", "to", "determine", "the", "safety/tolerability", "of", "IP", "administered", "GEN-1", "in", "platinum-resistant", "(Stage", "III", "and", "IV)", "ovarian", "cancer", "patients", "who", "had", "received", "2-6", "prior", "chemotherapy", "treatments.", "<tag3>"], "wordsA": ["Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia."], "wordsB": ["The", "First-In-Man,", "Phase", "1", "clinical", "trial", "of", "GEN-1", "monotherapy", "was", "conducted", "to", "determine", "the", "safety/tolerability", "of", "IP", "administered", "GEN-1", "in", "platinum-resistant", "(Stage", "III", "and", "IV)", "ovarian", "cancer", "patients", "who", "had", "received", "2-6", "prior", "chemotherapy", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p87_s1", "idA": "749647_14_item1_p66_s4", "sentA": "Both studies employed an open label 3+3 dose escalation study design to determine the Maximum Tolerated Dose, evaluate safety and determine early effects of ThermoDox in combination with mild hyperthermia.", "sentB": "This open label, non-randomized, dose escalation study enrolled a total of 13 patients in 4 dose escalation cohorts (0.6 (n=3), 3.0 (n=3), 12 (n=4), and 24 (n=3) mg/m 2 ).", "type": 1, "words": ["<tag1>", "Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia.", "<tag2>", "This", "open", "label,", "non-randomized,", "dose", "escalation", "study", "enrolled", "a", "total", "of", "13", "patients", "in", "4", "dose", "escalation", "cohorts", "(0.6", "(n=3),", "3.0", "(n=3),", "12", "(n=4),", "and", "24", "(n=3)", "mg/m", "2", ").", "<tag3>"], "wordsA": ["Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia."], "wordsB": ["This", "open", "label,", "non-randomized,", "dose", "escalation", "study", "enrolled", "a", "total", "of", "13", "patients", "in", "4", "dose", "escalation", "cohorts", "(0.6", "(n=3),", "3.0", "(n=3),", "12", "(n=4),", "and", "24", "(n=3)", "mg/m", "2", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p93_s0", "idA": "749647_14_item1_p66_s4", "sentA": "Both studies employed an open label 3+3 dose escalation study design to determine the Maximum Tolerated Dose, evaluate safety and determine early effects of ThermoDox in combination with mild hyperthermia.", "sentB": "This trial, which was a standard 3 + 3 Phase I, three cohort, dose escalation study in three cohorts which enrolled 16 evaluable patients receiving increasing doses of Doxil and GEN-1.", "type": 1, "words": ["<tag1>", "Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia.", "<tag2>", "This", "trial,", "which", "was", "a", "standard", "3", "+", "3", "Phase", "I,", "three", "cohort,", "dose", "escalation", "study", "in", "three", "cohorts", "which", "enrolled", "16", "evaluable", "patients", "receiving", "increasing", "doses", "of", "Doxil", "and", "GEN-1.", "<tag3>"], "wordsA": ["Both", "studies", "employed", "an", "open", "label", "3+3", "dose", "escalation", "study", "design", "to", "determine", "the", "Maximum", "Tolerated", "Dose,", "evaluate", "safety", "and", "determine", "early", "effects", "of", "ThermoDox", "in", "combination", "with", "mild", "hyperthermia."], "wordsB": ["This", "trial,", "which", "was", "a", "standard", "3", "+", "3", "Phase", "I,", "three", "cohort,", "dose", "escalation", "study", "in", "three", "cohorts", "which", "enrolled", "16", "evaluable", "patients", "receiving", "increasing", "doses", "of", "Doxil", "and", "GEN-1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p91_s0", "idA": "749647_14_item1_p66_s5", "sentA": "There were 29 patients treated in the two trials, including 11 patients in the DIGNITY study and 18 patients in the Duke study.", "sentB": "There were no apparent drug related, clinically significant negative trends in laboratory test results, vital sign measurements, or physical examination findings.", "type": 1, "words": ["<tag1>", "There", "were", "29", "patients", "treated", "in", "the", "two", "trials,", "including", "11", "patients", "in", "the", "DIGNITY", "study", "and", "18", "patients", "in", "the", "Duke", "study.", "<tag2>", "There", "were", "no", "apparent", "drug", "related,", "clinically", "significant", "negative", "trends", "in", "laboratory", "test", "results,", "vital", "sign", "measurements,", "or", "physical", "examination", "findings.", "<tag3>"], "wordsA": ["There", "were", "29", "patients", "treated", "in", "the", "two", "trials,", "including", "11", "patients", "in", "the", "DIGNITY", "study", "and", "18", "patients", "in", "the", "Duke", "study."], "wordsB": ["There", "were", "no", "apparent", "drug", "related,", "clinically", "significant", "negative", "trends", "in", "laboratory", "test", "results,", "vital", "sign", "measurements,", "or", "physical", "examination", "findings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p91_s1", "idA": "749647_14_item1_p66_s7", "sentA": "A local response rate of over 60 percent was reported in 14 of the 23 evaluable patients with five complete responses and nine partial responses.", "sentB": "The best clinical response rate was 92% including 17% CR, 33% PR and 42% SD.", "type": 1, "words": ["<tag1>", "A", "local", "response", "rate", "of", "over", "60", "percent", "was", "reported", "in", "14", "of", "the", "23", "evaluable", "patients", "with", "five", "complete", "responses", "and", "nine", "partial", "responses.", "<tag2>", "The", "best", "clinical", "response", "rate", "was", "92%", "including", "17%", "CR,", "33%", "PR", "and", "42%", "SD.", "<tag3>"], "wordsA": ["A", "local", "response", "rate", "of", "over", "60", "percent", "was", "reported", "in", "14", "of", "the", "23", "evaluable", "patients", "with", "five", "complete", "responses", "and", "nine", "partial", "responses."], "wordsB": ["The", "best", "clinical", "response", "rate", "was", "92%", "including", "17%", "CR,", "33%", "PR", "and", "42%", "SD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p22_s0", "idA": "749647_14_item1_p67_s0", "sentA": "In February 2014, we announced positive interim data from the ongoing open-label Phase II DIGNITY study.", "sentB": "A self-liquidating payment of 50% of all fees received from the licensing of TherSilence (up to $6.0 million).", "type": 1, "words": ["<tag1>", "In", "February", "2014,", "we", "announced", "positive", "interim", "data", "from", "the", "ongoing", "open-label", "Phase", "II", "DIGNITY", "study.", "<tag2>", "A", "self-liquidating", "payment", "of", "50%", "of", "all", "fees", "received", "from", "the", "licensing", "of", "TherSilence", "(up", "to", "$6.0", "million).", "<tag3>"], "wordsA": ["In", "February", "2014,", "we", "announced", "positive", "interim", "data", "from", "the", "ongoing", "open-label", "Phase", "II", "DIGNITY", "study."], "wordsB": ["A", "self-liquidating", "payment", "of", "50%", "of", "all", "fees", "received", "from", "the", "licensing", "of", "TherSilence", "(up", "to", "$6.0", "million)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p88_s1", "idA": "749647_14_item1_p67_s1", "sentA": "Based on the data available to date, a local response rate of approximately 80 percent has been observed in the five evaluable patients with refractory disease, notably two complete responses, two partial responses and one patient with stable disease.", "sentB": "Thirty nine percent (39%) of patients treated had stable disease.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "data", "available", "to", "date,", "a", "local", "response", "rate", "of", "approximately", "80", "percent", "has", "been", "observed", "in", "the", "five", "evaluable", "patients", "with", "refractory", "disease,", "notably", "two", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease.", "<tag2>", "Thirty", "nine", "percent", "(39%)", "of", "patients", "treated", "had", "stable", "disease.", "<tag3>"], "wordsA": ["Based", "on", "the", "data", "available", "to", "date,", "a", "local", "response", "rate", "of", "approximately", "80", "percent", "has", "been", "observed", "in", "the", "five", "evaluable", "patients", "with", "refractory", "disease,", "notably", "two", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease."], "wordsB": ["Thirty", "nine", "percent", "(39%)", "of", "patients", "treated", "had", "stable", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p86_s1", "idA": "749647_14_item1_p78_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "This DNA-based approach involves intraperitoneal (IP) administration of an IL-12 plasmid formulated with a proprietary lipopolymer delivery system PEG-PEI-Cholesterol.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "This", "DNA-based", "approach", "involves", "intraperitoneal", "(IP)", "administration", "of", "an", "IL-12", "plasmid", "formulated", "with", "a", "proprietary", "lipopolymer", "delivery", "system", "PEG-PEI-Cholesterol.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["This", "DNA-based", "approach", "involves", "intraperitoneal", "(IP)", "administration", "of", "an", "IL-12", "plasmid", "formulated", "with", "a", "proprietary", "lipopolymer", "delivery", "system", "PEG-PEI-Cholesterol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p97_s3", "idA": "749647_14_item1_p78_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "In one instance, chemical conjugation of a low molecular weight branched BPEI1800 with cholesterol and polyethylene glycol (PEG) to form PEG-PEI-Cholesterol (PPC) dramatically improved the transfection activity of BPEI1800 following in vivo delivery.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "In", "one", "instance,", "chemical", "conjugation", "of", "a", "low", "molecular", "weight", "branched", "BPEI1800", "with", "cholesterol", "and", "polyethylene", "glycol", "(PEG)", "to", "form", "PEG-PEI-Cholesterol", "(PPC)", "dramatically", "improved", "the", "transfection", "activity", "of", "BPEI1800", "following", "in", "vivo", "delivery.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["In", "one", "instance,", "chemical", "conjugation", "of", "a", "low", "molecular", "weight", "branched", "BPEI1800", "with", "cholesterol", "and", "polyethylene", "glycol", "(PEG)", "to", "form", "PEG-PEI-Cholesterol", "(PPC)", "dramatically", "improved", "the", "transfection", "activity", "of", "BPEI1800", "following", "in", "vivo", "delivery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p97_s1", "idA": "749647_14_item1_p78_s3", "sentA": "An IRB will consider, among other things, ethical factors and the safety of human subjects and the possible liability of the institution conducting the clinical trials.", "sentB": "The transfection activity and toxicity of PEI is tightly coupled to its molecular weight therefore the clinical application of PEI is limited.", "type": 1, "words": ["<tag1>", "An", "IRB", "will", "consider,", "among", "other", "things,", "ethical", "factors", "and", "the", "safety", "of", "human", "subjects", "and", "the", "possible", "liability", "of", "the", "institution", "conducting", "the", "clinical", "trials.", "<tag2>", "The", "transfection", "activity", "and", "toxicity", "of", "PEI", "is", "tightly", "coupled", "to", "its", "molecular", "weight", "therefore", "the", "clinical", "application", "of", "PEI", "is", "limited.", "<tag3>"], "wordsA": ["An", "IRB", "will", "consider,", "among", "other", "things,", "ethical", "factors", "and", "the", "safety", "of", "human", "subjects", "and", "the", "possible", "liability", "of", "the", "institution", "conducting", "the", "clinical", "trials."], "wordsB": ["The", "transfection", "activity", "and", "toxicity", "of", "PEI", "is", "tightly", "coupled", "to", "its", "molecular", "weight", "therefore", "the", "clinical", "application", "of", "PEI", "is", "limited."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p81_s0", "idA": "749647_14_item1_p79_s0", "sentA": "Clinical trials are typically conducted in two or three sequential phases, but the phases may overlap.", "sentB": "First-line chemotherapy regimens are typically platinum-based combination therapies.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "are", "typically", "conducted", "in", "two", "or", "three", "sequential", "phases,", "but", "the", "phases", "may", "overlap.", "<tag2>", "First-line", "chemotherapy", "regimens", "are", "typically", "platinum-based", "combination", "therapies.", "<tag3>"], "wordsA": ["Clinical", "trials", "are", "typically", "conducted", "in", "two", "or", "three", "sequential", "phases,", "but", "the", "phases", "may", "overlap."], "wordsB": ["First-line", "chemotherapy", "regimens", "are", "typically", "platinum-based", "combination", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p82_s0", "idA": "749647_14_item1_p80_s0", "sentA": "Phase I clinical trials involve the initial introduction of the therapy to a small number of subjects.", "sentB": "Patients whose cancer recurs or progresses after initially responding to surgery and first-line chemotherapy have been divided into one of the two groups based on the time from completion of platinum therapy to disease recurrence or progression.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "involve", "the", "initial", "introduction", "of", "the", "therapy", "to", "a", "small", "number", "of", "subjects.", "<tag2>", "Patients", "whose", "cancer", "recurs", "or", "progresses", "after", "initially", "responding", "to", "surgery", "and", "first-line", "chemotherapy", "have", "been", "divided", "into", "one", "of", "the", "two", "groups", "based", "on", "the", "time", "from", "completion", "of", "platinum", "therapy", "to", "disease", "recurrence", "or", "progression.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "involve", "the", "initial", "introduction", "of", "the", "therapy", "to", "a", "small", "number", "of", "subjects."], "wordsB": ["Patients", "whose", "cancer", "recurs", "or", "progresses", "after", "initially", "responding", "to", "surgery", "and", "first-line", "chemotherapy", "have", "been", "divided", "into", "one", "of", "the", "two", "groups", "based", "on", "the", "time", "from", "completion", "of", "platinum", "therapy", "to", "disease", "recurrence", "or", "progression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p89_s1", "idA": "749647_14_item1_p80_s1", "sentA": "Phase II trials are generally larger trials conducted in the target population.", "sentB": "The GEN-1 treatment was well tolerated within this Phase II Study..", "type": 1, "words": ["<tag1>", "Phase", "II", "trials", "are", "generally", "larger", "trials", "conducted", "in", "the", "target", "population.", "<tag2>", "The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study..", "<tag3>"], "wordsA": ["Phase", "II", "trials", "are", "generally", "larger", "trials", "conducted", "in", "the", "target", "population."], "wordsB": ["The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study.."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p26_s3", "idA": "749647_14_item1_p81_s1", "sentA": "When a drug or biological compound has shown evidence of efficacy and an acceptable safety profile in Phase II evaluations, Phase III clinical trials are undertaken to serve as the pivotal trials to demonstrate clinical efficacy and safety in an expanded patient population.", "sentB": "We plan to qualify and seek regulatory approval for HISUN to serve as an approved manufacturer for China and Europe.", "type": 1, "words": ["<tag1>", "When", "a", "drug", "or", "biological", "compound", "has", "shown", "evidence", "of", "efficacy", "and", "an", "acceptable", "safety", "profile", "in", "Phase", "II", "evaluations,", "Phase", "III", "clinical", "trials", "are", "undertaken", "to", "serve", "as", "the", "pivotal", "trials", "to", "demonstrate", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population.", "<tag2>", "We", "plan", "to", "qualify", "and", "seek", "regulatory", "approval", "for", "HISUN", "to", "serve", "as", "an", "approved", "manufacturer", "for", "China", "and", "Europe.", "<tag3>"], "wordsA": ["When", "a", "drug", "or", "biological", "compound", "has", "shown", "evidence", "of", "efficacy", "and", "an", "acceptable", "safety", "profile", "in", "Phase", "II", "evaluations,", "Phase", "III", "clinical", "trials", "are", "undertaken", "to", "serve", "as", "the", "pivotal", "trials", "to", "demonstrate", "clinical", "efficacy", "and", "safety", "in", "an", "expanded", "patient", "population."], "wordsB": ["We", "plan", "to", "qualify", "and", "seek", "regulatory", "approval", "for", "HISUN", "to", "serve", "as", "an", "approved", "manufacturer", "for", "China", "and", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p82_s1", "idA": "749647_14_item1_p82_s0", "sentA": "There can be no assurance that any of our clinical trials will be completed successfully within any specified time period or at all.", "sentB": "This time period is referred to as platinum-free interval.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "our", "clinical", "trials", "will", "be", "completed", "successfully", "within", "any", "specified", "time", "period", "or", "at", "all.", "<tag2>", "This", "time", "period", "is", "referred", "to", "as", "platinum-free", "interval.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "our", "clinical", "trials", "will", "be", "completed", "successfully", "within", "any", "specified", "time", "period", "or", "at", "all."], "wordsB": ["This", "time", "period", "is", "referred", "to", "as", "platinum-free", "interval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p94_s2", "idA": "749647_14_item1_p83_s1", "sentA": "Specifically, we determined, after conferring with the DMC, that the HEAT study did not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for the HEAT study.", "sentB": "The clinical trial will identify a safe, tolerable and potentially therapeutically active dose of GEN-1 while maximizing an immune response with the potential to identify an enhanced population for definitive study.", "type": 1, "words": ["<tag1>", "Specifically,", "we", "determined,", "after", "conferring", "with", "the", "DMC,", "that", "the", "HEAT", "study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "persuasive", "evidence", "of", "clinical", "effectiveness", "that", "could", "form", "the", "basis", "for", "regulatory", "approval", "in", "the", "population", "chosen", "for", "the", "HEAT", "study.", "<tag2>", "The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response", "with", "the", "potential", "to", "identify", "an", "enhanced", "population", "for", "definitive", "study.", "<tag3>"], "wordsA": ["Specifically,", "we", "determined,", "after", "conferring", "with", "the", "DMC,", "that", "the", "HEAT", "study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "persuasive", "evidence", "of", "clinical", "effectiveness", "that", "could", "form", "the", "basis", "for", "regulatory", "approval", "in", "the", "population", "chosen", "for", "the", "HEAT", "study."], "wordsB": ["The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response", "with", "the", "potential", "to", "identify", "an", "enhanced", "population", "for", "definitive", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p141_s2", "idA": "749647_14_item1_p86_s0", "sentA": "The primary endpoint for the trial is OS.", "sentB": "We have agreements for the supply of such drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "for", "the", "trial", "is", "OS.", "<tag2>", "We", "have", "agreements", "for", "the", "supply", "of", "such", "drug", "materials", "with", "manufacturers", "or", "suppliers", "that", "we", "believe", "have", "sufficient", "capacity", "to", "meet", "our", "demands.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "the", "trial", "is", "OS."], "wordsB": ["We", "have", "agreements", "for", "the", "supply", "of", "such", "drug", "materials", "with", "manufacturers", "or", "suppliers", "that", "we", "believe", "have", "sufficient", "capacity", "to", "meet", "our", "demands."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p49_s0", "idA": "749647_14_item1_p86_s0", "sentA": "The primary endpoint for the trial is OS.", "sentB": "A multivariate analysis we conducted supports our hypothesis that RFA time is the determining factor in improving OS.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "for", "the", "trial", "is", "OS.", "<tag2>", "A", "multivariate", "analysis", "we", "conducted", "supports", "our", "hypothesis", "that", "RFA", "time", "is", "the", "determining", "factor", "in", "improving", "OS.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "the", "trial", "is", "OS."], "wordsB": ["A", "multivariate", "analysis", "we", "conducted", "supports", "our", "hypothesis", "that", "RFA", "time", "is", "the", "determining", "factor", "in", "improving", "OS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p104_s0", "idA": "749647_14_item1_p8_s1", "sentA": "We are working to develop and commercialize more efficient, effective and targeted chemotherapeutic oncology drugs based on our proprietary heat-activated liposomal technology.", "sentB": "Compared to naked DNA or cationic lipids, TheraPlas is generally safer, more efficient, and cost effective.", "type": 1, "words": ["<tag1>", "We", "are", "working", "to", "develop", "and", "commercialize", "more", "efficient,", "effective", "and", "targeted", "chemotherapeutic", "oncology", "drugs", "based", "on", "our", "proprietary", "heat-activated", "liposomal", "technology.", "<tag2>", "Compared", "to", "naked", "DNA", "or", "cationic", "lipids,", "TheraPlas", "is", "generally", "safer,", "more", "efficient,", "and", "cost", "effective.", "<tag3>"], "wordsA": ["We", "are", "working", "to", "develop", "and", "commercialize", "more", "efficient,", "effective", "and", "targeted", "chemotherapeutic", "oncology", "drugs", "based", "on", "our", "proprietary", "heat-activated", "liposomal", "technology."], "wordsB": ["Compared", "to", "naked", "DNA", "or", "cationic", "lipids,", "TheraPlas", "is", "generally", "safer,", "more", "efficient,", "and", "cost", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p179_s0", "idA": "749647_14_item1_p92_s5", "sentA": "There can be no assurance that any of our current product candidates will receive regulatory approvals for marketing or, if approved, that approval will be for any or all of the indications that we request.", "sentB": "On June 20, 2014, we completed the acquisition of substantially all of the assets of EGEN, Inc.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request.", "<tag2>", "On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request."], "wordsB": ["On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p21_s0", "idA": "749647_14_item1_p92_s5", "sentA": "There can be no assurance that any of our current product candidates will receive regulatory approvals for marketing or, if approved, that approval will be for any or all of the indications that we request.", "sentB": "On June 20, 2014, we completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama Corporation (EGEN), pursuant to an Asset Purchase Agreement.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request.", "<tag2>", "On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc.,", "an", "Alabama", "Corporation", "(EGEN),", "pursuant", "to", "an", "Asset", "Purchase", "Agreement.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request."], "wordsB": ["On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc.,", "an", "Alabama", "Corporation", "(EGEN),", "pursuant", "to", "an", "Asset", "Purchase", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p75_s0", "idA": "749647_14_item1_p92_s5", "sentA": "There can be no assurance that any of our current product candidates will receive regulatory approvals for marketing or, if approved, that approval will be for any or all of the indications that we request.", "sentB": "On June 20, 2014, we completed the acquisition of substantially all of the assets of EGEN, Inc. (EGEN) pursuant to an Asset Purchase Agreement (EGEN Asset Purchase Agreement).", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request.", "<tag2>", "On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc.", "(EGEN)", "pursuant", "to", "an", "Asset", "Purchase", "Agreement", "(EGEN", "Asset", "Purchase", "Agreement).", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request."], "wordsB": ["On", "June", "20,", "2014,", "we", "completed", "the", "acquisition", "of", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "Inc.", "(EGEN)", "pursuant", "to", "an", "Asset", "Purchase", "Agreement", "(EGEN", "Asset", "Purchase", "Agreement)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p75_s1", "idA": "749647_14_item1_p92_s5", "sentA": "There can be no assurance that any of our current product candidates will receive regulatory approvals for marketing or, if approved, that approval will be for any or all of the indications that we request.", "sentB": "CLSN Laboratories acquired all of EGEN s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request.", "<tag2>", "CLSN", "Laboratories", "acquired", "all", "of", "EGEN", "s", "right,", "title", "and", "interest", "in", "and", "to", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "including", "cash", "and", "cash", "equivalents,", "patents,", "trademarks", "and", "other", "intellectual", "property", "rights,", "clinical", "data,", "certain", "contracts,", "licenses", "and", "permits,", "equipment,", "furniture,", "office", "equipment,", "furnishings,", "supplies", "and", "other", "tangible", "personal", "property.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "of", "our", "current", "product", "candidates", "will", "receive", "regulatory", "approvals", "for", "marketing", "or,", "if", "approved,", "that", "approval", "will", "be", "for", "any", "or", "all", "of", "the", "indications", "that", "we", "request."], "wordsB": ["CLSN", "Laboratories", "acquired", "all", "of", "EGEN", "s", "right,", "title", "and", "interest", "in", "and", "to", "substantially", "all", "of", "the", "assets", "of", "EGEN,", "including", "cash", "and", "cash", "equivalents,", "patents,", "trademarks", "and", "other", "intellectual", "property", "rights,", "clinical", "data,", "certain", "contracts,", "licenses", "and", "permits,", "equipment,", "furniture,", "office", "equipment,", "furnishings,", "supplies", "and", "other", "tangible", "personal", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p142_s0", "idA": "749647_14_item1_p95_s2", "sentA": "In order to ensure full technical compliance with such practices, manufacturers must expend funds, time and effort in the areas of production and quality control.", "sentB": "Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others.", "type": 1, "words": ["<tag1>", "In", "order", "to", "ensure", "full", "technical", "compliance", "with", "such", "practices,", "manufacturers", "must", "expend", "funds,", "time", "and", "effort", "in", "the", "areas", "of", "production", "and", "quality", "control.", "<tag2>", "Manufacturing", "is", "subject", "to", "extensive", "regulations", "that", "impose", "various", "procedural", "and", "documentation", "requirements,", "which", "govern", "record", "keeping,", "manufacturing", "processes", "and", "controls,", "personnel,", "quality", "control", "and", "quality", "assurance,", "among", "others.", "<tag3>"], "wordsA": ["In", "order", "to", "ensure", "full", "technical", "compliance", "with", "such", "practices,", "manufacturers", "must", "expend", "funds,", "time", "and", "effort", "in", "the", "areas", "of", "production", "and", "quality", "control."], "wordsB": ["Manufacturing", "is", "subject", "to", "extensive", "regulations", "that", "impose", "various", "procedural", "and", "documentation", "requirements,", "which", "govern", "record", "keeping,", "manufacturing", "processes", "and", "controls,", "personnel,", "quality", "control", "and", "quality", "assurance,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p21_s2", "idA": "749647_14_item1_p95_s3", "sentA": "In addition, the FDA may impose post-approval requirements on us, including the requirement that we conduct specified post-marketing studies.", "sentB": "In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "FDA", "may", "impose", "post-approval", "requirements", "on", "us,", "including", "the", "requirement", "that", "we", "conduct", "specified", "post-marketing", "studies.", "<tag2>", "In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date.", "<tag3>"], "wordsA": ["In", "addition,", "the", "FDA", "may", "impose", "post-approval", "requirements", "on", "us,", "including", "the", "requirement", "that", "we", "conduct", "specified", "post-marketing", "studies."], "wordsB": ["In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p75_s2", "idA": "749647_14_item1_p95_s3", "sentA": "In addition, the FDA may impose post-approval requirements on us, including the requirement that we conduct specified post-marketing studies.", "sentB": "In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "FDA", "may", "impose", "post-approval", "requirements", "on", "us,", "including", "the", "requirement", "that", "we", "conduct", "specified", "post-marketing", "studies.", "<tag2>", "In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date.", "<tag3>"], "wordsA": ["In", "addition,", "the", "FDA", "may", "impose", "post-approval", "requirements", "on", "us,", "including", "the", "requirement", "that", "we", "conduct", "specified", "post-marketing", "studies."], "wordsB": ["In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p166_s0", "idA": "749647_14_item1_p97_s0", "sentA": "The FDA has the authority to require the recall of our products in the event of material deficiencies or defects in manufacture.", "sentB": "In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from a third party.", "type": 1, "words": ["<tag1>", "The", "FDA", "has", "the", "authority", "to", "require", "the", "recall", "of", "our", "products", "in", "the", "event", "of", "material", "deficiencies", "or", "defects", "in", "manufacture.", "<tag2>", "In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party.", "<tag3>"], "wordsA": ["The", "FDA", "has", "the", "authority", "to", "require", "the", "recall", "of", "our", "products", "in", "the", "event", "of", "material", "deficiencies", "or", "defects", "in", "manufacture."], "wordsB": ["In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p162_s1", "idA": "749647_14_item1_p98_s1", "sentA": "These regulations require, among other things, the reporting to the FDA of adverse events alleged to have been associated with the use of a product or in connection with certain product failures.", "sentB": "Should the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming.", "type": 1, "words": ["<tag1>", "These", "regulations", "require,", "among", "other", "things,", "the", "reporting", "to", "the", "FDA", "of", "adverse", "events", "alleged", "to", "have", "been", "associated", "with", "the", "use", "of", "a", "product", "or", "in", "connection", "with", "certain", "product", "failures.", "<tag2>", "Should", "the", "validity", "of", "a", "patent", "be", "challenged,", "the", "legal", "process", "associated", "with", "defending", "the", "patent", "can", "be", "costly", "and", "time", "consuming.", "<tag3>"], "wordsA": ["These", "regulations", "require,", "among", "other", "things,", "the", "reporting", "to", "the", "FDA", "of", "adverse", "events", "alleged", "to", "have", "been", "associated", "with", "the", "use", "of", "a", "product", "or", "in", "connection", "with", "certain", "product", "failures."], "wordsB": ["Should", "the", "validity", "of", "a", "patent", "be", "challenged,", "the", "legal", "process", "associated", "with", "defending", "the", "patent", "can", "be", "costly", "and", "time", "consuming."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p152_s0", "idA": "749647_14_item1_p99_s1", "sentA": "We must also comply with record keeping requirements as well as requirements to report certain adverse events involving our products.", "sentB": "In product positioning for both indications, there currently is no direct immunotherapy competitor for GEN-1, which will be studied as an adjuvant to both chemotherapy standard of care regimens, as well as anti-angiogenesis compounds.", "type": 1, "words": ["<tag1>", "We", "must", "also", "comply", "with", "record", "keeping", "requirements", "as", "well", "as", "requirements", "to", "report", "certain", "adverse", "events", "involving", "our", "products.", "<tag2>", "In", "product", "positioning", "for", "both", "indications,", "there", "currently", "is", "no", "direct", "immunotherapy", "competitor", "for", "GEN-1,", "which", "will", "be", "studied", "as", "an", "adjuvant", "to", "both", "chemotherapy", "standard", "of", "care", "regimens,", "as", "well", "as", "anti-angiogenesis", "compounds.", "<tag3>"], "wordsA": ["We", "must", "also", "comply", "with", "record", "keeping", "requirements", "as", "well", "as", "requirements", "to", "report", "certain", "adverse", "events", "involving", "our", "products."], "wordsB": ["In", "product", "positioning", "for", "both", "indications,", "there", "currently", "is", "no", "direct", "immunotherapy", "competitor", "for", "GEN-1,", "which", "will", "be", "studied", "as", "an", "adjuvant", "to", "both", "chemotherapy", "standard", "of", "care", "regimens,", "as", "well", "as", "anti-angiogenesis", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_15_item1_p89_s0", "idA": "749647_14_item1_p9_s0", "sentA": "Our lead product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the OPTIMA study) starting in the first half of 2014 and is being evaluated in a Phase II clinical trial for recurrent chest wall breast cancer (the DIGNITY Study).", "sentB": "In a Phase II study, GEN-1 IP was administered at 24 mg/m 2 dose once every week until progression or intolerable toxicity in women with persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.", "type": 1, "words": ["<tag1>", "Our", "lead", "product", "ThermoDox", "is", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial", "for", "primary", "liver", "cancer", "(the", "OPTIMA", "study)", "starting", "in", "the", "first", "half", "of", "2014", "and", "is", "being", "evaluated", "in", "a", "Phase", "II", "clinical", "trial", "for", "recurrent", "chest", "wall", "breast", "cancer", "(the", "DIGNITY", "Study).", "<tag2>", "In", "a", "Phase", "II", "study,", "GEN-1", "IP", "was", "administered", "at", "24", "mg/m", "2", "dose", "once", "every", "week", "until", "progression", "or", "intolerable", "toxicity", "in", "women", "with", "persistent", "epithelial", "ovarian,", "fallopian", "tube", "or", "primary", "peritoneal", "cancer.", "<tag3>"], "wordsA": ["Our", "lead", "product", "ThermoDox", "is", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial", "for", "primary", "liver", "cancer", "(the", "OPTIMA", "study)", "starting", "in", "the", "first", "half", "of", "2014", "and", "is", "being", "evaluated", "in", "a", "Phase", "II", "clinical", "trial", "for", "recurrent", "chest", "wall", "breast", "cancer", "(the", "DIGNITY", "Study)."], "wordsB": ["In", "a", "Phase", "II", "study,", "GEN-1", "IP", "was", "administered", "at", "24", "mg/m", "2", "dose", "once", "every", "week", "until", "progression", "or", "intolerable", "toxicity", "in", "women", "with", "persistent", "epithelial", "ovarian,", "fallopian", "tube", "or", "primary", "peritoneal", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p123_s0", "idA": "749647_15_item1_p114_s1", "sentA": "The Federal Food, Drug and Cosmetic Act, the Public Health Service Act and the regulations promulgated by the FDA govern, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising, promotion, import and export of our products.", "sentB": "GOVERNMENT REGULATION Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, quality control, approval, manufacturing, labeling, post-approval monitoring and reporting, recordkeeping, packaging, promotion, storage, advertising, distribution, marketing and export and import of pharmaceutical products such as those we are developing.", "type": 1, "words": ["<tag1>", "The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act,", "the", "Public", "Health", "Service", "Act", "and", "the", "regulations", "promulgated", "by", "the", "FDA", "govern,", "among", "other", "things,", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising,", "promotion,", "import", "and", "export", "of", "our", "products.", "<tag2>", "GOVERNMENT", "REGULATION", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "in", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "quality", "control,", "approval,", "manufacturing,", "labeling,", "post-approval", "monitoring", "and", "reporting,", "recordkeeping,", "packaging,", "promotion,", "storage,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "pharmaceutical", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act,", "the", "Public", "Health", "Service", "Act", "and", "the", "regulations", "promulgated", "by", "the", "FDA", "govern,", "among", "other", "things,", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising,", "promotion,", "import", "and", "export", "of", "our", "products."], "wordsB": ["GOVERNMENT", "REGULATION", "Government", "authorities", "in", "the", "United", "States,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "in", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "quality", "control,", "approval,", "manufacturing,", "labeling,", "post-approval", "monitoring", "and", "reporting,", "recordkeeping,", "packaging,", "promotion,", "storage,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "pharmaceutical", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p26_s0", "idA": "749647_15_item1_p117_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "expression profile of a comprehensive panel of immune related genes in pre-treatment and GEN-1-treated tumor tissue.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "expression", "profile", "of", "a", "comprehensive", "panel", "of", "immune", "related", "genes", "in", "pre-treatment", "and", "GEN-1-treated", "tumor", "tissue.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["expression", "profile", "of", "a", "comprehensive", "panel", "of", "immune", "related", "genes", "in", "pre-treatment", "and", "GEN-1-treated", "tumor", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p92_s0", "idA": "749647_15_item1_p117_s0", "sentA": "Clinical trials involve the administration of therapy to humans under the supervision of a qualified principal investigator.", "sentB": "expression profile of a comprehensive panel of immune related genes in pre-treatment and GEN-1-treated tumor tissue.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator.", "<tag2>", "expression", "profile", "of", "a", "comprehensive", "panel", "of", "immune", "related", "genes", "in", "pre-treatment", "and", "GEN-1-treated", "tumor", "tissue.", "<tag3>"], "wordsA": ["Clinical", "trials", "involve", "the", "administration", "of", "therapy", "to", "humans", "under", "the", "supervision", "of", "a", "qualified", "principal", "investigator."], "wordsB": ["expression", "profile", "of", "a", "comprehensive", "panel", "of", "immune", "related", "genes", "in", "pre-treatment", "and", "GEN-1-treated", "tumor", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p124_s2", "idA": "749647_15_item1_p117_s1", "sentA": "Clinical trials must be conducted in accordance with good clinical practices under protocols submitted to the FDA as part of an IND.", "sentB": "These sanctions could include the FDA s imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "must", "be", "conducted", "in", "accordance", "with", "good", "clinical", "practices", "under", "protocols", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND.", "<tag2>", "These", "sanctions", "could", "include", "the", "FDA", "s", "imposition", "of", "a", "clinical", "hold", "on", "trials,", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "issuance", "of", "warning", "or", "untitled", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "civil", "penalties", "or", "criminal", "prosecution.", "<tag3>"], "wordsA": ["Clinical", "trials", "must", "be", "conducted", "in", "accordance", "with", "good", "clinical", "practices", "under", "protocols", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND."], "wordsB": ["These", "sanctions", "could", "include", "the", "FDA", "s", "imposition", "of", "a", "clinical", "hold", "on", "trials,", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "issuance", "of", "warning", "or", "untitled", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "civil", "penalties", "or", "criminal", "prosecution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p134_s1", "idA": "749647_15_item1_p127_s1", "sentA": "The testing and approval process requires substantial time and effort, and there can be no assurance that any approval will be granted for any product at any time, according to any schedule, or at all.", "sentB": "Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.", "type": 1, "words": ["<tag1>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time", "and", "effort,", "and", "there", "can", "be", "no", "assurance", "that", "any", "approval", "will", "be", "granted", "for", "any", "product", "at", "any", "time,", "according", "to", "any", "schedule,", "or", "at", "all.", "<tag2>", "Orphan", "drug", "designation", "does", "not", "convey", "any", "advantage", "in,", "or", "shorten", "the", "duration", "of,", "the", "regulatory", "review", "and", "approval", "process.", "<tag3>"], "wordsA": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time", "and", "effort,", "and", "there", "can", "be", "no", "assurance", "that", "any", "approval", "will", "be", "granted", "for", "any", "product", "at", "any", "time,", "according", "to", "any", "schedule,", "or", "at", "all."], "wordsB": ["Orphan", "drug", "designation", "does", "not", "convey", "any", "advantage", "in,", "or", "shorten", "the", "duration", "of,", "the", "regulatory", "review", "and", "approval", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p134_s3", "idA": "749647_15_item1_p128_s1", "sentA": "Orphan drug designation entitles the Company to seven years of market exclusivity following regulatory approval, if any, FDA assistance in clinical trial design, a reduction in FDA user fees, U.S. tax credits related to development expenses and the opportunity to apply for funding from the U.S. government to defray the costs of clinical trial expenses.", "sentB": "Orphan drug designation can also provide opportunities for grant funding towards clinical trial costs, tax advantages and FDA user-fee benefits.", "type": 1, "words": ["<tag1>", "Orphan", "drug", "designation", "entitles", "the", "Company", "to", "seven", "years", "of", "market", "exclusivity", "following", "regulatory", "approval,", "if", "any,", "FDA", "assistance", "in", "clinical", "trial", "design,", "a", "reduction", "in", "FDA", "user", "fees,", "U.S.", "tax", "credits", "related", "to", "development", "expenses", "and", "the", "opportunity", "to", "apply", "for", "funding", "from", "the", "U.S.", "government", "to", "defray", "the", "costs", "of", "clinical", "trial", "expenses.", "<tag2>", "Orphan", "drug", "designation", "can", "also", "provide", "opportunities", "for", "grant", "funding", "towards", "clinical", "trial", "costs,", "tax", "advantages", "and", "FDA", "user-fee", "benefits.", "<tag3>"], "wordsA": ["Orphan", "drug", "designation", "entitles", "the", "Company", "to", "seven", "years", "of", "market", "exclusivity", "following", "regulatory", "approval,", "if", "any,", "FDA", "assistance", "in", "clinical", "trial", "design,", "a", "reduction", "in", "FDA", "user", "fees,", "U.S.", "tax", "credits", "related", "to", "development", "expenses", "and", "the", "opportunity", "to", "apply", "for", "funding", "from", "the", "U.S.", "government", "to", "defray", "the", "costs", "of", "clinical", "trial", "expenses."], "wordsB": ["Orphan", "drug", "designation", "can", "also", "provide", "opportunities", "for", "grant", "funding", "towards", "clinical", "trial", "costs,", "tax", "advantages", "and", "FDA", "user-fee", "benefits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p94_s4", "idA": "749647_15_item1_p128_s1", "sentA": "Orphan drug designation entitles the Company to seven years of market exclusivity following regulatory approval, if any, FDA assistance in clinical trial design, a reduction in FDA user fees, U.S. tax credits related to development expenses and the opportunity to apply for funding from the U.S. government to defray the costs of clinical trial expenses.", "sentB": "A 50% reduction in CA-125 levels is considered meaningful.", "type": 1, "words": ["<tag1>", "Orphan", "drug", "designation", "entitles", "the", "Company", "to", "seven", "years", "of", "market", "exclusivity", "following", "regulatory", "approval,", "if", "any,", "FDA", "assistance", "in", "clinical", "trial", "design,", "a", "reduction", "in", "FDA", "user", "fees,", "U.S.", "tax", "credits", "related", "to", "development", "expenses", "and", "the", "opportunity", "to", "apply", "for", "funding", "from", "the", "U.S.", "government", "to", "defray", "the", "costs", "of", "clinical", "trial", "expenses.", "<tag2>", "A", "50%", "reduction", "in", "CA-125", "levels", "is", "considered", "meaningful.", "<tag3>"], "wordsA": ["Orphan", "drug", "designation", "entitles", "the", "Company", "to", "seven", "years", "of", "market", "exclusivity", "following", "regulatory", "approval,", "if", "any,", "FDA", "assistance", "in", "clinical", "trial", "design,", "a", "reduction", "in", "FDA", "user", "fees,", "U.S.", "tax", "credits", "related", "to", "development", "expenses", "and", "the", "opportunity", "to", "apply", "for", "funding", "from", "the", "U.S.", "government", "to", "defray", "the", "costs", "of", "clinical", "trial", "expenses."], "wordsB": ["A", "50%", "reduction", "in", "CA-125", "levels", "is", "considered", "meaningful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p135_s3", "idA": "749647_15_item1_p129_s0", "sentA": "Any FDA-approved drug utilizing the patented technologies may also be eligible for regulatory exclusivities, such as new chemical entity exclusivity of five years in the US, and orphan drug exclusivity of seven years in the US and ten years in Europe.", "sentB": "However, an ANDA or 505(b)(2) NDA referencing the new chemical entity may be submitted after four years if it contains a certification of patent invalidity or non-infringement.", "type": 1, "words": ["<tag1>", "Any", "FDA-approved", "drug", "utilizing", "the", "patented", "technologies", "may", "also", "be", "eligible", "for", "regulatory", "exclusivities,", "such", "as", "new", "chemical", "entity", "exclusivity", "of", "five", "years", "in", "the", "US,", "and", "orphan", "drug", "exclusivity", "of", "seven", "years", "in", "the", "US", "and", "ten", "years", "in", "Europe.", "<tag2>", "However,", "an", "ANDA", "or", "505(b)(2)", "NDA", "referencing", "the", "new", "chemical", "entity", "may", "be", "submitted", "after", "four", "years", "if", "it", "contains", "a", "certification", "of", "patent", "invalidity", "or", "non-infringement.", "<tag3>"], "wordsA": ["Any", "FDA-approved", "drug", "utilizing", "the", "patented", "technologies", "may", "also", "be", "eligible", "for", "regulatory", "exclusivities,", "such", "as", "new", "chemical", "entity", "exclusivity", "of", "five", "years", "in", "the", "US,", "and", "orphan", "drug", "exclusivity", "of", "seven", "years", "in", "the", "US", "and", "ten", "years", "in", "Europe."], "wordsB": ["However,", "an", "ANDA", "or", "505(b)(2)", "NDA", "referencing", "the", "new", "chemical", "entity", "may", "be", "submitted", "after", "four", "years", "if", "it", "contains", "a", "certification", "of", "patent", "invalidity", "or", "non-infringement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p184_s1", "idA": "749647_15_item1_p131_s0", "sentA": "Each U.S. drug manufacturing establishment must be registered with the FDA.", "sentB": "At least a 5-fold increase above pre-treatment level in IFN- was observed in most samples, with the highest increase observed at 120-fold.", "type": 1, "words": ["<tag1>", "Each", "U.S.", "drug", "manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA.", "<tag2>", "At", "least", "a", "5-fold", "increase", "above", "pre-treatment", "level", "in", "IFN-", "was", "observed", "in", "most", "samples,", "with", "the", "highest", "increase", "observed", "at", "120-fold.", "<tag3>"], "wordsA": ["Each", "U.S.", "drug", "manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA."], "wordsB": ["At", "least", "a", "5-fold", "increase", "above", "pre-treatment", "level", "in", "IFN-", "was", "observed", "in", "most", "samples,", "with", "the", "highest", "increase", "observed", "at", "120-fold."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p102_s5", "idA": "749647_15_item1_p135_s1", "sentA": "We must also comply with record keeping requirements as well as requirements to report certain adverse events involving our products.", "sentB": "In the study, the combination of GEN-1 with Avastin and Doxil showed a robust anti-tumor advantage compared to untreated animals as well as a statistically significant improvement over the combination of Avastin and Doxil as summarized below:", "type": 1, "words": ["<tag1>", "We", "must", "also", "comply", "with", "record", "keeping", "requirements", "as", "well", "as", "requirements", "to", "report", "certain", "adverse", "events", "involving", "our", "products.", "<tag2>", "In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:", "<tag3>"], "wordsA": ["We", "must", "also", "comply", "with", "record", "keeping", "requirements", "as", "well", "as", "requirements", "to", "report", "certain", "adverse", "events", "involving", "our", "products."], "wordsB": ["In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p23_s0", "idA": "749647_15_item1_p162_s2", "sentA": "Issued patents can be subject to oppositions, interferences and other third party challenges that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).", "sentB": "GEN-1, designed using the TheraPlas platform technology, is an Interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system which enables cell transfection followed by persistent, local secretion of the IL-12 protein.", "type": 1, "words": ["<tag1>", "Issued", "patents", "can", "be", "subject", "to", "oppositions,", "interferences", "and", "other", "third", "party", "challenges", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage).", "<tag2>", "GEN-1,", "designed", "using", "the", "TheraPlas", "platform", "technology,", "is", "an", "Interleukin-12", "(IL-12)", "DNA", "plasmid", "vector", "encased", "in", "a", "nanoparticle", "delivery", "system", "which", "enables", "cell", "transfection", "followed", "by", "persistent,", "local", "secretion", "of", "the", "IL-12", "protein.", "<tag3>"], "wordsA": ["Issued", "patents", "can", "be", "subject", "to", "oppositions,", "interferences", "and", "other", "third", "party", "challenges", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage)."], "wordsB": ["GEN-1,", "designed", "using", "the", "TheraPlas", "platform", "technology,", "is", "an", "Interleukin-12", "(IL-12)", "DNA", "plasmid", "vector", "encased", "in", "a", "nanoparticle", "delivery", "system", "which", "enables", "cell", "transfection", "followed", "by", "persistent,", "local", "secretion", "of", "the", "IL-12", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p177_s3", "idA": "749647_15_item1_p180_s4", "sentA": "We used approximately $4 million of the first tranche to repay the outstanding obligations under a loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation.", "sentB": "On October 2, 2015, the Company filed a prospectus supplement whereby it registered $7.5 million of the remaining availability under the ATM.", "type": 1, "words": ["<tag1>", "We", "used", "approximately", "$4", "million", "of", "the", "first", "tranche", "to", "repay", "the", "outstanding", "obligations", "under", "a", "loan", "agreement", "with", "Oxford", "Finance", "LLC", "and", "Horizon", "Technology", "Finance", "Corporation.", "<tag2>", "On", "October", "2,", "2015,", "the", "Company", "filed", "a", "prospectus", "supplement", "whereby", "it", "registered", "$7.5", "million", "of", "the", "remaining", "availability", "under", "the", "ATM.", "<tag3>"], "wordsA": ["We", "used", "approximately", "$4", "million", "of", "the", "first", "tranche", "to", "repay", "the", "outstanding", "obligations", "under", "a", "loan", "agreement", "with", "Oxford", "Finance", "LLC", "and", "Horizon", "Technology", "Finance", "Corporation."], "wordsB": ["On", "October", "2,", "2015,", "the", "Company", "filed", "a", "prospectus", "supplement", "whereby", "it", "registered", "$7.5", "million", "of", "the", "remaining", "availability", "under", "the", "ATM."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p177_s2", "idA": "749647_15_item1_p182_s1", "sentA": "We do not have any committed sources of financing and cannot give assurance that alternate funding will be available in a timely manner, on acceptable terms or at all.", "sentB": "The Company did not have any sales under the ATM from February 25, 2013 through September 30, 2015.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "any", "committed", "sources", "of", "financing", "and", "cannot", "give", "assurance", "that", "alternate", "funding", "will", "be", "available", "in", "a", "timely", "manner,", "on", "acceptable", "terms", "or", "at", "all.", "<tag2>", "The", "Company", "did", "not", "have", "any", "sales", "under", "the", "ATM", "from", "February", "25,", "2013", "through", "September", "30,", "2015.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "any", "committed", "sources", "of", "financing", "and", "cannot", "give", "assurance", "that", "alternate", "funding", "will", "be", "available", "in", "a", "timely", "manner,", "on", "acceptable", "terms", "or", "at", "all."], "wordsB": ["The", "Company", "did", "not", "have", "any", "sales", "under", "the", "ATM", "from", "February", "25,", "2013", "through", "September", "30,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p100_s1", "idA": "749647_15_item1_p23_s2", "sentA": "The clinical trial will identify a safe, tolerable and potentially therapeutically active dose of GEN-1 while maximizing an immune response.", "sentB": "Additionally, the anti-angiogenic activity of GEN-1 mediated through up regulation of the interferon gamma (IFN-g) pathway may help to explain the remarkable synergy between GEN-1 and Avastin and potentially addresses the VEGF escape mechanisms associated with resistance to Avastin therapy.", "type": 1, "words": ["<tag1>", "The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response.", "<tag2>", "Additionally,", "the", "anti-angiogenic", "activity", "of", "GEN-1", "mediated", "through", "up", "regulation", "of", "the", "interferon", "gamma", "(IFN-g)", "pathway", "may", "help", "to", "explain", "the", "remarkable", "synergy", "between", "GEN-1", "and", "Avastin", "and", "potentially", "addresses", "the", "VEGF", "escape", "mechanisms", "associated", "with", "resistance", "to", "Avastin", "therapy.", "<tag3>"], "wordsA": ["The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response."], "wordsB": ["Additionally,", "the", "anti-angiogenic", "activity", "of", "GEN-1", "mediated", "through", "up", "regulation", "of", "the", "interferon", "gamma", "(IFN-g)", "pathway", "may", "help", "to", "explain", "the", "remarkable", "synergy", "between", "GEN-1", "and", "Avastin", "and", "potentially", "addresses", "the", "VEGF", "escape", "mechanisms", "associated", "with", "resistance", "to", "Avastin", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p31_s1", "idA": "749647_15_item1_p23_s2", "sentA": "The clinical trial will identify a safe, tolerable and potentially therapeutically active dose of GEN-1 while maximizing an immune response.", "sentB": "Additionally, the anti-angiogenic activity of GEN-1 mediated through up regulation of the interferon gamma (IFN-g) pathway may help to explain the remarkable synergy between GEN-1 and Avastin and potentially addresses the VEGF escape mechanisms associated with resistance to Avastin therapy.", "type": 1, "words": ["<tag1>", "The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response.", "<tag2>", "Additionally,", "the", "anti-angiogenic", "activity", "of", "GEN-1", "mediated", "through", "up", "regulation", "of", "the", "interferon", "gamma", "(IFN-g)", "pathway", "may", "help", "to", "explain", "the", "remarkable", "synergy", "between", "GEN-1", "and", "Avastin", "and", "potentially", "addresses", "the", "VEGF", "escape", "mechanisms", "associated", "with", "resistance", "to", "Avastin", "therapy.", "<tag3>"], "wordsA": ["The", "clinical", "trial", "will", "identify", "a", "safe,", "tolerable", "and", "potentially", "therapeutically", "active", "dose", "of", "GEN-1", "while", "maximizing", "an", "immune", "response."], "wordsB": ["Additionally,", "the", "anti-angiogenic", "activity", "of", "GEN-1", "mediated", "through", "up", "regulation", "of", "the", "interferon", "gamma", "(IFN-g)", "pathway", "may", "help", "to", "explain", "the", "remarkable", "synergy", "between", "GEN-1", "and", "Avastin", "and", "potentially", "addresses", "the", "VEGF", "escape", "mechanisms", "associated", "with", "resistance", "to", "Avastin", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p182_s3", "idA": "749647_15_item1_p61_s0", "sentA": "Despite a variety of therapeutic approaches, up to 40% of the estimated 95,000 patients in the United States undergoing a mastectomy as their primary treatment will develop locally recurrent RCW breast cancer.", "sentB": "The translational research data is highlighted below:", "type": 1, "words": ["<tag1>", "Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer.", "<tag2>", "The", "translational", "research", "data", "is", "highlighted", "below:", "<tag3>"], "wordsA": ["Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer."], "wordsB": ["The", "translational", "research", "data", "is", "highlighted", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p28_s0", "idA": "749647_15_item1_p61_s0", "sentA": "Despite a variety of therapeutic approaches, up to 40% of the estimated 95,000 patients in the United States undergoing a mastectomy as their primary treatment will develop locally recurrent RCW breast cancer.", "sentB": "GEN-1 Plus Avastin and Doxil Trial.", "type": 1, "words": ["<tag1>", "Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer.", "<tag2>", "GEN-1", "Plus", "Avastin", "and", "Doxil", "Trial.", "<tag3>"], "wordsA": ["Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer."], "wordsB": ["GEN-1", "Plus", "Avastin", "and", "Doxil", "Trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p33_s0", "idA": "749647_15_item1_p61_s0", "sentA": "Despite a variety of therapeutic approaches, up to 40% of the estimated 95,000 patients in the United States undergoing a mastectomy as their primary treatment will develop locally recurrent RCW breast cancer.", "sentB": "Thermo D ox Manufacturing and Supply Developments.", "type": 1, "words": ["<tag1>", "Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer.", "<tag2>", "Thermo", "D", "ox", "Manufacturing", "and", "Supply", "Developments.", "<tag3>"], "wordsA": ["Despite", "a", "variety", "of", "therapeutic", "approaches,", "up", "to", "40%", "of", "the", "estimated", "95,000", "patients", "in", "the", "United", "States", "undergoing", "a", "mastectomy", "as", "their", "primary", "treatment", "will", "develop", "locally", "recurrent", "RCW", "breast", "cancer."], "wordsB": ["Thermo", "D", "ox", "Manufacturing", "and", "Supply", "Developments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p94_s5", "idA": "749647_15_item1_p70_s2", "sentA": "Based on data available to date, approximately 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the ten evaluable patients, notably three complete responses, two partial responses and one patient with stable disease.", "sentB": "Both patients CA-125 levels were below the normal healthy level of 35 U/mL. In addition, both patients experienced successful surgical resections of their tumors with one patient reporting a R0 resection which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.", "type": 1, "words": ["<tag1>", "Based", "on", "data", "available", "to", "date,", "approximately", "60%", "of", "patients", "experienced", "a", "stabilization", "of", "their", "highly", "refractory", "disease", "with", "a", "local", "response", "rate", "of", "50%", "observed", "in", "the", "ten", "evaluable", "patients,", "notably", "three", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease.", "<tag2>", "Both", "patients", "CA-125", "levels", "were", "below", "the", "normal", "healthy", "level", "of", "35", "U/mL.", "In", "addition,", "both", "patients", "experienced", "successful", "surgical", "resections", "of", "their", "tumors", "with", "one", "patient", "reporting", "a", "R0", "resection", "which", "indicates", "a", "microscopically", "margin-negative", "resection", "in", "which", "no", "gross", "or", "microscopic", "tumor", "remains", "in", "the", "tumor", "bed.", "<tag3>"], "wordsA": ["Based", "on", "data", "available", "to", "date,", "approximately", "60%", "of", "patients", "experienced", "a", "stabilization", "of", "their", "highly", "refractory", "disease", "with", "a", "local", "response", "rate", "of", "50%", "observed", "in", "the", "ten", "evaluable", "patients,", "notably", "three", "complete", "responses,", "two", "partial", "responses", "and", "one", "patient", "with", "stable", "disease."], "wordsB": ["Both", "patients", "CA-125", "levels", "were", "below", "the", "normal", "healthy", "level", "of", "35", "U/mL.", "In", "addition,", "both", "patients", "experienced", "successful", "surgical", "resections", "of", "their", "tumors", "with", "one", "patient", "reporting", "a", "R0", "resection", "which", "indicates", "a", "microscopically", "margin-negative", "resection", "in", "which", "no", "gross", "or", "microscopic", "tumor", "remains", "in", "the", "tumor", "bed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p182_s2", "idA": "749647_15_item1_p82_s3", "sentA": "This group generally responds to additional treatment with platinum-based therapies.", "sentB": "Furthermore, concomitant increases in IFN- and TNF- indicate that t he IL-12 produced following treatment with GEN-1 treatment is immunologically active.", "type": 1, "words": ["<tag1>", "This", "group", "generally", "responds", "to", "additional", "treatment", "with", "platinum-based", "therapies.", "<tag2>", "Furthermore,", "concomitant", "increases", "in", "IFN-", "and", "TNF-", "indicate", "that", "t", "he", "IL-12", "produced", "following", "treatment", "with", "GEN-1", "treatment", "is", "immunologically", "active.", "<tag3>"], "wordsA": ["This", "group", "generally", "responds", "to", "additional", "treatment", "with", "platinum-based", "therapies."], "wordsB": ["Furthermore,", "concomitant", "increases", "in", "IFN-", "and", "TNF-", "indicate", "that", "t", "he", "IL-12", "produced", "following", "treatment", "with", "GEN-1", "treatment", "is", "immunologically", "active."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p100_s0", "idA": "749647_15_item1_p83_s0", "sentA": "Pegylated liposomal doxorubicin, topotecan, and Avastin are the only approved second-line therapies for platinum-resistant ovarian cancer.", "sentB": "The distinct biological activities of GEN-1 (immune stimulation) and Avastin (inhibition of tumor blood vessel formation) makes a sound scientific rationale for this combination approach.", "type": 1, "words": ["<tag1>", "Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "The", "distinct", "biological", "activities", "of", "GEN-1", "(immune", "stimulation)", "and", "Avastin", "(inhibition", "of", "tumor", "blood", "vessel", "formation)", "makes", "a", "sound", "scientific", "rationale", "for", "this", "combination", "approach.", "<tag3>"], "wordsA": ["Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["The", "distinct", "biological", "activities", "of", "GEN-1", "(immune", "stimulation)", "and", "Avastin", "(inhibition", "of", "tumor", "blood", "vessel", "formation)", "makes", "a", "sound", "scientific", "rationale", "for", "this", "combination", "approach."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p31_s0", "idA": "749647_15_item1_p83_s0", "sentA": "Pegylated liposomal doxorubicin, topotecan, and Avastin are the only approved second-line therapies for platinum-resistant ovarian cancer.", "sentB": "The distinct biological activities of GEN-1 (immune stimulation) and Avastin (inhibition of tumor blood vessel formation) makes a sound scientific rationale for this combination approach.", "type": 1, "words": ["<tag1>", "Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "The", "distinct", "biological", "activities", "of", "GEN-1", "(immune", "stimulation)", "and", "Avastin", "(inhibition", "of", "tumor", "blood", "vessel", "formation)", "makes", "a", "sound", "scientific", "rationale", "for", "this", "combination", "approach.", "<tag3>"], "wordsA": ["Pegylated", "liposomal", "doxorubicin,", "topotecan,", "and", "Avastin", "are", "the", "only", "approved", "second-line", "therapies", "for", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["The", "distinct", "biological", "activities", "of", "GEN-1", "(immune", "stimulation)", "and", "Avastin", "(inhibition", "of", "tumor", "blood", "vessel", "formation)", "makes", "a", "sound", "scientific", "rationale", "for", "this", "combination", "approach."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p184_s0", "idA": "749647_15_item1_p86_s0", "sentA": "Celsion s GEN-1 approach for IL-12 delivery is designed to achieve local concentrations of IL-12 at the tumor site with minimal increases in systemic circulation.", "sentB": "Significant increases in levels of IFN- , a key downstream mediator of IL-12 action, were observed in peritoneal fluid but not in plasma samples.", "type": 1, "words": ["<tag1>", "Celsion", "s", "GEN-1", "approach", "for", "IL-12", "delivery", "is", "designed", "to", "achieve", "local", "concentrations", "of", "IL-12", "at", "the", "tumor", "site", "with", "minimal", "increases", "in", "systemic", "circulation.", "<tag2>", "Significant", "increases", "in", "levels", "of", "IFN-", ",", "a", "key", "downstream", "mediator", "of", "IL-12", "action,", "were", "observed", "in", "peritoneal", "fluid", "but", "not", "in", "plasma", "samples.", "<tag3>"], "wordsA": ["Celsion", "s", "GEN-1", "approach", "for", "IL-12", "delivery", "is", "designed", "to", "achieve", "local", "concentrations", "of", "IL-12", "at", "the", "tumor", "site", "with", "minimal", "increases", "in", "systemic", "circulation."], "wordsB": ["Significant", "increases", "in", "levels", "of", "IFN-", ",", "a", "key", "downstream", "mediator", "of", "IL-12", "action,", "were", "observed", "in", "peritoneal", "fluid", "but", "not", "in", "plasma", "samples."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p29_s1", "idA": "749647_15_item1_p89_s1", "sentA": "The GEN-1 treatment was well tolerated within this Phase II Study..", "sentB": "The effectiveness of the combined treatment was seen when GEN-1 was combined with various dose levels of Avastin (low-medium-high).", "type": 1, "words": ["<tag1>", "The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study..", "<tag2>", "The", "effectiveness", "of", "the", "combined", "treatment", "was", "seen", "when", "GEN-1", "was", "combined", "with", "various", "dose", "levels", "of", "Avastin", "(low-medium-high).", "<tag3>"], "wordsA": ["The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study.."], "wordsB": ["The", "effectiveness", "of", "the", "combined", "treatment", "was", "seen", "when", "GEN-1", "was", "combined", "with", "various", "dose", "levels", "of", "Avastin", "(low-medium-high)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p98_s1", "idA": "749647_15_item1_p89_s1", "sentA": "The GEN-1 treatment was well tolerated within this Phase II Study..", "sentB": "The effectiveness of the combined treatment was seen when GEN-1 was combined with various dose levels of Avastin (low-medium-high).", "type": 1, "words": ["<tag1>", "The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study..", "<tag2>", "The", "effectiveness", "of", "the", "combined", "treatment", "was", "seen", "when", "GEN-1", "was", "combined", "with", "various", "dose", "levels", "of", "Avastin", "(low-medium-high).", "<tag3>"], "wordsA": ["The", "GEN-1", "treatment", "was", "well", "tolerated", "within", "this", "Phase", "II", "Study.."], "wordsB": ["The", "effectiveness", "of", "the", "combined", "treatment", "was", "seen", "when", "GEN-1", "was", "combined", "with", "various", "dose", "levels", "of", "Avastin", "(low-medium-high)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p183_s1", "idA": "749647_15_item1_p90_s1", "sentA": "The GEN-1 treatment administered in combination with carboplatin/docetaxel was well tolerated.", "sentB": "IL-12 levels were quantifiable in 91% of evaluable fluid samples collected post GEN-1 treatment.", "type": 1, "words": ["<tag1>", "The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated.", "<tag2>", "IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment.", "<tag3>"], "wordsA": ["The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated."], "wordsB": ["IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p29_s2", "idA": "749647_15_item1_p90_s1", "sentA": "The GEN-1 treatment administered in combination with carboplatin/docetaxel was well tolerated.", "sentB": "Additionally, it was shown that GEN-1 treatment alone resulted in anti-tumor activity that was as good as or better than Avastin treatment alone.", "type": 1, "words": ["<tag1>", "The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated.", "<tag2>", "Additionally,", "it", "was", "shown", "that", "GEN-1", "treatment", "alone", "resulted", "in", "anti-tumor", "activity", "that", "was", "as", "good", "as", "or", "better", "than", "Avastin", "treatment", "alone.", "<tag3>"], "wordsA": ["The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated."], "wordsB": ["Additionally,", "it", "was", "shown", "that", "GEN-1", "treatment", "alone", "resulted", "in", "anti-tumor", "activity", "that", "was", "as", "good", "as", "or", "better", "than", "Avastin", "treatment", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_16_item1_p98_s2", "idA": "749647_15_item1_p90_s1", "sentA": "The GEN-1 treatment administered in combination with carboplatin/docetaxel was well tolerated.", "sentB": "Additionally, it was shown that GEN-1 treatment alone resulted in anti-tumor activity that was as good as or better than Avastin treatment alone.", "type": 1, "words": ["<tag1>", "The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated.", "<tag2>", "Additionally,", "it", "was", "shown", "that", "GEN-1", "treatment", "alone", "resulted", "in", "anti-tumor", "activity", "that", "was", "as", "good", "as", "or", "better", "than", "Avastin", "treatment", "alone.", "<tag3>"], "wordsA": ["The", "GEN-1", "treatment", "administered", "in", "combination", "with", "carboplatin/docetaxel", "was", "well", "tolerated."], "wordsB": ["Additionally,", "it", "was", "shown", "that", "GEN-1", "treatment", "alone", "resulted", "in", "anti-tumor", "activity", "that", "was", "as", "good", "as", "or", "better", "than", "Avastin", "treatment", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p24_s1", "idA": "749647_16_item1_p128_s1", "sentA": "Phase I clinical trials may be conducted in patients or healthy volunteers to evaluate the product s safety, dosage tolerance and pharmacokinetics and, if possible, seek to gain an early indication of its effectiveness.", "sentB": "The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival in patients treated with RFA plus ThermoDox compared to patients treated with RFA alone.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "may", "be", "conducted", "in", "patients", "or", "healthy", "volunteers", "to", "evaluate", "the", "product", "s", "safety,", "dosage", "tolerance", "and", "pharmacokinetics", "and,", "if", "possible,", "seek", "to", "gain", "an", "early", "indication", "of", "its", "effectiveness.", "<tag2>", "The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "may", "be", "conducted", "in", "patients", "or", "healthy", "volunteers", "to", "evaluate", "the", "product", "s", "safety,", "dosage", "tolerance", "and", "pharmacokinetics", "and,", "if", "possible,", "seek", "to", "gain", "an", "early", "indication", "of", "its", "effectiveness."], "wordsB": ["The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p91_s1", "idA": "749647_16_item1_p128_s1", "sentA": "Phase I clinical trials may be conducted in patients or healthy volunteers to evaluate the product s safety, dosage tolerance and pharmacokinetics and, if possible, seek to gain an early indication of its effectiveness.", "sentB": "The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival in patients treated with RFA plus ThermoDox compared to patients treated with RFA alone.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "may", "be", "conducted", "in", "patients", "or", "healthy", "volunteers", "to", "evaluate", "the", "product", "s", "safety,", "dosage", "tolerance", "and", "pharmacokinetics", "and,", "if", "possible,", "seek", "to", "gain", "an", "early", "indication", "of", "its", "effectiveness.", "<tag2>", "The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "may", "be", "conducted", "in", "patients", "or", "healthy", "volunteers", "to", "evaluate", "the", "product", "s", "safety,", "dosage", "tolerance", "and", "pharmacokinetics", "and,", "if", "possible,", "seek", "to", "gain", "an", "early", "indication", "of", "its", "effectiveness."], "wordsB": ["The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p64_s1", "idA": "749647_16_item1_p134_s0", "sentA": "In 2009, the FDA granted orphan drug designation for ThermoDox for the treatment of HCC.", "sentB": "A local China partner affords Celsion access to accelerated CFDA review and potential regulatory exclusivity for the approved indication.", "type": 1, "words": ["<tag1>", "In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC.", "<tag2>", "A", "local", "China", "partner", "affords", "Celsion", "access", "to", "accelerated", "CFDA", "review", "and", "potential", "regulatory", "exclusivity", "for", "the", "approved", "indication.", "<tag3>"], "wordsA": ["In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC."], "wordsB": ["A", "local", "China", "partner", "affords", "Celsion", "access", "to", "accelerated", "CFDA", "review", "and", "potential", "regulatory", "exclusivity", "for", "the", "approved", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p133_s2", "idA": "749647_16_item1_p13_s0", "sentA": "In the trial, ThermoDox was well-tolerated with no unexpected serious adverse events.", "sentB": "In the other patient the debulking surgery was not performed due to disease related complications.", "type": 1, "words": ["<tag1>", "In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events.", "<tag2>", "In", "the", "other", "patient", "the", "debulking", "surgery", "was", "not", "performed", "due", "to", "disease", "related", "complications.", "<tag3>"], "wordsA": ["In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events."], "wordsB": ["In", "the", "other", "patient", "the", "debulking", "surgery", "was", "not", "performed", "due", "to", "disease", "related", "complications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p50_s2", "idA": "749647_16_item1_p13_s0", "sentA": "In the trial, ThermoDox was well-tolerated with no unexpected serious adverse events.", "sentB": "In the other patient the debulking surgery was not performed due to disease related complications.", "type": 1, "words": ["<tag1>", "In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events.", "<tag2>", "In", "the", "other", "patient", "the", "debulking", "surgery", "was", "not", "performed", "due", "to", "disease", "related", "complications.", "<tag3>"], "wordsA": ["In", "the", "trial,", "ThermoDox", "was", "well-tolerated", "with", "no", "unexpected", "serious", "adverse", "events."], "wordsB": ["In", "the", "other", "patient", "the", "debulking", "surgery", "was", "not", "performed", "due", "to", "disease", "related", "complications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p60_s4", "idA": "749647_16_item1_p152_s1", "sentA": "In addition, the Company is not aware of any other Phase III clinical trial for the treatment of HCC or primary liver cancer.", "sentB": "The future manufacturing of clinical and commercial supplies by Hisun will result in a cost structure allowing Celsion to profitably access all global markets, including third world countries, and help accelerate the Company s product development program in China for ThermoDox in primary liver cancer and other approved indications.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "Company", "is", "not", "aware", "of", "any", "other", "Phase", "III", "clinical", "trial", "for", "the", "treatment", "of", "HCC", "or", "primary", "liver", "cancer.", "<tag2>", "The", "future", "manufacturing", "of", "clinical", "and", "commercial", "supplies", "by", "Hisun", "will", "result", "in", "a", "cost", "structure", "allowing", "Celsion", "to", "profitably", "access", "all", "global", "markets,", "including", "third", "world", "countries,", "and", "help", "accelerate", "the", "Company", "s", "product", "development", "program", "in", "China", "for", "ThermoDox", "in", "primary", "liver", "cancer", "and", "other", "approved", "indications.", "<tag3>"], "wordsA": ["In", "addition,", "the", "Company", "is", "not", "aware", "of", "any", "other", "Phase", "III", "clinical", "trial", "for", "the", "treatment", "of", "HCC", "or", "primary", "liver", "cancer."], "wordsB": ["The", "future", "manufacturing", "of", "clinical", "and", "commercial", "supplies", "by", "Hisun", "will", "result", "in", "a", "cost", "structure", "allowing", "Celsion", "to", "profitably", "access", "all", "global", "markets,", "including", "third", "world", "countries,", "and", "help", "accelerate", "the", "Company", "s", "product", "development", "program", "in", "China", "for", "ThermoDox", "in", "primary", "liver", "cancer", "and", "other", "approved", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p211_s2", "idA": "749647_16_item1_p167_s2", "sentA": "The failure to obtain a license may have a material adverse effect on our business, results of operations and financial condition.", "sentB": "The Series AA Warrants have an exercise price of $0.23 per share, have a five year life and are immediately exercisable.", "type": 1, "words": ["<tag1>", "The", "failure", "to", "obtain", "a", "license", "may", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "The", "Series", "AA", "Warrants", "have", "an", "exercise", "price", "of", "$0.23", "per", "share,", "have", "a", "five", "year", "life", "and", "are", "immediately", "exercisable.", "<tag3>"], "wordsA": ["The", "failure", "to", "obtain", "a", "license", "may", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["The", "Series", "AA", "Warrants", "have", "an", "exercise", "price", "of", "$0.23", "per", "share,", "have", "a", "five", "year", "life", "and", "are", "immediately", "exercisable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p134_s0", "idA": "749647_16_item1_p183_s1", "sentA": "IL-12 levels were quantifiable in 91% of evaluable fluid samples collected post GEN-1 treatment.", "sentB": "In plasma samples, there was no significant change in T-cell density following the treatment.", "type": 1, "words": ["<tag1>", "IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment.", "<tag2>", "In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment.", "<tag3>"], "wordsA": ["IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment."], "wordsB": ["In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p51_s0", "idA": "749647_16_item1_p183_s1", "sentA": "IL-12 levels were quantifiable in 91% of evaluable fluid samples collected post GEN-1 treatment.", "sentB": "In plasma samples, there was no significant change in T-cell density following the treatment.", "type": 1, "words": ["<tag1>", "IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment.", "<tag2>", "In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment.", "<tag3>"], "wordsA": ["IL-12", "levels", "were", "quantifiable", "in", "91%", "of", "evaluable", "fluid", "samples", "collected", "post", "GEN-1", "treatment."], "wordsB": ["In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p132_s0", "idA": "749647_16_item1_p19_s1", "sentA": "The approval will allow Celsion to enroll patients at up to 20 clinical sites in China.", "sentB": "In tumor tissue, there was an increase in cytotoxic CD8+ T-cell density in three out of four evaluable patients at debulking surgery.", "type": 1, "words": ["<tag1>", "The", "approval", "will", "allow", "Celsion", "to", "enroll", "patients", "at", "up", "to", "20", "clinical", "sites", "in", "China.", "<tag2>", "In", "tumor", "tissue,", "there", "was", "an", "increase", "in", "cytotoxic", "CD8+", "T-cell", "density", "in", "three", "out", "of", "four", "evaluable", "patients", "at", "debulking", "surgery.", "<tag3>"], "wordsA": ["The", "approval", "will", "allow", "Celsion", "to", "enroll", "patients", "at", "up", "to", "20", "clinical", "sites", "in", "China."], "wordsB": ["In", "tumor", "tissue,", "there", "was", "an", "increase", "in", "cytotoxic", "CD8+", "T-cell", "density", "in", "three", "out", "of", "four", "evaluable", "patients", "at", "debulking", "surgery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p49_s0", "idA": "749647_16_item1_p19_s1", "sentA": "The approval will allow Celsion to enroll patients at up to 20 clinical sites in China.", "sentB": "In tumor tissue, there was an increase in cytotoxic CD8+ T-cell density in three out of four evaluable patients at debulking surgery.", "type": 1, "words": ["<tag1>", "The", "approval", "will", "allow", "Celsion", "to", "enroll", "patients", "at", "up", "to", "20", "clinical", "sites", "in", "China.", "<tag2>", "In", "tumor", "tissue,", "there", "was", "an", "increase", "in", "cytotoxic", "CD8+", "T-cell", "density", "in", "three", "out", "of", "four", "evaluable", "patients", "at", "debulking", "surgery.", "<tag3>"], "wordsA": ["The", "approval", "will", "allow", "Celsion", "to", "enroll", "patients", "at", "up", "to", "20", "clinical", "sites", "in", "China."], "wordsB": ["In", "tumor", "tissue,", "there", "was", "an", "increase", "in", "cytotoxic", "CD8+", "T-cell", "density", "in", "three", "out", "of", "four", "evaluable", "patients", "at", "debulking", "surgery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p125_s0", "idA": "749647_16_item1_p27_s1", "sentA": "In February 2016, we announced the completion of enrollment of the first cohort of three patients in the OVATION Study.", "sentB": "Of the first twelve patients dosed, one (1) patient demonstrated a complete response ( CR ), eight (8) patients demonstrated partial response ( PR ) and three patients demonstrated stable disease ( SD ), as measured by RECIST criteria.", "type": 1, "words": ["<tag1>", "In", "February", "2016,", "we", "announced", "the", "completion", "of", "enrollment", "of", "the", "first", "cohort", "of", "three", "patients", "in", "the", "OVATION", "Study.", "<tag2>", "Of", "the", "first", "twelve", "patients", "dosed,", "one", "(1)", "patient", "demonstrated", "a", "complete", "response", "(", "CR", "),", "eight", "(8)", "patients", "demonstrated", "partial", "response", "(", "PR", ")", "and", "three", "patients", "demonstrated", "stable", "disease", "(", "SD", "),", "as", "measured", "by", "RECIST", "criteria.", "<tag3>"], "wordsA": ["In", "February", "2016,", "we", "announced", "the", "completion", "of", "enrollment", "of", "the", "first", "cohort", "of", "three", "patients", "in", "the", "OVATION", "Study."], "wordsB": ["Of", "the", "first", "twelve", "patients", "dosed,", "one", "(1)", "patient", "demonstrated", "a", "complete", "response", "(", "CR", "),", "eight", "(8)", "patients", "demonstrated", "partial", "response", "(", "PR", ")", "and", "three", "patients", "demonstrated", "stable", "disease", "(", "SD", "),", "as", "measured", "by", "RECIST", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p42_s0", "idA": "749647_16_item1_p27_s1", "sentA": "In February 2016, we announced the completion of enrollment of the first cohort of three patients in the OVATION Study.", "sentB": "Of the first twelve patients dosed, one (1) patient demonstrated a complete response ( CR ), eight (8) patients demonstrated partial response ( PR ) and three patients demonstrated stable disease ( SD ), as measured by RECIST criteria.", "type": 1, "words": ["<tag1>", "In", "February", "2016,", "we", "announced", "the", "completion", "of", "enrollment", "of", "the", "first", "cohort", "of", "three", "patients", "in", "the", "OVATION", "Study.", "<tag2>", "Of", "the", "first", "twelve", "patients", "dosed,", "one", "(1)", "patient", "demonstrated", "a", "complete", "response", "(", "CR", "),", "eight", "(8)", "patients", "demonstrated", "partial", "response", "(", "PR", ")", "and", "three", "patients", "demonstrated", "stable", "disease", "(", "SD", "),", "as", "measured", "by", "RECIST", "criteria.", "<tag3>"], "wordsA": ["In", "February", "2016,", "we", "announced", "the", "completion", "of", "enrollment", "of", "the", "first", "cohort", "of", "three", "patients", "in", "the", "OVATION", "Study."], "wordsB": ["Of", "the", "first", "twelve", "patients", "dosed,", "one", "(1)", "patient", "demonstrated", "a", "complete", "response", "(", "CR", "),", "eight", "(8)", "patients", "demonstrated", "partial", "response", "(", "PR", ")", "and", "three", "patients", "demonstrated", "stable", "disease", "(", "SD", "),", "as", "measured", "by", "RECIST", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p132_s3", "idA": "749647_16_item1_p29_s0", "sentA": "In two preclinical studies using an animal model of disseminated ovarian cancer, GEN-1 in combination with Avastin led to a significant reduction in tumor burden and disease progression.", "sentB": "High tumor infiltrating CD8+ T-cell density, low FoxP3+ T-cell density or high CD8+/FoxP3+ ratio demonstrate a potential shift in tumor environment to favoring immune stimulation following NACT + GEN-1 therapy.", "type": 1, "words": ["<tag1>", "In", "two", "preclinical", "studies", "using", "an", "animal", "model", "of", "disseminated", "ovarian", "cancer,", "GEN-1", "in", "combination", "with", "Avastin", "led", "to", "a", "significant", "reduction", "in", "tumor", "burden", "and", "disease", "progression.", "<tag2>", "High", "tumor", "infiltrating", "CD8+", "T-cell", "density,", "low", "FoxP3+", "T-cell", "density", "or", "high", "CD8+/FoxP3+", "ratio", "demonstrate", "a", "potential", "shift", "in", "tumor", "environment", "to", "favoring", "immune", "stimulation", "following", "NACT", "+", "GEN-1", "therapy.", "<tag3>"], "wordsA": ["In", "two", "preclinical", "studies", "using", "an", "animal", "model", "of", "disseminated", "ovarian", "cancer,", "GEN-1", "in", "combination", "with", "Avastin", "led", "to", "a", "significant", "reduction", "in", "tumor", "burden", "and", "disease", "progression."], "wordsB": ["High", "tumor", "infiltrating", "CD8+", "T-cell", "density,", "low", "FoxP3+", "T-cell", "density", "or", "high", "CD8+/FoxP3+", "ratio", "demonstrate", "a", "potential", "shift", "in", "tumor", "environment", "to", "favoring", "immune", "stimulation", "following", "NACT", "+", "GEN-1", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p49_s3", "idA": "749647_16_item1_p29_s0", "sentA": "In two preclinical studies using an animal model of disseminated ovarian cancer, GEN-1 in combination with Avastin led to a significant reduction in tumor burden and disease progression.", "sentB": "High tumor infiltrating CD8+ T-cell density, low FoxP3+ T-cell density or high CD8+/FoxP3+ ratio demonstrate a potential shift in tumor environment to favoring immune stimulation following NACT + GEN-1 therapy.", "type": 1, "words": ["<tag1>", "In", "two", "preclinical", "studies", "using", "an", "animal", "model", "of", "disseminated", "ovarian", "cancer,", "GEN-1", "in", "combination", "with", "Avastin", "led", "to", "a", "significant", "reduction", "in", "tumor", "burden", "and", "disease", "progression.", "<tag2>", "High", "tumor", "infiltrating", "CD8+", "T-cell", "density,", "low", "FoxP3+", "T-cell", "density", "or", "high", "CD8+/FoxP3+", "ratio", "demonstrate", "a", "potential", "shift", "in", "tumor", "environment", "to", "favoring", "immune", "stimulation", "following", "NACT", "+", "GEN-1", "therapy.", "<tag3>"], "wordsA": ["In", "two", "preclinical", "studies", "using", "an", "animal", "model", "of", "disseminated", "ovarian", "cancer,", "GEN-1", "in", "combination", "with", "Avastin", "led", "to", "a", "significant", "reduction", "in", "tumor", "burden", "and", "disease", "progression."], "wordsB": ["High", "tumor", "infiltrating", "CD8+", "T-cell", "density,", "low", "FoxP3+", "T-cell", "density", "or", "high", "CD8+/FoxP3+", "ratio", "demonstrate", "a", "potential", "shift", "in", "tumor", "environment", "to", "favoring", "immune", "stimulation", "following", "NACT", "+", "GEN-1", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p60_s1", "idA": "749647_16_item1_p44_s0", "sentA": "Liver Cancer Overview Primary liver cancer (hepatocellular carcinoma or HCC) is one of the most common and deadliest forms of cancer worldwide.", "sentB": "Hisun is one the largest manufacturers of chemotherapy agents globally, including doxorubicin.", "type": 1, "words": ["<tag1>", "Liver", "Cancer", "Overview", "Primary", "liver", "cancer", "(hepatocellular", "carcinoma", "or", "HCC)", "is", "one", "of", "the", "most", "common", "and", "deadliest", "forms", "of", "cancer", "worldwide.", "<tag2>", "Hisun", "is", "one", "the", "largest", "manufacturers", "of", "chemotherapy", "agents", "globally,", "including", "doxorubicin.", "<tag3>"], "wordsA": ["Liver", "Cancer", "Overview", "Primary", "liver", "cancer", "(hepatocellular", "carcinoma", "or", "HCC)", "is", "one", "of", "the", "most", "common", "and", "deadliest", "forms", "of", "cancer", "worldwide."], "wordsB": ["Hisun", "is", "one", "the", "largest", "manufacturers", "of", "chemotherapy", "agents", "globally,", "including", "doxorubicin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p20_s0", "idA": "749647_16_item1_p49_s0", "sentA": "Local recurrence rates after RFA directly correlate to the size of the tumor.", "sentB": "Additional findings from this most recent analysis specific to the Chinese patient cohort of 223 patients are summarized below:", "type": 1, "words": ["<tag1>", "Local", "recurrence", "rates", "after", "RFA", "directly", "correlate", "to", "the", "size", "of", "the", "tumor.", "<tag2>", "Additional", "findings", "from", "this", "most", "recent", "analysis", "specific", "to", "the", "Chinese", "patient", "cohort", "of", "223", "patients", "are", "summarized", "below:", "<tag3>"], "wordsA": ["Local", "recurrence", "rates", "after", "RFA", "directly", "correlate", "to", "the", "size", "of", "the", "tumor."], "wordsB": ["Additional", "findings", "from", "this", "most", "recent", "analysis", "specific", "to", "the", "Chinese", "patient", "cohort", "of", "223", "patients", "are", "summarized", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p132_s1", "idA": "749647_16_item1_p52_s1", "sentA": "The study also permitted multiple dosing in liver cancer patients.", "sentB": "There was a decrease in immunosuppressive FoxP3+ T-cells in two out of those 4 patients.", "type": 1, "words": ["<tag1>", "The", "study", "also", "permitted", "multiple", "dosing", "in", "liver", "cancer", "patients.", "<tag2>", "There", "was", "a", "decrease", "in", "immunosuppressive", "FoxP3+", "T-cells", "in", "two", "out", "of", "those", "4", "patients.", "<tag3>"], "wordsA": ["The", "study", "also", "permitted", "multiple", "dosing", "in", "liver", "cancer", "patients."], "wordsB": ["There", "was", "a", "decrease", "in", "immunosuppressive", "FoxP3+", "T-cells", "in", "two", "out", "of", "those", "4", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p49_s1", "idA": "749647_16_item1_p52_s1", "sentA": "The study also permitted multiple dosing in liver cancer patients.", "sentB": "There was a decrease in immunosuppressive FoxP3+ T-cells in two out of those 4 patients.", "type": 1, "words": ["<tag1>", "The", "study", "also", "permitted", "multiple", "dosing", "in", "liver", "cancer", "patients.", "<tag2>", "There", "was", "a", "decrease", "in", "immunosuppressive", "FoxP3+", "T-cells", "in", "two", "out", "of", "those", "4", "patients.", "<tag3>"], "wordsA": ["The", "study", "also", "permitted", "multiple", "dosing", "in", "liver", "cancer", "patients."], "wordsB": ["There", "was", "a", "decrease", "in", "immunosuppressive", "FoxP3+", "T-cells", "in", "two", "out", "of", "those", "4", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p127_s0", "idA": "749647_16_item1_p74_s6", "sentA": "Of the 29 patients, 23 were eligible for evaluation of efficacy.", "sentB": "Of the eleven surgically treated and evaluable patients, one patient demonstrated a complete pathological response ( cPR ), five (5) patients demonstrated a micro pathological response ( microPR ), and five (5) patients demonstrated a macroPR.", "type": 1, "words": ["<tag1>", "Of", "the", "29", "patients,", "23", "were", "eligible", "for", "evaluation", "of", "efficacy.", "<tag2>", "Of", "the", "eleven", "surgically", "treated", "and", "evaluable", "patients,", "one", "patient", "demonstrated", "a", "complete", "pathological", "response", "(", "cPR", "),", "five", "(5)", "patients", "demonstrated", "a", "micro", "pathological", "response", "(", "microPR", "),", "and", "five", "(5)", "patients", "demonstrated", "a", "macroPR.", "<tag3>"], "wordsA": ["Of", "the", "29", "patients,", "23", "were", "eligible", "for", "evaluation", "of", "efficacy."], "wordsB": ["Of", "the", "eleven", "surgically", "treated", "and", "evaluable", "patients,", "one", "patient", "demonstrated", "a", "complete", "pathological", "response", "(", "cPR", "),", "five", "(5)", "patients", "demonstrated", "a", "micro", "pathological", "response", "(", "microPR", "),", "and", "five", "(5)", "patients", "demonstrated", "a", "macroPR."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p44_s0", "idA": "749647_16_item1_p74_s6", "sentA": "Of the 29 patients, 23 were eligible for evaluation of efficacy.", "sentB": "Of the eleven surgically treated and evaluable patients, one patient demonstrated a complete pathological response ( cPR ), five (5) patients demonstrated a micro pathological response ( microPR ), and five (5) patients demonstrated a macroPR.", "type": 1, "words": ["<tag1>", "Of", "the", "29", "patients,", "23", "were", "eligible", "for", "evaluation", "of", "efficacy.", "<tag2>", "Of", "the", "eleven", "surgically", "treated", "and", "evaluable", "patients,", "one", "patient", "demonstrated", "a", "complete", "pathological", "response", "(", "cPR", "),", "five", "(5)", "patients", "demonstrated", "a", "micro", "pathological", "response", "(", "microPR", "),", "and", "five", "(5)", "patients", "demonstrated", "a", "macroPR.", "<tag3>"], "wordsA": ["Of", "the", "29", "patients,", "23", "were", "eligible", "for", "evaluation", "of", "efficacy."], "wordsB": ["Of", "the", "eleven", "surgically", "treated", "and", "evaluable", "patients,", "one", "patient", "demonstrated", "a", "complete", "pathological", "response", "(", "cPR", "),", "five", "(5)", "patients", "demonstrated", "a", "micro", "pathological", "response", "(", "microPR", "),", "and", "five", "(5)", "patients", "demonstrated", "a", "macroPR."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p125_s1", "idA": "749647_16_item1_p86_s1", "sentA": "The overall response rate for these therapies is 10 to 20 percent with median overall survival of eleven to twelve months.", "sentB": "This translates to a 100% disease control rate ( DCR ) and 75% objective response rate ( ORR ).", "type": 1, "words": ["<tag1>", "The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months.", "<tag2>", "This", "translates", "to", "a", "100%", "disease", "control", "rate", "(", "DCR", ")", "and", "75%", "objective", "response", "rate", "(", "ORR", ").", "<tag3>"], "wordsA": ["The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months."], "wordsB": ["This", "translates", "to", "a", "100%", "disease", "control", "rate", "(", "DCR", ")", "and", "75%", "objective", "response", "rate", "(", "ORR", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p42_s1", "idA": "749647_16_item1_p86_s1", "sentA": "The overall response rate for these therapies is 10 to 20 percent with median overall survival of eleven to twelve months.", "sentB": "This translates to a 100% disease control rate ( DCR ) and 75% objective response rate ( ORR ).", "type": 1, "words": ["<tag1>", "The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months.", "<tag2>", "This", "translates", "to", "a", "100%", "disease", "control", "rate", "(", "DCR", ")", "and", "75%", "objective", "response", "rate", "(", "ORR", ").", "<tag3>"], "wordsA": ["The", "overall", "response", "rate", "for", "these", "therapies", "is", "10", "to", "20", "percent", "with", "median", "overall", "survival", "of", "eleven", "to", "twelve", "months."], "wordsB": ["This", "translates", "to", "a", "100%", "disease", "control", "rate", "(", "DCR", ")", "and", "75%", "objective", "response", "rate", "(", "ORR", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p133_s0", "idA": "749647_16_item1_p94_s1", "sentA": "The first two patients in the OVATION Study who completed treatment have shown promising results.", "sentB": "For the remaining two patients the post-treatment tumor tissue was not available.", "type": 1, "words": ["<tag1>", "The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results.", "<tag2>", "For", "the", "remaining", "two", "patients", "the", "post-treatment", "tumor", "tissue", "was", "not", "available.", "<tag3>"], "wordsA": ["The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results."], "wordsB": ["For", "the", "remaining", "two", "patients", "the", "post-treatment", "tumor", "tissue", "was", "not", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p133_s1", "idA": "749647_16_item1_p94_s1", "sentA": "The first two patients in the OVATION Study who completed treatment have shown promising results.", "sentB": "In one of those two patients there was complete pathological response hence no tumor tissue was present to provide a post-treatment comparison.", "type": 1, "words": ["<tag1>", "The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results.", "<tag2>", "In", "one", "of", "those", "two", "patients", "there", "was", "complete", "pathological", "response", "hence", "no", "tumor", "tissue", "was", "present", "to", "provide", "a", "post-treatment", "comparison.", "<tag3>"], "wordsA": ["The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results."], "wordsB": ["In", "one", "of", "those", "two", "patients", "there", "was", "complete", "pathological", "response", "hence", "no", "tumor", "tissue", "was", "present", "to", "provide", "a", "post-treatment", "comparison."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p50_s0", "idA": "749647_16_item1_p94_s1", "sentA": "The first two patients in the OVATION Study who completed treatment have shown promising results.", "sentB": "For the remaining two patients the post-treatment tumor tissue was not available.", "type": 1, "words": ["<tag1>", "The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results.", "<tag2>", "For", "the", "remaining", "two", "patients", "the", "post-treatment", "tumor", "tissue", "was", "not", "available.", "<tag3>"], "wordsA": ["The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results."], "wordsB": ["For", "the", "remaining", "two", "patients", "the", "post-treatment", "tumor", "tissue", "was", "not", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p50_s1", "idA": "749647_16_item1_p94_s1", "sentA": "The first two patients in the OVATION Study who completed treatment have shown promising results.", "sentB": "In one of those two patients there was complete pathological response hence no tumor tissue was present to provide a post-treatment comparison.", "type": 1, "words": ["<tag1>", "The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results.", "<tag2>", "In", "one", "of", "those", "two", "patients", "there", "was", "complete", "pathological", "response", "hence", "no", "tumor", "tissue", "was", "present", "to", "provide", "a", "post-treatment", "comparison.", "<tag3>"], "wordsA": ["The", "first", "two", "patients", "in", "the", "OVATION", "Study", "who", "completed", "treatment", "have", "shown", "promising", "results."], "wordsB": ["In", "one", "of", "those", "two", "patients", "there", "was", "complete", "pathological", "response", "hence", "no", "tumor", "tissue", "was", "present", "to", "provide", "a", "post-treatment", "comparison."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_17_item1_p64_s0", "idA": "749647_16_item1_p95_s0", "sentA": "The OVATION Study will continue into 2016 at higher doses of GEN-1 with the goal to identify a safe, tolerable and therapeutically active dose of GEN-1 by recruiting and maximizing an immune response.", "sentB": "Hisun will collaborate with Celsion around the regulatory approval activities for GEN-1 with the CFDA.", "type": 1, "words": ["<tag1>", "The", "OVATION", "Study", "will", "continue", "into", "2016", "at", "higher", "doses", "of", "GEN-1", "with", "the", "goal", "to", "identify", "a", "safe,", "tolerable", "and", "therapeutically", "active", "dose", "of", "GEN-1", "by", "recruiting", "and", "maximizing", "an", "immune", "response.", "<tag2>", "Hisun", "will", "collaborate", "with", "Celsion", "around", "the", "regulatory", "approval", "activities", "for", "GEN-1", "with", "the", "CFDA.", "<tag3>"], "wordsA": ["The", "OVATION", "Study", "will", "continue", "into", "2016", "at", "higher", "doses", "of", "GEN-1", "with", "the", "goal", "to", "identify", "a", "safe,", "tolerable", "and", "therapeutically", "active", "dose", "of", "GEN-1", "by", "recruiting", "and", "maximizing", "an", "immune", "response."], "wordsB": ["Hisun", "will", "collaborate", "with", "Celsion", "around", "the", "regulatory", "approval", "activities", "for", "GEN-1", "with", "the", "CFDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p355_s0", "idA": "749647_17_item1_p0_s0", "sentA": "Certain of the statements contained in this Annual Report on Form 10-K are forward-looking and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.", "sentB": "On December 22, 2017, the President of the United States signed into law the Tax Reform Act.", "type": 1, "words": ["<tag1>", "Certain", "of", "the", "statements", "contained", "in", "this", "Annual", "Report", "on", "Form", "10-K", "are", "forward-looking", "and", "constitute", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995.", "<tag2>", "On", "December", "22,", "2017,", "the", "President", "of", "the", "United", "States", "signed", "into", "law", "the", "Tax", "Reform", "Act.", "<tag3>"], "wordsA": ["Certain", "of", "the", "statements", "contained", "in", "this", "Annual", "Report", "on", "Form", "10-K", "are", "forward-looking", "and", "constitute", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995."], "wordsB": ["On", "December", "22,", "2017,", "the", "President", "of", "the", "United", "States", "signed", "into", "law", "the", "Tax", "Reform", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p353_s0", "idA": "749647_17_item1_p104_s1", "sentA": "The Euro-DIGNITY Study is expected to commence in 2017 and is expected to enroll up to 70 patients affected by recurrent breast adenocarcinoma on the chest wall with/without nodes over a period of two years.", "sentB": "The capital and credit markets have experienced extreme volatility and disruption in recent years.", "type": 1, "words": ["<tag1>", "The", "Euro-DIGNITY", "Study", "is", "expected", "to", "commence", "in", "2017", "and", "is", "expected", "to", "enroll", "up", "to", "70", "patients", "affected", "by", "recurrent", "breast", "adenocarcinoma", "on", "the", "chest", "wall", "with/without", "nodes", "over", "a", "period", "of", "two", "years.", "<tag2>", "The", "capital", "and", "credit", "markets", "have", "experienced", "extreme", "volatility", "and", "disruption", "in", "recent", "years.", "<tag3>"], "wordsA": ["The", "Euro-DIGNITY", "Study", "is", "expected", "to", "commence", "in", "2017", "and", "is", "expected", "to", "enroll", "up", "to", "70", "patients", "affected", "by", "recurrent", "breast", "adenocarcinoma", "on", "the", "chest", "wall", "with/without", "nodes", "over", "a", "period", "of", "two", "years."], "wordsB": ["The", "capital", "and", "credit", "markets", "have", "experienced", "extreme", "volatility", "and", "disruption", "in", "recent", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p170_s1", "idA": "749647_17_item1_p114_s2", "sentA": "The platinum-sensitive group has a platinum-free interval of longer than six months.", "sentB": "Once the NDA/BLA is accepted for filing, most standard reviews applications are completed within ten months of filing; most priority review applications are reviewed within six months of filing.", "type": 1, "words": ["<tag1>", "The", "platinum-sensitive", "group", "has", "a", "platinum-free", "interval", "of", "longer", "than", "six", "months.", "<tag2>", "Once", "the", "NDA/BLA", "is", "accepted", "for", "filing,", "most", "standard", "reviews", "applications", "are", "completed", "within", "ten", "months", "of", "filing;", "most", "priority", "review", "applications", "are", "reviewed", "within", "six", "months", "of", "filing.", "<tag3>"], "wordsA": ["The", "platinum-sensitive", "group", "has", "a", "platinum-free", "interval", "of", "longer", "than", "six", "months."], "wordsB": ["Once", "the", "NDA/BLA", "is", "accepted", "for", "filing,", "most", "standard", "reviews", "applications", "are", "completed", "within", "ten", "months", "of", "filing;", "most", "priority", "review", "applications", "are", "reviewed", "within", "six", "months", "of", "filing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p173_s0", "idA": "749647_17_item1_p119_s4", "sentA": "The activation of the body s immune system will potentially eliminate the chemotherapy resistant cells and lower the risk of recurrence.", "sentB": "To help reduce the increased risk of the introduction of adventitious a gents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined.", "type": 1, "words": ["<tag1>", "The", "activation", "of", "the", "body", "s", "immune", "system", "will", "potentially", "eliminate", "the", "chemotherapy", "resistant", "cells", "and", "lower", "the", "risk", "of", "recurrence.", "<tag2>", "To", "help", "reduce", "the", "increased", "risk", "of", "the", "introduction", "of", "adventitious", "a", "gents,", "the", "PHSA", "emphasizes", "the", "importance", "of", "manufacturing", "controls", "for", "products", "whose", "attributes", "cannot", "be", "precisely", "defined.", "<tag3>"], "wordsA": ["The", "activation", "of", "the", "body", "s", "immune", "system", "will", "potentially", "eliminate", "the", "chemotherapy", "resistant", "cells", "and", "lower", "the", "risk", "of", "recurrence."], "wordsB": ["To", "help", "reduce", "the", "increased", "risk", "of", "the", "introduction", "of", "adventitious", "a", "gents,", "the", "PHSA", "emphasizes", "the", "importance", "of", "manufacturing", "controls", "for", "products", "whose", "attributes", "cannot", "be", "precisely", "defined."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p359_s0", "idA": "749647_17_item1_p134_s0", "sentA": "In plasma samples, there was no significant change in T-cell density following the treatment.", "sentB": "Anti-takeover provisions in our charter documents and Delaware law could prevent or delay a change in control.", "type": 1, "words": ["<tag1>", "In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment.", "<tag2>", "Anti-takeover", "provisions", "in", "our", "charter", "documents", "and", "Delaware", "law", "could", "prevent", "or", "delay", "a", "change", "in", "control.", "<tag3>"], "wordsA": ["In", "plasma", "samples,", "there", "was", "no", "significant", "change", "in", "T-cell", "density", "following", "the", "treatment."], "wordsB": ["Anti-takeover", "provisions", "in", "our", "charter", "documents", "and", "Delaware", "law", "could", "prevent", "or", "delay", "a", "change", "in", "control."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p177_s2", "idA": "749647_17_item1_p139_s0", "sentA": "The preclinical studies indicated that no obvious overt toxicities were associated with the combined treatments.", "sentB": "Generally, product candidates that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.", "type": 1, "words": ["<tag1>", "The", "preclinical", "studies", "indicated", "that", "no", "obvious", "overt", "toxicities", "were", "associated", "with", "the", "combined", "treatments.", "<tag2>", "Generally,", "product", "candidates", "that", "are", "eligible", "for", "these", "programs", "are", "those", "for", "serious", "or", "life-threatening", "conditions,", "those", "with", "the", "potential", "to", "address", "unmet", "medical", "needs", "and", "those", "that", "offer", "meaningful", "benefits", "over", "existing", "treatments.", "<tag3>"], "wordsA": ["The", "preclinical", "studies", "indicated", "that", "no", "obvious", "overt", "toxicities", "were", "associated", "with", "the", "combined", "treatments."], "wordsB": ["Generally,", "product", "candidates", "that", "are", "eligible", "for", "these", "programs", "are", "those", "for", "serious", "or", "life-threatening", "conditions,", "those", "with", "the", "potential", "to", "address", "unmet", "medical", "needs", "and", "those", "that", "offer", "meaningful", "benefits", "over", "existing", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p127_s1", "idA": "749647_17_item1_p143_s0", "sentA": "In the study, the combination of GEN-1 with Avastin and Doxil showed a robust anti-tumor advantage compared to untreated animals as well as a statistically significant improvement over the combination of Avastin and Doxil as summarized below:", "sentB": "GEN-1 plus standard chemotherapy produced positive clinical results, with no dose limiting toxicities and positive dose dependent efficacy signals which correlate well with positive surgical outcomes as summarized below:", "type": 1, "words": ["<tag1>", "In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:", "<tag2>", "GEN-1", "plus", "standard", "chemotherapy", "produced", "positive", "clinical", "results,", "with", "no", "dose", "limiting", "toxicities", "and", "positive", "dose", "dependent", "efficacy", "signals", "which", "correlate", "well", "with", "positive", "surgical", "outcomes", "as", "summarized", "below:", "<tag3>"], "wordsA": ["In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:"], "wordsB": ["GEN-1", "plus", "standard", "chemotherapy", "produced", "positive", "clinical", "results,", "with", "no", "dose", "limiting", "toxicities", "and", "positive", "dose", "dependent", "efficacy", "signals", "which", "correlate", "well", "with", "positive", "surgical", "outcomes", "as", "summarized", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p53_s1", "idA": "749647_17_item1_p143_s0", "sentA": "In the study, the combination of GEN-1 with Avastin and Doxil showed a robust anti-tumor advantage compared to untreated animals as well as a statistically significant improvement over the combination of Avastin and Doxil as summarized below:", "sentB": "GEN-1 plus standard chemotherapy produced positive clinical results, with no dose limiting toxicities and positive dose dependent efficacy signals which correlate well with positive surgical outcomes as summarized below:", "type": 1, "words": ["<tag1>", "In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:", "<tag2>", "GEN-1", "plus", "standard", "chemotherapy", "produced", "positive", "clinical", "results,", "with", "no", "dose", "limiting", "toxicities", "and", "positive", "dose", "dependent", "efficacy", "signals", "which", "correlate", "well", "with", "positive", "surgical", "outcomes", "as", "summarized", "below:", "<tag3>"], "wordsA": ["In", "the", "study,", "the", "combination", "of", "GEN-1", "with", "Avastin", "and", "Doxil", "showed", "a", "robust", "anti-tumor", "advantage", "compared", "to", "untreated", "animals", "as", "well", "as", "a", "statistically", "significant", "improvement", "over", "the", "combination", "of", "Avastin", "and", "Doxil", "as", "summarized", "below:"], "wordsB": ["GEN-1", "plus", "standard", "chemotherapy", "produced", "positive", "clinical", "results,", "with", "no", "dose", "limiting", "toxicities", "and", "positive", "dose", "dependent", "efficacy", "signals", "which", "correlate", "well", "with", "positive", "surgical", "outcomes", "as", "summarized", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p269_s0", "idA": "749647_17_item1_p145_s2", "sentA": "The delivery system is designed to protect the DNA/RNA from degradation and promote trafficking into cells and through intracellular compartments.", "sentB": "The delivery technology platforms, TheraPlas and TheraSilence, are in preclinical stages of development.", "type": 1, "words": ["<tag1>", "The", "delivery", "system", "is", "designed", "to", "protect", "the", "DNA/RNA", "from", "degradation", "and", "promote", "trafficking", "into", "cells", "and", "through", "intracellular", "compartments.", "<tag2>", "The", "delivery", "technology", "platforms,", "TheraPlas", "and", "TheraSilence,", "are", "in", "preclinical", "stages", "of", "development.", "<tag3>"], "wordsA": ["The", "delivery", "system", "is", "designed", "to", "protect", "the", "DNA/RNA", "from", "degradation", "and", "promote", "trafficking", "into", "cells", "and", "through", "intracellular", "compartments."], "wordsB": ["The", "delivery", "technology", "platforms,", "TheraPlas", "and", "TheraSilence,", "are", "in", "preclinical", "stages", "of", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p186_s4", "idA": "749647_17_item1_p151_s1", "sentA": "Two cross-linked polymers have been synthesized with this approach and optimized for transfection activity.", "sentB": "To date, a handful of biosimilar products and no interchangeable products have been approved under the BPCIA.", "type": 1, "words": ["<tag1>", "Two", "cross-linked", "polymers", "have", "been", "synthesized", "with", "this", "approach", "and", "optimized", "for", "transfection", "activity.", "<tag2>", "To", "date,", "a", "handful", "of", "biosimilar", "products", "and", "no", "interchangeable", "products", "have", "been", "approved", "under", "the", "BPCIA.", "<tag3>"], "wordsA": ["Two", "cross-linked", "polymers", "have", "been", "synthesized", "with", "this", "approach", "and", "optimized", "for", "transfection", "activity."], "wordsB": ["To", "date,", "a", "handful", "of", "biosimilar", "products", "and", "no", "interchangeable", "products", "have", "been", "approved", "under", "the", "BPCIA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p360_s0", "idA": "749647_17_item1_p156_s0", "sentA": "We may also consider and evaluate strategic alternatives, including investment in, or acquisition of, complementary businesses, technologies or products.", "sentB": "Our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that a stockholder may consider favorable by authorizing the issuance of blank check preferred stock.", "type": 1, "words": ["<tag1>", "We", "may", "also", "consider", "and", "evaluate", "strategic", "alternatives,", "including", "investment", "in,", "or", "acquisition", "of,", "complementary", "businesses,", "technologies", "or", "products.", "<tag2>", "Our", "certificate", "of", "incorporation", "and", "bylaws", "may", "discourage,", "delay", "or", "prevent", "a", "merger", "or", "acquisition", "that", "a", "stockholder", "may", "consider", "favorable", "by", "authorizing", "the", "issuance", "of", "blank", "check", "preferred", "stock.", "<tag3>"], "wordsA": ["We", "may", "also", "consider", "and", "evaluate", "strategic", "alternatives,", "including", "investment", "in,", "or", "acquisition", "of,", "complementary", "businesses,", "technologies", "or", "products."], "wordsB": ["Our", "certificate", "of", "incorporation", "and", "bylaws", "may", "discourage,", "delay", "or", "prevent", "a", "merger", "or", "acquisition", "that", "a", "stockholder", "may", "consider", "favorable", "by", "authorizing", "the", "issuance", "of", "blank", "check", "preferred", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p33_s0", "idA": "749647_17_item1_p157_s0", "sentA": "As demonstrated by the HEAT Study results, drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval.", "sentB": "The lead author is Won Young Tak, M.D., Ph.D., Professor Internal Medicine, Gastroenterology Hepatology, Kyungpook National University Hospital Daegu, Republic of Korea, and there are 22 HEAT Study co-authors along with Nicholas Borys, M.D., Celsion s senior vice president and chief medical officer.", "type": 1, "words": ["<tag1>", "As", "demonstrated", "by", "the", "HEAT", "Study", "results,", "drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval.", "<tag2>", "The", "lead", "author", "is", "Won", "Young", "Tak,", "M.D.,", "Ph.D.,", "Professor", "Internal", "Medicine,", "Gastroenterology", "Hepatology,", "Kyungpook", "National", "University", "Hospital", "Daegu,", "Republic", "of", "Korea,", "and", "there", "are", "22", "HEAT", "Study", "co-authors", "along", "with", "Nicholas", "Borys,", "M.D.,", "Celsion", "s", "senior", "vice", "president", "and", "chief", "medical", "officer.", "<tag3>"], "wordsA": ["As", "demonstrated", "by", "the", "HEAT", "Study", "results,", "drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval."], "wordsB": ["The", "lead", "author", "is", "Won", "Young", "Tak,", "M.D.,", "Ph.D.,", "Professor", "Internal", "Medicine,", "Gastroenterology", "Hepatology,", "Kyungpook", "National", "University", "Hospital", "Daegu,", "Republic", "of", "Korea,", "and", "there", "are", "22", "HEAT", "Study", "co-authors", "along", "with", "Nicholas", "Borys,", "M.D.,", "Celsion", "s", "senior", "vice", "president", "and", "chief", "medical", "officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p267_s1", "idA": "749647_17_item1_p159_s0", "sentA": "Our current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development and commercialization of our product candidates.", "sentB": "Our lead product candidate, ThermoDox and the product candidates we purchased in our acquisition of EGEN, including GEN-1, are still in various stages of development and trials and cannot be marketed until we have completed clinical testing and obtained necessary governmental approval.", "type": 1, "words": ["<tag1>", "Our", "current", "business", "strategy", "includes", "the", "possibility", "of", "entering", "into", "collaborative", "arrangements", "with", "third", "parties", "to", "complete", "the", "development", "and", "commercialization", "of", "our", "product", "candidates.", "<tag2>", "Our", "lead", "product", "candidate,", "ThermoDox", "and", "the", "product", "candidates", "we", "purchased", "in", "our", "acquisition", "of", "EGEN,", "including", "GEN-1,", "are", "still", "in", "various", "stages", "of", "development", "and", "trials", "and", "cannot", "be", "marketed", "until", "we", "have", "completed", "clinical", "testing", "and", "obtained", "necessary", "governmental", "approval.", "<tag3>"], "wordsA": ["Our", "current", "business", "strategy", "includes", "the", "possibility", "of", "entering", "into", "collaborative", "arrangements", "with", "third", "parties", "to", "complete", "the", "development", "and", "commercialization", "of", "our", "product", "candidates."], "wordsB": ["Our", "lead", "product", "candidate,", "ThermoDox", "and", "the", "product", "candidates", "we", "purchased", "in", "our", "acquisition", "of", "EGEN,", "including", "GEN-1,", "are", "still", "in", "various", "stages", "of", "development", "and", "trials", "and", "cannot", "be", "marketed", "until", "we", "have", "completed", "clinical", "testing", "and", "obtained", "necessary", "governmental", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p333_s4", "idA": "749647_17_item1_p159_s1", "sentA": "In the event that third parties take over the clinical trial process for one or more of our product candidates, the estimated completion date would largely be under the control of that third party rather than us.", "sentB": "One or more of these companies or institutions could succeed in developing products or other technologies that are more effective than the products and technologies that we have been or are developing, or which would render our technology and products obsolete and non-competitive.", "type": 1, "words": ["<tag1>", "In", "the", "event", "that", "third", "parties", "take", "over", "the", "clinical", "trial", "process", "for", "one", "or", "more", "of", "our", "product", "candidates,", "the", "estimated", "completion", "date", "would", "largely", "be", "under", "the", "control", "of", "that", "third", "party", "rather", "than", "us.", "<tag2>", "One", "or", "more", "of", "these", "companies", "or", "institutions", "could", "succeed", "in", "developing", "products", "or", "other", "technologies", "that", "are", "more", "effective", "than", "the", "products", "and", "technologies", "that", "we", "have", "been", "or", "are", "developing,", "or", "which", "would", "render", "our", "technology", "and", "products", "obsolete", "and", "non-competitive.", "<tag3>"], "wordsA": ["In", "the", "event", "that", "third", "parties", "take", "over", "the", "clinical", "trial", "process", "for", "one", "or", "more", "of", "our", "product", "candidates,", "the", "estimated", "completion", "date", "would", "largely", "be", "under", "the", "control", "of", "that", "third", "party", "rather", "than", "us."], "wordsB": ["One", "or", "more", "of", "these", "companies", "or", "institutions", "could", "succeed", "in", "developing", "products", "or", "other", "technologies", "that", "are", "more", "effective", "than", "the", "products", "and", "technologies", "that", "we", "have", "been", "or", "are", "developing,", "or", "which", "would", "render", "our", "technology", "and", "products", "obsolete", "and", "non-competitive."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p273_s0", "idA": "749647_17_item1_p159_s2", "sentA": "We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our development plan or capital requirements.", "sentB": "the incurrence of significant exit charges if products or technologies acquired in business combinations are unsuccessful.", "type": 1, "words": ["<tag1>", "We", "cannot", "forecast", "with", "any", "degree", "of", "certainty", "which", "proprietary", "products", "or", "indications,", "if", "any,", "will", "be", "subject", "to", "future", "collaborative", "arrangements,", "in", "whole", "or", "in", "part,", "and", "how", "such", "arrangements", "would", "affect", "our", "development", "plan", "or", "capital", "requirements.", "<tag2>", "the", "incurrence", "of", "significant", "exit", "charges", "if", "products", "or", "technologies", "acquired", "in", "business", "combinations", "are", "unsuccessful.", "<tag3>"], "wordsA": ["We", "cannot", "forecast", "with", "any", "degree", "of", "certainty", "which", "proprietary", "products", "or", "indications,", "if", "any,", "will", "be", "subject", "to", "future", "collaborative", "arrangements,", "in", "whole", "or", "in", "part,", "and", "how", "such", "arrangements", "would", "affect", "our", "development", "plan", "or", "capital", "requirements."], "wordsB": ["the", "incurrence", "of", "significant", "exit", "charges", "if", "products", "or", "technologies", "acquired", "in", "business", "combinations", "are", "unsuccessful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p186_s1", "idA": "749647_17_item1_p160_s1", "sentA": "Given our development plans, we anticipate cash resources will be sufficient to fund our operations into mid-2017 and the Company has no committed sources of additional capital.", "sentB": "Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product candidate and the reference product in terms of safety, purity, and potency.", "type": 1, "words": ["<tag1>", "Given", "our", "development", "plans,", "we", "anticipate", "cash", "resources", "will", "be", "sufficient", "to", "fund", "our", "operations", "into", "mid-2017", "and", "the", "Company", "has", "no", "committed", "sources", "of", "additional", "capital.", "<tag2>", "Biosimilarity", "sufficient", "to", "reference", "a", "prior", "FDA-approved", "product", "requires", "that", "there", "be", "no", "differences", "in", "conditions", "of", "use,", "route", "of", "administration,", "dosage", "form,", "and", "strength,", "and", "no", "clinically", "meaningful", "differences", "between", "the", "biological", "product", "candidate", "and", "the", "reference", "product", "in", "terms", "of", "safety,", "purity,", "and", "potency.", "<tag3>"], "wordsA": ["Given", "our", "development", "plans,", "we", "anticipate", "cash", "resources", "will", "be", "sufficient", "to", "fund", "our", "operations", "into", "mid-2017", "and", "the", "Company", "has", "no", "committed", "sources", "of", "additional", "capital."], "wordsB": ["Biosimilarity", "sufficient", "to", "reference", "a", "prior", "FDA-approved", "product", "requires", "that", "there", "be", "no", "differences", "in", "conditions", "of", "use,", "route", "of", "administration,", "dosage", "form,", "and", "strength,", "and", "no", "clinically", "meaningful", "differences", "between", "the", "biological", "product", "candidate", "and", "the", "reference", "product", "in", "terms", "of", "safety,", "purity,", "and", "potency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p292_s2", "idA": "749647_17_item1_p162_s0", "sentA": "As a result of the risks and uncertainties discussed in this Annual Report on Form 10-K, among others, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product if one of our product candidates receives regulatory approval for marketing, if at all.", "sentB": "If we cannot contract with acceptable third parties on commercially reasonable terms or at all, if these third parties are unable to carry out their contractual duties or obligations in a manner that is consistent with our expectations or meet expected deadlines, if they do not carry out the trials in accordance with budgeted amounts, if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, or if they fail to maintain compliance with applicable government regulations and standards, our clinical trials may be extended, delayed or terminated or may become significantly more expensive, we may not receive development milestone payments when expected or at all, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.", "type": 1, "words": ["<tag1>", "As", "a", "result", "of", "the", "risks", "and", "uncertainties", "discussed", "in", "this", "Annual", "Report", "on", "Form", "10-K,", "among", "others,", "we", "are", "unable", "to", "estimate", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects", "or", "when,", "if", "ever,", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "the", "commercialization", "and", "sale", "of", "a", "product", "if", "one", "of", "our", "product", "candidates", "receives", "regulatory", "approval", "for", "marketing,", "if", "at", "all.", "<tag2>", "If", "we", "cannot", "contract", "with", "acceptable", "third", "parties", "on", "commercially", "reasonable", "terms", "or", "at", "all,", "if", "these", "third", "parties", "are", "unable", "to", "carry", "out", "their", "contractual", "duties", "or", "obligations", "in", "a", "manner", "that", "is", "consistent", "with", "our", "expectations", "or", "meet", "expected", "deadlines,", "if", "they", "do", "not", "carry", "out", "the", "trials", "in", "accordance", "with", "budgeted", "amounts,", "if", "the", "quality", "or", "accuracy", "of", "the", "clinical", "data", "they", "obtain", "is", "compromised", "due", "to", "their", "failure", "to", "adhere", "to", "our", "clinical", "protocols", "or", "for", "other", "reasons,", "or", "if", "they", "fail", "to", "maintain", "compliance", "with", "applicable", "government", "regulations", "and", "standards,", "our", "clinical", "trials", "may", "be", "extended,", "delayed", "or", "terminated", "or", "may", "become", "significantly", "more", "expensive,", "we", "may", "not", "receive", "development", "milestone", "payments", "when", "expected", "or", "at", "all,", "and", "we", "may", "not", "be", "able", "to", "obtain", "regulatory", "approval", "for", "or", "successfully", "commercialize", "our", "product", "candidates.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "risks", "and", "uncertainties", "discussed", "in", "this", "Annual", "Report", "on", "Form", "10-K,", "among", "others,", "we", "are", "unable", "to", "estimate", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects", "or", "when,", "if", "ever,", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "the", "commercialization", "and", "sale", "of", "a", "product", "if", "one", "of", "our", "product", "candidates", "receives", "regulatory", "approval", "for", "marketing,", "if", "at", "all."], "wordsB": ["If", "we", "cannot", "contract", "with", "acceptable", "third", "parties", "on", "commercially", "reasonable", "terms", "or", "at", "all,", "if", "these", "third", "parties", "are", "unable", "to", "carry", "out", "their", "contractual", "duties", "or", "obligations", "in", "a", "manner", "that", "is", "consistent", "with", "our", "expectations", "or", "meet", "expected", "deadlines,", "if", "they", "do", "not", "carry", "out", "the", "trials", "in", "accordance", "with", "budgeted", "amounts,", "if", "the", "quality", "or", "accuracy", "of", "the", "clinical", "data", "they", "obtain", "is", "compromised", "due", "to", "their", "failure", "to", "adhere", "to", "our", "clinical", "protocols", "or", "for", "other", "reasons,", "or", "if", "they", "fail", "to", "maintain", "compliance", "with", "applicable", "government", "regulations", "and", "standards,", "our", "clinical", "trials", "may", "be", "extended,", "delayed", "or", "terminated", "or", "may", "become", "significantly", "more", "expensive,", "we", "may", "not", "receive", "development", "milestone", "payments", "when", "expected", "or", "at", "all,", "and", "we", "may", "not", "be", "able", "to", "obtain", "regulatory", "approval", "for", "or", "successfully", "commercialize", "our", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p355_s1", "idA": "749647_17_item1_p164_s0", "sentA": "Government authorities in the U.S., at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, quality control, approval, manufacturing, labeling, post-approval monitoring and reporting, recordkeeping, packaging, promotion, storage, advertising, distribution, marketing and export and import of pharmaceutical products such as those we are developing.", "sentB": "The Tax Reform Act significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a quasi-territorial tax system, providing a one-time transition toll charge on foreign earnings, creating a new limitation on the deductibility of interest expenses and modifying the limitation on officer compensation.", "type": 1, "words": ["<tag1>", "Government", "authorities", "in", "the", "U.S.,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "in", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "quality", "control,", "approval,", "manufacturing,", "labeling,", "post-approval", "monitoring", "and", "reporting,", "recordkeeping,", "packaging,", "promotion,", "storage,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "pharmaceutical", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "The", "Tax", "Reform", "Act", "significantly", "changes", "U.S.", "tax", "law", "by,", "among", "other", "things,", "lowering", "corporate", "income", "tax", "rates,", "implementing", "a", "quasi-territorial", "tax", "system,", "providing", "a", "one-time", "transition", "toll", "charge", "on", "foreign", "earnings,", "creating", "a", "new", "limitation", "on", "the", "deductibility", "of", "interest", "expenses", "and", "modifying", "the", "limitation", "on", "officer", "compensation.", "<tag3>"], "wordsA": ["Government", "authorities", "in", "the", "U.S.,", "at", "the", "federal,", "state", "and", "local", "level,", "and", "in", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "quality", "control,", "approval,", "manufacturing,", "labeling,", "post-approval", "monitoring", "and", "reporting,", "recordkeeping,", "packaging,", "promotion,", "storage,", "advertising,", "distribution,", "marketing", "and", "export", "and", "import", "of", "pharmaceutical", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["The", "Tax", "Reform", "Act", "significantly", "changes", "U.S.", "tax", "law", "by,", "among", "other", "things,", "lowering", "corporate", "income", "tax", "rates,", "implementing", "a", "quasi-territorial", "tax", "system,", "providing", "a", "one-time", "transition", "toll", "charge", "on", "foreign", "earnings,", "creating", "a", "new", "limitation", "on", "the", "deductibility", "of", "interest", "expenses", "and", "modifying", "the", "limitation", "on", "officer", "compensation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p102_s2", "idA": "749647_17_item1_p167_s0", "sentA": "Pre-clinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies, to assess the potential safety and efficacy of the product.", "sentB": "As part of its review of the first 275 patients, the DMC monitored a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current as well as other data collection and quality criteria.", "type": 1, "words": ["<tag1>", "Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product.", "<tag2>", "As", "part", "of", "its", "review", "of", "the", "first", "275", "patients,", "the", "DMC", "monitored", "a", "quality", "matrix", "relating", "to", "the", "total", "clinical", "data", "set,", "confirming", "the", "timely", "collection", "of", "data,", "that", "all", "data", "are", "current", "as", "well", "as", "other", "data", "collection", "and", "quality", "criteria.", "<tag3>"], "wordsA": ["Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product."], "wordsB": ["As", "part", "of", "its", "review", "of", "the", "first", "275", "patients,", "the", "DMC", "monitored", "a", "quality", "matrix", "relating", "to", "the", "total", "clinical", "data", "set,", "confirming", "the", "timely", "collection", "of", "data,", "that", "all", "data", "are", "current", "as", "well", "as", "other", "data", "collection", "and", "quality", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p189_s2", "idA": "749647_17_item1_p167_s0", "sentA": "Pre-clinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies, to assess the potential safety and efficacy of the product.", "sentB": "The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product candidate.", "type": 1, "words": ["<tag1>", "Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product.", "<tag2>", "The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "quality,", "purity", "and", "potency", "of", "the", "product", "candidate.", "<tag3>"], "wordsA": ["Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product."], "wordsB": ["The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "quality,", "purity", "and", "potency", "of", "the", "product", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p18_s2", "idA": "749647_17_item1_p167_s0", "sentA": "Pre-clinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies, to assess the potential safety and efficacy of the product.", "sentB": "As part of its review of the first 275 patients, the DMC monitored a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current as well as other data collection and quality criteria.", "type": 1, "words": ["<tag1>", "Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product.", "<tag2>", "As", "part", "of", "its", "review", "of", "the", "first", "275", "patients,", "the", "DMC", "monitored", "a", "quality", "matrix", "relating", "to", "the", "total", "clinical", "data", "set,", "confirming", "the", "timely", "collection", "of", "data,", "that", "all", "data", "are", "current", "as", "well", "as", "other", "data", "collection", "and", "quality", "criteria.", "<tag3>"], "wordsA": ["Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product."], "wordsB": ["As", "part", "of", "its", "review", "of", "the", "first", "275", "patients,", "the", "DMC", "monitored", "a", "quality", "matrix", "relating", "to", "the", "total", "clinical", "data", "set,", "confirming", "the", "timely", "collection", "of", "data,", "that", "all", "data", "are", "current", "as", "well", "as", "other", "data", "collection", "and", "quality", "criteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s4", "idA": "749647_17_item1_p167_s0", "sentA": "Pre-clinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies, to assess the potential safety and efficacy of the product.", "sentB": "New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our product candidates hold the potential to severely limit market opportunities of such products.", "type": 1, "words": ["<tag1>", "Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product.", "<tag2>", "New", "government", "legislation", "or", "regulations", "related", "to", "pricing", "or", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system", "as", "well", "as", "a", "government", "or", "third-party", "payer", "decision", "not", "to", "approve", "pricing", "for,", "or", "provide", "adequate", "coverage", "or", "reimbursement", "of,", "our", "product", "candidates", "hold", "the", "potential", "to", "severely", "limit", "market", "opportunities", "of", "such", "products.", "<tag3>"], "wordsA": ["Pre-clinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies,", "to", "assess", "the", "potential", "safety", "and", "efficacy", "of", "the", "product."], "wordsB": ["New", "government", "legislation", "or", "regulations", "related", "to", "pricing", "or", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system", "as", "well", "as", "a", "government", "or", "third-party", "payer", "decision", "not", "to", "approve", "pricing", "for,", "or", "provide", "adequate", "coverage", "or", "reimbursement", "of,", "our", "product", "candidates", "hold", "the", "potential", "to", "severely", "limit", "market", "opportunities", "of", "such", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p247_s0", "idA": "749647_17_item1_p167_s2", "sentA": "The results of pre-clinical tests are submitted to the FDA as part of an IND and are reviewed by the FDA before the commencement of human clinical trials.", "sentB": "To obtain regulatory approvals from the FDA and foreign regulatory agencies, we must conduct clinical trials demonstrating that our products are safe and effective.", "type": 1, "words": ["<tag1>", "The", "results", "of", "pre-clinical", "tests", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "the", "commencement", "of", "human", "clinical", "trials.", "<tag2>", "To", "obtain", "regulatory", "approvals", "from", "the", "FDA", "and", "foreign", "regulatory", "agencies,", "we", "must", "conduct", "clinical", "trials", "demonstrating", "that", "our", "products", "are", "safe", "and", "effective.", "<tag3>"], "wordsA": ["The", "results", "of", "pre-clinical", "tests", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "the", "commencement", "of", "human", "clinical", "trials."], "wordsB": ["To", "obtain", "regulatory", "approvals", "from", "the", "FDA", "and", "foreign", "regulatory", "agencies,", "we", "must", "conduct", "clinical", "trials", "demonstrating", "that", "our", "products", "are", "safe", "and", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s0", "idA": "749647_17_item1_p167_s2", "sentA": "The results of pre-clinical tests are submitted to the FDA as part of an IND and are reviewed by the FDA before the commencement of human clinical trials.", "sentB": "Government, private health insurers and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new therapeutic products approved for marketing by the FDA.", "type": 1, "words": ["<tag1>", "The", "results", "of", "pre-clinical", "tests", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "the", "commencement", "of", "human", "clinical", "trials.", "<tag2>", "Government,", "private", "health", "insurers", "and", "other", "third-party", "payors", "are", "increasingly", "attempting", "to", "contain", "healthcare", "costs", "by", "limiting", "both", "coverage", "and", "the", "level", "of", "reimbursement", "for", "new", "therapeutic", "products", "approved", "for", "marketing", "by", "the", "FDA.", "<tag3>"], "wordsA": ["The", "results", "of", "pre-clinical", "tests", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "the", "commencement", "of", "human", "clinical", "trials."], "wordsB": ["Government,", "private", "health", "insurers", "and", "other", "third-party", "payors", "are", "increasingly", "attempting", "to", "contain", "healthcare", "costs", "by", "limiting", "both", "coverage", "and", "the", "level", "of", "reimbursement", "for", "new", "therapeutic", "products", "approved", "for", "marketing", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p170_s0", "idA": "749647_17_item1_p167_s3", "sentA": "Submission of an IND will not necessarily result in FDA authorization to commence clinical trials, and the absence of FDA objection to an IND does not necessarily mean that the FDA will ultimately approve an NDA or that a product candidate otherwise will come to market.", "sentB": "The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency s threshold determination that it is sufficiently complete to permit substantive review.", "type": 1, "words": ["<tag1>", "Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market.", "<tag2>", "The", "FDA", "has", "60", "days", "from", "its", "receipt", "of", "an", "NDA", "or", "BLA", "to", "determine", "whether", "the", "application", "will", "be", "accepted", "for", "filing", "based", "on", "the", "agency", "s", "threshold", "determination", "that", "it", "is", "sufficiently", "complete", "to", "permit", "substantive", "review.", "<tag3>"], "wordsA": ["Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market."], "wordsB": ["The", "FDA", "has", "60", "days", "from", "its", "receipt", "of", "an", "NDA", "or", "BLA", "to", "determine", "whether", "the", "application", "will", "be", "accepted", "for", "filing", "based", "on", "the", "agency", "s", "threshold", "determination", "that", "it", "is", "sufficiently", "complete", "to", "permit", "substantive", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p181_s2", "idA": "749647_17_item1_p167_s3", "sentA": "Submission of an IND will not necessarily result in FDA authorization to commence clinical trials, and the absence of FDA objection to an IND does not necessarily mean that the FDA will ultimately approve an NDA or that a product candidate otherwise will come to market.", "sentB": "In May 2014, the FDA published a final Guidance for Industry titled Expedited Programs for Serious Conditions Drugs and Biologics, which provides guidance on FDA programs that are intended to facilitate and expedite development and review of new product candidates as well as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and review programs.", "type": 1, "words": ["<tag1>", "Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market.", "<tag2>", "In", "May", "2014,", "the", "FDA", "published", "a", "final", "Guidance", "for", "Industry", "titled", "Expedited", "Programs", "for", "Serious", "Conditions", "Drugs", "and", "Biologics,", "which", "provides", "guidance", "on", "FDA", "programs", "that", "are", "intended", "to", "facilitate", "and", "expedite", "development", "and", "review", "of", "new", "product", "candidates", "as", "well", "as", "threshold", "criteria", "generally", "applicable", "to", "concluding", "that", "a", "product", "candidate", "is", "a", "candidate", "for", "these", "expedited", "development", "and", "review", "programs.", "<tag3>"], "wordsA": ["Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market."], "wordsB": ["In", "May", "2014,", "the", "FDA", "published", "a", "final", "Guidance", "for", "Industry", "titled", "Expedited", "Programs", "for", "Serious", "Conditions", "Drugs", "and", "Biologics,", "which", "provides", "guidance", "on", "FDA", "programs", "that", "are", "intended", "to", "facilitate", "and", "expedite", "development", "and", "review", "of", "new", "product", "candidates", "as", "well", "as", "threshold", "criteria", "generally", "applicable", "to", "concluding", "that", "a", "product", "candidate", "is", "a", "candidate", "for", "these", "expedited", "development", "and", "review", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p288_s3", "idA": "749647_17_item1_p167_s3", "sentA": "Submission of an IND will not necessarily result in FDA authorization to commence clinical trials, and the absence of FDA objection to an IND does not necessarily mean that the FDA will ultimately approve an NDA or that a product candidate otherwise will come to market.", "sentB": "Alternatively, we may initiate litigation against the third-party patent holder to request that a court declare that we are not infringing the third party s patent and/or that the third party s patent is invalid or unenforceable.", "type": 1, "words": ["<tag1>", "Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market.", "<tag2>", "Alternatively,", "we", "may", "initiate", "litigation", "against", "the", "third-party", "patent", "holder", "to", "request", "that", "a", "court", "declare", "that", "we", "are", "not", "infringing", "the", "third", "party", "s", "patent", "and/or", "that", "the", "third", "party", "s", "patent", "is", "invalid", "or", "unenforceable.", "<tag3>"], "wordsA": ["Submission", "of", "an", "IND", "will", "not", "necessarily", "result", "in", "FDA", "authorization", "to", "commence", "clinical", "trials,", "and", "the", "absence", "of", "FDA", "objection", "to", "an", "IND", "does", "not", "necessarily", "mean", "that", "the", "FDA", "will", "ultimately", "approve", "an", "NDA", "or", "that", "a", "product", "candidate", "otherwise", "will", "come", "to", "market."], "wordsB": ["Alternatively,", "we", "may", "initiate", "litigation", "against", "the", "third-party", "patent", "holder", "to", "request", "that", "a", "court", "declare", "that", "we", "are", "not", "infringing", "the", "third", "party", "s", "patent", "and/or", "that", "the", "third", "party", "s", "patent", "is", "invalid", "or", "unenforceable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p166_s1", "idA": "749647_17_item1_p168_s1", "sentA": "Clinical trials must be conducted in accordance with good clinical practices under protocols submitted to the FDA as part of an IND and with patient informed consent.", "sentB": "Among other things, the FDA reviews an NDA to determine whether the product is safe and effective for its intended use and reviews a BLA to determine whether the product is safe, pure, and potent, and in each case, whether the product candidate is being manufactured in accordance with cGMP.", "type": 1, "words": ["<tag1>", "Clinical", "trials", "must", "be", "conducted", "in", "accordance", "with", "good", "clinical", "practices", "under", "protocols", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "with", "patient", "informed", "consent.", "<tag2>", "Among", "other", "things,", "the", "FDA", "reviews", "an", "NDA", "to", "determine", "whether", "the", "product", "is", "safe", "and", "effective", "for", "its", "intended", "use", "and", "reviews", "a", "BLA", "to", "determine", "whether", "the", "product", "is", "safe,", "pure,", "and", "potent,", "and", "in", "each", "case,", "whether", "the", "product", "candidate", "is", "being", "manufactured", "in", "accordance", "with", "cGMP.", "<tag3>"], "wordsA": ["Clinical", "trials", "must", "be", "conducted", "in", "accordance", "with", "good", "clinical", "practices", "under", "protocols", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "IND", "and", "with", "patient", "informed", "consent."], "wordsB": ["Among", "other", "things,", "the", "FDA", "reviews", "an", "NDA", "to", "determine", "whether", "the", "product", "is", "safe", "and", "effective", "for", "its", "intended", "use", "and", "reviews", "a", "BLA", "to", "determine", "whether", "the", "product", "is", "safe,", "pure,", "and", "potent,", "and", "in", "each", "case,", "whether", "the", "product", "candidate", "is", "being", "manufactured", "in", "accordance", "with", "cGMP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p186_s2", "idA": "749647_17_item1_p168_s2", "sentA": "Also, each clinical trial must be approved by an Institutional Review Board (IRB), and is subject to ongoing IRB monitoring.", "sentB": "Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element.", "type": 1, "words": ["<tag1>", "Also,", "each", "clinical", "trial", "must", "be", "approved", "by", "an", "Institutional", "Review", "Board", "(IRB),", "and", "is", "subject", "to", "ongoing", "IRB", "monitoring.", "<tag2>", "Biosimilarity", "must", "be", "shown", "through", "analytical", "trials,", "animal", "trials,", "and", "a", "clinical", "trial", "or", "trials,", "unless", "the", "Secretary", "of", "Health", "and", "Human", "Services", "waives", "a", "required", "element.", "<tag3>"], "wordsA": ["Also,", "each", "clinical", "trial", "must", "be", "approved", "by", "an", "Institutional", "Review", "Board", "(IRB),", "and", "is", "subject", "to", "ongoing", "IRB", "monitoring."], "wordsB": ["Biosimilarity", "must", "be", "shown", "through", "analytical", "trials,", "animal", "trials,", "and", "a", "clinical", "trial", "or", "trials,", "unless", "the", "Secretary", "of", "Health", "and", "Human", "Services", "waives", "a", "required", "element."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p356_s1", "idA": "749647_17_item1_p168_s2", "sentA": "Also, each clinical trial must be approved by an Institutional Review Board (IRB), and is subject to ongoing IRB monitoring.", "sentB": "In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the Code), a corporation that undergoes an ownership change is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income.", "type": 1, "words": ["<tag1>", "Also,", "each", "clinical", "trial", "must", "be", "approved", "by", "an", "Institutional", "Review", "Board", "(IRB),", "and", "is", "subject", "to", "ongoing", "IRB", "monitoring.", "<tag2>", "In", "general,", "under", "Section", "382", "of", "the", "Internal", "Revenue", "Code", "of", "1986,", "as", "amended", "(the", "Code),", "a", "corporation", "that", "undergoes", "an", "ownership", "change", "is", "subject", "to", "limitations", "on", "its", "ability", "to", "utilize", "its", "pre-change", "NOLs", "to", "offset", "future", "taxable", "income.", "<tag3>"], "wordsA": ["Also,", "each", "clinical", "trial", "must", "be", "approved", "by", "an", "Institutional", "Review", "Board", "(IRB),", "and", "is", "subject", "to", "ongoing", "IRB", "monitoring."], "wordsB": ["In", "general,", "under", "Section", "382", "of", "the", "Internal", "Revenue", "Code", "of", "1986,", "as", "amended", "(the", "Code),", "a", "corporation", "that", "undergoes", "an", "ownership", "change", "is", "subject", "to", "limitations", "on", "its", "ability", "to", "utilize", "its", "pre-change", "NOLs", "to", "offset", "future", "taxable", "income."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p240_s2", "idA": "749647_17_item1_p16_s3", "sentA": "The primary endpoint for this clinical trial is overall survival ( OS ), and the secondary endpoints are progression free survival and safety.", "sentB": "The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes including insufficient efficacy, safety concerns, or our own financial constraints.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "for", "this", "clinical", "trial", "is", "overall", "survival", "(", "OS", "),", "and", "the", "secondary", "endpoints", "are", "progression", "free", "survival", "and", "safety.", "<tag2>", "The", "start", "or", "end", "of", "a", "clinical", "trial", "is", "often", "delayed", "or", "halted", "due", "to", "changing", "regulatory", "requirements,", "manufacturing", "challenges,", "required", "clinical", "trial", "administrative", "actions,", "slower", "than", "anticipated", "patient", "enrollment,", "changing", "standards", "of", "care,", "availability", "or", "prevalence", "of", "use", "of", "a", "comparator", "drug", "or", "required", "prior", "therapy,", "clinical", "outcomes", "including", "insufficient", "efficacy,", "safety", "concerns,", "or", "our", "own", "financial", "constraints.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "this", "clinical", "trial", "is", "overall", "survival", "(", "OS", "),", "and", "the", "secondary", "endpoints", "are", "progression", "free", "survival", "and", "safety."], "wordsB": ["The", "start", "or", "end", "of", "a", "clinical", "trial", "is", "often", "delayed", "or", "halted", "due", "to", "changing", "regulatory", "requirements,", "manufacturing", "challenges,", "required", "clinical", "trial", "administrative", "actions,", "slower", "than", "anticipated", "patient", "enrollment,", "changing", "standards", "of", "care,", "availability", "or", "prevalence", "of", "use", "of", "a", "comparator", "drug", "or", "required", "prior", "therapy,", "clinical", "outcomes", "including", "insufficient", "efficacy,", "safety", "concerns,", "or", "our", "own", "financial", "constraints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p194_s1", "idA": "749647_17_item1_p172_s0", "sentA": "The conduct of clinical trials is complex and difficult, and there can be no assurance that the design or the performance of the pivotal clinical trial protocols of any of our current or future product candidates will be successful.", "sentB": "A clinical trial may commence only once the relevant Ethics Committee(s) has (have) issued a favorable opinion and the competent authority of the EU Member State(s) concerned has (have) not informed the sponsor of any grounds for non-acceptance.", "type": 1, "words": ["<tag1>", "The", "conduct", "of", "clinical", "trials", "is", "complex", "and", "difficult,", "and", "there", "can", "be", "no", "assurance", "that", "the", "design", "or", "the", "performance", "of", "the", "pivotal", "clinical", "trial", "protocols", "of", "any", "of", "our", "current", "or", "future", "product", "candidates", "will", "be", "successful.", "<tag2>", "A", "clinical", "trial", "may", "commence", "only", "once", "the", "relevant", "Ethics", "Committee(s)", "has", "(have)", "issued", "a", "favorable", "opinion", "and", "the", "competent", "authority", "of", "the", "EU", "Member", "State(s)", "concerned", "has", "(have)", "not", "informed", "the", "sponsor", "of", "any", "grounds", "for", "non-acceptance.", "<tag3>"], "wordsA": ["The", "conduct", "of", "clinical", "trials", "is", "complex", "and", "difficult,", "and", "there", "can", "be", "no", "assurance", "that", "the", "design", "or", "the", "performance", "of", "the", "pivotal", "clinical", "trial", "protocols", "of", "any", "of", "our", "current", "or", "future", "product", "candidates", "will", "be", "successful."], "wordsB": ["A", "clinical", "trial", "may", "commence", "only", "once", "the", "relevant", "Ethics", "Committee(s)", "has", "(have)", "issued", "a", "favorable", "opinion", "and", "the", "competent", "authority", "of", "the", "EU", "Member", "State(s)", "concerned", "has", "(have)", "not", "informed", "the", "sponsor", "of", "any", "grounds", "for", "non-acceptance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p312_s4", "idA": "749647_17_item1_p173_s1", "sentA": "The testing and approval process requires substantial time, effort, and financial resources, and there can be no assurance that any approval will be granted for any product at any time, according to any schedule, or at all.", "sentB": "It is uncertain whether or when any legislative proposals will be adopted or what actions federal, state, or private payors for health care treatment and services may take in response to any healthcare reform proposals or legislation.", "type": 1, "words": ["<tag1>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort,", "and", "financial", "resources,", "and", "there", "can", "be", "no", "assurance", "that", "any", "approval", "will", "be", "granted", "for", "any", "product", "at", "any", "time,", "according", "to", "any", "schedule,", "or", "at", "all.", "<tag2>", "It", "is", "uncertain", "whether", "or", "when", "any", "legislative", "proposals", "will", "be", "adopted", "or", "what", "actions", "federal,", "state,", "or", "private", "payors", "for", "health", "care", "treatment", "and", "services", "may", "take", "in", "response", "to", "any", "healthcare", "reform", "proposals", "or", "legislation.", "<tag3>"], "wordsA": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort,", "and", "financial", "resources,", "and", "there", "can", "be", "no", "assurance", "that", "any", "approval", "will", "be", "granted", "for", "any", "product", "at", "any", "time,", "according", "to", "any", "schedule,", "or", "at", "all."], "wordsB": ["It", "is", "uncertain", "whether", "or", "when", "any", "legislative", "proposals", "will", "be", "adopted", "or", "what", "actions", "federal,", "state,", "or", "private", "payors", "for", "health", "care", "treatment", "and", "services", "may", "take", "in", "response", "to", "any", "healthcare", "reform", "proposals", "or", "legislation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p258_s2", "idA": "749647_17_item1_p173_s3", "sentA": "The FDA may also require additional testing for safety and efficacy.", "sentB": "The FDA has established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research (CBER), to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.", "type": 1, "words": ["<tag1>", "The", "FDA", "may", "also", "require", "additional", "testing", "for", "safety", "and", "efficacy.", "<tag2>", "The", "FDA", "has", "established", "the", "Office", "of", "Cellular,", "Tissue", "and", "Gene", "Therapies", "within", "its", "Center", "for", "Biologics", "Evaluation", "and", "Research", "(CBER),", "to", "consolidate", "the", "review", "of", "gene", "therapy", "and", "related", "products,", "and", "has", "established", "the", "Cellular,", "Tissue", "and", "Gene", "Therapies", "Advisory", "Committee", "to", "advise", "CBER", "in", "its", "review.", "<tag3>"], "wordsA": ["The", "FDA", "may", "also", "require", "additional", "testing", "for", "safety", "and", "efficacy."], "wordsB": ["The", "FDA", "has", "established", "the", "Office", "of", "Cellular,", "Tissue", "and", "Gene", "Therapies", "within", "its", "Center", "for", "Biologics", "Evaluation", "and", "Research", "(CBER),", "to", "consolidate", "the", "review", "of", "gene", "therapy", "and", "related", "products,", "and", "has", "established", "the", "Cellular,", "Tissue", "and", "Gene", "Therapies", "Advisory", "Committee", "to", "advise", "CBER", "in", "its", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p167_s1", "idA": "749647_17_item1_p174_s0", "sentA": "In 2009, the FDA granted orphan drug designation for ThermoDox for the treatment of HCC.", "sentB": "On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017 (FDARA) which reauthorizes the various user fees to facilitate the FDA s product review and oversight.", "type": 1, "words": ["<tag1>", "In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC.", "<tag2>", "On", "August", "3,", "2017,", "Congress", "passed", "the", "FDA", "Reauthorization", "Act", "of", "2017", "(FDARA)", "which", "reauthorizes", "the", "various", "user", "fees", "to", "facilitate", "the", "FDA", "s", "product", "review", "and", "oversight.", "<tag3>"], "wordsA": ["In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC."], "wordsB": ["On", "August", "3,", "2017,", "Congress", "passed", "the", "FDA", "Reauthorization", "Act", "of", "2017", "(FDARA)", "which", "reauthorizes", "the", "various", "user", "fees", "to", "facilitate", "the", "FDA", "s", "product", "review", "and", "oversight."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p181_s1", "idA": "749647_17_item1_p174_s0", "sentA": "In 2009, the FDA granted orphan drug designation for ThermoDox for the treatment of HCC.", "sentB": "The law required the FDA to issue related guidance and also promulgate confirming regulatory changes.", "type": 1, "words": ["<tag1>", "In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC.", "<tag2>", "The", "law", "required", "the", "FDA", "to", "issue", "related", "guidance", "and", "also", "promulgate", "confirming", "regulatory", "changes.", "<tag3>"], "wordsA": ["In", "2009,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "ThermoDox", "for", "the", "treatment", "of", "HCC."], "wordsB": ["The", "law", "required", "the", "FDA", "to", "issue", "related", "guidance", "and", "also", "promulgate", "confirming", "regulatory", "changes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p162_s0", "idA": "749647_17_item1_p175_s0", "sentA": "The FDCA provides a five-year period of non-patent data exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity.", "sentB": "Pursuant to the 21st Century Cures Act (Cures Act) which was signed into law in December 2016, the manufacturer of an investigational product for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational product.", "type": 1, "words": ["<tag1>", "The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "data", "exclusivity", "within", "the", "U.S.", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity.", "<tag2>", "Pursuant", "to", "the", "21st", "Century", "Cures", "Act", "(Cures", "Act)", "which", "was", "signed", "into", "law", "in", "December", "2016,", "the", "manufacturer", "of", "an", "investigational", "product", "for", "a", "serious", "disease", "or", "condition", "is", "required", "to", "make", "available,", "such", "as", "by", "posting", "on", "its", "website,", "its", "policy", "on", "evaluating", "and", "responding", "to", "requests", "for", "individual", "patient", "access", "to", "such", "investigational", "product.", "<tag3>"], "wordsA": ["The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "data", "exclusivity", "within", "the", "U.S.", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity."], "wordsB": ["Pursuant", "to", "the", "21st", "Century", "Cures", "Act", "(Cures", "Act)", "which", "was", "signed", "into", "law", "in", "December", "2016,", "the", "manufacturer", "of", "an", "investigational", "product", "for", "a", "serious", "disease", "or", "condition", "is", "required", "to", "make", "available,", "such", "as", "by", "posting", "on", "its", "website,", "its", "policy", "on", "evaluating", "and", "responding", "to", "requests", "for", "individual", "patient", "access", "to", "such", "investigational", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p252_s0", "idA": "749647_17_item1_p175_s1", "sentA": "A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety.", "sentB": "It takes years to complete the testing of a new drug or biological product and development delays and/or failure can occur at any stage of testing.", "type": 1, "words": ["<tag1>", "A", "drug", "is", "a", "new", "chemical", "entity", "if", "the", "FDA", "has", "not", "previously", "approved", "any", "other", "new", "drug", "containing", "the", "same", "active", "moiety.", "<tag2>", "It", "takes", "years", "to", "complete", "the", "testing", "of", "a", "new", "drug", "or", "biological", "product", "and", "development", "delays", "and/or", "failure", "can", "occur", "at", "any", "stage", "of", "testing.", "<tag3>"], "wordsA": ["A", "drug", "is", "a", "new", "chemical", "entity", "if", "the", "FDA", "has", "not", "previously", "approved", "any", "other", "new", "drug", "containing", "the", "same", "active", "moiety."], "wordsB": ["It", "takes", "years", "to", "complete", "the", "testing", "of", "a", "new", "drug", "or", "biological", "product", "and", "development", "delays", "and/or", "failure", "can", "occur", "at", "any", "stage", "of", "testing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p195_s0", "idA": "749647_17_item1_p176_s0", "sentA": "After FDA approval of a product is obtained, we and our contract manufacturers are required to comply with various post-approval requirements, including establishment registration and product listing, record-keeping requirements, reporting of adverse reactions and production problems to the FDA, providing updated safety and efficacy information, and complying with requirements concerning advertising and promotional labeling.", "sentB": "The sponsor is required to record and report to the relevant national competent authorities (and to the Ethics Committee) information about suspected serious unexpected adverse reactions ( SU.S.A.Rs ).", "type": 1, "words": ["<tag1>", "After", "FDA", "approval", "of", "a", "product", "is", "obtained,", "we", "and", "our", "contract", "manufacturers", "are", "required", "to", "comply", "with", "various", "post-approval", "requirements,", "including", "establishment", "registration", "and", "product", "listing,", "record-keeping", "requirements,", "reporting", "of", "adverse", "reactions", "and", "production", "problems", "to", "the", "FDA,", "providing", "updated", "safety", "and", "efficacy", "information,", "and", "complying", "with", "requirements", "concerning", "advertising", "and", "promotional", "labeling.", "<tag2>", "The", "sponsor", "is", "required", "to", "record", "and", "report", "to", "the", "relevant", "national", "competent", "authorities", "(and", "to", "the", "Ethics", "Committee)", "information", "about", "suspected", "serious", "unexpected", "adverse", "reactions", "(", "SU.S.A.Rs", ").", "<tag3>"], "wordsA": ["After", "FDA", "approval", "of", "a", "product", "is", "obtained,", "we", "and", "our", "contract", "manufacturers", "are", "required", "to", "comply", "with", "various", "post-approval", "requirements,", "including", "establishment", "registration", "and", "product", "listing,", "record-keeping", "requirements,", "reporting", "of", "adverse", "reactions", "and", "production", "problems", "to", "the", "FDA,", "providing", "updated", "safety", "and", "efficacy", "information,", "and", "complying", "with", "requirements", "concerning", "advertising", "and", "promotional", "labeling."], "wordsB": ["The", "sponsor", "is", "required", "to", "record", "and", "report", "to", "the", "relevant", "national", "competent", "authorities", "(and", "to", "the", "Ethics", "Committee)", "information", "about", "suspected", "serious", "unexpected", "adverse", "reactions", "(", "SU.S.A.Rs", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p247_s1", "idA": "749647_17_item1_p176_s1", "sentA": "As a condition of approval of an NDA, the FDA may require the applicant to conduct additional clinical trials or other post market testing and surveillance to further monitor and assess the drug's safety and efficacy.", "sentB": "We may need to amend ongoing trials, or the FDA and/or foreign regulatory agencies may require us to perform additional trials beyond those we planned.", "type": 1, "words": ["<tag1>", "As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy.", "<tag2>", "We", "may", "need", "to", "amend", "ongoing", "trials,", "or", "the", "FDA", "and/or", "foreign", "regulatory", "agencies", "may", "require", "us", "to", "perform", "additional", "trials", "beyond", "those", "we", "planned.", "<tag3>"], "wordsA": ["As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy."], "wordsB": ["We", "may", "need", "to", "amend", "ongoing", "trials,", "or", "the", "FDA", "and/or", "foreign", "regulatory", "agencies", "may", "require", "us", "to", "perform", "additional", "trials", "beyond", "those", "we", "planned."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p271_s1", "idA": "749647_17_item1_p176_s1", "sentA": "As a condition of approval of an NDA, the FDA may require the applicant to conduct additional clinical trials or other post market testing and surveillance to further monitor and assess the drug's safety and efficacy.", "sentB": "Any strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business.", "type": 1, "words": ["<tag1>", "As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy.", "<tag2>", "Any", "strategic", "transaction", "may", "require", "us", "to", "incur", "non-recurring", "or", "other", "charges,", "increase", "our", "near-", "and", "long-term", "expenditures", "and", "pose", "significant", "integration", "or", "implementation", "challenges", "or", "disrupt", "our", "management", "or", "business.", "<tag3>"], "wordsA": ["As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy."], "wordsB": ["Any", "strategic", "transaction", "may", "require", "us", "to", "incur", "non-recurring", "or", "other", "charges,", "increase", "our", "near-", "and", "long-term", "expenditures", "and", "pose", "significant", "integration", "or", "implementation", "challenges", "or", "disrupt", "our", "management", "or", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p299_s1", "idA": "749647_17_item1_p176_s1", "sentA": "As a condition of approval of an NDA, the FDA may require the applicant to conduct additional clinical trials or other post market testing and surveillance to further monitor and assess the drug's safety and efficacy.", "sentB": "Following such inspections, the FDA may issue notices on Form 483 and warning letters that could cause us to modify certain activities identified during the inspection.", "type": 1, "words": ["<tag1>", "As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy.", "<tag2>", "Following", "such", "inspections,", "the", "FDA", "may", "issue", "notices", "on", "Form", "483", "and", "warning", "letters", "that", "could", "cause", "us", "to", "modify", "certain", "activities", "identified", "during", "the", "inspection.", "<tag3>"], "wordsA": ["As", "a", "condition", "of", "approval", "of", "an", "NDA,", "the", "FDA", "may", "require", "the", "applicant", "to", "conduct", "additional", "clinical", "trials", "or", "other", "post", "market", "testing", "and", "surveillance", "to", "further", "monitor", "and", "assess", "the", "drug's", "safety", "and", "efficacy."], "wordsB": ["Following", "such", "inspections,", "the", "FDA", "may", "issue", "notices", "on", "Form", "483", "and", "warning", "letters", "that", "could", "cause", "us", "to", "modify", "certain", "activities", "identified", "during", "the", "inspection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p312_s1", "idA": "749647_17_item1_p176_s4", "sentA": "A governmentally mandated recall, or a voluntary recall by us, could result from a number of events or factors, including component failures, manufacturing errors, instability of product or defects in labeling.", "sentB": "There have been a number of government and private sector initiatives during the last several years to limit the growth of healthcare costs, including price regulation, competitive pricing, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements.", "type": 1, "words": ["<tag1>", "A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling.", "<tag2>", "There", "have", "been", "a", "number", "of", "government", "and", "private", "sector", "initiatives", "during", "the", "last", "several", "years", "to", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "price", "regulation,", "competitive", "pricing,", "coverage", "and", "payment", "policies,", "comparative", "effectiveness", "of", "therapies,", "technology", "assessments", "and", "managed-care", "arrangements.", "<tag3>"], "wordsA": ["A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling."], "wordsB": ["There", "have", "been", "a", "number", "of", "government", "and", "private", "sector", "initiatives", "during", "the", "last", "several", "years", "to", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "price", "regulation,", "competitive", "pricing,", "coverage", "and", "payment", "policies,", "comparative", "effectiveness", "of", "therapies,", "technology", "assessments", "and", "managed-care", "arrangements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p312_s2", "idA": "749647_17_item1_p176_s4", "sentA": "A governmentally mandated recall, or a voluntary recall by us, could result from a number of events or factors, including component failures, manufacturing errors, instability of product or defects in labeling.", "sentB": "For example, the Affordable Care Act, passed in 2010, enacted a number of reforms to expand access to health insurance while also reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms.", "type": 1, "words": ["<tag1>", "A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling.", "<tag2>", "For", "example,", "the", "Affordable", "Care", "Act,", "passed", "in", "2010,", "enacted", "a", "number", "of", "reforms", "to", "expand", "access", "to", "health", "insurance", "while", "also", "reducing", "or", "constraining", "the", "growth", "of", "healthcare", "spending,", "enhancing", "remedies", "against", "fraud", "and", "abuse,", "adding", "new", "transparency", "requirements", "for", "healthcare", "industries,", "and", "imposing", "new", "taxes", "on", "fees", "on", "healthcare", "industry", "participants,", "among", "other", "policy", "reforms.", "<tag3>"], "wordsA": ["A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling."], "wordsB": ["For", "example,", "the", "Affordable", "Care", "Act,", "passed", "in", "2010,", "enacted", "a", "number", "of", "reforms", "to", "expand", "access", "to", "health", "insurance", "while", "also", "reducing", "or", "constraining", "the", "growth", "of", "healthcare", "spending,", "enhancing", "remedies", "against", "fraud", "and", "abuse,", "adding", "new", "transparency", "requirements", "for", "healthcare", "industries,", "and", "imposing", "new", "taxes", "on", "fees", "on", "healthcare", "industry", "participants,", "among", "other", "policy", "reforms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s1", "idA": "749647_17_item1_p176_s4", "sentA": "A governmentally mandated recall, or a voluntary recall by us, could result from a number of events or factors, including component failures, manufacturing errors, instability of product or defects in labeling.", "sentB": "For example, Congress passed the Affordable Care Act in 2010 which enacted a number of reforms to expand access to health insurance while also reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms.", "type": 1, "words": ["<tag1>", "A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling.", "<tag2>", "For", "example,", "Congress", "passed", "the", "Affordable", "Care", "Act", "in", "2010", "which", "enacted", "a", "number", "of", "reforms", "to", "expand", "access", "to", "health", "insurance", "while", "also", "reducing", "or", "constraining", "the", "growth", "of", "healthcare", "spending,", "enhancing", "remedies", "against", "fraud", "and", "abuse,", "adding", "new", "transparency", "requirements", "for", "healthcare", "industries,", "and", "imposing", "new", "taxes", "on", "fees", "on", "healthcare", "industry", "participants,", "among", "other", "policy", "reforms.", "<tag3>"], "wordsA": ["A", "governmentally", "mandated", "recall,", "or", "a", "voluntary", "recall", "by", "us,", "could", "result", "from", "a", "number", "of", "events", "or", "factors,", "including", "component", "failures,", "manufacturing", "errors,", "instability", "of", "product", "or", "defects", "in", "labeling."], "wordsB": ["For", "example,", "Congress", "passed", "the", "Affordable", "Care", "Act", "in", "2010", "which", "enacted", "a", "number", "of", "reforms", "to", "expand", "access", "to", "health", "insurance", "while", "also", "reducing", "or", "constraining", "the", "growth", "of", "healthcare", "spending,", "enhancing", "remedies", "against", "fraud", "and", "abuse,", "adding", "new", "transparency", "requirements", "for", "healthcare", "industries,", "and", "imposing", "new", "taxes", "on", "fees", "on", "healthcare", "industry", "participants,", "among", "other", "policy", "reforms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p274_s3", "idA": "749647_17_item1_p177_s0", "sentA": "In addition, manufacturing establishments in the U.S. and abroad are subject to periodic inspections by the FDA and must comply with current good manufacturing practices (cGMP).", "sentB": "In addition, our effective tax rate for future periods could be negatively impacted by the EGEN acquisition or potential future transactions.", "type": 1, "words": ["<tag1>", "In", "addition,", "manufacturing", "establishments", "in", "the", "U.S.", "and", "abroad", "are", "subject", "to", "periodic", "inspections", "by", "the", "FDA", "and", "must", "comply", "with", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag2>", "In", "addition,", "our", "effective", "tax", "rate", "for", "future", "periods", "could", "be", "negatively", "impacted", "by", "the", "EGEN", "acquisition", "or", "potential", "future", "transactions.", "<tag3>"], "wordsA": ["In", "addition,", "manufacturing", "establishments", "in", "the", "U.S.", "and", "abroad", "are", "subject", "to", "periodic", "inspections", "by", "the", "FDA", "and", "must", "comply", "with", "current", "good", "manufacturing", "practices", "(cGMP)."], "wordsB": ["In", "addition,", "our", "effective", "tax", "rate", "for", "future", "periods", "could", "be", "negatively", "impacted", "by", "the", "EGEN", "acquisition", "or", "potential", "future", "transactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p194_s4", "idA": "749647_17_item1_p177_s1", "sentA": "To maintain compliance with cGMP, manufacturers must expend funds, time and effort in the areas of production and quality control.", "sentB": "EU Member State inspections are regularly conducted to verify the sponsor s compliance with applicable rules.", "type": 1, "words": ["<tag1>", "To", "maintain", "compliance", "with", "cGMP,", "manufacturers", "must", "expend", "funds,", "time", "and", "effort", "in", "the", "areas", "of", "production", "and", "quality", "control.", "<tag2>", "EU", "Member", "State", "inspections", "are", "regularly", "conducted", "to", "verify", "the", "sponsor", "s", "compliance", "with", "applicable", "rules.", "<tag3>"], "wordsA": ["To", "maintain", "compliance", "with", "cGMP,", "manufacturers", "must", "expend", "funds,", "time", "and", "effort", "in", "the", "areas", "of", "production", "and", "quality", "control."], "wordsB": ["EU", "Member", "State", "inspections", "are", "regularly", "conducted", "to", "verify", "the", "sponsor", "s", "compliance", "with", "applicable", "rules."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p182_s0", "idA": "749647_17_item1_p178_s0", "sentA": "In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates.", "sentB": "In addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new program for Breakthrough Therapy designation, established by FDASIA to subject a new category of product candidates to accelerated approval.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates.", "<tag2>", "In", "addition", "to", "the", "Fast", "Track,", "accelerated", "approval", "and", "priority", "review", "programs", "discussed", "above,", "the", "FDA", "also", "provided", "guidance", "on", "a", "new", "program", "for", "Breakthrough", "Therapy", "designation,", "established", "by", "FDASIA", "to", "subject", "a", "new", "category", "of", "product", "candidates", "to", "accelerated", "approval.", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates."], "wordsB": ["In", "addition", "to", "the", "Fast", "Track,", "accelerated", "approval", "and", "priority", "review", "programs", "discussed", "above,", "the", "FDA", "also", "provided", "guidance", "on", "a", "new", "program", "for", "Breakthrough", "Therapy", "designation,", "established", "by", "FDASIA", "to", "subject", "a", "new", "category", "of", "product", "candidates", "to", "accelerated", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p245_s2", "idA": "749647_17_item1_p178_s0", "sentA": "In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates.", "sentB": "Furthermore, if we cannot fund our ongoing development and other operating requirements, particularly those associated with our obligations to conduct clinical trials under our licensing agreements, we will be in breach of these licensing agreements and could therefore lose our license rights, which could have material adverse effects on our business.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates.", "<tag2>", "Furthermore,", "if", "we", "cannot", "fund", "our", "ongoing", "development", "and", "other", "operating", "requirements,", "particularly", "those", "associated", "with", "our", "obligations", "to", "conduct", "clinical", "trials", "under", "our", "licensing", "agreements,", "we", "will", "be", "in", "breach", "of", "these", "licensing", "agreements", "and", "could", "therefore", "lose", "our", "license", "rights,", "which", "could", "have", "material", "adverse", "effects", "on", "our", "business.", "<tag3>"], "wordsA": ["In", "addition", "to", "regulations", "in", "the", "U.S.,", "we", "will", "be", "subject", "to", "regulations", "of", "other", "countries", "governing", "any", "clinical", "trials", "and", "commercial", "sales", "and", "distribution", "of", "our", "product", "candidates."], "wordsB": ["Furthermore,", "if", "we", "cannot", "fund", "our", "ongoing", "development", "and", "other", "operating", "requirements,", "particularly", "those", "associated", "with", "our", "obligations", "to", "conduct", "clinical", "trials", "under", "our", "licensing", "agreements,", "we", "will", "be", "in", "breach", "of", "these", "licensing", "agreements", "and", "could", "therefore", "lose", "our", "license", "rights,", "which", "could", "have", "material", "adverse", "effects", "on", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p360_s1", "idA": "749647_17_item1_p179_s0", "sentA": "The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.", "sentB": "This preferred stock may be issued by our Board of Directors on such terms as it determines, without further stockholder approval.", "type": 1, "words": ["<tag1>", "The", "approval", "process", "and", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "greatly", "from", "place", "to", "place,", "and", "the", "time", "may", "be", "longer", "or", "shorter", "than", "that", "required", "for", "FDA", "approval.", "<tag2>", "This", "preferred", "stock", "may", "be", "issued", "by", "our", "Board", "of", "Directors", "on", "such", "terms", "as", "it", "determines,", "without", "further", "stockholder", "approval.", "<tag3>"], "wordsA": ["The", "approval", "process", "and", "requirements", "governing", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "greatly", "from", "place", "to", "place,", "and", "the", "time", "may", "be", "longer", "or", "shorter", "than", "that", "required", "for", "FDA", "approval."], "wordsB": ["This", "preferred", "stock", "may", "be", "issued", "by", "our", "Board", "of", "Directors", "on", "such", "terms", "as", "it", "determines,", "without", "further", "stockholder", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p177_s0", "idA": "749647_17_item1_p180_s1", "sentA": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "sentB": "The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough therapy, which are intended to expedite or simplify the process for reviewing product candidates, or provide for the approval of a product candidate on the basis of a surrogate endpoint.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "accelerated", "approval", "and", "breakthrough", "therapy,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "product", "candidates,", "or", "provide", "for", "the", "approval", "of", "a", "product", "candidate", "on", "the", "basis", "of", "a", "surrogate", "endpoint.", "<tag3>"], "wordsA": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "accelerated", "approval", "and", "breakthrough", "therapy,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "product", "candidates,", "or", "provide", "for", "the", "approval", "of", "a", "product", "candidate", "on", "the", "basis", "of", "a", "surrogate", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p179_s0", "idA": "749647_17_item1_p180_s1", "sentA": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "sentB": "Accelerated approval provides for an earlier approval for a new product candidate that meets the following criteria: is intended to treat a serious or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "Accelerated", "approval", "provides", "for", "an", "earlier", "approval", "for", "a", "new", "product", "candidate", "that", "meets", "the", "following", "criteria:", "is", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition,", "generally", "provides", "a", "meaningful", "advantage", "over", "available", "therapies", "and", "demonstrates", "an", "effect", "on", "a", "surrogate", "endpoint", "that", "is", "reasonably", "likely", "to", "predict", "clinical", "benefit", "or", "on", "a", "clinical", "endpoint", "that", "can", "be", "measured", "earlier", "than", "irreversible", "morbidity", "or", "mortality", "(IMM)", "that", "is", "reasonably", "likely", "to", "predict", "an", "effect", "on", "IMM", "or", "other", "clinical", "benefit.", "<tag3>"], "wordsA": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["Accelerated", "approval", "provides", "for", "an", "earlier", "approval", "for", "a", "new", "product", "candidate", "that", "meets", "the", "following", "criteria:", "is", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition,", "generally", "provides", "a", "meaningful", "advantage", "over", "available", "therapies", "and", "demonstrates", "an", "effect", "on", "a", "surrogate", "endpoint", "that", "is", "reasonably", "likely", "to", "predict", "clinical", "benefit", "or", "on", "a", "clinical", "endpoint", "that", "can", "be", "measured", "earlier", "than", "irreversible", "morbidity", "or", "mortality", "(IMM)", "that", "is", "reasonably", "likely", "to", "predict", "an", "effect", "on", "IMM", "or", "other", "clinical", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p197_s3", "idA": "749647_17_item1_p180_s1", "sentA": "The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states.", "sentB": "Marketing authorizations granted via the centralized procedure are valid for all EU Member States.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states.", "<tag2>", "Marketing", "authorizations", "granted", "via", "the", "centralized", "procedure", "are", "valid", "for", "all", "EU", "Member", "States.", "<tag3>"], "wordsA": ["The", "centralized", "procedure,", "which", "is", "compulsory", "for", "medicines", "produced", "by", "biotechnology", "or", "those", "medicines", "intended", "to", "treat", "AIDS,", "cancer,", "neurodegenerative", "disorders", "or", "diabetes", "and", "is", "optional", "for", "those", "medicines", "that", "are", "highly", "innovative,", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "for", "all", "European", "Union", "member", "states."], "wordsB": ["Marketing", "authorizations", "granted", "via", "the", "centralized", "procedure", "are", "valid", "for", "all", "EU", "Member", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p201_s2", "idA": "749647_17_item1_p182_s1", "sentA": "As established by the European Medicines Agency ( EMA ), orphan drug designation provides for scientific advice and regulatory assistance from the EMA, direct access to centralized marketing authorization and certain financial incentives, such as reduction of fees associated with pre-authorization inspections and marketing authorization application fees.", "sentB": "Sponsors who obtain orphan designation benefit from a type of scientific advice specific for designated orphan medicinal products and protocol assistance from the EMA.", "type": 1, "words": ["<tag1>", "As", "established", "by", "the", "European", "Medicines", "Agency", "(", "EMA", "),", "orphan", "drug", "designation", "provides", "for", "scientific", "advice", "and", "regulatory", "assistance", "from", "the", "EMA,", "direct", "access", "to", "centralized", "marketing", "authorization", "and", "certain", "financial", "incentives,", "such", "as", "reduction", "of", "fees", "associated", "with", "pre-authorization", "inspections", "and", "marketing", "authorization", "application", "fees.", "<tag2>", "Sponsors", "who", "obtain", "orphan", "designation", "benefit", "from", "a", "type", "of", "scientific", "advice", "specific", "for", "designated", "orphan", "medicinal", "products", "and", "protocol", "assistance", "from", "the", "EMA.", "<tag3>"], "wordsA": ["As", "established", "by", "the", "European", "Medicines", "Agency", "(", "EMA", "),", "orphan", "drug", "designation", "provides", "for", "scientific", "advice", "and", "regulatory", "assistance", "from", "the", "EMA,", "direct", "access", "to", "centralized", "marketing", "authorization", "and", "certain", "financial", "incentives,", "such", "as", "reduction", "of", "fees", "associated", "with", "pre-authorization", "inspections", "and", "marketing", "authorization", "application", "fees."], "wordsB": ["Sponsors", "who", "obtain", "orphan", "designation", "benefit", "from", "a", "type", "of", "scientific", "advice", "specific", "for", "designated", "orphan", "medicinal", "products", "and", "protocol", "assistance", "from", "the", "EMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p257_s0", "idA": "749647_17_item1_p183_s0", "sentA": "We do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our product candidates.", "sentB": "The regulatory approval process for novel product candidates such as ours can be significantly more expensive and take longer than for other, better known or more extensively studied product candidates.", "type": 1, "words": ["<tag1>", "We", "do", "not", "currently", "own", "or", "operate", "manufacturing", "facilities", "for", "the", "production", "of", "preclinical,", "clinical", "or", "commercial", "quantities", "of", "any", "of", "our", "product", "candidates.", "<tag2>", "The", "regulatory", "approval", "process", "for", "novel", "product", "candidates", "such", "as", "ours", "can", "be", "significantly", "more", "expensive", "and", "take", "longer", "than", "for", "other,", "better", "known", "or", "more", "extensively", "studied", "product", "candidates.", "<tag3>"], "wordsA": ["We", "do", "not", "currently", "own", "or", "operate", "manufacturing", "facilities", "for", "the", "production", "of", "preclinical,", "clinical", "or", "commercial", "quantities", "of", "any", "of", "our", "product", "candidates."], "wordsB": ["The", "regulatory", "approval", "process", "for", "novel", "product", "candidates", "such", "as", "ours", "can", "be", "significantly", "more", "expensive", "and", "take", "longer", "than", "for", "other,", "better", "known", "or", "more", "extensively", "studied", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p294_s0", "idA": "749647_17_item1_p183_s1", "sentA": "We currently contract with third party contract manufacturing organizations (CMOs) for our preclinical and clinical trial supplies, and we expect to continue to do so to meet the preclinical and any clinical requirements of our product candidates.", "sentB": "Because we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.", "type": 1, "words": ["<tag1>", "We", "currently", "contract", "with", "third", "party", "contract", "manufacturing", "organizations", "(CMOs)", "for", "our", "preclinical", "and", "clinical", "trial", "supplies,", "and", "we", "expect", "to", "continue", "to", "do", "so", "to", "meet", "the", "preclinical", "and", "any", "clinical", "requirements", "of", "our", "product", "candidates.", "<tag2>", "Because", "we", "rely", "on", "third", "party", "manufacturing", "and", "supply", "partners,", "our", "supply", "of", "research", "and", "development,", "preclinical", "and", "clinical", "development", "materials", "may", "become", "limited", "or", "interrupted", "or", "may", "not", "be", "of", "satisfactory", "quantity", "or", "quality.", "<tag3>"], "wordsA": ["We", "currently", "contract", "with", "third", "party", "contract", "manufacturing", "organizations", "(CMOs)", "for", "our", "preclinical", "and", "clinical", "trial", "supplies,", "and", "we", "expect", "to", "continue", "to", "do", "so", "to", "meet", "the", "preclinical", "and", "any", "clinical", "requirements", "of", "our", "product", "candidates."], "wordsB": ["Because", "we", "rely", "on", "third", "party", "manufacturing", "and", "supply", "partners,", "our", "supply", "of", "research", "and", "development,", "preclinical", "and", "clinical", "development", "materials", "may", "become", "limited", "or", "interrupted", "or", "may", "not", "be", "of", "satisfactory", "quantity", "or", "quality."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p186_s0", "idA": "749647_17_item1_p185_s0", "sentA": "Our CMOs manufacture our product candidates under current Good Manufacturing Practice (cGMP) conditions.", "sentB": "The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed reference product.", "type": 1, "words": ["<tag1>", "Our", "CMOs", "manufacture", "our", "product", "candidates", "under", "current", "Good", "Manufacturing", "Practice", "(cGMP)", "conditions.", "<tag2>", "The", "Biologics", "Price", "Competition", "and", "Innovation", "Act", "of", "2009", "(BPCIA)", "created", "an", "abbreviated", "approval", "pathway", "for", "biological", "product", "candidates", "shown", "to", "be", "highly", "similar", "to", "or", "interchangeable", "with", "an", "FDA", "licensed", "reference", "product.", "<tag3>"], "wordsA": ["Our", "CMOs", "manufacture", "our", "product", "candidates", "under", "current", "Good", "Manufacturing", "Practice", "(cGMP)", "conditions."], "wordsB": ["The", "Biologics", "Price", "Competition", "and", "Innovation", "Act", "of", "2009", "(BPCIA)", "created", "an", "abbreviated", "approval", "pathway", "for", "biological", "product", "candidates", "shown", "to", "be", "highly", "similar", "to", "or", "interchangeable", "with", "an", "FDA", "licensed", "reference", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p295_s3", "idA": "749647_17_item1_p185_s0", "sentA": "Our CMOs manufacture our product candidates under current Good Manufacturing Practice (cGMP) conditions.", "sentB": "Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by FDA and foreign regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices.", "type": 1, "words": ["<tag1>", "Our", "CMOs", "manufacture", "our", "product", "candidates", "under", "current", "Good", "Manufacturing", "Practice", "(cGMP)", "conditions.", "<tag2>", "Suppliers", "and", "manufacturers", "must", "meet", "applicable", "manufacturing", "requirements", "and", "undergo", "rigorous", "facility", "and", "process", "validation", "tests", "required", "by", "FDA", "and", "foreign", "regulatory", "authorities", "in", "order", "to", "comply", "with", "regulatory", "standards,", "such", "as", "current", "Good", "Manufacturing", "Practices.", "<tag3>"], "wordsA": ["Our", "CMOs", "manufacture", "our", "product", "candidates", "under", "current", "Good", "Manufacturing", "Practice", "(cGMP)", "conditions."], "wordsB": ["Suppliers", "and", "manufacturers", "must", "meet", "applicable", "manufacturing", "requirements", "and", "undergo", "rigorous", "facility", "and", "process", "validation", "tests", "required", "by", "FDA", "and", "foreign", "regulatory", "authorities", "in", "order", "to", "comply", "with", "regulatory", "standards,", "such", "as", "current", "Good", "Manufacturing", "Practices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p264_s0", "idA": "749647_17_item1_p186_s0", "sentA": "Our current focus is on the development of our existing portfolio, the completion of clinical trials and, if and where appropriate, the registration of our product candidates.", "sentB": "Even if our product candidates initially show promise in these early clinical trials, the side effects of drugs are frequently only detectable after they are tested in large, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval.", "type": 1, "words": ["<tag1>", "Our", "current", "focus", "is", "on", "the", "development", "of", "our", "existing", "portfolio,", "the", "completion", "of", "clinical", "trials", "and,", "if", "and", "where", "appropriate,", "the", "registration", "of", "our", "product", "candidates.", "<tag2>", "Even", "if", "our", "product", "candidates", "initially", "show", "promise", "in", "these", "early", "clinical", "trials,", "the", "side", "effects", "of", "drugs", "are", "frequently", "only", "detectable", "after", "they", "are", "tested", "in", "large,", "Phase", "3", "clinical", "trials", "or,", "in", "some", "cases,", "after", "they", "are", "made", "available", "to", "patients", "on", "a", "commercial", "scale", "after", "approval.", "<tag3>"], "wordsA": ["Our", "current", "focus", "is", "on", "the", "development", "of", "our", "existing", "portfolio,", "the", "completion", "of", "clinical", "trials", "and,", "if", "and", "where", "appropriate,", "the", "registration", "of", "our", "product", "candidates."], "wordsB": ["Even", "if", "our", "product", "candidates", "initially", "show", "promise", "in", "these", "early", "clinical", "trials,", "the", "side", "effects", "of", "drugs", "are", "frequently", "only", "detectable", "after", "they", "are", "tested", "in", "large,", "Phase", "3", "clinical", "trials", "or,", "in", "some", "cases,", "after", "they", "are", "made", "available", "to", "patients", "on", "a", "commercial", "scale", "after", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p236_s5", "idA": "749647_17_item1_p186_s2", "sentA": "If we receive marketing and commercialization approval for any of our product candidates, we intend to market the product either directly or through strategic alliances and distribution agreements with third parties.", "sentB": "Our ability to achieve profitability, if ever, will depend on, among other things, us or our collaborators successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third party alternatives for any approved product and raising sufficient funds to finance business activities.", "type": 1, "words": ["<tag1>", "If", "we", "receive", "marketing", "and", "commercialization", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "market", "the", "product", "either", "directly", "or", "through", "strategic", "alliances", "and", "distribution", "agreements", "with", "third", "parties.", "<tag2>", "Our", "ability", "to", "achieve", "profitability,", "if", "ever,", "will", "depend", "on,", "among", "other", "things,", "us", "or", "our", "collaborators", "successfully", "developing", "product", "candidates,", "obtaining", "regulatory", "approvals", "to", "market", "and", "commercialize", "product", "candidates,", "manufacturing", "any", "approved", "products", "on", "commercially", "reasonable", "terms,", "establishing", "a", "sales", "and", "marketing", "organization", "or", "suitable", "third", "party", "alternatives", "for", "any", "approved", "product", "and", "raising", "sufficient", "funds", "to", "finance", "business", "activities.", "<tag3>"], "wordsA": ["If", "we", "receive", "marketing", "and", "commercialization", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "market", "the", "product", "either", "directly", "or", "through", "strategic", "alliances", "and", "distribution", "agreements", "with", "third", "parties."], "wordsB": ["Our", "ability", "to", "achieve", "profitability,", "if", "ever,", "will", "depend", "on,", "among", "other", "things,", "us", "or", "our", "collaborators", "successfully", "developing", "product", "candidates,", "obtaining", "regulatory", "approvals", "to", "market", "and", "commercialize", "product", "candidates,", "manufacturing", "any", "approved", "products", "on", "commercially", "reasonable", "terms,", "establishing", "a", "sales", "and", "marketing", "organization", "or", "suitable", "third", "party", "alternatives", "for", "any", "approved", "product", "and", "raising", "sufficient", "funds", "to", "finance", "business", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p308_s5", "idA": "749647_17_item1_p186_s2", "sentA": "If we receive marketing and commercialization approval for any of our product candidates, we intend to market the product either directly or through strategic alliances and distribution agreements with third parties.", "sentB": "In addition, while we may seek Orphan Drug Designation for other product candidates, we may never receive such designations.", "type": 1, "words": ["<tag1>", "If", "we", "receive", "marketing", "and", "commercialization", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "market", "the", "product", "either", "directly", "or", "through", "strategic", "alliances", "and", "distribution", "agreements", "with", "third", "parties.", "<tag2>", "In", "addition,", "while", "we", "may", "seek", "Orphan", "Drug", "Designation", "for", "other", "product", "candidates,", "we", "may", "never", "receive", "such", "designations.", "<tag3>"], "wordsA": ["If", "we", "receive", "marketing", "and", "commercialization", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "market", "the", "product", "either", "directly", "or", "through", "strategic", "alliances", "and", "distribution", "agreements", "with", "third", "parties."], "wordsB": ["In", "addition,", "while", "we", "may", "seek", "Orphan", "Drug", "Designation", "for", "other", "product", "candidates,", "we", "may", "never", "receive", "such", "designations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p265_s0", "idA": "749647_17_item1_p187_s0", "sentA": "Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic products.", "sentB": "In addition, d rug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial, result in potential product liability claims, reputational harm, withdrawal of approvals, a requirement to include additional warnings on the label or to create a medication guide outlining the risks of such side effects for distribution to patients.", "type": 1, "words": ["<tag1>", "Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products.", "<tag2>", "In", "addition,", "d", "rug-related", "side", "effects", "could", "also", "affect", "subject", "recruitment", "or", "the", "ability", "of", "enrolled", "subjects", "to", "complete", "the", "trial,", "result", "in", "potential", "product", "liability", "claims,", "reputational", "harm,", "withdrawal", "of", "approvals,", "a", "requirement", "to", "include", "additional", "warnings", "on", "the", "label", "or", "to", "create", "a", "medication", "guide", "outlining", "the", "risks", "of", "such", "side", "effects", "for", "distribution", "to", "patients.", "<tag3>"], "wordsA": ["Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products."], "wordsB": ["In", "addition,", "d", "rug-related", "side", "effects", "could", "also", "affect", "subject", "recruitment", "or", "the", "ability", "of", "enrolled", "subjects", "to", "complete", "the", "trial,", "result", "in", "potential", "product", "liability", "claims,", "reputational", "harm,", "withdrawal", "of", "approvals,", "a", "requirement", "to", "include", "additional", "warnings", "on", "the", "label", "or", "to", "create", "a", "medication", "guide", "outlining", "the", "risks", "of", "such", "side", "effects", "for", "distribution", "to", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p331_s0", "idA": "749647_17_item1_p187_s0", "sentA": "Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic products.", "sentB": "Our business strategy contemplates growth and diversification.", "type": 1, "words": ["<tag1>", "Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products.", "<tag2>", "Our", "business", "strategy", "contemplates", "growth", "and", "diversification.", "<tag3>"], "wordsA": ["Our", "business", "exposes", "us", "to", "potential", "product", "liability", "risks", "that", "are", "inherent", "in", "the", "testing,", "manufacturing", "and", "marketing", "of", "human", "therapeutic", "products."], "wordsB": ["Our", "business", "strategy", "contemplates", "growth", "and", "diversification."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p282_s0", "idA": "749647_17_item1_p187_s1", "sentA": "We presently have product liability insurance limited to $10 million per incident, and if we were to be subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim out of our own limited resources.", "sentB": "Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.", "type": 1, "words": ["<tag1>", "We", "presently", "have", "product", "liability", "insurance", "limited", "to", "$10", "million", "per", "incident,", "and", "if", "we", "were", "to", "be", "subject", "to", "a", "claim", "in", "excess", "of", "this", "coverage", "or", "to", "a", "claim", "not", "covered", "by", "our", "insurance", "and", "the", "claim", "succeeded,", "we", "would", "be", "required", "to", "pay", "the", "claim", "out", "of", "our", "own", "limited", "resources.", "<tag2>", "Since", "publication", "of", "discoveries", "in", "scientific", "or", "patent", "literature", "often", "lags", "behind", "the", "date", "of", "such", "discoveries,", "we", "cannot", "be", "certain", "that", "we", "were", "the", "first", "inventor", "of", "inventions", "covered", "by", "our", "patents", "or", "patent", "applications.", "<tag3>"], "wordsA": ["We", "presently", "have", "product", "liability", "insurance", "limited", "to", "$10", "million", "per", "incident,", "and", "if", "we", "were", "to", "be", "subject", "to", "a", "claim", "in", "excess", "of", "this", "coverage", "or", "to", "a", "claim", "not", "covered", "by", "our", "insurance", "and", "the", "claim", "succeeded,", "we", "would", "be", "required", "to", "pay", "the", "claim", "out", "of", "our", "own", "limited", "resources."], "wordsB": ["Since", "publication", "of", "discoveries", "in", "scientific", "or", "patent", "literature", "often", "lags", "behind", "the", "date", "of", "such", "discoveries,", "we", "cannot", "be", "certain", "that", "we", "were", "the", "first", "inventor", "of", "inventions", "covered", "by", "our", "patents", "or", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s5", "idA": "749647_17_item1_p187_s1", "sentA": "We presently have product liability insurance limited to $10 million per incident, and if we were to be subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim out of our own limited resources.", "sentB": "Accordingly, even if coverage and reimbursement are provided by government, private health insurers and third-party payors for uses of our products, market acceptance of these products would be adversely affected if the reimbursement available proves to be unprofitable for health care providers.", "type": 1, "words": ["<tag1>", "We", "presently", "have", "product", "liability", "insurance", "limited", "to", "$10", "million", "per", "incident,", "and", "if", "we", "were", "to", "be", "subject", "to", "a", "claim", "in", "excess", "of", "this", "coverage", "or", "to", "a", "claim", "not", "covered", "by", "our", "insurance", "and", "the", "claim", "succeeded,", "we", "would", "be", "required", "to", "pay", "the", "claim", "out", "of", "our", "own", "limited", "resources.", "<tag2>", "Accordingly,", "even", "if", "coverage", "and", "reimbursement", "are", "provided", "by", "government,", "private", "health", "insurers", "and", "third-party", "payors", "for", "uses", "of", "our", "products,", "market", "acceptance", "of", "these", "products", "would", "be", "adversely", "affected", "if", "the", "reimbursement", "available", "proves", "to", "be", "unprofitable", "for", "health", "care", "providers.", "<tag3>"], "wordsA": ["We", "presently", "have", "product", "liability", "insurance", "limited", "to", "$10", "million", "per", "incident,", "and", "if", "we", "were", "to", "be", "subject", "to", "a", "claim", "in", "excess", "of", "this", "coverage", "or", "to", "a", "claim", "not", "covered", "by", "our", "insurance", "and", "the", "claim", "succeeded,", "we", "would", "be", "required", "to", "pay", "the", "claim", "out", "of", "our", "own", "limited", "resources."], "wordsB": ["Accordingly,", "even", "if", "coverage", "and", "reimbursement", "are", "provided", "by", "government,", "private", "health", "insurers", "and", "third-party", "payors", "for", "uses", "of", "our", "products,", "market", "acceptance", "of", "these", "products", "would", "be", "adversely", "affected", "if", "the", "reimbursement", "available", "proves", "to", "be", "unprofitable", "for", "health", "care", "providers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p292_s0", "idA": "749647_17_item1_p189_s1", "sentA": "In addition, most of these organizations, either alone or together with their collaborators, have significantly greater experience than we do in developing products, undertaking preclinical testing and clinical trials, obtaining FDA and other regulatory approvals of products, and manufacturing and marketing products.", "sentB": "Because we do not conduct our own clinical trials, we must rely on the efforts of others and have reduced control over aspects of these activities, including, the timing of such trials, the costs associated with such trials and the procedures that are followed for such trials.", "type": 1, "words": ["<tag1>", "In", "addition,", "most", "of", "these", "organizations,", "either", "alone", "or", "together", "with", "their", "collaborators,", "have", "significantly", "greater", "experience", "than", "we", "do", "in", "developing", "products,", "undertaking", "preclinical", "testing", "and", "clinical", "trials,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products,", "and", "manufacturing", "and", "marketing", "products.", "<tag2>", "Because", "we", "do", "not", "conduct", "our", "own", "clinical", "trials,", "we", "must", "rely", "on", "the", "efforts", "of", "others", "and", "have", "reduced", "control", "over", "aspects", "of", "these", "activities,", "including,", "the", "timing", "of", "such", "trials,", "the", "costs", "associated", "with", "such", "trials", "and", "the", "procedures", "that", "are", "followed", "for", "such", "trials.", "<tag3>"], "wordsA": ["In", "addition,", "most", "of", "these", "organizations,", "either", "alone", "or", "together", "with", "their", "collaborators,", "have", "significantly", "greater", "experience", "than", "we", "do", "in", "developing", "products,", "undertaking", "preclinical", "testing", "and", "clinical", "trials,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products,", "and", "manufacturing", "and", "marketing", "products."], "wordsB": ["Because", "we", "do", "not", "conduct", "our", "own", "clinical", "trials,", "we", "must", "rely", "on", "the", "efforts", "of", "others", "and", "have", "reduced", "control", "over", "aspects", "of", "these", "activities,", "including,", "the", "timing", "of", "such", "trials,", "the", "costs", "associated", "with", "such", "trials", "and", "the", "procedures", "that", "are", "followed", "for", "such", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p265_s1", "idA": "749647_17_item1_p190_s0", "sentA": "Mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated among our competitors.", "sentB": "It can also result in patient harm, liability lawsuits, and reputational harm.", "type": 1, "words": ["<tag1>", "Mergers", "and", "acquisitions", "in", "the", "pharmaceutical", "industry", "may", "result", "in", "even", "more", "resources", "being", "concentrated", "among", "our", "competitors.", "<tag2>", "It", "can", "also", "result", "in", "patient", "harm,", "liability", "lawsuits,", "and", "reputational", "harm.", "<tag3>"], "wordsA": ["Mergers", "and", "acquisitions", "in", "the", "pharmaceutical", "industry", "may", "result", "in", "even", "more", "resources", "being", "concentrated", "among", "our", "competitors."], "wordsB": ["It", "can", "also", "result", "in", "patient", "harm,", "liability", "lawsuits,", "and", "reputational", "harm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p314_s0", "idA": "749647_17_item1_p190_s2", "sentA": "Our ability to compete successfully with other companies in the pharmaceutical and biotechnology field also depends on the status of our collaborations and on the continuing availability of capital to us.", "sentB": "Our ability to commercialize our new cancer treatment systems successfully will depend in part on the extent to which reimbursement for the costs of such products and related treatments will be available from government health administration authorities, private health insurers and other third-party payors.", "type": 1, "words": ["<tag1>", "Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us.", "<tag2>", "Our", "ability", "to", "commercialize", "our", "new", "cancer", "treatment", "systems", "successfully", "will", "depend", "in", "part", "on", "the", "extent", "to", "which", "reimbursement", "for", "the", "costs", "of", "such", "products", "and", "related", "treatments", "will", "be", "available", "from", "government", "health", "administration", "authorities,", "private", "health", "insurers", "and", "other", "third-party", "payors.", "<tag3>"], "wordsA": ["Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us."], "wordsB": ["Our", "ability", "to", "commercialize", "our", "new", "cancer", "treatment", "systems", "successfully", "will", "depend", "in", "part", "on", "the", "extent", "to", "which", "reimbursement", "for", "the", "costs", "of", "such", "products", "and", "related", "treatments", "will", "be", "available", "from", "government", "health", "administration", "authorities,", "private", "health", "insurers", "and", "other", "third-party", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p331_s1", "idA": "749647_17_item1_p190_s2", "sentA": "Our ability to compete successfully with other companies in the pharmaceutical and biotechnology field also depends on the status of our collaborations and on the continuing availability of capital to us.", "sentB": "Our ability to manage growth effectively will require that we continue to expend funds to improve our operational, financial and management controls, reporting systems and procedures.", "type": 1, "words": ["<tag1>", "Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us.", "<tag2>", "Our", "ability", "to", "manage", "growth", "effectively", "will", "require", "that", "we", "continue", "to", "expend", "funds", "to", "improve", "our", "operational,", "financial", "and", "management", "controls,", "reporting", "systems", "and", "procedures.", "<tag3>"], "wordsA": ["Our", "ability", "to", "compete", "successfully", "with", "other", "companies", "in", "the", "pharmaceutical", "and", "biotechnology", "field", "also", "depends", "on", "the", "status", "of", "our", "collaborations", "and", "on", "the", "continuing", "availability", "of", "capital", "to", "us."], "wordsB": ["Our", "ability", "to", "manage", "growth", "effectively", "will", "require", "that", "we", "continue", "to", "expend", "funds", "to", "improve", "our", "operational,", "financial", "and", "management", "controls,", "reporting", "systems", "and", "procedures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p242_s2", "idA": "749647_17_item1_p194_s2", "sentA": "We have also licensed from Valentis, CA certain global rights covering the use of pegylation for temperature sensitive liposomes.", "sentB": "We have incurred approximately $262 million of cumulated net losses.", "type": 1, "words": ["<tag1>", "We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes.", "<tag2>", "We", "have", "incurred", "approximately", "$262", "million", "of", "cumulated", "net", "losses.", "<tag3>"], "wordsA": ["We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes."], "wordsB": ["We", "have", "incurred", "approximately", "$262", "million", "of", "cumulated", "net", "losses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p324_s0", "idA": "749647_17_item1_p194_s2", "sentA": "We have also licensed from Valentis, CA certain global rights covering the use of pegylation for temperature sensitive liposomes.", "sentB": "We have no internal sales or marketing capability.", "type": 1, "words": ["<tag1>", "We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes.", "<tag2>", "We", "have", "no", "internal", "sales", "or", "marketing", "capability.", "<tag3>"], "wordsA": ["We", "have", "also", "licensed", "from", "Valentis,", "CA", "certain", "global", "rights", "covering", "the", "use", "of", "pegylation", "for", "temperature", "sensitive", "liposomes."], "wordsB": ["We", "have", "no", "internal", "sales", "or", "marketing", "capability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p244_s1", "idA": "749647_17_item1_p195_s0", "sentA": "In 2003, our obligations under the license agreement with Duke University with respect to the testing and regulatory milestones and other licensed technology performance deadlines were eliminated in exchange for a payment of shares of our common stock.", "sentB": "Our future capital requirements will depend upon numerous unpredictable factors, including, without limitation, the cost, timing, progress and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates, our efforts to implement new collaborations, licenses and strategic transactions, general and administrative expenses, capital expenditures and other unforeseen uses of cash.", "type": 1, "words": ["<tag1>", "In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock.", "<tag2>", "Our", "future", "capital", "requirements", "will", "depend", "upon", "numerous", "unpredictable", "factors,", "including,", "without", "limitation,", "the", "cost,", "timing,", "progress", "and", "outcomes", "of", "clinical", "studies", "and", "regulatory", "reviews", "of", "our", "proprietary", "drug", "candidates,", "our", "efforts", "to", "implement", "new", "collaborations,", "licenses", "and", "strategic", "transactions,", "general", "and", "administrative", "expenses,", "capital", "expenditures", "and", "other", "unforeseen", "uses", "of", "cash.", "<tag3>"], "wordsA": ["In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock."], "wordsB": ["Our", "future", "capital", "requirements", "will", "depend", "upon", "numerous", "unpredictable", "factors,", "including,", "without", "limitation,", "the", "cost,", "timing,", "progress", "and", "outcomes", "of", "clinical", "studies", "and", "regulatory", "reviews", "of", "our", "proprietary", "drug", "candidates,", "our", "efforts", "to", "implement", "new", "collaborations,", "licenses", "and", "strategic", "transactions,", "general", "and", "administrative", "expenses,", "capital", "expenditures", "and", "other", "unforeseen", "uses", "of", "cash."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p337_s0", "idA": "749647_17_item1_p195_s0", "sentA": "In 2003, our obligations under the license agreement with Duke University with respect to the testing and regulatory milestones and other licensed technology performance deadlines were eliminated in exchange for a payment of shares of our common stock.", "sentB": "Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.", "type": 1, "words": ["<tag1>", "In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock.", "<tag2>", "Despite", "the", "implementation", "of", "security", "measures,", "our", "internal", "computer", "systems", "and", "those", "of", "our", "CROs", "and", "other", "contractors", "and", "consultants", "are", "vulnerable", "to", "damage", "from", "computer", "viruses,", "unauthorized", "access,", "natural", "disasters,", "terrorism,", "war", "and", "telecommunication", "and", "electrical", "failures.", "<tag3>"], "wordsA": ["In", "2003,", "our", "obligations", "under", "the", "license", "agreement", "with", "Duke", "University", "with", "respect", "to", "the", "testing", "and", "regulatory", "milestones", "and", "other", "licensed", "technology", "performance", "deadlines", "were", "eliminated", "in", "exchange", "for", "a", "payment", "of", "shares", "of", "our", "common", "stock."], "wordsB": ["Despite", "the", "implementation", "of", "security", "measures,", "our", "internal", "computer", "systems", "and", "those", "of", "our", "CROs", "and", "other", "contractors", "and", "consultants", "are", "vulnerable", "to", "damage", "from", "computer", "viruses,", "unauthorized", "access,", "natural", "disasters,", "terrorism,", "war", "and", "telecommunication", "and", "electrical", "failures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p302_s0", "idA": "749647_17_item1_p195_s1", "sentA": "The license agreement continues to be subject to agreements to pay a royalty based upon future sales.", "sentB": "We are also subject to recordkeeping and reporting regulations.", "type": 1, "words": ["<tag1>", "The", "license", "agreement", "continues", "to", "be", "subject", "to", "agreements", "to", "pay", "a", "royalty", "based", "upon", "future", "sales.", "<tag2>", "We", "are", "also", "subject", "to", "recordkeeping", "and", "reporting", "regulations.", "<tag3>"], "wordsA": ["The", "license", "agreement", "continues", "to", "be", "subject", "to", "agreements", "to", "pay", "a", "royalty", "based", "upon", "future", "sales."], "wordsB": ["We", "are", "also", "subject", "to", "recordkeeping", "and", "reporting", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p182_s2", "idA": "749647_17_item1_p197_s0", "sentA": "Our rights under the license agreement with Duke University extend for the longer of 20 years or the end of any term for which any relevant patents are issued by the United States Patent and Trademark Office.", "sentB": "A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment to, an IND, but ideally no later than the end of Phase 2 meeting.", "type": 1, "words": ["<tag1>", "Our", "rights", "under", "the", "license", "agreement", "with", "Duke", "University", "extend", "for", "the", "longer", "of", "20", "years", "or", "the", "end", "of", "any", "term", "for", "which", "any", "relevant", "patents", "are", "issued", "by", "the", "United", "States", "Patent", "and", "Trademark", "Office.", "<tag2>", "A", "request", "for", "Breakthrough", "Therapy", "designation", "should", "be", "submitted", "concurrently", "with,", "or", "as", "an", "amendment", "to,", "an", "IND,", "but", "ideally", "no", "later", "than", "the", "end", "of", "Phase", "2", "meeting.", "<tag3>"], "wordsA": ["Our", "rights", "under", "the", "license", "agreement", "with", "Duke", "University", "extend", "for", "the", "longer", "of", "20", "years", "or", "the", "end", "of", "any", "term", "for", "which", "any", "relevant", "patents", "are", "issued", "by", "the", "United", "States", "Patent", "and", "Trademark", "Office."], "wordsB": ["A", "request", "for", "Breakthrough", "Therapy", "designation", "should", "be", "submitted", "concurrently", "with,", "or", "as", "an", "amendment", "to,", "an", "IND,", "but", "ideally", "no", "later", "than", "the", "end", "of", "Phase", "2", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p197_s4", "idA": "749647_17_item1_p197_s2", "sentA": "The European grant provides coverage in the European Community.", "sentB": "Products submitted for approval via the centralized procedure are assessed by the Committee for Medicinal Products for Human Use (CHMP), a committee within the European Medicine Agency (EMA).", "type": 1, "words": ["<tag1>", "The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community.", "<tag2>", "Products", "submitted", "for", "approval", "via", "the", "centralized", "procedure", "are", "assessed", "by", "the", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP),", "a", "committee", "within", "the", "European", "Medicine", "Agency", "(EMA).", "<tag3>"], "wordsA": ["The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community."], "wordsB": ["Products", "submitted", "for", "approval", "via", "the", "centralized", "procedure", "are", "assessed", "by", "the", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP),", "a", "committee", "within", "the", "European", "Medicine", "Agency", "(EMA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p347_s0", "idA": "749647_17_item1_p197_s2", "sentA": "The European grant provides coverage in the European Community.", "sentB": "Investors purchasing shares or other securities in the future could have rights superior to existing stockholders.", "type": 1, "words": ["<tag1>", "The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community.", "<tag2>", "Investors", "purchasing", "shares", "or", "other", "securities", "in", "the", "future", "could", "have", "rights", "superior", "to", "existing", "stockholders.", "<tag3>"], "wordsA": ["The", "European", "grant", "provides", "coverage", "in", "the", "European", "Community."], "wordsB": ["Investors", "purchasing", "shares", "or", "other", "securities", "in", "the", "future", "could", "have", "rights", "superior", "to", "existing", "stockholders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p236_s4", "idA": "749647_17_item1_p198_s4", "sentA": "This extended patent runway to 2026 allows for the evaluation of future development activities for ThermoDox and Celsion's heat-sensitive liposome technology platform.", "sentB": "The amount of future losses is uncertain.", "type": 1, "words": ["<tag1>", "This", "extended", "patent", "runway", "to", "2026", "allows", "for", "the", "evaluation", "of", "future", "development", "activities", "for", "ThermoDox", "and", "Celsion's", "heat-sensitive", "liposome", "technology", "platform.", "<tag2>", "The", "amount", "of", "future", "losses", "is", "uncertain.", "<tag3>"], "wordsA": ["This", "extended", "patent", "runway", "to", "2026", "allows", "for", "the", "evaluation", "of", "future", "development", "activities", "for", "ThermoDox", "and", "Celsion's", "heat-sensitive", "liposome", "technology", "platform."], "wordsB": ["The", "amount", "of", "future", "losses", "is", "uncertain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p305_s0", "idA": "749647_17_item1_p198_s4", "sentA": "This extended patent runway to 2026 allows for the evaluation of future development activities for ThermoDox and Celsion's heat-sensitive liposome technology platform.", "sentB": "We have obtained Orphan Drug Designation for for ThermoDox and may seek Orphan Drug Designation for other pr oduct candidates, but we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.", "type": 1, "words": ["<tag1>", "This", "extended", "patent", "runway", "to", "2026", "allows", "for", "the", "evaluation", "of", "future", "development", "activities", "for", "ThermoDox", "and", "Celsion's", "heat-sensitive", "liposome", "technology", "platform.", "<tag2>", "We", "have", "obtained", "Orphan", "Drug", "Designation", "for", "for", "ThermoDox", "and", "may", "seek", "Orphan", "Drug", "Designation", "for", "other", "pr", "oduct", "candidates,", "but", "we", "may", "be", "unsuccessful", "or", "may", "be", "unable", "to", "maintain", "the", "benefits", "associated", "with", "Orphan", "Drug", "Designation,", "including", "the", "potential", "for", "market", "exclusivity.", "<tag3>"], "wordsA": ["This", "extended", "patent", "runway", "to", "2026", "allows", "for", "the", "evaluation", "of", "future", "development", "activities", "for", "ThermoDox", "and", "Celsion's", "heat-sensitive", "liposome", "technology", "platform."], "wordsB": ["We", "have", "obtained", "Orphan", "Drug", "Designation", "for", "for", "ThermoDox", "and", "may", "seek", "Orphan", "Drug", "Designation", "for", "other", "pr", "oduct", "candidates,", "but", "we", "may", "be", "unsuccessful", "or", "may", "be", "unable", "to", "maintain", "the", "benefits", "associated", "with", "Orphan", "Drug", "Designation,", "including", "the", "potential", "for", "market", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p187_s1", "idA": "749647_17_item1_p19_s5", "sentA": "Median OS for the ThermoDox group has been reached which translates into a two year survival benefit over the optimized RFA group (projected to be greater than 80 months for the ThermoDox plus optimized RFA group compared to less than 60 months projection for the optimized RFA only group).", "sentB": "The first biological product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biological products for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference product in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar s application has been approved if a patent lawsuit is ongoing within the 42-month period.", "type": 1, "words": ["<tag1>", "Median", "OS", "for", "the", "ThermoDox", "group", "has", "been", "reached", "which", "translates", "into", "a", "two", "year", "survival", "benefit", "over", "the", "optimized", "RFA", "group", "(projected", "to", "be", "greater", "than", "80", "months", "for", "the", "ThermoDox", "plus", "optimized", "RFA", "group", "compared", "to", "less", "than", "60", "months", "projection", "for", "the", "optimized", "RFA", "only", "group).", "<tag2>", "The", "first", "biological", "product", "candidate", "submitted", "under", "the", "abbreviated", "approval", "pathway", "that", "is", "determined", "to", "be", "interchangeable", "with", "the", "reference", "product", "has", "exclusivity", "against", "a", "finding", "of", "interchangeability", "for", "other", "biological", "products", "for", "the", "same", "condition", "of", "use", "for", "the", "lesser", "of", "(i)", "one", "year", "after", "first", "commercial", "marketing", "of", "the", "first", "interchangeable", "biosimilar,", "(ii)", "18", "months", "after", "the", "first", "interchangeable", "biosimilar", "is", "approved", "if", "there", "is", "no", "patent", "challenge,", "(iii)", "18", "months", "after", "resolution", "of", "a", "lawsuit", "over", "the", "patents", "of", "the", "reference", "product", "in", "favor", "of", "the", "first", "interchangeable", "biosimilar", "applicant,", "or", "(iv)", "42", "months", "after", "the", "first", "interchangeable", "biosimilar", "s", "application", "has", "been", "approved", "if", "a", "patent", "lawsuit", "is", "ongoing", "within", "the", "42-month", "period.", "<tag3>"], "wordsA": ["Median", "OS", "for", "the", "ThermoDox", "group", "has", "been", "reached", "which", "translates", "into", "a", "two", "year", "survival", "benefit", "over", "the", "optimized", "RFA", "group", "(projected", "to", "be", "greater", "than", "80", "months", "for", "the", "ThermoDox", "plus", "optimized", "RFA", "group", "compared", "to", "less", "than", "60", "months", "projection", "for", "the", "optimized", "RFA", "only", "group)."], "wordsB": ["The", "first", "biological", "product", "candidate", "submitted", "under", "the", "abbreviated", "approval", "pathway", "that", "is", "determined", "to", "be", "interchangeable", "with", "the", "reference", "product", "has", "exclusivity", "against", "a", "finding", "of", "interchangeability", "for", "other", "biological", "products", "for", "the", "same", "condition", "of", "use", "for", "the", "lesser", "of", "(i)", "one", "year", "after", "first", "commercial", "marketing", "of", "the", "first", "interchangeable", "biosimilar,", "(ii)", "18", "months", "after", "the", "first", "interchangeable", "biosimilar", "is", "approved", "if", "there", "is", "no", "patent", "challenge,", "(iii)", "18", "months", "after", "resolution", "of", "a", "lawsuit", "over", "the", "patents", "of", "the", "reference", "product", "in", "favor", "of", "the", "first", "interchangeable", "biosimilar", "applicant,", "or", "(iv)", "42", "months", "after", "the", "first", "interchangeable", "biosimilar", "s", "application", "has", "been", "approved", "if", "a", "patent", "lawsuit", "is", "ongoing", "within", "the", "42-month", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p172_s1", "idA": "749647_17_item1_p202_s0", "sentA": "Competitors may be able to circumvent our patents.", "sentB": "Biological products intended for therapeutic use may be regulated by either the Center for Biologics Evaluation Research (CBER) or the Center for Biologics Evaluation Research (CDER).", "type": 1, "words": ["<tag1>", "Competitors", "may", "be", "able", "to", "circumvent", "our", "patents.", "<tag2>", "Biological", "products", "intended", "for", "therapeutic", "use", "may", "be", "regulated", "by", "either", "the", "Center", "for", "Biologics", "Evaluation", "Research", "(CBER)", "or", "the", "Center", "for", "Biologics", "Evaluation", "Research", "(CDER).", "<tag3>"], "wordsA": ["Competitors", "may", "be", "able", "to", "circumvent", "our", "patents."], "wordsB": ["Biological", "products", "intended", "for", "therapeutic", "use", "may", "be", "regulated", "by", "either", "the", "Center", "for", "Biologics", "Evaluation", "Research", "(CBER)", "or", "the", "Center", "for", "Biologics", "Evaluation", "Research", "(CDER)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p356_s0", "idA": "749647_17_item1_p202_s0", "sentA": "Competitors may be able to circumvent our patents.", "sentB": "We currently have significant net operating losses (NOLs) that may be used to offset future taxable income.", "type": 1, "words": ["<tag1>", "Competitors", "may", "be", "able", "to", "circumvent", "our", "patents.", "<tag2>", "We", "currently", "have", "significant", "net", "operating", "losses", "(NOLs)", "that", "may", "be", "used", "to", "offset", "future", "taxable", "income.", "<tag3>"], "wordsA": ["Competitors", "may", "be", "able", "to", "circumvent", "our", "patents."], "wordsB": ["We", "currently", "have", "significant", "net", "operating", "losses", "(NOLs)", "that", "may", "be", "used", "to", "offset", "future", "taxable", "income."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p187_s0", "idA": "749647_17_item1_p203_s0", "sentA": "Development and commercialization of pharmaceutical products can be subject to substantial delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short period of time following commercialization.", "sentB": "A reference product is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product.", "type": 1, "words": ["<tag1>", "Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization.", "<tag2>", "A", "reference", "product", "is", "granted", "12", "years", "of", "exclusivity", "from", "the", "time", "of", "first", "licensure", "of", "the", "reference", "product,", "and", "no", "application", "for", "a", "biosimilar", "can", "be", "submitted", "for", "four", "years", "from", "the", "date", "of", "licensure", "of", "the", "reference", "product.", "<tag3>"], "wordsA": ["Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization."], "wordsB": ["A", "reference", "product", "is", "granted", "12", "years", "of", "exclusivity", "from", "the", "time", "of", "first", "licensure", "of", "the", "reference", "product,", "and", "no", "application", "for", "a", "biosimilar", "can", "be", "submitted", "for", "four", "years", "from", "the", "date", "of", "licensure", "of", "the", "reference", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p264_s1", "idA": "749647_17_item1_p203_s0", "sentA": "Development and commercialization of pharmaceutical products can be subject to substantial delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short period of time following commercialization.", "sentB": "Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications.", "type": 1, "words": ["<tag1>", "Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization.", "<tag2>", "Sometimes,", "it", "can", "be", "difficult", "to", "determine", "if", "the", "serious", "adverse", "or", "unexpected", "side", "effects", "were", "caused", "by", "the", "product", "candidate", "or", "another", "factor,", "especially", "in", "oncology", "subjects", "who", "may", "suffer", "from", "other", "medical", "conditions", "and", "be", "taking", "other", "medications.", "<tag3>"], "wordsA": ["Development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays", "and", "it", "is", "possible", "that", "at", "the", "time", "of", "commercialization", "any", "patent", "covering", "the", "product", "has", "expired", "or", "will", "be", "in", "force", "for", "only", "a", "short", "period", "of", "time", "following", "commercialization."], "wordsB": ["Sometimes,", "it", "can", "be", "difficult", "to", "determine", "if", "the", "serious", "adverse", "or", "unexpected", "side", "effects", "were", "caused", "by", "the", "product", "candidate", "or", "another", "factor,", "especially", "in", "oncology", "subjects", "who", "may", "suffer", "from", "other", "medical", "conditions", "and", "be", "taking", "other", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p315_s1", "idA": "749647_17_item1_p204_s0", "sentA": "We cannot predict with any certainty if any third party U.S. or foreign patent rights, other proprietary rights, will be deemed infringed by the use of our technology.", "sentB": "We cannot guarantee that adequate third-party insurance coverage will be available for us to establish and maintain price levels sufficient for us to realize an appropriate return on our investment in developing new therapies.", "type": 1, "words": ["<tag1>", "We", "cannot", "predict", "with", "any", "certainty", "if", "any", "third", "party", "U.S.", "or", "foreign", "patent", "rights,", "other", "proprietary", "rights,", "will", "be", "deemed", "infringed", "by", "the", "use", "of", "our", "technology.", "<tag2>", "We", "cannot", "guarantee", "that", "adequate", "third-party", "insurance", "coverage", "will", "be", "available", "for", "us", "to", "establish", "and", "maintain", "price", "levels", "sufficient", "for", "us", "to", "realize", "an", "appropriate", "return", "on", "our", "investment", "in", "developing", "new", "therapies.", "<tag3>"], "wordsA": ["We", "cannot", "predict", "with", "any", "certainty", "if", "any", "third", "party", "U.S.", "or", "foreign", "patent", "rights,", "other", "proprietary", "rights,", "will", "be", "deemed", "infringed", "by", "the", "use", "of", "our", "technology."], "wordsB": ["We", "cannot", "guarantee", "that", "adequate", "third-party", "insurance", "coverage", "will", "be", "available", "for", "us", "to", "establish", "and", "maintain", "price", "levels", "sufficient", "for", "us", "to", "realize", "an", "appropriate", "return", "on", "our", "investment", "in", "developing", "new", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p192_s2", "idA": "749647_17_item1_p204_s1", "sentA": "Nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties.", "sentB": "It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.", "type": 1, "words": ["<tag1>", "Nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties.", "<tag2>", "It", "is", "impossible", "to", "predict", "whether", "further", "legislative", "changes", "will", "be", "enacted", "or", "whether", "FDA", "regulations,", "guidance,", "policies", "or", "interpretations", "will", "be", "changed", "or", "what", "the", "effect", "of", "such", "changes,", "if", "any,", "may", "be.", "<tag3>"], "wordsA": ["Nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties."], "wordsB": ["It", "is", "impossible", "to", "predict", "whether", "further", "legislative", "changes", "will", "be", "enacted", "or", "whether", "FDA", "regulations,", "guidance,", "policies", "or", "interpretations", "will", "be", "changed", "or", "what", "the", "effect", "of", "such", "changes,", "if", "any,", "may", "be."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p303_s0", "idA": "749647_17_item1_p204_s1", "sentA": "Nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties.", "sentB": "Many states in which we do or may do business, or in which our products may be sold, if at all, impose licensing, labeling or certification requirements that are in addition to those imposed by the FDA.", "type": 1, "words": ["<tag1>", "Nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties.", "<tag2>", "Many", "states", "in", "which", "we", "do", "or", "may", "do", "business,", "or", "in", "which", "our", "products", "may", "be", "sold,", "if", "at", "all,", "impose", "licensing,", "labeling", "or", "certification", "requirements", "that", "are", "in", "addition", "to", "those", "imposed", "by", "the", "FDA.", "<tag3>"], "wordsA": ["Nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties."], "wordsB": ["Many", "states", "in", "which", "we", "do", "or", "may", "do", "business,", "or", "in", "which", "our", "products", "may", "be", "sold,", "if", "at", "all,", "impose", "licensing,", "labeling", "or", "certification", "requirements", "that", "are", "in", "addition", "to", "those", "imposed", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p191_s0", "idA": "749647_17_item1_p204_s3", "sentA": "Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad, and could result in the award of substantial damages.", "sentB": "Regulatory applications based solely on foreign clinical data meeting these criteria may be approved if the foreign data are applicable to the U.S. population and U.S. medical practice, the trials have been performed by clinical investigators of recognized competence, and the data may be considered valid without the need for an on-site inspection by FDA or, if FDA considers such an inspection to be necessary, FDA is able to validate the data through an on-site inspection or other appropriate means.", "type": 1, "words": ["<tag1>", "Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad,", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages.", "<tag2>", "Regulatory", "applications", "based", "solely", "on", "foreign", "clinical", "data", "meeting", "these", "criteria", "may", "be", "approved", "if", "the", "foreign", "data", "are", "applicable", "to", "the", "U.S.", "population", "and", "U.S.", "medical", "practice,", "the", "trials", "have", "been", "performed", "by", "clinical", "investigators", "of", "recognized", "competence,", "and", "the", "data", "may", "be", "considered", "valid", "without", "the", "need", "for", "an", "on-site", "inspection", "by", "FDA", "or,", "if", "FDA", "considers", "such", "an", "inspection", "to", "be", "necessary,", "FDA", "is", "able", "to", "validate", "the", "data", "through", "an", "on-site", "inspection", "or", "other", "appropriate", "means.", "<tag3>"], "wordsA": ["Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad,", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages."], "wordsB": ["Regulatory", "applications", "based", "solely", "on", "foreign", "clinical", "data", "meeting", "these", "criteria", "may", "be", "approved", "if", "the", "foreign", "data", "are", "applicable", "to", "the", "U.S.", "population", "and", "U.S.", "medical", "practice,", "the", "trials", "have", "been", "performed", "by", "clinical", "investigators", "of", "recognized", "competence,", "and", "the", "data", "may", "be", "considered", "valid", "without", "the", "need", "for", "an", "on-site", "inspection", "by", "FDA", "or,", "if", "FDA", "considers", "such", "an", "inspection", "to", "be", "necessary,", "FDA", "is", "able", "to", "validate", "the", "data", "through", "an", "on-site", "inspection", "or", "other", "appropriate", "means."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p277_s4", "idA": "749647_17_item1_p204_s3", "sentA": "Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad, and could result in the award of substantial damages.", "sentB": "Litigation, which could result in substantial costs, may also be necessary to enforce any patents issued to or licensed by us or to determine the scope and validity of another s claimed proprietary rights.", "type": 1, "words": ["<tag1>", "Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad,", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages.", "<tag2>", "Litigation,", "which", "could", "result", "in", "substantial", "costs,", "may", "also", "be", "necessary", "to", "enforce", "any", "patents", "issued", "to", "or", "licensed", "by", "us", "or", "to", "determine", "the", "scope", "and", "validity", "of", "another", "s", "claimed", "proprietary", "rights.", "<tag3>"], "wordsA": ["Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad,", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages."], "wordsB": ["Litigation,", "which", "could", "result", "in", "substantial", "costs,", "may", "also", "be", "necessary", "to", "enforce", "any", "patents", "issued", "to", "or", "licensed", "by", "us", "or", "to", "determine", "the", "scope", "and", "validity", "of", "another", "s", "claimed", "proprietary", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p197_s1", "idA": "749647_17_item1_p205_s0", "sentA": "In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from a third party.", "sentB": "In the EU, medicinal products may be authorized either via the mutual recognition and decentralized procedure, the national procedure or the centralized procedure.", "type": 1, "words": ["<tag1>", "In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party.", "<tag2>", "In", "the", "EU,", "medicinal", "products", "may", "be", "authorized", "either", "via", "the", "mutual", "recognition", "and", "decentralized", "procedure,", "the", "national", "procedure", "or", "the", "centralized", "procedure.", "<tag3>"], "wordsA": ["In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party."], "wordsB": ["In", "the", "EU,", "medicinal", "products", "may", "be", "authorized", "either", "via", "the", "mutual", "recognition", "and", "decentralized", "procedure,", "the", "national", "procedure", "or", "the", "centralized", "procedure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p288_s5", "idA": "749647_17_item1_p205_s0", "sentA": "In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from a third party.", "sentB": "If we have supplied infringing products to third parties or have licensed third parties to manufacture, use or market infringing products, we may be obligated to indemnify these third parties for damages they may be required to pay to the patent holder and for any losses they may sustain.", "type": 1, "words": ["<tag1>", "In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party.", "<tag2>", "If", "we", "have", "supplied", "infringing", "products", "to", "third", "parties", "or", "have", "licensed", "third", "parties", "to", "manufacture,", "use", "or", "market", "infringing", "products,", "we", "may", "be", "obligated", "to", "indemnify", "these", "third", "parties", "for", "damages", "they", "may", "be", "required", "to", "pay", "to", "the", "patent", "holder", "and", "for", "any", "losses", "they", "may", "sustain.", "<tag3>"], "wordsA": ["In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "a", "third", "party."], "wordsB": ["If", "we", "have", "supplied", "infringing", "products", "to", "third", "parties", "or", "have", "licensed", "third", "parties", "to", "manufacture,", "use", "or", "market", "infringing", "products,", "we", "may", "be", "obligated", "to", "indemnify", "these", "third", "parties", "for", "damages", "they", "may", "be", "required", "to", "pay", "to", "the", "patent", "holder", "and", "for", "any", "losses", "they", "may", "sustain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p186_s3", "idA": "749647_17_item1_p206_s1", "sentA": "There can be no assurance that these proprietary information agreements will not be breached, that we will have adequate remedies for any breach, or that these agreements, even if fully enforced, will be adequate to prevent third-party use of the Company s proprietary technology.", "sentB": "A biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic al product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference product.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "these", "proprietary", "information", "agreements", "will", "not", "be", "breached,", "that", "we", "will", "have", "adequate", "remedies", "for", "any", "breach,", "or", "that", "these", "agreements,", "even", "if", "fully", "enforced,", "will", "be", "adequate", "to", "prevent", "third-party", "use", "of", "the", "Company", "s", "proprietary", "technology.", "<tag2>", "A", "biosimilar", "product", "candidate", "may", "be", "deemed", "interchangeable", "with", "a", "prior", "approved", "product", "if", "it", "meets", "the", "higher", "hurdle", "of", "demonstrating", "that", "it", "can", "be", "expected", "to", "produce", "the", "same", "clinical", "results", "as", "the", "reference", "product", "and,", "for", "products", "administered", "multiple", "times,", "the", "biologic", "al", "product", "and", "the", "reference", "product", "may", "be", "switched", "after", "one", "has", "been", "previously", "administered", "without", "increasing", "safety", "risks", "or", "risks", "of", "diminished", "efficacy", "relative", "to", "exclusive", "use", "of", "the", "reference", "product.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "these", "proprietary", "information", "agreements", "will", "not", "be", "breached,", "that", "we", "will", "have", "adequate", "remedies", "for", "any", "breach,", "or", "that", "these", "agreements,", "even", "if", "fully", "enforced,", "will", "be", "adequate", "to", "prevent", "third-party", "use", "of", "the", "Company", "s", "proprietary", "technology."], "wordsB": ["A", "biosimilar", "product", "candidate", "may", "be", "deemed", "interchangeable", "with", "a", "prior", "approved", "product", "if", "it", "meets", "the", "higher", "hurdle", "of", "demonstrating", "that", "it", "can", "be", "expected", "to", "produce", "the", "same", "clinical", "results", "as", "the", "reference", "product", "and,", "for", "products", "administered", "multiple", "times,", "the", "biologic", "al", "product", "and", "the", "reference", "product", "may", "be", "switched", "after", "one", "has", "been", "previously", "administered", "without", "increasing", "safety", "risks", "or", "risks", "of", "diminished", "efficacy", "relative", "to", "exclusive", "use", "of", "the", "reference", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p285_s2", "idA": "749647_17_item1_p206_s1", "sentA": "There can be no assurance that these proprietary information agreements will not be breached, that we will have adequate remedies for any breach, or that these agreements, even if fully enforced, will be adequate to prevent third-party use of the Company s proprietary technology.", "sentB": "Furthermore, others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "these", "proprietary", "information", "agreements", "will", "not", "be", "breached,", "that", "we", "will", "have", "adequate", "remedies", "for", "any", "breach,", "or", "that", "these", "agreements,", "even", "if", "fully", "enforced,", "will", "be", "adequate", "to", "prevent", "third-party", "use", "of", "the", "Company", "s", "proprietary", "technology.", "<tag2>", "Furthermore,", "others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to", "our", "trade", "secrets", "or", "disclose", "such", "technology.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "these", "proprietary", "information", "agreements", "will", "not", "be", "breached,", "that", "we", "will", "have", "adequate", "remedies", "for", "any", "breach,", "or", "that", "these", "agreements,", "even", "if", "fully", "enforced,", "will", "be", "adequate", "to", "prevent", "third-party", "use", "of", "the", "Company", "s", "proprietary", "technology."], "wordsB": ["Furthermore,", "others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to", "our", "trade", "secrets", "or", "disclose", "such", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p283_s0", "idA": "749647_17_item1_p207_s2", "sentA": "Please refer to Item 1A, Risk Factors, including, but not limited to, Our business depends on licensing agreements with third parties to permit us to use patented technologies.", "sentB": "An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.", "type": 1, "words": ["<tag1>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including,", "but", "not", "limited", "to,", "Our", "business", "depends", "on", "licensing", "agreements", "with", "third", "parties", "to", "permit", "us", "to", "use", "patented", "technologies.", "<tag2>", "An", "adverse", "outcome", "in", "any", "judicial", "proceeding", "involving", "intellectual", "property,", "including", "patents,", "could", "subject", "us", "to", "significant", "liabilities", "to", "third", "parties,", "require", "disputed", "rights", "to", "be", "licensed", "from", "or", "to", "third", "parties", "or", "require", "us", "to", "cease", "using", "the", "technology", "in", "dispute.", "<tag3>"], "wordsA": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including,", "but", "not", "limited", "to,", "Our", "business", "depends", "on", "licensing", "agreements", "with", "third", "parties", "to", "permit", "us", "to", "use", "patented", "technologies."], "wordsB": ["An", "adverse", "outcome", "in", "any", "judicial", "proceeding", "involving", "intellectual", "property,", "including", "patents,", "could", "subject", "us", "to", "significant", "liabilities", "to", "third", "parties,", "require", "disputed", "rights", "to", "be", "licensed", "from", "or", "to", "third", "parties", "or", "require", "us", "to", "cease", "using", "the", "technology", "in", "dispute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p261_s0", "idA": "749647_17_item1_p207_s3", "sentA": "The loss of any of our rights under these agreements could impair our ability to develop and market our products.", "sentB": "Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.", "type": 1, "words": ["<tag1>", "The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products.", "<tag2>", "Even", "if", "our", "products", "receive", "regulatory", "approval,", "they", "may", "still", "face", "future", "development", "and", "regulatory", "difficulties.", "<tag3>"], "wordsA": ["The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products."], "wordsB": ["Even", "if", "our", "products", "receive", "regulatory", "approval,", "they", "may", "still", "face", "future", "development", "and", "regulatory", "difficulties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p264_s2", "idA": "749647_17_item1_p207_s3", "sentA": "The loss of any of our rights under these agreements could impair our ability to develop and market our products.", "sentB": "If serious adverse or unexpected side effects are identified during development and are determined to be attributed to our product candidate, we may be required to develop a Risk Evaluation and Mitigation Strategy (REMS) to mitigate those serious safety risks, which could impose significant distribution and use restrictions on our products.", "type": 1, "words": ["<tag1>", "The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products.", "<tag2>", "If", "serious", "adverse", "or", "unexpected", "side", "effects", "are", "identified", "during", "development", "and", "are", "determined", "to", "be", "attributed", "to", "our", "product", "candidate,", "we", "may", "be", "required", "to", "develop", "a", "Risk", "Evaluation", "and", "Mitigation", "Strategy", "(REMS)", "to", "mitigate", "those", "serious", "safety", "risks,", "which", "could", "impose", "significant", "distribution", "and", "use", "restrictions", "on", "our", "products.", "<tag3>"], "wordsA": ["The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products."], "wordsB": ["If", "serious", "adverse", "or", "unexpected", "side", "effects", "are", "identified", "during", "development", "and", "are", "determined", "to", "be", "attributed", "to", "our", "product", "candidate,", "we", "may", "be", "required", "to", "develop", "a", "Risk", "Evaluation", "and", "Mitigation", "Strategy", "(REMS)", "to", "mitigate", "those", "serious", "safety", "risks,", "which", "could", "impose", "significant", "distribution", "and", "use", "restrictions", "on", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p330_s0", "idA": "749647_17_item1_p207_s3", "sentA": "The loss of any of our rights under these agreements could impair our ability to develop and market our products.", "sentB": "Our success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth effectively.", "type": 1, "words": ["<tag1>", "The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products.", "<tag2>", "Our", "success", "will", "depend", "in", "part", "on", "our", "ability", "to", "grow", "and", "diversify,", "which", "in", "turn", "will", "require", "that", "we", "manage", "and", "control", "our", "growth", "effectively.", "<tag3>"], "wordsA": ["The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products."], "wordsB": ["Our", "success", "will", "depend", "in", "part", "on", "our", "ability", "to", "grow", "and", "diversify,", "which", "in", "turn", "will", "require", "that", "we", "manage", "and", "control", "our", "growth", "effectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p337_s1", "idA": "749647_17_item1_p207_s3", "sentA": "The loss of any of our rights under these agreements could impair our ability to develop and market our products.", "sentB": "Such events could cause interruptions of our operations.", "type": 1, "words": ["<tag1>", "The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products.", "<tag2>", "Such", "events", "could", "cause", "interruptions", "of", "our", "operations.", "<tag3>"], "wordsA": ["The", "loss", "of", "any", "of", "our", "rights", "under", "these", "agreements", "could", "impair", "our", "ability", "to", "develop", "and", "market", "our", "products."], "wordsB": ["Such", "events", "could", "cause", "interruptions", "of", "our", "operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p103_s0", "idA": "749647_17_item1_p209_s3", "sentA": "The Company s website is www.celsion.com .", "sentB": "The Company hosted an Investigators Meeting with physicians in South East Asia and key opinion leaders on July 22-23, 2017 in Bangkok, Thailand.", "type": 1, "words": ["<tag1>", "The", "Company", "s", "website", "is", "www.celsion.com", ".", "<tag2>", "The", "Company", "hosted", "an", "Investigators", "Meeting", "with", "physicians", "in", "South", "East", "Asia", "and", "key", "opinion", "leaders", "on", "July", "22-23,", "2017", "in", "Bangkok,", "Thailand.", "<tag3>"], "wordsA": ["The", "Company", "s", "website", "is", "www.celsion.com", "."], "wordsB": ["The", "Company", "hosted", "an", "Investigators", "Meeting", "with", "physicians", "in", "South", "East", "Asia", "and", "key", "opinion", "leaders", "on", "July", "22-23,", "2017", "in", "Bangkok,", "Thailand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p19_s0", "idA": "749647_17_item1_p209_s3", "sentA": "The Company s website is www.celsion.com .", "sentB": "The Company hosted an Investigators Meeting with physicians in South East Asia and key opinion leaders on July 22-23, 2017 in Bangkok, Thailand.", "type": 1, "words": ["<tag1>", "The", "Company", "s", "website", "is", "www.celsion.com", ".", "<tag2>", "The", "Company", "hosted", "an", "Investigators", "Meeting", "with", "physicians", "in", "South", "East", "Asia", "and", "key", "opinion", "leaders", "on", "July", "22-23,", "2017", "in", "Bangkok,", "Thailand.", "<tag3>"], "wordsA": ["The", "Company", "s", "website", "is", "www.celsion.com", "."], "wordsB": ["The", "Company", "hosted", "an", "Investigators", "Meeting", "with", "physicians", "in", "South", "East", "Asia", "and", "key", "opinion", "leaders", "on", "July", "22-23,", "2017", "in", "Bangkok,", "Thailand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p244_s3", "idA": "749647_17_item1_p211_s3", "sentA": "The Pre-Funded Series BB Warrants were offered at $0.22 per share, are immediately exercisable for $0.01 per share of common stock, do not have an expiration date and were issued in lieu of shares of common stock to the extent that the purchase of common stock would cause the beneficial ownership of the purchaser of such shares, together with its affiliates and certain related parties, to exceed 9.99% of our common stock.", "sentB": "We may need to pursue dilutive equity financings, such as the issuance of shares of common stock, convertible debt or other convertible or exercisable securities.", "type": 1, "words": ["<tag1>", "The", "Pre-Funded", "Series", "BB", "Warrants", "were", "offered", "at", "$0.22", "per", "share,", "are", "immediately", "exercisable", "for", "$0.01", "per", "share", "of", "common", "stock,", "do", "not", "have", "an", "expiration", "date", "and", "were", "issued", "in", "lieu", "of", "shares", "of", "common", "stock", "to", "the", "extent", "that", "the", "purchase", "of", "common", "stock", "would", "cause", "the", "beneficial", "ownership", "of", "the", "purchaser", "of", "such", "shares,", "together", "with", "its", "affiliates", "and", "certain", "related", "parties,", "to", "exceed", "9.99%", "of", "our", "common", "stock.", "<tag2>", "We", "may", "need", "to", "pursue", "dilutive", "equity", "financings,", "such", "as", "the", "issuance", "of", "shares", "of", "common", "stock,", "convertible", "debt", "or", "other", "convertible", "or", "exercisable", "securities.", "<tag3>"], "wordsA": ["The", "Pre-Funded", "Series", "BB", "Warrants", "were", "offered", "at", "$0.22", "per", "share,", "are", "immediately", "exercisable", "for", "$0.01", "per", "share", "of", "common", "stock,", "do", "not", "have", "an", "expiration", "date", "and", "were", "issued", "in", "lieu", "of", "shares", "of", "common", "stock", "to", "the", "extent", "that", "the", "purchase", "of", "common", "stock", "would", "cause", "the", "beneficial", "ownership", "of", "the", "purchaser", "of", "such", "shares,", "together", "with", "its", "affiliates", "and", "certain", "related", "parties,", "to", "exceed", "9.99%", "of", "our", "common", "stock."], "wordsB": ["We", "may", "need", "to", "pursue", "dilutive", "equity", "financings,", "such", "as", "the", "issuance", "of", "shares", "of", "common", "stock,", "convertible", "debt", "or", "other", "convertible", "or", "exercisable", "securities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p125_s1", "idA": "749647_17_item1_p24_s1", "sentA": "The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival in patients treated with RFA plus ThermoDox compared to patients treated with RFA alone.", "sentB": "An increase in CD8+ to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved overall survival.", "type": 1, "words": ["<tag1>", "The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone.", "<tag2>", "An", "increase", "in", "CD8+", "to", "immunosuppressive", "T-cell", "populations", "is", "a", "leading", "indicator", "and", "believed", "to", "be", "a", "good", "predictor", "of", "improved", "overall", "survival.", "<tag3>"], "wordsA": ["The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone."], "wordsB": ["An", "increase", "in", "CD8+", "to", "immunosuppressive", "T-cell", "populations", "is", "a", "leading", "indicator", "and", "believed", "to", "be", "a", "good", "predictor", "of", "improved", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p51_s1", "idA": "749647_17_item1_p24_s1", "sentA": "The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival in patients treated with RFA plus ThermoDox compared to patients treated with RFA alone.", "sentB": "An increase in CD8+ to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved overall survival.", "type": 1, "words": ["<tag1>", "The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone.", "<tag2>", "An", "increase", "in", "CD8+", "to", "immunosuppressive", "T-cell", "populations", "is", "a", "leading", "indicator", "and", "believed", "to", "be", "a", "good", "predictor", "of", "improved", "overall", "survival.", "<tag3>"], "wordsA": ["The", "NIH", "analysis,", "which", "sought", "to", "evaluate", "the", "correlation", "between", "RFA", "burn", "time", "per", "tumor", "volume", "(min/ml)", "and", "clinical", "outcome,", "concluded", "that", "increased", "burn", "time", "per", "tumor", "volume", "significantly", "improved", "overall", "survival", "in", "patients", "treated", "with", "RFA", "plus", "ThermoDox", "compared", "to", "patients", "treated", "with", "RFA", "alone."], "wordsB": ["An", "increase", "in", "CD8+", "to", "immunosuppressive", "T-cell", "populations", "is", "a", "leading", "indicator", "and", "believed", "to", "be", "a", "good", "predictor", "of", "improved", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p182_s1", "idA": "749647_17_item1_p25_s0", "sentA": "On January 31, 2013, the Company announced that the HEAT Study, ThermoDox in combination with RFA, did not meet the primary endpoint, PFS, of a Phase III clinical trial enrolling 701 patients with primary liver cancer.", "sentB": "A sponsor may seek FDA designation of a product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other therapeutics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.", "type": 1, "words": ["<tag1>", "On", "January", "31,", "2013,", "the", "Company", "announced", "that", "the", "HEAT", "Study,", "ThermoDox", "in", "combination", "with", "RFA,", "did", "not", "meet", "the", "primary", "endpoint,", "PFS,", "of", "a", "Phase", "III", "clinical", "trial", "enrolling", "701", "patients", "with", "primary", "liver", "cancer.", "<tag2>", "A", "sponsor", "may", "seek", "FDA", "designation", "of", "a", "product", "candidate", "as", "a", "breakthrough", "therapy", "if", "the", "product", "candidate", "is", "intended,", "alone", "or", "in", "combination", "with", "one", "or", "more", "other", "therapeutics,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition,", "and", "preliminary", "clinical", "evidence", "indicates", "that", "the", "product", "candidate", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "one", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development.", "<tag3>"], "wordsA": ["On", "January", "31,", "2013,", "the", "Company", "announced", "that", "the", "HEAT", "Study,", "ThermoDox", "in", "combination", "with", "RFA,", "did", "not", "meet", "the", "primary", "endpoint,", "PFS,", "of", "a", "Phase", "III", "clinical", "trial", "enrolling", "701", "patients", "with", "primary", "liver", "cancer."], "wordsB": ["A", "sponsor", "may", "seek", "FDA", "designation", "of", "a", "product", "candidate", "as", "a", "breakthrough", "therapy", "if", "the", "product", "candidate", "is", "intended,", "alone", "or", "in", "combination", "with", "one", "or", "more", "other", "therapeutics,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition,", "and", "preliminary", "clinical", "evidence", "indicates", "that", "the", "product", "candidate", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "one", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p180_s0", "idA": "749647_17_item1_p25_s1", "sentA": "This determination was made after conferring with the HEAT Study independent Data Monitoring Committee, that the HEAT Study did not meet the goal of demonstrating a clinically meaningful improvement in progression free survival.", "sentB": "A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome.", "type": 1, "words": ["<tag1>", "This", "determination", "was", "made", "after", "conferring", "with", "the", "HEAT", "Study", "independent", "Data", "Monitoring", "Committee,", "that", "the", "HEAT", "Study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "a", "clinically", "meaningful", "improvement", "in", "progression", "free", "survival.", "<tag2>", "A", "surrogate", "endpoint", "is", "a", "laboratory", "measurement", "or", "physical", "sign", "used", "as", "an", "indirect", "or", "substitute", "measurement", "representing", "a", "clinically", "meaningful", "outcome.", "<tag3>"], "wordsA": ["This", "determination", "was", "made", "after", "conferring", "with", "the", "HEAT", "Study", "independent", "Data", "Monitoring", "Committee,", "that", "the", "HEAT", "Study", "did", "not", "meet", "the", "goal", "of", "demonstrating", "a", "clinically", "meaningful", "improvement", "in", "progression", "free", "survival."], "wordsB": ["A", "surrogate", "endpoint", "is", "a", "laboratory", "measurement", "or", "physical", "sign", "used", "as", "an", "indirect", "or", "substitute", "measurement", "representing", "a", "clinically", "meaningful", "outcome."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p312_s3", "idA": "749647_17_item1_p27_s1", "sentA": "We have conducted a comprehensive analysis of the data from the HEAT Study to assess the future strategic value and development strategy for ThermoDox .", "sentB": "Further, the 2016 Presidential and Congressional elections and subsequent developments have caused the future state of many core aspects of the current health care marketplace to be uncertain, as the new Presidential Administration and Congress have repeatedly expressed a desire to repeal all or portions of the Affordable Care Act.", "type": 1, "words": ["<tag1>", "We", "have", "conducted", "a", "comprehensive", "analysis", "of", "the", "data", "from", "the", "HEAT", "Study", "to", "assess", "the", "future", "strategic", "value", "and", "development", "strategy", "for", "ThermoDox", ".", "<tag2>", "Further,", "the", "2016", "Presidential", "and", "Congressional", "elections", "and", "subsequent", "developments", "have", "caused", "the", "future", "state", "of", "many", "core", "aspects", "of", "the", "current", "health", "care", "marketplace", "to", "be", "uncertain,", "as", "the", "new", "Presidential", "Administration", "and", "Congress", "have", "repeatedly", "expressed", "a", "desire", "to", "repeal", "all", "or", "portions", "of", "the", "Affordable", "Care", "Act.", "<tag3>"], "wordsA": ["We", "have", "conducted", "a", "comprehensive", "analysis", "of", "the", "data", "from", "the", "HEAT", "Study", "to", "assess", "the", "future", "strategic", "value", "and", "development", "strategy", "for", "ThermoDox", "."], "wordsB": ["Further,", "the", "2016", "Presidential", "and", "Congressional", "elections", "and", "subsequent", "developments", "have", "caused", "the", "future", "state", "of", "many", "core", "aspects", "of", "the", "current", "health", "care", "marketplace", "to", "be", "uncertain,", "as", "the", "new", "Presidential", "Administration", "and", "Congress", "have", "repeatedly", "expressed", "a", "desire", "to", "repeal", "all", "or", "portions", "of", "the", "Affordable", "Care", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s3", "idA": "749647_17_item1_p32_s2", "sentA": "In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.", "sentB": "In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts.", "type": 1, "words": ["<tag1>", "In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date.", "<tag2>", "In", "addition,", "in", "recent", "years,", "Congress", "has", "enacted", "various", "laws", "seeking", "to", "reduce", "the", "federal", "debt", "level", "and", "contain", "healthcare", "expenditures,", "and", "the", "Medicare", "and", "other", "healthcare", "programs", "are", "frequently", "identified", "as", "potential", "targets", "for", "spending", "cuts.", "<tag3>"], "wordsA": ["In", "addition,", "CLSN", "Laboratories", "assumed", "certain", "specified", "liabilities", "of", "EGEN,", "including", "the", "liabilities", "arising", "out", "of", "the", "acquired", "contracts", "and", "other", "assets", "relating", "to", "periods", "after", "the", "closing", "date."], "wordsB": ["In", "addition,", "in", "recent", "years,", "Congress", "has", "enacted", "various", "laws", "seeking", "to", "reduce", "the", "federal", "debt", "level", "and", "contain", "healthcare", "expenditures,", "and", "the", "Medicare", "and", "other", "healthcare", "programs", "are", "frequently", "identified", "as", "potential", "targets", "for", "spending", "cuts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p340_s3", "idA": "749647_17_item1_p33_s1", "sentA": "At the closing, we paid approximately $3.0 million in cash after the expense adjustment and issued 2,712,188 shares of our common stock to EGEN.", "sentB": "The closing price of our common stock as reported on The NASDAQ Capital Market had a high price of $27.02 and a low price of $4.20 in the 52-week period ended December 31, 2016, a high price of $7.14 and a low price of $1.28 in the 52-week period ended December 31, 2017, and a high price of $2.82 and a low price of $2.12 from January 1, 2018 through March 26, 2018.", "type": 1, "words": ["<tag1>", "At", "the", "closing,", "we", "paid", "approximately", "$3.0", "million", "in", "cash", "after", "the", "expense", "adjustment", "and", "issued", "2,712,188", "shares", "of", "our", "common", "stock", "to", "EGEN.", "<tag2>", "The", "closing", "price", "of", "our", "common", "stock", "as", "reported", "on", "The", "NASDAQ", "Capital", "Market", "had", "a", "high", "price", "of", "$27.02", "and", "a", "low", "price", "of", "$4.20", "in", "the", "52-week", "period", "ended", "December", "31,", "2016,", "a", "high", "price", "of", "$7.14", "and", "a", "low", "price", "of", "$1.28", "in", "the", "52-week", "period", "ended", "December", "31,", "2017,", "and", "a", "high", "price", "of", "$2.82", "and", "a", "low", "price", "of", "$2.12", "from", "January", "1,", "2018", "through", "March", "26,", "2018.", "<tag3>"], "wordsA": ["At", "the", "closing,", "we", "paid", "approximately", "$3.0", "million", "in", "cash", "after", "the", "expense", "adjustment", "and", "issued", "2,712,188", "shares", "of", "our", "common", "stock", "to", "EGEN."], "wordsB": ["The", "closing", "price", "of", "our", "common", "stock", "as", "reported", "on", "The", "NASDAQ", "Capital", "Market", "had", "a", "high", "price", "of", "$27.02", "and", "a", "low", "price", "of", "$4.20", "in", "the", "52-week", "period", "ended", "December", "31,", "2016,", "a", "high", "price", "of", "$7.14", "and", "a", "low", "price", "of", "$1.28", "in", "the", "52-week", "period", "ended", "December", "31,", "2017,", "and", "a", "high", "price", "of", "$2.82", "and", "a", "low", "price", "of", "$2.12", "from", "January", "1,", "2018", "through", "March", "26,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p350_s1", "idA": "749647_17_item1_p33_s1", "sentA": "At the closing, we paid approximately $3.0 million in cash after the expense adjustment and issued 2,712,188 shares of our common stock to EGEN.", "sentB": "To maintain the listing of our common stock on The NASDAQ Capital Market, we are required to meet certain listing requirements, including, among others, either: (i) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and stockholders equity of at least $2.5 million; or (ii) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and a total market value of listed securities of at least $35 million.", "type": 1, "words": ["<tag1>", "At", "the", "closing,", "we", "paid", "approximately", "$3.0", "million", "in", "cash", "after", "the", "expense", "adjustment", "and", "issued", "2,712,188", "shares", "of", "our", "common", "stock", "to", "EGEN.", "<tag2>", "To", "maintain", "the", "listing", "of", "our", "common", "stock", "on", "The", "NASDAQ", "Capital", "Market,", "we", "are", "required", "to", "meet", "certain", "listing", "requirements,", "including,", "among", "others,", "either:", "(i)", "a", "minimum", "closing", "bid", "price", "of", "$1.00", "per", "share,", "a", "market", "value", "of", "publicly", "held", "shares", "(excluding", "shares", "held", "by", "our", "executive", "officers,", "directors", "and", "10%", "or", "more", "stockholders)", "of", "at", "least", "$1", "million", "and", "stockholders", "equity", "of", "at", "least", "$2.5", "million;", "or", "(ii)", "a", "minimum", "closing", "bid", "price", "of", "$1.00", "per", "share,", "a", "market", "value", "of", "publicly", "held", "shares", "(excluding", "shares", "held", "by", "our", "executive", "officers,", "directors", "and", "10%", "or", "more", "stockholders)", "of", "at", "least", "$1", "million", "and", "a", "total", "market", "value", "of", "listed", "securities", "of", "at", "least", "$35", "million.", "<tag3>"], "wordsA": ["At", "the", "closing,", "we", "paid", "approximately", "$3.0", "million", "in", "cash", "after", "the", "expense", "adjustment", "and", "issued", "2,712,188", "shares", "of", "our", "common", "stock", "to", "EGEN."], "wordsB": ["To", "maintain", "the", "listing", "of", "our", "common", "stock", "on", "The", "NASDAQ", "Capital", "Market,", "we", "are", "required", "to", "meet", "certain", "listing", "requirements,", "including,", "among", "others,", "either:", "(i)", "a", "minimum", "closing", "bid", "price", "of", "$1.00", "per", "share,", "a", "market", "value", "of", "publicly", "held", "shares", "(excluding", "shares", "held", "by", "our", "executive", "officers,", "directors", "and", "10%", "or", "more", "stockholders)", "of", "at", "least", "$1", "million", "and", "stockholders", "equity", "of", "at", "least", "$2.5", "million;", "or", "(ii)", "a", "minimum", "closing", "bid", "price", "of", "$1.00", "per", "share,", "a", "market", "value", "of", "publicly", "held", "shares", "(excluding", "shares", "held", "by", "our", "executive", "officers,", "directors", "and", "10%", "or", "more", "stockholders)", "of", "at", "least", "$1", "million", "and", "a", "total", "market", "value", "of", "listed", "securities", "of", "at", "least", "$35", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p234_s1", "idA": "749647_17_item1_p34_s0", "sentA": "The shares of common stock were issued in a private transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof.", "sentB": "We note these factors for investors as permitted by Section 21E of the Securities Exchange Act , and Section 27A of the Securities Act.", "type": 1, "words": ["<tag1>", "The", "shares", "of", "common", "stock", "were", "issued", "in", "a", "private", "transaction", "exempt", "from", "registration", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "pursuant", "to", "Section", "4(2)", "thereof.", "<tag2>", "We", "note", "these", "factors", "for", "investors", "as", "permitted", "by", "Section", "21E", "of", "the", "Securities", "Exchange", "Act", ",", "and", "Section", "27A", "of", "the", "Securities", "Act.", "<tag3>"], "wordsA": ["The", "shares", "of", "common", "stock", "were", "issued", "in", "a", "private", "transaction", "exempt", "from", "registration", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "pursuant", "to", "Section", "4(2)", "thereof."], "wordsB": ["We", "note", "these", "factors", "for", "investors", "as", "permitted", "by", "Section", "21E", "of", "the", "Securities", "Exchange", "Act", ",", "and", "Section", "27A", "of", "the", "Securities", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p344_s1", "idA": "749647_17_item1_p34_s0", "sentA": "The shares of common stock were issued in a private transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof.", "sentB": "As of March 26, 2018, we had 17,740,035 shares of common stock outstanding, all of which shares, other than shares held by our directors and certain officers, were eligible for sale in the public market, subject in some cases to compliance with the requirements of Rule 144, including the volume limitations and manner of sale requirements.", "type": 1, "words": ["<tag1>", "The", "shares", "of", "common", "stock", "were", "issued", "in", "a", "private", "transaction", "exempt", "from", "registration", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "pursuant", "to", "Section", "4(2)", "thereof.", "<tag2>", "As", "of", "March", "26,", "2018,", "we", "had", "17,740,035", "shares", "of", "common", "stock", "outstanding,", "all", "of", "which", "shares,", "other", "than", "shares", "held", "by", "our", "directors", "and", "certain", "officers,", "were", "eligible", "for", "sale", "in", "the", "public", "market,", "subject", "in", "some", "cases", "to", "compliance", "with", "the", "requirements", "of", "Rule", "144,", "including", "the", "volume", "limitations", "and", "manner", "of", "sale", "requirements.", "<tag3>"], "wordsA": ["The", "shares", "of", "common", "stock", "were", "issued", "in", "a", "private", "transaction", "exempt", "from", "registration", "under", "the", "Securities", "Act", "of", "1933,", "as", "amended,", "pursuant", "to", "Section", "4(2)", "thereof."], "wordsB": ["As", "of", "March", "26,", "2018,", "we", "had", "17,740,035", "shares", "of", "common", "stock", "outstanding,", "all", "of", "which", "shares,", "other", "than", "shares", "held", "by", "our", "directors", "and", "certain", "officers,", "were", "eligible", "for", "sale", "in", "the", "public", "market,", "subject", "in", "some", "cases", "to", "compliance", "with", "the", "requirements", "of", "Rule", "144,", "including", "the", "volume", "limitations", "and", "manner", "of", "sale", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p318_s3", "idA": "749647_17_item1_p37_s0", "sentA": "Our obligations to make the earnout payments will terminate on the seventh anniversary of the closing date.", "sentB": "Market acceptance depends upon physicians and hospitals obtaining adequate reimbursement rates from third-party payors to make our products commercially viable.", "type": 1, "words": ["<tag1>", "Our", "obligations", "to", "make", "the", "earnout", "payments", "will", "terminate", "on", "the", "seventh", "anniversary", "of", "the", "closing", "date.", "<tag2>", "Market", "acceptance", "depends", "upon", "physicians", "and", "hospitals", "obtaining", "adequate", "reimbursement", "rates", "from", "third-party", "payors", "to", "make", "our", "products", "commercially", "viable.", "<tag3>"], "wordsA": ["Our", "obligations", "to", "make", "the", "earnout", "payments", "will", "terminate", "on", "the", "seventh", "anniversary", "of", "the", "closing", "date."], "wordsB": ["Market", "acceptance", "depends", "upon", "physicians", "and", "hospitals", "obtaining", "adequate", "reimbursement", "rates", "from", "third-party", "payors", "to", "make", "our", "products", "commercially", "viable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p339_s2", "idA": "749647_17_item1_p37_s0", "sentA": "Our obligations to make the earnout payments will terminate on the seventh anniversary of the closing date.", "sentB": "Plaintiffs securities litigation firms have publicly announced that they are investigating potential securities fraud claims that they may wish to make against us.", "type": 1, "words": ["<tag1>", "Our", "obligations", "to", "make", "the", "earnout", "payments", "will", "terminate", "on", "the", "seventh", "anniversary", "of", "the", "closing", "date.", "<tag2>", "Plaintiffs", "securities", "litigation", "firms", "have", "publicly", "announced", "that", "they", "are", "investigating", "potential", "securities", "fraud", "claims", "that", "they", "may", "wish", "to", "make", "against", "us.", "<tag3>"], "wordsA": ["Our", "obligations", "to", "make", "the", "earnout", "payments", "will", "terminate", "on", "the", "seventh", "anniversary", "of", "the", "closing", "date."], "wordsB": ["Plaintiffs", "securities", "litigation", "firms", "have", "publicly", "announced", "that", "they", "are", "investigating", "potential", "securities", "fraud", "claims", "that", "they", "may", "wish", "to", "make", "against", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p272_s0", "idA": "749647_17_item1_p3_s0", "sentA": "In evaluating such forward-looking statements, you should specifically consider various factors, including the risks outlined under Risk Factors.", "sentB": "Strategic transactions, such as acquisitions, partnerships and collaborations, including the EGEN acquisition, involve numerous risks, including:", "type": 1, "words": ["<tag1>", "In", "evaluating", "such", "forward-looking", "statements,", "you", "should", "specifically", "consider", "various", "factors,", "including", "the", "risks", "outlined", "under", "Risk", "Factors.", "<tag2>", "Strategic", "transactions,", "such", "as", "acquisitions,", "partnerships", "and", "collaborations,", "including", "the", "EGEN", "acquisition,", "involve", "numerous", "risks,", "including:", "<tag3>"], "wordsA": ["In", "evaluating", "such", "forward-looking", "statements,", "you", "should", "specifically", "consider", "various", "factors,", "including", "the", "risks", "outlined", "under", "Risk", "Factors."], "wordsB": ["Strategic", "transactions,", "such", "as", "acquisitions,", "partnerships", "and", "collaborations,", "including", "the", "EGEN", "acquisition,", "involve", "numerous", "risks,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p356_s3", "idA": "749647_17_item1_p41_s3", "sentA": "Enrollment of three additional patients in the fourth cohort is ongoing, and Celsion expects to complete the OVATION Study in the first half of 2017.", "sentB": "We determined we experienced ownership changes, as defined by Section 382, in connection with certain common stock offerings in 2011, 2013, 2015 and 2017.", "type": 1, "words": ["<tag1>", "Enrollment", "of", "three", "additional", "patients", "in", "the", "fourth", "cohort", "is", "ongoing,", "and", "Celsion", "expects", "to", "complete", "the", "OVATION", "Study", "in", "the", "first", "half", "of", "2017.", "<tag2>", "We", "determined", "we", "experienced", "ownership", "changes,", "as", "defined", "by", "Section", "382,", "in", "connection", "with", "certain", "common", "stock", "offerings", "in", "2011,", "2013,", "2015", "and", "2017.", "<tag3>"], "wordsA": ["Enrollment", "of", "three", "additional", "patients", "in", "the", "fourth", "cohort", "is", "ongoing,", "and", "Celsion", "expects", "to", "complete", "the", "OVATION", "Study", "in", "the", "first", "half", "of", "2017."], "wordsB": ["We", "determined", "we", "experienced", "ownership", "changes,", "as", "defined", "by", "Section", "382,", "in", "connection", "with", "certain", "common", "stock", "offerings", "in", "2011,", "2013,", "2015", "and", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p38_s2", "idA": "749647_17_item1_p41_s3", "sentA": "Enrollment of three additional patients in the fourth cohort is ongoing, and Celsion expects to complete the OVATION Study in the first half of 2017.", "sentB": "These shares were issued on June 16, 2017.", "type": 1, "words": ["<tag1>", "Enrollment", "of", "three", "additional", "patients", "in", "the", "fourth", "cohort", "is", "ongoing,", "and", "Celsion", "expects", "to", "complete", "the", "OVATION", "Study", "in", "the", "first", "half", "of", "2017.", "<tag2>", "These", "shares", "were", "issued", "on", "June", "16,", "2017.", "<tag3>"], "wordsA": ["Enrollment", "of", "three", "additional", "patients", "in", "the", "fourth", "cohort", "is", "ongoing,", "and", "Celsion", "expects", "to", "complete", "the", "OVATION", "Study", "in", "the", "first", "half", "of", "2017."], "wordsB": ["These", "shares", "were", "issued", "on", "June", "16,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p360_s2", "idA": "749647_17_item1_p43_s2", "sentA": "One patient in the second cohort was ineligible for debulking surgery due to a medical complication unrelated to the study or the study drug.", "sentB": "Therefore, our Board of Directors may issue such preferred stock on terms unfavorable to a potential bidder in the event that our Board of Directors opposes a merger or acquisition.", "type": 1, "words": ["<tag1>", "One", "patient", "in", "the", "second", "cohort", "was", "ineligible", "for", "debulking", "surgery", "due", "to", "a", "medical", "complication", "unrelated", "to", "the", "study", "or", "the", "study", "drug.", "<tag2>", "Therefore,", "our", "Board", "of", "Directors", "may", "issue", "such", "preferred", "stock", "on", "terms", "unfavorable", "to", "a", "potential", "bidder", "in", "the", "event", "that", "our", "Board", "of", "Directors", "opposes", "a", "merger", "or", "acquisition.", "<tag3>"], "wordsA": ["One", "patient", "in", "the", "second", "cohort", "was", "ineligible", "for", "debulking", "surgery", "due", "to", "a", "medical", "complication", "unrelated", "to", "the", "study", "or", "the", "study", "drug."], "wordsB": ["Therefore,", "our", "Board", "of", "Directors", "may", "issue", "such", "preferred", "stock", "on", "terms", "unfavorable", "to", "a", "potential", "bidder", "in", "the", "event", "that", "our", "Board", "of", "Directors", "opposes", "a", "merger", "or", "acquisition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p126_s0", "idA": "749647_17_item1_p48_s1", "sentA": "Top line data demonstrates intriguing immunological changes in the tumor that are consistent with the activation of the immune system.", "sentB": "Analysis of peritoneal fluid by cell sorting, not reported before, shows treatment-related decrease in the percentage of immunosuppressive T-cell (Foxp3+), which is consistent with the reduction of Foxp3+ T-cells in the primary tumor tissue, and a shift in tumor na ve CD8+ cell population to more efficient tumor killing memory effector CD8+ cells.", "type": 1, "words": ["<tag1>", "Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system.", "<tag2>", "Analysis", "of", "peritoneal", "fluid", "by", "cell", "sorting,", "not", "reported", "before,", "shows", "treatment-related", "decrease", "in", "the", "percentage", "of", "immunosuppressive", "T-cell", "(Foxp3+),", "which", "is", "consistent", "with", "the", "reduction", "of", "Foxp3+", "T-cells", "in", "the", "primary", "tumor", "tissue,", "and", "a", "shift", "in", "tumor", "na", "ve", "CD8+", "cell", "population", "to", "more", "efficient", "tumor", "killing", "memory", "effector", "CD8+", "cells.", "<tag3>"], "wordsA": ["Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system."], "wordsB": ["Analysis", "of", "peritoneal", "fluid", "by", "cell", "sorting,", "not", "reported", "before,", "shows", "treatment-related", "decrease", "in", "the", "percentage", "of", "immunosuppressive", "T-cell", "(Foxp3+),", "which", "is", "consistent", "with", "the", "reduction", "of", "Foxp3+", "T-cells", "in", "the", "primary", "tumor", "tissue,", "and", "a", "shift", "in", "tumor", "na", "ve", "CD8+", "cell", "population", "to", "more", "efficient", "tumor", "killing", "memory", "effector", "CD8+", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p356_s2", "idA": "749647_17_item1_p48_s1", "sentA": "Top line data demonstrates intriguing immunological changes in the tumor that are consistent with the activation of the immune system.", "sentB": "During 2017, 2016 and years prior, we performed analyses to determine if there were changes in ownership, as defined by Section 382 of the Internal Revenue Code that would limit our ability to utilize certain net operating loss and tax credit carry forwards.", "type": 1, "words": ["<tag1>", "Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system.", "<tag2>", "During", "2017,", "2016", "and", "years", "prior,", "we", "performed", "analyses", "to", "determine", "if", "there", "were", "changes", "in", "ownership,", "as", "defined", "by", "Section", "382", "of", "the", "Internal", "Revenue", "Code", "that", "would", "limit", "our", "ability", "to", "utilize", "certain", "net", "operating", "loss", "and", "tax", "credit", "carry", "forwards.", "<tag3>"], "wordsA": ["Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system."], "wordsB": ["During", "2017,", "2016", "and", "years", "prior,", "we", "performed", "analyses", "to", "determine", "if", "there", "were", "changes", "in", "ownership,", "as", "defined", "by", "Section", "382", "of", "the", "Internal", "Revenue", "Code", "that", "would", "limit", "our", "ability", "to", "utilize", "certain", "net", "operating", "loss", "and", "tax", "credit", "carry", "forwards."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p52_s0", "idA": "749647_17_item1_p48_s1", "sentA": "Top line data demonstrates intriguing immunological changes in the tumor that are consistent with the activation of the immune system.", "sentB": "Analysis of peritoneal fluid by cell sorting, not reported before, shows treatment-related decrease in the percentage of immunosuppressive T-cell (Foxp3+), which is consistent with the reduction of Foxp3+ T-cells in the primary tumor tissue, and a shift in tumor na ve CD8+ cell population to more efficient tumor killing memory effector CD8+ cells.", "type": 1, "words": ["<tag1>", "Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system.", "<tag2>", "Analysis", "of", "peritoneal", "fluid", "by", "cell", "sorting,", "not", "reported", "before,", "shows", "treatment-related", "decrease", "in", "the", "percentage", "of", "immunosuppressive", "T-cell", "(Foxp3+),", "which", "is", "consistent", "with", "the", "reduction", "of", "Foxp3+", "T-cells", "in", "the", "primary", "tumor", "tissue,", "and", "a", "shift", "in", "tumor", "na", "ve", "CD8+", "cell", "population", "to", "more", "efficient", "tumor", "killing", "memory", "effector", "CD8+", "cells.", "<tag3>"], "wordsA": ["Top", "line", "data", "demonstrates", "intriguing", "immunological", "changes", "in", "the", "tumor", "that", "are", "consistent", "with", "the", "activation", "of", "the", "immune", "system."], "wordsB": ["Analysis", "of", "peritoneal", "fluid", "by", "cell", "sorting,", "not", "reported", "before,", "shows", "treatment-related", "decrease", "in", "the", "percentage", "of", "immunosuppressive", "T-cell", "(Foxp3+),", "which", "is", "consistent", "with", "the", "reduction", "of", "Foxp3+", "T-cells", "in", "the", "primary", "tumor", "tissue,", "and", "a", "shift", "in", "tumor", "na", "ve", "CD8+", "cell", "population", "to", "more", "efficient", "tumor", "killing", "memory", "effector", "CD8+", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p316_s2", "idA": "749647_17_item1_p57_s1", "sentA": "There are two components of the TheraPlas system, a plasmid DNA or mRNA payload encoding a therapeutic protein and a delivery system.", "sentB": "Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system.", "type": 1, "words": ["<tag1>", "There", "are", "two", "components", "of", "the", "TheraPlas", "system,", "a", "plasmid", "DNA", "or", "mRNA", "payload", "encoding", "a", "therapeutic", "protein", "and", "a", "delivery", "system.", "<tag2>", "Federal", "agencies,", "Congress", "and", "state", "legislatures", "have", "continued", "to", "show", "interest", "in", "implementing", "cost", "containment", "programs", "to", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system.", "<tag3>"], "wordsA": ["There", "are", "two", "components", "of", "the", "TheraPlas", "system,", "a", "plasmid", "DNA", "or", "mRNA", "payload", "encoding", "a", "therapeutic", "protein", "and", "a", "delivery", "system."], "wordsB": ["Federal", "agencies,", "Congress", "and", "state", "legislatures", "have", "continued", "to", "show", "interest", "in", "implementing", "cost", "containment", "programs", "to", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p331_s3", "idA": "749647_17_item1_p5_s0", "sentA": "We operate in a highly competitive, highly regulated and rapidly changing environment and our business is in a state of evolution.", "sentB": "We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner.", "type": 1, "words": ["<tag1>", "We", "operate", "in", "a", "highly", "competitive,", "highly", "regulated", "and", "rapidly", "changing", "environment", "and", "our", "business", "is", "in", "a", "state", "of", "evolution.", "<tag2>", "We", "will", "be", "unable", "to", "manage", "our", "business", "effectively", "if", "we", "are", "unable", "to", "alleviate", "the", "strain", "on", "resources", "caused", "by", "growth", "in", "a", "timely", "and", "successful", "manner.", "<tag3>"], "wordsA": ["We", "operate", "in", "a", "highly", "competitive,", "highly", "regulated", "and", "rapidly", "changing", "environment", "and", "our", "business", "is", "in", "a", "state", "of", "evolution."], "wordsB": ["We", "will", "be", "unable", "to", "manage", "our", "business", "effectively", "if", "we", "are", "unable", "to", "alleviate", "the", "strain", "on", "resources", "caused", "by", "growth", "in", "a", "timely", "and", "successful", "manner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p274_s0", "idA": "749647_17_item1_p63_s0", "sentA": "Key provisions of the GEN-1 Agreement are as follows:", "sentB": "We may never realize the perceived benefits of the EGEN acquisition or potential future transactions.", "type": 1, "words": ["<tag1>", "Key", "provisions", "of", "the", "GEN-1", "Agreement", "are", "as", "follows:", "<tag2>", "We", "may", "never", "realize", "the", "perceived", "benefits", "of", "the", "EGEN", "acquisition", "or", "potential", "future", "transactions.", "<tag3>"], "wordsA": ["Key", "provisions", "of", "the", "GEN-1", "Agreement", "are", "as", "follows:"], "wordsB": ["We", "may", "never", "realize", "the", "perceived", "benefits", "of", "the", "EGEN", "acquisition", "or", "potential", "future", "transactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p329_s9", "idA": "749647_17_item1_p63_s0", "sentA": "Key provisions of the GEN-1 Agreement are as follows:", "sentB": "Therefore, loss of the services of key personnel would not be ameliorated by the receipt of the proceeds from such insurance.", "type": 1, "words": ["<tag1>", "Key", "provisions", "of", "the", "GEN-1", "Agreement", "are", "as", "follows:", "<tag2>", "Therefore,", "loss", "of", "the", "services", "of", "key", "personnel", "would", "not", "be", "ameliorated", "by", "the", "receipt", "of", "the", "proceeds", "from", "such", "insurance.", "<tag3>"], "wordsA": ["Key", "provisions", "of", "the", "GEN-1", "Agreement", "are", "as", "follows:"], "wordsB": ["Therefore,", "loss", "of", "the", "services", "of", "key", "personnel", "would", "not", "be", "ameliorated", "by", "the", "receipt", "of", "the", "proceeds", "from", "such", "insurance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p289_s3", "idA": "749647_17_item1_p64_s0", "sentA": "Hisun will collaborate with Celsion around the regulatory approval activities for GEN-1 with the CFDA.", "sentB": "Any infringement action asserted against us, even if we are ultimately successful in defending against such action, would likely delay the regulatory approval process of our products, harm our competitive position, be expensive and require the time and attention of our key management and technical personnel.", "type": 1, "words": ["<tag1>", "Hisun", "will", "collaborate", "with", "Celsion", "around", "the", "regulatory", "approval", "activities", "for", "GEN-1", "with", "the", "CFDA.", "<tag2>", "Any", "infringement", "action", "asserted", "against", "us,", "even", "if", "we", "are", "ultimately", "successful", "in", "defending", "against", "such", "action,", "would", "likely", "delay", "the", "regulatory", "approval", "process", "of", "our", "products,", "harm", "our", "competitive", "position,", "be", "expensive", "and", "require", "the", "time", "and", "attention", "of", "our", "key", "management", "and", "technical", "personnel.", "<tag3>"], "wordsA": ["Hisun", "will", "collaborate", "with", "Celsion", "around", "the", "regulatory", "approval", "activities", "for", "GEN-1", "with", "the", "CFDA."], "wordsB": ["Any", "infringement", "action", "asserted", "against", "us,", "even", "if", "we", "are", "ultimately", "successful", "in", "defending", "against", "such", "action,", "would", "likely", "delay", "the", "regulatory", "approval", "process", "of", "our", "products,", "harm", "our", "competitive", "position,", "be", "expensive", "and", "require", "the", "time", "and", "attention", "of", "our", "key", "management", "and", "technical", "personnel."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p351_s0", "idA": "749647_17_item1_p65_s1", "sentA": "Our inability to complete any of our research and development activities, preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements and could adversely impact our liquidity.", "sentB": "The adverse capital and credit market conditions could affect our liquidity.", "type": 1, "words": ["<tag1>", "Our", "inability", "to", "complete", "any", "of", "our", "research", "and", "development", "activities,", "preclinical", "studies", "or", "clinical", "trials", "in", "a", "timely", "manner", "or", "our", "failure", "to", "enter", "into", "collaborative", "agreements", "when", "appropriate", "could", "significantly", "increase", "our", "capital", "requirements", "and", "could", "adversely", "impact", "our", "liquidity.", "<tag2>", "The", "adverse", "capital", "and", "credit", "market", "conditions", "could", "affect", "our", "liquidity.", "<tag3>"], "wordsA": ["Our", "inability", "to", "complete", "any", "of", "our", "research", "and", "development", "activities,", "preclinical", "studies", "or", "clinical", "trials", "in", "a", "timely", "manner", "or", "our", "failure", "to", "enter", "into", "collaborative", "agreements", "when", "appropriate", "could", "significantly", "increase", "our", "capital", "requirements", "and", "could", "adversely", "impact", "our", "liquidity."], "wordsB": ["The", "adverse", "capital", "and", "credit", "market", "conditions", "could", "affect", "our", "liquidity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p345_s0", "idA": "749647_17_item1_p65_s2", "sentA": "While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our product candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialize approved products, if any.", "sentB": "Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants.", "type": 1, "words": ["<tag1>", "While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "activities,", "preclinical", "studies", "and", "clinical", "trials,", "or", "if", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "development", "and", "clinical", "trials,", "obtain", "regulatory", "approvals", "and", "manufacture", "and", "commercialize", "approved", "products,", "if", "any.", "<tag2>", "Our", "stockholders", "may", "experience", "significant", "dilution", "as", "a", "result", "of", "future", "equity", "offerings", "or", "issuances", "and", "exercise", "of", "outstanding", "options", "and", "warrants.", "<tag3>"], "wordsA": ["While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "activities,", "preclinical", "studies", "and", "clinical", "trials,", "or", "if", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "development", "and", "clinical", "trials,", "obtain", "regulatory", "approvals", "and", "manufacture", "and", "commercialize", "approved", "products,", "if", "any."], "wordsB": ["Our", "stockholders", "may", "experience", "significant", "dilution", "as", "a", "result", "of", "future", "equity", "offerings", "or", "issuances", "and", "exercise", "of", "outstanding", "options", "and", "warrants."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p346_s1", "idA": "749647_17_item1_p65_s2", "sentA": "While our estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research, development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization activities, we will need significant additional capital to develop our product candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialize approved products, if any.", "sentB": "Our stockholders may experience significant dilution as a result of future equity offerings or issuances.", "type": 1, "words": ["<tag1>", "While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "activities,", "preclinical", "studies", "and", "clinical", "trials,", "or", "if", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "development", "and", "clinical", "trials,", "obtain", "regulatory", "approvals", "and", "manufacture", "and", "commercialize", "approved", "products,", "if", "any.", "<tag2>", "Our", "stockholders", "may", "experience", "significant", "dilution", "as", "a", "result", "of", "future", "equity", "offerings", "or", "issuances.", "<tag3>"], "wordsA": ["While", "our", "estimated", "future", "capital", "requirements", "are", "uncertain", "and", "could", "increase", "or", "decrease", "as", "a", "result", "of", "many", "factors,", "including", "the", "extent", "to", "which", "we", "choose", "to", "advance", "our", "research,", "development", "activities,", "preclinical", "studies", "and", "clinical", "trials,", "or", "if", "we", "are", "in", "a", "position", "to", "pursue", "manufacturing", "or", "commercialization", "activities,", "we", "will", "need", "significant", "additional", "capital", "to", "develop", "our", "product", "candidates", "through", "development", "and", "clinical", "trials,", "obtain", "regulatory", "approvals", "and", "manufacture", "and", "commercialize", "approved", "products,", "if", "any."], "wordsB": ["Our", "stockholders", "may", "experience", "significant", "dilution", "as", "a", "result", "of", "future", "equity", "offerings", "or", "issuances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p360_s4", "idA": "749647_17_item1_p65_s3", "sentA": "We do not know whether we will be able to access additional capital when needed or on terms favorable to us or our stockholders.", "sentB": "Certain other provisions of our bylaws and of Delaware law may also discourage, delay or prevent a third party from acquiring or merging with us, even if such action were beneficial to some, or even a majority, of our stockholders.", "type": 1, "words": ["<tag1>", "We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders.", "<tag2>", "Certain", "other", "provisions", "of", "our", "bylaws", "and", "of", "Delaware", "law", "may", "also", "discourage,", "delay", "or", "prevent", "a", "third", "party", "from", "acquiring", "or", "merging", "with", "us,", "even", "if", "such", "action", "were", "beneficial", "to", "some,", "or", "even", "a", "majority,", "of", "our", "stockholders.", "<tag3>"], "wordsA": ["We", "do", "not", "know", "whether", "we", "will", "be", "able", "to", "access", "additional", "capital", "when", "needed", "or", "on", "terms", "favorable", "to", "us", "or", "our", "stockholders."], "wordsB": ["Certain", "other", "provisions", "of", "our", "bylaws", "and", "of", "Delaware", "law", "may", "also", "discourage,", "delay", "or", "prevent", "a", "third", "party", "from", "acquiring", "or", "merging", "with", "us,", "even", "if", "such", "action", "were", "beneficial", "to", "some,", "or", "even", "a", "majority,", "of", "our", "stockholders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p271_s2", "idA": "749647_17_item1_p65_s4", "sentA": "Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.", "sentB": "These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.", "type": 1, "words": ["<tag1>", "Our", "inability", "to", "raise", "additional", "capital,", "or", "to", "do", "so", "on", "terms", "reasonably", "acceptable", "to", "us,", "would", "jeopardize", "the", "future", "success", "of", "our", "business.", "<tag2>", "These", "transactions", "would", "entail", "numerous", "operational", "and", "financial", "risks,", "including", "exposure", "to", "unknown", "liabilities,", "disruption", "of", "our", "business", "and", "diversion", "of", "our", "management", "s", "time", "and", "attention", "in", "order", "to", "manage", "a", "collaboration", "or", "develop", "acquired", "products,", "product", "candidates", "or", "technologies,", "incurrence", "of", "substantial", "debt", "or", "dilutive", "issuances", "of", "equity", "securities", "to", "pay", "transaction", "consideration", "or", "costs,", "higher", "than", "expected", "collaboration,", "acquisition", "or", "integration", "costs,", "write-downs", "of", "assets", "or", "goodwill", "or", "impairment", "charges,", "increased", "amortization", "expenses,", "difficulty", "and", "cost", "in", "facilitating", "the", "collaboration", "or", "combining", "the", "operations", "and", "personnel", "of", "any", "acquired", "business,", "impairment", "of", "relationships", "with", "key", "suppliers,", "manufacturers", "or", "customers", "of", "any", "acquired", "business", "due", "to", "changes", "in", "management", "and", "ownership", "and", "the", "inability", "to", "retain", "key", "employees", "of", "any", "acquired", "business.", "<tag3>"], "wordsA": ["Our", "inability", "to", "raise", "additional", "capital,", "or", "to", "do", "so", "on", "terms", "reasonably", "acceptable", "to", "us,", "would", "jeopardize", "the", "future", "success", "of", "our", "business."], "wordsB": ["These", "transactions", "would", "entail", "numerous", "operational", "and", "financial", "risks,", "including", "exposure", "to", "unknown", "liabilities,", "disruption", "of", "our", "business", "and", "diversion", "of", "our", "management", "s", "time", "and", "attention", "in", "order", "to", "manage", "a", "collaboration", "or", "develop", "acquired", "products,", "product", "candidates", "or", "technologies,", "incurrence", "of", "substantial", "debt", "or", "dilutive", "issuances", "of", "equity", "securities", "to", "pay", "transaction", "consideration", "or", "costs,", "higher", "than", "expected", "collaboration,", "acquisition", "or", "integration", "costs,", "write-downs", "of", "assets", "or", "goodwill", "or", "impairment", "charges,", "increased", "amortization", "expenses,", "difficulty", "and", "cost", "in", "facilitating", "the", "collaboration", "or", "combining", "the", "operations", "and", "personnel", "of", "any", "acquired", "business,", "impairment", "of", "relationships", "with", "key", "suppliers,", "manufacturers", "or", "customers", "of", "any", "acquired", "business", "due", "to", "changes", "in", "management", "and", "ownership", "and", "the", "inability", "to", "retain", "key", "employees", "of", "any", "acquired", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p234_s6", "idA": "749647_17_item1_p6_s0", "sentA": "Except as required by law, we assume no obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf for any reason, even if new information becomes available in the future.", "sentB": "We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise.", "type": 1, "words": ["<tag1>", "Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future.", "<tag2>", "We", "undertake", "no", "obligation", "to", "publicly", "update", "forward-looking", "statements,", "whether", "as", "a", "result", "of", "new", "information,", "future", "events,", "or", "otherwise.", "<tag3>"], "wordsA": ["Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future."], "wordsB": ["We", "undertake", "no", "obligation", "to", "publicly", "update", "forward-looking", "statements,", "whether", "as", "a", "result", "of", "new", "information,", "future", "events,", "or", "otherwise."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p255_s0", "idA": "749647_17_item1_p6_s0", "sentA": "Except as required by law, we assume no obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf for any reason, even if new information becomes available in the future.", "sentB": "As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.", "type": 1, "words": ["<tag1>", "Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future.", "<tag2>", "As", "more", "product", "candidates", "within", "a", "particular", "class", "of", "drugs", "proceed", "through", "clinical", "development", "to", "regulatory", "review", "and", "approval,", "the", "amount", "and", "type", "of", "clinical", "data", "that", "may", "be", "required", "by", "regulatory", "authorities", "may", "increase", "or", "change.", "<tag3>"], "wordsA": ["Except", "as", "required", "by", "law,", "we", "assume", "no", "obligation", "to", "revise", "or", "update", "any", "forward-looking", "statement", "that", "may", "be", "made", "from", "time", "to", "time", "by", "us", "or", "on", "our", "behalf", "for", "any", "reason,", "even", "if", "new", "information", "becomes", "available", "in", "the", "future."], "wordsB": ["As", "more", "product", "candidates", "within", "a", "particular", "class", "of", "drugs", "proceed", "through", "clinical", "development", "to", "regulatory", "review", "and", "approval,", "the", "amount", "and", "type", "of", "clinical", "data", "that", "may", "be", "required", "by", "regulatory", "authorities", "may", "increase", "or", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p37_s1", "idA": "749647_17_item1_p71_s3", "sentA": "The incidence of primary liver cancer is approximately 30,000 cases per year in the U.S., approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 850,000 cases per year.", "sentB": "The earn-out milestone liability was valued on the date of acquisition and is being valued at the end of each quarter with any change in its value recognized in the financial statements.", "type": 1, "words": ["<tag1>", "The", "incidence", "of", "primary", "liver", "cancer", "is", "approximately", "30,000", "cases", "per", "year", "in", "the", "U.S.,", "approximately", "40,000", "cases", "per", "year", "in", "Europe", "and", "is", "rapidly", "growing", "worldwide", "at", "approximately", "850,000", "cases", "per", "year.", "<tag2>", "The", "earn-out", "milestone", "liability", "was", "valued", "on", "the", "date", "of", "acquisition", "and", "is", "being", "valued", "at", "the", "end", "of", "each", "quarter", "with", "any", "change", "in", "its", "value", "recognized", "in", "the", "financial", "statements.", "<tag3>"], "wordsA": ["The", "incidence", "of", "primary", "liver", "cancer", "is", "approximately", "30,000", "cases", "per", "year", "in", "the", "U.S.,", "approximately", "40,000", "cases", "per", "year", "in", "Europe", "and", "is", "rapidly", "growing", "worldwide", "at", "approximately", "850,000", "cases", "per", "year."], "wordsB": ["The", "earn-out", "milestone", "liability", "was", "valued", "on", "the", "date", "of", "acquisition", "and", "is", "being", "valued", "at", "the", "end", "of", "each", "quarter", "with", "any", "change", "in", "its", "value", "recognized", "in", "the", "financial", "statements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p175_s0", "idA": "749647_17_item1_p78_s1", "sentA": "The study was carried out at the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) and Queen Mary Hospital in Hong Kong.", "sentB": "As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution.", "type": 1, "words": ["<tag1>", "The", "study", "was", "carried", "out", "at", "the", "National", "Cancer", "Institute", "(NCI),", "which", "is", "part", "of", "the", "National", "Institutes", "of", "Health", "(NIH)", "and", "Queen", "Mary", "Hospital", "in", "Hong", "Kong.", "<tag2>", "As", "part", "of", "the", "manufacturing", "process,", "the", "manufacturer", "is", "required", "to", "perform", "certain", "tests", "on", "each", "lot", "of", "the", "product", "before", "it", "is", "released", "for", "distribution.", "<tag3>"], "wordsA": ["The", "study", "was", "carried", "out", "at", "the", "National", "Cancer", "Institute", "(NCI),", "which", "is", "part", "of", "the", "National", "Institutes", "of", "Health", "(NIH)", "and", "Queen", "Mary", "Hospital", "in", "Hong", "Kong."], "wordsB": ["As", "part", "of", "the", "manufacturing", "process,", "the", "manufacturer", "is", "required", "to", "perform", "certain", "tests", "on", "each", "lot", "of", "the", "product", "before", "it", "is", "released", "for", "distribution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p200_s0", "idA": "749647_17_item1_p78_s1", "sentA": "The study was carried out at the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) and Queen Mary Hospital in Hong Kong.", "sentB": "Governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers.", "type": 1, "words": ["<tag1>", "The", "study", "was", "carried", "out", "at", "the", "National", "Cancer", "Institute", "(NCI),", "which", "is", "part", "of", "the", "National", "Institutes", "of", "Health", "(NIH)", "and", "Queen", "Mary", "Hospital", "in", "Hong", "Kong.", "<tag2>", "Governments", "influence", "the", "price", "of", "pharmaceutical", "products", "through", "their", "pricing", "and", "reimbursement", "rules", "and", "control", "of", "national", "health", "care", "systems", "that", "fund", "a", "large", "part", "of", "the", "cost", "of", "those", "products", "to", "consumers.", "<tag3>"], "wordsA": ["The", "study", "was", "carried", "out", "at", "the", "National", "Cancer", "Institute", "(NCI),", "which", "is", "part", "of", "the", "National", "Institutes", "of", "Health", "(NIH)", "and", "Queen", "Mary", "Hospital", "in", "Hong", "Kong."], "wordsB": ["Governments", "influence", "the", "price", "of", "pharmaceutical", "products", "through", "their", "pricing", "and", "reimbursement", "rules", "and", "control", "of", "national", "health", "care", "systems", "that", "fund", "a", "large", "part", "of", "the", "cost", "of", "those", "products", "to", "consumers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p190_s2", "idA": "749647_17_item1_p88_s0", "sentA": "The primary endpoint for the trial is Overall Survival, and the secondary endpoints for the trial are PFS and safety.", "sentB": "This information includes the investigator s qualifications; a description of the research facilities; a detailed summary of the protocol and trial results and, if requested, case records or additional background data; a description of the drug substance and drug product, including the components, formulation, specifications, and, if available, the bioavailability of the product candidate; information showing that the trial is adequate and well controlled; the name and address of the independent ethics committee that reviewed the trial and a statement that the independent ethics committee meets the required definition; a summary of the independent ethics committee s decision to approve or modify and approve the trial, or to provide a favorable opinion; a description of how informed consent was obtained; a description of what incentives, if any, were provided to subjects to participate; a description of how the sponsor monitored the trial and ensured that the trial was consistent with the protocol; a description of how investigators were trained to comply with GCP and to conduct the trial in accordance with the trial protocol; and a statement on whether written commitments by investigators to comply with GCP and the protocol were obtained.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "for", "the", "trial", "is", "Overall", "Survival,", "and", "the", "secondary", "endpoints", "for", "the", "trial", "are", "PFS", "and", "safety.", "<tag2>", "This", "information", "includes", "the", "investigator", "s", "qualifications;", "a", "description", "of", "the", "research", "facilities;", "a", "detailed", "summary", "of", "the", "protocol", "and", "trial", "results", "and,", "if", "requested,", "case", "records", "or", "additional", "background", "data;", "a", "description", "of", "the", "drug", "substance", "and", "drug", "product,", "including", "the", "components,", "formulation,", "specifications,", "and,", "if", "available,", "the", "bioavailability", "of", "the", "product", "candidate;", "information", "showing", "that", "the", "trial", "is", "adequate", "and", "well", "controlled;", "the", "name", "and", "address", "of", "the", "independent", "ethics", "committee", "that", "reviewed", "the", "trial", "and", "a", "statement", "that", "the", "independent", "ethics", "committee", "meets", "the", "required", "definition;", "a", "summary", "of", "the", "independent", "ethics", "committee", "s", "decision", "to", "approve", "or", "modify", "and", "approve", "the", "trial,", "or", "to", "provide", "a", "favorable", "opinion;", "a", "description", "of", "how", "informed", "consent", "was", "obtained;", "a", "description", "of", "what", "incentives,", "if", "any,", "were", "provided", "to", "subjects", "to", "participate;", "a", "description", "of", "how", "the", "sponsor", "monitored", "the", "trial", "and", "ensured", "that", "the", "trial", "was", "consistent", "with", "the", "protocol;", "a", "description", "of", "how", "investigators", "were", "trained", "to", "comply", "with", "GCP", "and", "to", "conduct", "the", "trial", "in", "accordance", "with", "the", "trial", "protocol;", "and", "a", "statement", "on", "whether", "written", "commitments", "by", "investigators", "to", "comply", "with", "GCP", "and", "the", "protocol", "were", "obtained.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "for", "the", "trial", "is", "Overall", "Survival,", "and", "the", "secondary", "endpoints", "for", "the", "trial", "are", "PFS", "and", "safety."], "wordsB": ["This", "information", "includes", "the", "investigator", "s", "qualifications;", "a", "description", "of", "the", "research", "facilities;", "a", "detailed", "summary", "of", "the", "protocol", "and", "trial", "results", "and,", "if", "requested,", "case", "records", "or", "additional", "background", "data;", "a", "description", "of", "the", "drug", "substance", "and", "drug", "product,", "including", "the", "components,", "formulation,", "specifications,", "and,", "if", "available,", "the", "bioavailability", "of", "the", "product", "candidate;", "information", "showing", "that", "the", "trial", "is", "adequate", "and", "well", "controlled;", "the", "name", "and", "address", "of", "the", "independent", "ethics", "committee", "that", "reviewed", "the", "trial", "and", "a", "statement", "that", "the", "independent", "ethics", "committee", "meets", "the", "required", "definition;", "a", "summary", "of", "the", "independent", "ethics", "committee", "s", "decision", "to", "approve", "or", "modify", "and", "approve", "the", "trial,", "or", "to", "provide", "a", "favorable", "opinion;", "a", "description", "of", "how", "informed", "consent", "was", "obtained;", "a", "description", "of", "what", "incentives,", "if", "any,", "were", "provided", "to", "subjects", "to", "participate;", "a", "description", "of", "how", "the", "sponsor", "monitored", "the", "trial", "and", "ensured", "that", "the", "trial", "was", "consistent", "with", "the", "protocol;", "a", "description", "of", "how", "investigators", "were", "trained", "to", "comply", "with", "GCP", "and", "to", "conduct", "the", "trial", "in", "accordance", "with", "the", "trial", "protocol;", "and", "a", "statement", "on", "whether", "written", "commitments", "by", "investigators", "to", "comply", "with", "GCP", "and", "the", "protocol", "were", "obtained."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p201_s1", "idA": "749647_17_item1_p90_s3", "sentA": "On April 26, 2016, we announced that the first patient in China has been enrolled in the OPTIMA Study.", "sentB": "In the EU, as we understand it, a medicinal product may be designated as an orphan medicinal product if the sponsor can establish that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand persons, or that, for the same purposes, it is unlikely that the marketing of the medicinal product would generate sufficient return; and that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition.", "type": 1, "words": ["<tag1>", "On", "April", "26,", "2016,", "we", "announced", "that", "the", "first", "patient", "in", "China", "has", "been", "enrolled", "in", "the", "OPTIMA", "Study.", "<tag2>", "In", "the", "EU,", "as", "we", "understand", "it,", "a", "medicinal", "product", "may", "be", "designated", "as", "an", "orphan", "medicinal", "product", "if", "the", "sponsor", "can", "establish", "that", "it", "is", "intended", "for", "the", "diagnosis,", "prevention", "or", "treatment", "of", "a", "life-threatening", "or", "chronically", "debilitating", "condition", "affecting", "not", "more", "than", "five", "in", "10", "thousand", "persons,", "or", "that,", "for", "the", "same", "purposes,", "it", "is", "unlikely", "that", "the", "marketing", "of", "the", "medicinal", "product", "would", "generate", "sufficient", "return;", "and", "that", "there", "exists", "no", "satisfactory", "method", "of", "diagnosis,", "prevention", "or", "treatment", "of", "the", "condition", "in", "question", "that", "has", "been", "authorized", "in", "the", "EU", "or,", "if", "such", "method", "exists,", "that", "the", "medicinal", "product", "will", "be", "of", "significant", "benefit", "to", "those", "affected", "by", "that", "condition.", "<tag3>"], "wordsA": ["On", "April", "26,", "2016,", "we", "announced", "that", "the", "first", "patient", "in", "China", "has", "been", "enrolled", "in", "the", "OPTIMA", "Study."], "wordsB": ["In", "the", "EU,", "as", "we", "understand", "it,", "a", "medicinal", "product", "may", "be", "designated", "as", "an", "orphan", "medicinal", "product", "if", "the", "sponsor", "can", "establish", "that", "it", "is", "intended", "for", "the", "diagnosis,", "prevention", "or", "treatment", "of", "a", "life-threatening", "or", "chronically", "debilitating", "condition", "affecting", "not", "more", "than", "five", "in", "10", "thousand", "persons,", "or", "that,", "for", "the", "same", "purposes,", "it", "is", "unlikely", "that", "the", "marketing", "of", "the", "medicinal", "product", "would", "generate", "sufficient", "return;", "and", "that", "there", "exists", "no", "satisfactory", "method", "of", "diagnosis,", "prevention", "or", "treatment", "of", "the", "condition", "in", "question", "that", "has", "been", "authorized", "in", "the", "EU", "or,", "if", "such", "method", "exists,", "that", "the", "medicinal", "product", "will", "be", "of", "significant", "benefit", "to", "those", "affected", "by", "that", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p340_s0", "idA": "749647_17_item1_p92_s2", "sentA": "As we evaluate strategic alternatives, we will need to consider a number of factors, including investment in, or acquisition of, complementary businesses, technologies or products, possible capital raising transactions, partnering opportunities and working capital requirements.", "sentB": "The price at which our common stock trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation, announcements of technological innovations or new products by us or our competitors, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions.", "type": 1, "words": ["<tag1>", "As", "we", "evaluate", "strategic", "alternatives,", "we", "will", "need", "to", "consider", "a", "number", "of", "factors,", "including", "investment", "in,", "or", "acquisition", "of,", "complementary", "businesses,", "technologies", "or", "products,", "possible", "capital", "raising", "transactions,", "partnering", "opportunities", "and", "working", "capital", "requirements.", "<tag2>", "The", "price", "at", "which", "our", "common", "stock", "trades", "depends", "upon", "a", "number", "of", "factors,", "including", "our", "historical", "and", "anticipated", "operating", "results,", "our", "financial", "situation,", "announcements", "of", "technological", "innovations", "or", "new", "products", "by", "us", "or", "our", "competitors,", "our", "ability", "or", "inability", "to", "raise", "the", "additional", "capital", "we", "may", "need", "and", "the", "terms", "on", "which", "we", "raise", "it,", "and", "general", "market", "and", "economic", "conditions.", "<tag3>"], "wordsA": ["As", "we", "evaluate", "strategic", "alternatives,", "we", "will", "need", "to", "consider", "a", "number", "of", "factors,", "including", "investment", "in,", "or", "acquisition", "of,", "complementary", "businesses,", "technologies", "or", "products,", "possible", "capital", "raising", "transactions,", "partnering", "opportunities", "and", "working", "capital", "requirements."], "wordsB": ["The", "price", "at", "which", "our", "common", "stock", "trades", "depends", "upon", "a", "number", "of", "factors,", "including", "our", "historical", "and", "anticipated", "operating", "results,", "our", "financial", "situation,", "announcements", "of", "technological", "innovations", "or", "new", "products", "by", "us", "or", "our", "competitors,", "our", "ability", "or", "inability", "to", "raise", "the", "additional", "capital", "we", "may", "need", "and", "the", "terms", "on", "which", "we", "raise", "it,", "and", "general", "market", "and", "economic", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p310_s0", "idA": "749647_17_item1_p94_s0", "sentA": "Breast cancer is the most common malignancy in women in both the U.S. and the world.", "sentB": "ThermoDox has received U.S. FDA Fast Track Designation.", "type": 1, "words": ["<tag1>", "Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "U.S.", "and", "the", "world.", "<tag2>", "ThermoDox", "has", "received", "U.S.", "FDA", "Fast", "Track", "Designation.", "<tag3>"], "wordsA": ["Breast", "cancer", "is", "the", "most", "common", "malignancy", "in", "women", "in", "both", "the", "U.S.", "and", "the", "world."], "wordsB": ["ThermoDox", "has", "received", "U.S.", "FDA", "Fast", "Track", "Designation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "749647_18_item1_p261_s1", "idA": "749647_17_item1_p98_s0", "sentA": "Our liposomal encapsulated doxorubicin is released by heat generated from an external microwave tissue hyperthermia device that is placed on a woman s chest.", "sentB": "Government regulators may impose significant restrictions on a product s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies.", "type": 1, "words": ["<tag1>", "Our", "liposomal", "encapsulated", "doxorubicin", "is", "released", "by", "heat", "generated", "from", "an", "external", "microwave", "tissue", "hyperthermia", "device", "that", "is", "placed", "on", "a", "woman", "s", "chest.", "<tag2>", "Government", "regulators", "may", "impose", "significant", "restrictions", "on", "a", "product", "s", "indicated", "uses", "or", "marketing", "or", "impose", "ongoing", "requirements", "for", "potentially", "costly", "post-approval", "studies.", "<tag3>"], "wordsA": ["Our", "liposomal", "encapsulated", "doxorubicin", "is", "released", "by", "heat", "generated", "from", "an", "external", "microwave", "tissue", "hyperthermia", "device", "that", "is", "placed", "on", "a", "woman", "s", "chest."], "wordsB": ["Government", "regulators", "may", "impose", "significant", "restrictions", "on", "a", "product", "s", "indicated", "uses", "or", "marketing", "or", "impose", "ongoing", "requirements", "for", "potentially", "costly", "post-approval", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
